TrialID,url,Scientific_title,Conditions,Interventions,Public_title,Source_registry,Date_registration_format,Date_enrollment_format,Day_inferred,Study_type,Study_design,Phase,Target_size,Primary_sponsor,Countries,Bridging_flag,Retrospective_flag,Date_registration,Date_enrollment,Trial_prefix,Unknown,SecondaryIDs,Public_Contact_Firstname,Public_Contact_Lastname,Public_Contact_Address,Public_Contact_Email,Public_Contact_Tel,Public_Contact_Affiliation,Scientific_Contact_Firstname,Scientific_Contact_Lastname,Scientific_Contact_Address,Scientific_Contact_Email,Scientific_Contact_Tel,Scientific_Contact_Affiliation,Recruitment_status,Secondary_sponsors,Source_Support,Agemin,Agemax,Gender,Inclusion_Criteria,Exclusion_Criteria,Primary_Outcome,Secondary_Outcomes,Bridged_type,Childs,type_enrolment,results_actual_enrollment,results_url_link,results_summary,results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan,results_IPD_description,results_date_completed,results_yes_no,Ethics_Status,Ethics_Approval_Date,Ethics_Contact_Name,Ethics_Contact_Address,Ethics_Contact_Phone,Ethics_Contact_Email
ACTRN12619000828123,https://anzctr.org.au/ACTRN12619000828123.aspx,Resuscitation in Paediatric Sepsis Using Early Inotropes– – A Randomized Controlled Trial to Assess Impact on Survival Free of Organ Dysfunction,Sepsis;Septic Shock; <br>Sepsis <br>Septic Shock;Infection - Studies of infection and infectious agents;Emergency medicine - Resuscitation,"Intervention: Early Inotropes: <br>Early Inotropes: Goal-Directed Therapy with initiation of intravenous inotropes after the initial fluid bolus (20ml/kg, minimal amount 10-20ml/kg fluid bolus;  (or 500-1000ml fluid bolus in patients >50kg). The inotrope used is diluted adrenaline initiated at 0.05 to 0.1 (up to 0.3) mcg/kg/min. Dilution is used to fasten drug delivery and response to drug rate changes, to reduce risks with extravasation, and to facilitate peripheral application. Adrenaline will be prepared in 50ml syringes in 5% Dextrose solution that will be connected to peripheral, intraosseus, or central vascular access device. Drug delivery will occur through guardrails or similar system to ensure safe delivery of applied standardized drug concentrations. <br><br>The study treatment will be given as continuous infusion for the duration of resuscitation until resolution of shock, discharge from intensive care unit, death, decision of the treating physician to stop or replace with other inotrope, or occurrence of major side effects, whichever occurs first. <br>Compliance with protocol will be assessed through the prospective institutional drug charts, and the prospective study case report form<br>",Resuscitation in Paediatric Sepsis Using Early Inotropes (RESPOND-ED),ANZCTR,07/06/2019,21/07/2019,FALSE,Interventional,Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy;,Phase 2,80,University of Queensland,Australia,NA,NULL,07/06/2019,21/07/2019,ACTRN1,25-Nov-19,University of Queensland: 2019000089,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Recruiting,NULL,Emergency Medicine Foundation;Gold Coast Hospital Foundation,28 Days,17 Years,Both males and females,"Inclusion criteria: Reword to:<br>Children age =>28days and <18 years where the decision is made by the treating physician to launch the institutional paediatric sepsis bundle treating for sepsis or septic shock. To be eligible, the child must have received at least 20ml/kg of intravenous fluid bolus(es) in the past four hours with the clinician deciding to continue treating for signs of shock.","Exclusion criteria: - Preterm babies born <34 weeks gestation that have a corrected age of <28 days<br>- Children who received =>40ml/kg of fluid during the 4 hours pre enrolment<br>- Children on Inotrope infusion<br>- Lack of access (intraosseus, central venous, peripheral) to administer fluids and/or inotropes after 60minutes of enrolment. <br>- Known cardiomyopathy or chronic cardiac failure<br>- Chronic hypertension due to cardiovascular or renal disease, requiring regular antihypertensive treatment. <br>- Known chronic renal failure<br>- Known chronic hepatic failure <br>- Palliative care patient/patient with limitation of treatment (not for inotropes, CPR, ECLS, intubation and ventilation) <br>- Cardiopulmonary arrest in the past two hours requiring CPR >2 min, or death is deemed to be imminent or inevitable during this admission. <br>- Major bleeding with haemorrhagic shock<br>- Sepsis is not likely to be the cause of shock<br>- Enrolment in RESPOND study <6 months ago (except for RESPOND ED randomization prior to RESPOND PICU within the same sepsis episode)","The main feasibility outcome is compliance with study protocol during the pilot. <br><br>We will assess the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form to assess compliance with the study protocol.[28 days after randomisation];The primary outcome is defined as survival free of organ dysfunction, censored at 28 days.<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form to assess organ dysfunction as defined by established organ dysfunction scoring using laboratory and clinical variables. Organ dysfunction will be defined as per the 2005 International Pediatric Sepsis Consensus Definition Conference criteria.[28 days after randomisation]","<br>PICU free survival at 7 and 28 days.<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation]; Survival free of vasopressor support at 7 and 28 days<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation];Survival free of multiorgan dysfunction at 7 and 28 days<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomization];28-day mortality<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomization];Hospital length of stay<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation];Quality of life  6 months post enrolment<br><br>Parents will be sent questionnaires by the study team. The questionnaires will be built using validated tools (Pediatric Quality of Life).[<br>6 months from randomisation];<br>Time to normalisation of lactate<br><br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation ];Time to reversal of shock<br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation ];Time to reversal of tachycardia<br>We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation ];Functional Status 6 months post enrolment.  Parents will be sent questionnaires by the study team. The questionnaires will be built using validated tools (Functional Status Score and age specific assessment). [6 months post randomisation];PICU length of stay. We will access the prospective hospital charts (including electronic health records and paper-based charts) and the study case report form[28 days from randomisation];Economic evaluation.<br>Evaluation will be undertaken from the health system perspective to compare the cost of providing the study interventions to that of usual care. <br>Resources to be measured and costed will include the number of length of stay (in PICU and/or non-intensive stay), and the length of hospital treatment. [For the duration of hospitalisation]",NA,NULL,Actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,No,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Children's Health Queensland Hospital and Health Human Research Ethics Committee.,NA,NA
ACTRN12617001086358,http://www.anzctr.org.au/ACTRN12617001086358.aspx,A prospective pilot study investigating the impact of obesity on seroprotection after influenza vaccination in children aged 11-17 years.,Obesity in children and adolescents;Response to influenza vaccination,"This is a pilot case control study to study the effect, if any, of obesity, on the immune response to the annual licensed quadrivalent influenza vaccination in Australian children aged 11-17 years.<br>Cases -  25 obese children (BMI >=95th percentile for age and gender) aged 11-17 years.<br>Controls - 25 non-obese children (BMI 5th - <95th percentile for age and gender) aged 11-17 years.<br>The dose of the influenza vaccine is 0.5 ml administered as a single dose IM injection. All vaccines will be administered by a qualified and experienced practitioners (medical officer or registered nurse) within the unit, according to current vaccination guidelines. <br>All participants will have bloods samples collected by the recruiting medical officer before vaccination and at the follow-up visits at 1 and 6 months after vaccination.",A study on the influence of obesity on the protection after influenza vaccination in children aged 11-17 years.,ANZCTR,26/07/2017,02/04/2018,FALSE,Interventional,NULL,Phase 4,50,Women's and Children's Hospital,Australia,NA,NULL,26/07/2017,02/04/2018,ACTRN1,26-Feb-18,None,NULL,Mrs Michelle Clarke,"Women''s and Children''s Health Network,Department of Paediatrics,Level 2, Clarence Rieger Building72 King William Road,North Adelaide,SA 5006, Australia",michelle.clarke@adelaide.edu.au,+61 8 81618115,NULL,NULL,Mrs Michelle Clarke,"Women''s and Children''s Health Network,Department of Paediatrics,Level 2, Clarence Rieger Building72 King William Road,North Adelaide,SA 5006, Australia",michelle.clarke@adelaide.edu.au,+61 8 81618115,NULL,Not yet recruiting,NA,"Women's and Children's Hospital Foundation, MS McLeod Research Fund",11 Years,17 Years,Both males and females,"Inclusion criteria: All participants must satisfy ALL the following criteria at study entry:<br>1. Participants are healthy children aged between 11-17 years at the time of enrolment. <br>2. Participants who, in the opinion of the study staff, can and will comply with the requirements of the protocol (eg return for follow-up visits, blood collection). <br>3. Participants who can provide assent and have a parent willing to provide consent. <br><br>Additional criteria specific to cases and controls include:<br>Cases -  Obese children (BMI >=95th percentile for age and gender) aged 11-17 years. Total number to be enrolled is 25 cases. <br>Controls - Non-obese children (BMI 5th - <95th percentile for age and gender) aged 11-17 years. Total number to be enrolled is 25 controls. <br><br><br>","Exclusion criteria: Presence of any of the following criteria will exclude the subject from receipt of influenza vaccination as part of the study:<br>1. History of serious medical conditions (eg cardiac, respiratory, renal, hepatic disorders, diabetes mellitus requiring treatment with insulin).<br>2. Any syndromal and/or endocrinological causes for obesity.<br>3. History of seasonal influenza vaccination within the last six months prior to enrolment. <br>4. History of any immunosuppressive condition (eg HIV infection) or on immunosuppressing medication.<br>5. Any contraindication to influenza immunisation according to the Australian Immunisation Handbook.<br>6. Anaphylaxis following a previous dose of any influenza vaccine<br>7. Anaphylaxis following any vaccine component. <br>8. History of egg allergy. <br>9. History of Guillain Barre syndrome.<br>10. Bleeding diathesis or condition associated with prolonged bleeding that may contraindicate intramuscular injection or blood draw.<br>11. Any major illness that, in the investigator’s judgment, will substantially increase the risk associated with the subject’s participation in the study, or interfere with the evaluation of the study objectives.",The count and proportion in the case and control groups with seroprotective Haemagglutination Inhibition Assay (HIA)  titres (>=40) at 1 and 6 months post vaccination.;Proportion in the case and control groups who achieve a four-fold rise in Haemagglutination Inhibition Assay (HIA) titres after influenza vaccination.<br>,Mean geometric increase in Haemagglutination Inhibition Assay (HIA) titres in the case and control groups.;Geometric mean Haemagglutination Inhibition Assay titres in the case and control groups.<br>,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
ACTRN12618001090202,https://anzctr.org.au/ACTRN12618001090202.aspx,Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells,Acute Leukaemia;Cytomegalovirus;Epstein-Barr Virus;Varicella Zoster Virus;BK Virus;Influenza virus;Aspergillus; <br>Acute Leukaemia <br>Cytomegalovirus <br>Epstein-Barr Virus <br>Varicella Zoster Virus <br>BK Virus <br>Influenza virus <br>Aspergillus;Cancer - Leukaemia - Acute leukaemia;Infection - Studies of infection and infectious agents,"The study treatment will consist of an infusion of CD34 selected donor stem cells on day 0 of the fully-matched related allogeneic bone marrow transplant. A minimum of 21 days following the transplant, one intravenous infusion of 2 x 107/m2 of pathogen specific T cells will be given over 1 minute to all patients following myeloid engraftment. In addition, up to a total of four intravenous infusions of 2x107/m2 either WT1 specific T cells for patients with AML or CAR19 T cells for patients with ALL will be given to the patient no less than 28 days apart unless contraindicated. Such contraindications are fever, hypotension, tachycardia, hypoxemia, graft versus host disease greater than or equal to grade II in the week prior to infusion, abnormal liver function >3x upper limit normal. The pathogen specific and malignancy specific cells can be given and monitored as an outpatient (eg: the Cancer Day Suite) by study investigators or other staff as delegated by the investigator's (eg: BMT Fellow, Clinical Nurse Specialists, Nurse Practitioners). The patients will be followed up at 3 months post transplant and 6 months post transplant.  ALL patients will be followed up at additional time points of 12months and yearly for 15 years for the detection of long term adverse event outcomes.  The bone marrow transplant will occur and delivered as an inpatient as per standard of care.",Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells,ANZCTR,29/06/2018,12/10/2018,FALSE,Interventional,Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy;,Phase 1,20,"Western Sydney Local Health District, Westmead Hospital",Australia,NA,NULL,29/06/2018,12/10/2018,ACTRN1,15-Jul-19,None,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Recruiting,NULL,Cancer Council New South Wales,1 Years,69 Years,Both males and females,"Inclusion criteria: 1. Patients aged 1-69 years undergoing first myeloablative or non-myeloablative allogeneic transplantation from an HLA identical family or 10 out of 10 HLA matched (A, B, C, DRB1, DQB1) unrelated donor<br>2. Transplant performed for acute myeloid leukaemia or acute lymphoblastic leukemia in morphological first complete remission<br>3. For AML, where diagnosis or relapse samples are available, leukaemia blasts express the WT1 tumour antigen as determined by the European LeukaemiaNet standardised assay described in Candoni (et al.) 2009. WT1 overexpression will be defined by greater than 250 copies/104ABL copies in bone marrow samples or greater than 50 copies/104ABL copies in peripheral blood. For ALL, leukemia blasts express the CD19 antigen<br>4. Recipients of peripheral blood or bone marrow stem cells<br>5. Adequate hepatic and renal function (< 3 x upper limit of normal for AST, ALT, < 2 x upper limit of normal for total bilirubin, serum creatinine)<br>6. Estimated life expectancy of at least 6 months<br>7. Patient (or legal representative) has given informed consent<br>","Exclusion criteria: 1. Use of anti-lymphocyte globulin (ALG, ATG, Campath or other broad spectrum anti-lymphocyte antibody) given in the 28 days immediately prior to malignancy or infection specific T cell infusion (MITI) or planned within 28 days after infusion<br>2. Grade II or greater graft versus host disease within 1 week prior to infusion<br>3. Prednisone or methylprednisone at a dose of > 1 mg/kg (or equivalent) administered within 2 days prior to T cell infusion<br>4. Intercurrent medical, surgical or psychiatric condition which may interfere with the conduct or safety of the trial<br>5. Patients taking anti-viral or anti-fungal medication for CMV or proven or probable Aspergillus infection at the time of commencement of transplant conditioning<br>6. Previous unmanipulated donor lymphocyte infusion after transplant<br>7. Prior history of seizures if undergoing transplant for ALL<br>8. Privately insured in or outpatients (see Indemnity Issues, Section 11.4<br>","Event-free survival.<br>Events captured will be graft failure, disease relapse or death from any cause.  This information will be collected from hospital records. [Within 6 months post-transplant]","If receiving CAR-19 Tcells:  functional capacity of persisting cells<br>Information will be collected from hospital records including laboratory results.[From first CAR19 infusion till end of 15 years];If receiving CAR-19 Tcells:, persistence of cells<br>Information will be collected from hospital records including laboratory results.[From first CAR19 infusion till end of 15 years];Secondary graft failure<br>Information will be collected from hospital records.[From transplant to 12 months post transplant];T cell immune reconstitution <br>T cell immune reconstitution is measured by CD3, CD4, CD8, CD16 and CD20 count and ELIspot in response to viral, fungal and leukaemia antigens on peripheral blood.<br>[From bone marrow transplant till 12 months post transplant];If receiving CAR-19 Tcells: incidence of tumor lysis syndrome<br>Information will be collected from hospital records including laboratory results.[From first CAR19 infusion till end of 15 years];Incidence of EBV related post-transplant lymphoproliferative disorder.<br>Information will be collected from hospital records including laboratory results.[From transplant till end of follow up (12 months for an AML patient  or 15 years if an ALL patient)];Incidence of infection <br>Information will be collected from hospital records and laboratory results.[From transplant till end of follow up (12 months for an AML patient  or 15 years if an ALL patient)];Overall survival<br>Information will be collected from hospital records.[At 6 months post-transplant];Primary graft failure<br>Information will be collected from hospital records.[From transplant to 12 months post transplant];Chronic GVHD incidence and severity (composite outcomes)<br>Chronic GVHD will be graded using the National Institute of Health Consensus criteria. Information will be collected from hospital records.[Within 6 months post-transplant];Graft versus host disease (GVHD) incidence and severity (composite secondary outcome)<br>Information will be collected from hospital records.[Within 6 months post-transplant];Relapse incidence<br>Recurrence of disease (AML or ALL) will be captured as a secondary outcome. Information will be collected from hospital records.[Within 6 months post-transplant];Non-relapse mortality<br>If the patient dies from any other cause than relapse of their disease, being acute myeloid leukaemia (AML) acute lymphoblastic leukaemia (ALL), this will be captured as a secondary outcome. This information will be collected from hospital records. [Within 6 months post transplant]",NA,NULL,Actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,No,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Western Sydney Local Health District Human Research Ethics Committee,NA,NA
ChiCTR-IPQ-16008781,http://www.chictr.org.cn/showproj.aspx?proj=14665,Effects of glucocorticoid on Changes of pulmonary function and serum cortisol during rheumatic valve replacemental perioperation,Rheumatic heart valve disease; cardiac insufficiency; respiratory insufficiency,Group A:Dexamethasone;Group B:Placebo ;,Effects of glucocorticoid on changes of pulmonary function and serum cortisol during rheumatic valve replacemental perioperation,ChiCTR,04/07/2016,01/10/2016,FALSE,Interventional study,Quasi-randomized controlled,Post-market,Group A:90;Group B:90;,Department of Cardiothoracic Surgery of the First Affiliated Hospital of Chongqing Medical University,China,NA,NULL,04/07/2016,01/10/2016,ChiCTR,18-Apr-17,NULL,Jiang Ying-jiu,NA,"1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China",jiangyinjiu@aliyun.com,+86 13101348339,Department of Cardiothoracic Surgery of the First Affiliated Hospital of Chongqing Medical University,Wang Qiang,NA,"1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China",965839288@qq.com,+86 18983149852,Department of Cardiothoracic Surgery of the First Affiliated Hospital of Chongqing Medical University,Pending,NULL,Science and Technique Plan Projects of Chongqing,30,65,Both,"Inclusion criteria: All patients were diagnosed as rheumatic heart disease, and there were indications for bypass valve replacement. All patients voluntarily joined in the study.","Exclusion criteria: Exclusion criteria: Patients with hypertension, peptic ulcer disease, mental disease, glaucoma, hypercortisolism, diabetes, hyperthyroidism and hyperthyroidism or thyroid dysfunctionendocrine or other endocrine disease. and the patients used glucocorticoids before operation in one month.",Peak expiratory flow;plasma cortisol concentration;24-hour urinary cortisol;,NULL,NA,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
ChiCTR1900023507,http://www.chictr.org.cn/showproj.aspx?proj=31221,The study of ideal anesthetic regimen for drug-induced sleep endoscopy based on EEG monitoring in children with obstructive sleep apnea,Obstructive Sleep Apnea,Experimental groups:Different anesthetic drugs; Intravenous ketamine was administered as soon as dexmedetomidine induction;,The study of ideal anesthetic regimen for drug-induced sleep endoscopy based on EEG monitoring in children with obstructive sleep apnea,ChiCTR,31/05/2019,01/08/2018,FALSE,Interventional study,Parallel,0,Experimental groups:100;,"Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai",China,NA,1,31/05/2019,01/08/2018,ChiCTR,03-Jun-19,NULL,Zhang Ruidong,NA,"1678 Dongfang Road, Pudong District, Shanghai, China",doctorruidong@163.com,+86 18221150942,NA,Zhang Ruidong,NA,"1678 Dongfang Road, Pudong District, Shanghai, China",doctorruidong@163.com,+86 18221150942,"Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai",Recruiting,NULL,Shanghai Science and technology commission,2,12,Both,"Inclusion criteria: 1. Aged from 2-12 years;<br>2. ASA I or II;<br>3. Symptoms of OSA were inconsistent with the results of existing examinations (such as nasopharyngeal lateral X-ray, polysomnography, etc.),and children with residual OSA who had a history of adenoidectomy and/or tonsillectomy<br>4. Signing informed consent.",Exclusion criteria: The children with a recent history of upper respiratory infections and allergies to ketamine and other drugs were excluded.,heart rate;Systolic blood pressure;Diastolic blood pressure;Pulse oxygen saturation;movement;,NULL,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jul 28 2018 12:00AM,NA,Huang HuiMin,+86 021-38626161-83015,NA
ChiCTR1800014694,http://www.chictr.org.cn/showproj.aspx?proj=25120,Clinical observation on efficacy of ulinastatin and antibiotic treatment for severe pneumonia in ICU,severe pneumonia,"control group:conventional treatment based on the use of antimicrobial therapy;Combination group:On the basis of the treatment of the control group, the combination of ulinastatin;",Clinical observation on efficacy of ulinastatin and antibiotic treatment for severe pneumonia in ICU,ChiCTR,30/01/2018,01/10/2015,FALSE,Interventional study,Randomized parallel controlled trial,Other,control group:30;Combination group:30;,Wuxi Huishan District People's Hospital,China,NA,1,30/01/2018,01/10/2015,ChiCTR,05-Feb-18,NULL,Wang Kaicheng,NA,"2 Zhanqian Road North, Luoshe Town, Huishan District, Wuxi, Jiangsu, China",wxhsqrmyy@163.com,+86 0510-83830976,Wuxi Huishan District People's Hospital,Wang Kaicheng,NA,"2 Zhanqian Road North, Luoshe Town, Huishan District, Wuxi, Jiangsu, China",wxhsqrmyy@163.com,+86 0510-83830976,Wuxi Huishan District People's Hospital,Completed,NULL,Self-raised,NA,NA,Both,Inclusion criteria: All patients should meet the diagnostic criteria for severe pneumonia developed by the 2007 Infectious Diseases Society / American Thoracic Society. All patients should meet the criteria of ICU admitted to severe pneumonia. All subjects and their families have signed informed consent and obtained the approval of Medical Ethics Committee of Huishan District People's Hospital of Wuxi.,"Exclusion criteria: Malignant tumor, connective tissue disease, tuberculosis, pulmonary embolism, hyperthyroidism, immune dysfunction, severe heart, liver, kidney dysfunction, allergic to the study drug.",WBC;PCT;CRP;,NULL,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan  1 1990 12:00AM,NA,NA,+86 0510-83830976,NA
ChiCTR1900024894,http://www.chictr.org.cn/showproj.aspx?proj=41373,Clinical study for moderate sedation with low dose propofol combined with sufentanil at BIS's direction in gastroscopy of patients with snoring,Sleep apnea,S group:Moderate sedation with low dose propofol combined with sufentanil;Control group:Slow intravenous injection of propofol 1.5-2.5 mg/kg until the patient holds a 20 ml syringe and drops off;,Clinical study for moderate sedation with low dose propofol combined with sufentanil at BIS's direction in gastroscopy of patients with snoring,ChiCTR,02/08/2019,03/08/2019,FALSE,Interventional study,Parallel,0,S group:68;Control group:68;,"The Second Affiliated Hospital, Jiaxing College",China,NA,NULL,02/08/2019,03/08/2019,ChiCTR,27-Aug-19,NULL,Kang Shuai,NA,"1518 Huancheng Road North, Jiaxing, Zhejiang, China",15024340122@163.com,+86 15024340122,"The Second Affiliated Hospital, Jiaxing College",Kang Shuai,NA,"1518 Huancheng Road North, Jiaxing, Zhejiang, China",15024340122@163.com,+86 15024340122,"The Second Affiliated Hospital, Jiaxing College",Pending,NULL,self-raised,NA,NA,Both,Inclusion criteria: 1. Aged 18-70 years;<br>2. Grade 1-3 snoring (grade 0: never snore; Level 1: breathing sound is heavier than normal people; Level 2: snoring is louder than ordinary people; Level 3: unable to sleep; Level 4: intermittent sleep breathing).,"Exclusion criteria: 1. Patients with delayed waking at night or severe snoring who had been diagnosed with obstructive sleep apnea syndrome (OSAS); <br>2. Severe cardiovascular and cerebrovascular diseases, heart block disease, liver and kidney dysfunction and neuropsychiatric diseases; <br>3. Pregnancy, lactation or preparation for a recent pregnancy; <br>4. Allergic to propofol or opioids; <br>5. Contraindications to painless gastroscopy or surgery may affect patient safety during the study; <br>With serious cardiovascular and cerebrovascular diseases, heart block diseases, liver and kidney dysfunction or neuropsychiatric diseases; <br>With pain - free gastroscopy anesthesia or surgical contraindications.",Spo2;body movement;HR;MAP;,NULL,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Apr  9 2019 12:00AM,NA,Zhou Qinghe,NA,NA
ChiCTR-IIR-16008507,http://www.chictr.org.cn/showproj.aspx?proj=14377,"A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old",Influenza,trial group:2 dose  of trial vaccine (trivalent) for 21 days interval (+/- 7days);control group A:2 dose of vaccine A (tetravalent) for 21 days interval (+/- 7days);Control group B:2 dose of vaccine B (trivalent) for 21 days interval (+/- 7days);,"A Randomized, Blind, active-controlled trials to evaluate the safety and immunogenicity of Quadrivalent influenza vaccine (Split Virion) for Human use in the healthy subjects among 6-months to 3 years old",ChiCTR,20/05/2016,20/05/2016,FALSE,Interventional study,Randomized parallel controlled trial,III (Phase III study),trial group:690;control group A:690;Control group B:690;,Hubei provincial center for disease control and prevention,China,NA,NULL,20/05/2016,20/05/2016,ChiCTR,18-Apr-17,NULL,Beifang Yang,NA,"6 North Zhuodaoquan Road, Hongshan District, Wuhan, Hubei, China",308041407@qq.com,+86 15927292485,Hubei provincial center for disease control and prevention,Xiaoai Qian,NA,"6 North Zhuodaoquan Road, Hongshan District, Wuhan, Hubei, China",840273693@qq.com,+86 15207183058,Hubei provincial center for disease control and prevention,Recruiting,NULL,Changchun Changsheng Biological Technology Limited company self-financing,0,3,Both,"Inclusion criteria: 1. Healthy permanent residents aged 6 months to 3 years old;<br>2. Subjects'guardians or the subjects who are old than 10 years old agree to participate the trial, and signed the informed consent form;<br>3. The subjects and their guardians can comply with the requirements of clinical trial scheme;<br>4. The axillary temperature is not higher than 37.0 degree.","Exclusion criteria: 1. Patients with influenza or having been infected with influenza within 3 months;<br>2. Subjects have any allergy history to vaccine or any ingredients of the experimental vaccine,such as eggs ,ovalbumin, etc;<br>3. There are serious side effects, such as allergies, hives, eczema, dyspnea, angioedema or abdominal pain;<br>4. Subjects with symptoms of acute infection within a week;<br>5. Subjects have a autoimmune disease or being immune deficiencies or have received immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids within the past six months;<br>6. subjects with congenital malformations, developmental disorders or severe chronic (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders);<br>7. Subjects with asthma, being the instability phase and in need of emergency treatment ,hospitalization, intubation, oral or intravenous corticosteroids;<br>8. Subjects with a medical diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or coagulopathy;<br>9. Subjects with convulsions, epilepsy, encephalopathy, mental illness or a history of family medical history;<br>10. Subjects who are asplenia or functional asplenia, and any resulting asplenia or splenectomy;<br>11. Subjects with Guillain-Barre syndrome and other serious neurological and other diseases;<br>12. Subjects who received blood products or seasonal flu vaccine within a month;<br>13. Subjects who have attended another clinical trial within a month;<br>14. Subjects who received attenuated live vaccine within 14 days, any subunit or inactivated vaccine within 7 days;<br>15. Subjects who received allergy treatment within 14 days;<br>16. Subjects who are under therapeutic of anti-TB;<br>17. Subjects with a fever (axillary temperature> 37.0 degree);<br>18. Not suitable for clinical trials according the researchersjudgement.",Adverse reaction rate;,NULL,NA,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
ChiCTR1900028497,http://www.chictr.org.cn/showproj.aspx?proj=42626,"A randomized, double-blind, placebo controlled trial for Chai-shi-Tui-Re (CHASE) granules for influenza A",Influenza A,Experimental group:Oseltamivir phosphate capsules +  Chai-shi-Tui-Re granules;Control Group:Oseltamivir phosphate capsules + Placebo of Chai-shi-Tui-Re granules;,Effectiveness of Chai-shi-Tui-Re (CHASE)  granules for influenza A: a randomized controlled trial,ChiCTR,23/12/2019,23/12/2019,FALSE,Interventional study,Parallel,4,Experimental group:85;Control Group:85;,Guangdong Provincial Hospital of  Chinese Medicine,China,NA,NULL,23/12/2019,23/12/2019,ChiCTR,06-Jan-20,ChiMCTR1900002866,Lin Lin,NA,"111 Dade Road, Yuexiu District, Guangzhou, China",drlinlin620@163.com,+86 13903002015,Guangdong Provincial Hospital of  Chinese Medicine,Chen Yuanbin,NA,"111 Dade Road, Yuexiu District, Guangzhou, China",chenyuanbin110@163.com,+86 15920174645,Guangdong Provincial Hospital of  Chinese Medicine,Pending,NULL,"Sinopharm Group Guangdong Medi-World Pharmaceutical Co.,Ltd.",18,65,Both,Inclusion criteria: 1. Defined according to influenza A diagnostic criteria;<br>2. TCM syndrome differentiation is wind-heat invading defensive qi or heat-toxicity attacking lung;<br>3. Onset within 48 hours;<br>4. Temperature equal or more then 38.0? within 24 hours;<br>5. Complete blood count shows normal or lower white blood cell count;<br>6. Aged 18 to 65 years;<br>7. Patients signed informed consent.,"Exclusion criteria: 1. Chest imaging shows that there is a tracheobronchitis, lung infection or active lung tuberculosis; <br>2. Those with a history of lung cancer, pneumoconiosis, lung abscess, chronic obstructive pulmonary disease and pulmonary heart diseases; <br>3. Patients with severe primary diseases such as cardiovascular, renal, liver, hematopoiesis, brain, digestive system and psychiatric and malignant tumors; <br>4. Those who injected influenza vaccination in the past 12 months; <br>5. Those who have used antivirals, antipyretics, analgesics or traditional Chinese medicine in the past 24 hours; <br>6. Those who are using systemic glucocorticoids or immunosuppressants; <br>7. Pregnancy or breast-feeding women;<br>8. Allergic constitution or those who are allergic to multiple drugs.",Defervescence time;,Defervescence rate;symptom score;Incidence of flu complications;Negative rate of viral nucleic acid;Utilization rate of analgesic-antipyretic;,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Aug  2 2019 12:00AM,NA,Li Xiaoyan,NA,NA
NCT04160260,https://clinicaltrials.gov/show/NCT04160260,A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP),Community-acquired Pneumonia,Drug: Omadacycline,Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia,CT.gov,08/11/2019,28/11/2019,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,18,Paratek Pharmaceuticals Inc,United States,NA,NULL,08/11/2019,"November 28, 2019",NCT041,22-Jun-20,PTK0796-CABPPO-19109,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Male or female subjects, age 18 or older who have signed the informed consent form<br><br>          -  Must have a qualifying community-acquired bacterial pneumonia<br><br>          -  Has disease severity such that oral antibiotics therapy is appropriate<br><br>          -  Subjects must not be pregnant at the time of enrollment<br><br>          -  Must agree to a reliable method of birth control during the study and for 30 days<br>             following the last dose of study drug<br><br>          -  Must be able to swallow tablets and comply with all of the requirements of the study<br><br>        Exclusion Criteria:<br><br>          -  Has received more than 24 hours of a potentially effective systemic antibacterial<br>             therapy within the 72 hours prior to the first dose of test article<br><br>          -  Known or suspected infection caused by a pathogen that may be resistant to test<br>             article<br><br>          -  Subjects who reside in a long-term care or nursing home<br><br>          -  Evidence of empyema<br><br>          -  Evidence of significant immunological disease<br><br>          -  Evidence of liver impairment or disease<br><br>          -  Evidence of unstable cardiac disease<br><br>          -  Severe renal disease or requirement for dialysis<br><br>          -  Evidence of septic shock<br><br>          -  Has a history of hypersensitivity or allergic reaction to any tetracycline<br><br>          -  Has received an investigational drug within the past 30 days<br><br>          -  Subjects who are pregnant or nursing<br><br>          -  Unable or unwilling to comply with the protocol requirements<br>",NULL,Investigator's assessment of clinical response at End of Treatment,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03441373,https://clinicaltrials.gov/show/NCT03441373,"Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)",Influenza;Acute Respiratory Infection,Drug: XC8 20 mg;Drug: XC8 100 mg;Drug: XC8 200 mg;Drug: Placebo,XC8 in the Treatment of Patients With Acute Respiratory Viral Infection,CT.gov,14/02/2018,03/02/2016,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 2/Phase 3,320,PHARMENTERPRISES LLC,Russian Federation,NA,1,14/02/2018,"February 3, 2016",NCT034,05-Mar-18,FLU-XC8-01,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,45 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Men and women aged 18 to 45 years (inclusively).<br><br>          2. Clinically diagnosed influenza or other acute or moderate ARVI based on the patient's<br>             body temperature =37.5º?, nasal congestion or profuse rhinorrhea and at least 1 of the<br>             following symptoms of intoxication: headache, general malaise, myalgia, pain in the<br>             eyeballs.<br><br>          3. Uncomplicated course of ARVI or influenza.<br><br>          4. The onset of symptoms no more than 36h prior to the inclusion into the study.<br><br>          5. Women of reproductive age (who are not in menopause and who have not undergone<br>             surgical sterilization) and men who have sexual activity should use a reliable method<br>             of contraception (acceptable methods of contraception in this study are: intrauterine<br>             devices, oral contraceptives, contraceptive patch, long-acting injectable<br>             contraceptives, a double barrier method (condom and diaphragm with spermicide)<br>             throughout the study period.<br><br>          6. Compliance with the treatment regimen, visits and laboratory examinations provided by<br>             the protocol.<br><br>          7. Signed Informant Consent Form.<br><br>        Exclusion Criteria:<br><br>        The patient will be deemed ineligible for the study meeting any of the following criteria:<br><br>          1. Complicated course of influenza or ARVI (including the presence / development of<br>             bacterial infection).<br><br>          2. Antiviral medications in 7 days prior to screening (antiviral agents, interferons and<br>             interferon inducers, drugs that have immunomodulating action) or anti-infective agents<br>             of systemic or local action.<br><br>          3. Severe infection with signs of cardiovascular insufficiency development and other<br>             manifestations of infectious-toxic shock, as well as with the presence of<br>             neuroinfection syndrome (encephalic and meningoencephalic reactions,<br>             polyradiculoneuritis, neuritis).<br><br>          4. Signs of the development of viral pneumonia (the presence of two or more of the<br>             following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of<br>             percussion sound with a symmetrical evaluation of the upper and lower sections of the<br>             lungs).<br><br>          5. Infectious diseases during the last week before including into the study.<br><br>          6. History of bronchial asthma.<br><br>          7. History of increased convulsive activity.<br><br>          8. Severe, decompensated or unstable somatic diseases (any diseases or conditions that<br>             are life-threatening or may worsen the patient's prognosis, and make him/her<br>             ineligible for the clinical study).<br><br>          9. History of oncological diseases, HIV, tuberculosis.<br><br>         10. Hypersensitivity to excipients of the XC8.<br><br>         11. Diabetes mellitus, lactose intolerance, lactase deficiency.<br><br>         12. Drug or alcohol abuse.<br><br>         13. Participation in any other clinical trial in the last 90 days.<br><br>         14. Pregnancy or lactation.<br><br>         15. Military or prison populations.<br><br>         16. Impossibility or inability to comply with the study procedures.<br><br>         17. A member of the investigator's family or other person interested in the results of the<br>             study<br><br>         18. Abnormal laboratory results, which, according to the study doctor, interfere with the<br>             patient's inclusion in the study.<br><br>         19. History of renal insufficiency.<br><br>         20. Only for patients participating in Phase III study: Patient involvement in the first<br>             part of the study (Phase II) of FLU-XC8-01.<br>",NULL,Time to sustained improvement in clinical symptoms,Body temperature below 37°C without further elevation,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04094857,https://clinicaltrials.gov/show/NCT04094857,A Phase 1 First-In-Human Study of HBN-1 in Patients Resuscitated Following Out-of-Hospital Cardiac Arrest,Cardiac Arrest,Drug: HBN-1,Phase 1 Study of HBN-1,CT.gov,17/09/2019,30/10/2019,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1,18,"Hibernaid, Inc",United States,NA,NULL,17/09/2019,"October 30, 2019",NCT040,22-Oct-19,HBN-1-001-US,; ;,"Laurence Katz, MD;David B Seder, MD;Eric Berrios",NULL,;;eric.berrios@pharpoint.com,;;919-433-2159,"Hibernaid, Inc;Maine Medical Center;",; ;,"Laurence Katz, MD;David B Seder, MD;Eric Berrios",NULL,;;eric.berrios@pharpoint.com,;;919-433-2159,"Hibernaid, Inc;Maine Medical Center;",Not yet recruiting,NULL,Please refer to primary and secondary sponsors,40 Years,80 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Age 40 to 80 years, inclusive<br><br>          2. Documented diagnosis of OHCA with ventricular tachycardia/fibrillation, asystole or<br>             pulseless electrical activity<br><br>          3. Return of spontaneous circulation within 50 minutes of the event<br><br>          4. FOUR Motor Score <4<br><br>          5. Maximum estimated weight not to exceed 100 kg<br><br>        Exclusion Criteria:<br><br>          1. Return of spontaneous circulation >8 hours<br><br>          2. Known history of prior cardiac arrest, alcohol, or substance abuse or dependence<br><br>          3. Presumed etiology of cardiac arrest is trauma, hemorrhage, or sepsis<br><br>          4. Comfort measures only or anticipated withdrawal of life-support within 24 hours<br><br>          5. Is within a protected population group (eg, pregnant or breastfeeding or incarcerated<br>             persons)<br><br>          6. Has history or evidence of significant hepatic dysfunction (Sequential Organ Failure<br>             Assessment Hepatic score >2)<br><br>          7. Any other condition, that in the opinion of the investigator, would preclude the<br>             subject from being a suitable candidate, e.g. end-stage chronic illness with no<br>             reasonable expectation of survival to hospital discharge<br><br>          8. Is able to obey to verbal commands<br><br>          9. Is receiving IV vasopressin or lidocaine hydrochloride<br>",NULL,Characterize the safety and recommended Phase 2 loading dose infusion rate of HBN-1,Determine the incidence of the need for implementation of treatment to offset shivering,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02708173,https://clinicaltrials.gov/show/NCT02708173,NA,Quadrivalent Influenza Virus Vaccine,Biological: One dose of Quadrivalent Influenza Virus Vaccine;Biological: One dose of Quadrivalent Influenza Virus Vaccine,Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older,CT.gov,10/03/2016,01/03/2016,TRUE,Interventional,"Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention",Phase 1,40,Beijing Chaoyang District Centre for Disease Control and Prevention,China,NA,NULL,10/03/2016,Mar-16,NCT027,22-Aug-16,cycdc2015-5,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,3 Years,60 Years,Both,"<br>        Inclusion Criteria:<br><br>          -  healthy subjects more than 3 years old, and the subjects can be informed consent, and<br>             sign the informed consent.<br><br>          -  the subjects and his guardians can obey the demands of the scheme .<br><br>          -  Axillary temperature less than 37?<br><br>        Exclusion Criteria:<br><br>          -  The people who has a vaccine allergies, or who allergic to any kind of composition in<br>             experimental vaccine, such as eggs,ovalbumin etc.<br><br>          -  The people who has serious side effects to vaccine, such as allergy,urticaria, skin<br>             eczema, dyspnea, angioneurotic edema or abdominal pain.<br><br>          -  the subject who has symptoms of acute infection within a week.<br><br>          -  Autoimmune diseases or Immune function defect, people has immunosuppressive therapy,<br>             cytotoxic treatment or inhaled corticosteroids in the past 6 months.<br><br>          -  People has congenital malformations, developmental disorder or serious chronic<br>             diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system<br>             disease)<br><br>          -  People has asthma Unstable that need emergency treatment, hospitalization,<br>             intubation, oral or intravenous corticosteroid in the past 2 years.<br><br>          -  Diagnosed abnormal coagulation(Lack of clotting factors,Clotting disorders,Platelet<br>             abnormality) or significant bruising or coagulopathy<br><br>          -  people has history or family history of convulsions, seizures, encephalopathy and<br>             psychiatric.<br><br>          -  alienia, functional asplenia, and alienia or splenectomy in any situation.<br><br>          -  Serious neurological disorders such as Green Barry syndrome.<br><br>          -  people who has received blood products or immunoglobulin products in the past one<br>             months.<br><br>          -  people who has received other study drug in the past one month.<br><br>          -  people who received live attenuated vaccine, subunit vaccine or inactivated vaccine.<br><br>          -  people who has received allergy treatment in in the past 14 days.<br><br>          -  People who is on anti-TB treatment.<br><br>          -  People whose axillary temperature is more than 37? before the vaccination.<br><br>          -  People who is pregnant.<br><br>          -  Any factors unsuitable for clinical trail according to the researchers.<br>",NULL,The rate of adverse reactions of Quadrivalent Influenza Virus Vaccine,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03337373,https://clinicaltrials.gov/show/NCT03337373,The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients,"Critical Illness;Respiratory Distress Syndrome, Adult;Neuromuscular Blockade;Respiratory Failure;Paralysis;ARDS, Human",Drug: cisatracurium,The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium,CT.gov,02/11/2017,15/12/2017,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 4,10,Mahidol University,Thailand,NA,NULL,02/11/2017,"December 15, 2017",NCT033,18-Mar-19,06-60-07,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Inclusion Criteria:<br><br>          -  Age greater than 18 years<br><br>          -  Admission for ICU care<br><br>          -  Require paralysis with cisatracurium as part of their clinical care<br><br>          -  Patients or legal representatives who are able to understand and are willing and able<br>             to give their signed informed consent before any trial-related procedures are<br>             performed<br><br>        Exclusion Criteria:<br><br>          -  Lactating women<br><br>          -  Pregnancy women<br><br>          -  Documented history of hypersensitivity to cisatracurium<br><br>          -  Pre-existing neuromuscular disease<br><br>          -  Patients with burn lesions<br><br>          -  Currently diagnosed of hypothermia condition (tympanic body temperature = 36 °C)<br><br>          -  Patients currently receiving intravenous bolus or push of cisatracurium within 24<br>             hours or receiving intravenous continuous infusion of cisatracurium within 48 hours<br>             prior to enrollment<br><br>          -  Patients who have to receive intravenous continuous infusion of cisatracurium within<br>             30 minutes after given intravenous bolus of 0.2 mg/ kg cisatracurium<br>,NULL,Total plasma concentration-time data;Patient-ventilator asynchrony - time data;The degree of neuromuscular block by train-of-four-watch monitor - time data,Time to maximum concentration;Half-life;Clearance;Elimination rate constant;Time to maximum block;Percentage of maximum block;Time to patient-ventilator synchrony,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03782259,https://clinicaltrials.gov/show/NCT03782259,Effects of SGLT-2 Inhibition With Dapagliflozin on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI With T1- and T2-mapping in Patients With Type-2 Diabetes,Type 2 Diabetes Mellitus;Myocardial Fibrosis;Myocardial Inflammation,Drug: dapagliflozin;Other: Placebo,Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2,CT.gov,24/10/2018,26/02/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 4,60,University of Washington,United States,NA,NULL,24/10/2018,"February 26, 2019",NCT037,11-Mar-19,ESR 17-13124;STUDY00004982,; ;,"Xue-Qiao Zhao, MD;Xue-Qiao Zhao, MD;Xue-Qiao Zhao, MD",NULL,;xueqiao@uw.edu;xueqiao@uw.edu,;206-744-8305;206-744-8305,University of Washington;,; ;,"Xue-Qiao Zhao, MD;Xue-Qiao Zhao, MD;Xue-Qiao Zhao, MD",NULL,;xueqiao@uw.edu;xueqiao@uw.edu,;206-744-8305;206-744-8305,University of Washington;,Recruiting,AstraZeneca,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Men and women at least 18 years of age<br><br>          2. Subjects with type-2 diabetes history >=5 years<br><br>          3. HbA1C 7-10% with glucose control medications including insulin, metformin or<br>             sulfonylurea<br><br>          4. Medically stable<br><br>          5. Willing to participate and sign informed consent.<br><br>        Exclusion Criteria:<br><br>          1. Contraindication to MRI<br><br>          2. Currently or within last three months treatment with a SGLT2 inhibitor<br><br>          3. Currently taking GLP-1 receptor antagonist<br><br>          4. GFR <60 mL/min/1.73 m2<br><br>          5. Unstable or rapidly progressive renal disease<br><br>          6. Hypotension with SBP <100 mmHg<br><br>          7. Hypersensitivity to dapagliflozin or any excipients<br><br>          8. Patients with severe hepatic impairment (Child-Pugh class C)<br><br>          9. Patients with active hepatitis B or C infection<br><br>         10. Any of the following CV/Vascular Diseases within 3 months prior to signing the consent<br>             at enrollment, as assessed by the investigator:<br><br>               1. Myocardial infarction<br><br>               2. Cardiac surgery or revascularization (CABG/PTCA)<br><br>               3. Unstable angina<br><br>               4. HF New York Heart Association (NYHA) Class IV<br><br>               5. Transient ischemic attack (TIA) or significant cerebrovascular disease<br><br>               6. Unstable or previously undiagnosed arrhythmia<br><br>               7. Established PAD<br><br>        (18) Active bladder cancer (19) Recent episode of Diabetic ketoacidosis (DKA), frequent<br>        episodes of DKA (20) High risk of fractures, amputations and fibrosis (21) Women of<br>        child-bearing potential (ie, those who are not chemically or surgically sterilized or who<br>        are not post-menopausal) who have a positive pregnancy test at enrollment or randomization,<br>        OR women who are not willing to use a medically accepted method of contraception that is<br>        considered reliable in the judgment of the investigator, from the time of signing the<br>        informed consent until two weeks after the last dose of IP, OR women who are<br>        breast-feeding.<br>",NULL,Extracellular volume fraction (ECV),T2 relaxation time,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04146623,https://clinicaltrials.gov/show/NCT04146623,"A Randomized Double-Blind, Placebo Controlled, Phase I Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated H1N1 Vaccine in Healthy Individuals",Influenza,Biological: CodaVax-H1N1 influenza vaccine;Biological: Normal Saline Placebo,"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray",CT.gov,28/10/2019,07/05/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Care Provider).",Phase 1,33,"Codagenix, Inc",Australia,NA,NULL,28/10/2019,"May 7, 2019",NCT041,22-Jun-20,CODA01-002,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,18 Years,45 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Adult volunteers, aged 18 to 45 years (at the time of screening) in good general<br>             health in the opinion of the Medical Investigator or delegate, with no significant<br>             medical history and no clinically significant abnormal findings at screening.<br><br>          2. Participants must use highly effective, double contraception from the Screening Visit<br>             and up to the Follow-up Visit (Day 30).<br><br>          3. Must be willing to comply with the following conditions to prevent the spread of<br>             Genetically modified organisms (GMO) according the Office of Gene Technology Regulator<br>             (OGTR) Licence (DIR 144):<br><br>               1. Hygiene measures intended to prevent interpersonal transmission of study drug<br>                  must be implemented, including but not limited to frequent handwashing with soap<br>                  or hand disinfectant, respiratory hygiene and cough etiquette within 7 days<br>                  following vaccination<br><br>               2. Blood, tissue or organs must not be donated within 7 days of vaccination<br><br>               3. Severely immunosuppressed persons who require a protective environment are not to<br>                  be cared for by the participant within 7 days of vaccination<br><br>               4. Contact is not to be made with severely immunosuppressed persons who require a<br>                  protective environment within 7 days of vaccination<br><br>               5. All tissues and materials used to collect respiratory secretions are to be sealed<br>                  in a primary container and placed within a secondary container so that it is not<br>                  accessible to children or animals for 7 days until it is returned to the study<br>                  site for disposal, for 7 days within vaccination<br><br>          4. Contact is not to be made with infants <6 months of age within 7 days of vaccination.<br><br>          5. Adequate venous access in the left or right arms to allow collection of a number of<br>             blood samples.<br><br>          6. Must be sero-susceptible =10 hemagglutination inhibition (HAI) titre to CA/07/2009<br>             Influenza virus (pre-screen).<br><br>          7. Laboratory Testing:<br><br>               1. Full blood examination and biochemistry within the laboratory defined normal<br>                  range unless deemed not clinically significant by the investigator, however a<br>                  small drop below the normal range for Absolute Neutrophil Count (ANC) may be<br>                  acceptable as per investigator discretion;<br><br>               2. Urinalysis: Negative urine glucose, negative or trace urine protein, negative or<br>                  trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic<br>                  urinalysis within institutional range)<br><br>          8. Able to communicate effectively with study personnel and considered reliable, willing<br>             and cooperative in terms of compliance with the protocol requirements<br><br>          9. Participant does not intend to start or change an existing physical conditioning<br>             regimen prior to or during the study period<br><br>         10. Participant has voluntarily given written informed consent to participate in the study<br>             (prior study entry)<br><br>         11. Participant is available for the duration of the study<br><br>        Exclusion Criteria:<br><br>          1. Immunodeficiency (including HIV) or autoimmune disorder, or participant is currently<br>             taking drugs (excluding steroids, see exclusion criteria 16) or was undergoing a form<br>             of treatment within 3 months prior to study entry that affects the immune system, or<br>             participant is living with somebody with the same<br><br>          2. Participant is not to have had Guillain-Barre Syndrome<br><br>          3. Received blood or blood products in the 3 months prior to screening<br><br>          4. Received another vaccine within 30 days before screening<br><br>          5. Received another influenza vaccine from 2016 to present year<br><br>          6. Participants with plans to travel to the Northern Hemisphere during the Screening<br>             period<br><br>          7. Participated in another clinical study (involving any investigational product or<br>             device) within 60 days before screening<br><br>          8. Suffered previous anaphylactic reaction to foods, vaccines, drugs or hymenoptera<br>             stings, or has a history of severe allergic reactions (e.g. clinically severe<br>             urticaria, asthma)<br><br>          9. Participants with active asthma or a history of childhood asthma which was treated<br>             with corticosteroids.<br><br>         10. Participants with a known egg allergy<br><br>         11. If female, pregnant, planning to become pregnant, or lactating, or participants is<br>             living with somebody who is pregnant or lactating.<br><br>         12. Participant has a history of, or current evidence at the time of screening of abuse of<br>             alcohol or any drug substance, licit or illicit, or current alcohol consumption is > 4<br>             standard drinks (or equivalent) per day<br><br>         13. History of any psychiatric illness or psychological disorder which may impair the<br>             ability to provide written informed consent or participate in the study<br><br>         14. Current or history of significant neurological, cardiovascular, pulmonary (including<br>             asthma), hepatic, rheumatic, autoimmune, hematological, metabolic or renal disorder<br><br>         15. Clinically significant abnormal laboratory value at screening as determined by the<br>             Investigator<br><br>         16. Known or suspected impairment/alteration of immune function, including: Chronic use of<br>             oral steroids (equivalent to 20 mg/day prednisone =12 weeks /=2 mg/kg body weight /<br>             day prednisone =2 weeks) within 60 days prior to Day 0 (use of inhaled, IN, or topical<br>             corticosteroids is allowed, unless used for the management of asthma - see exclusion<br>             criteria 9). Receipt of parenteral steroids (equivalent to 20 mg/day prednisone =12<br>             weeks /=2 mg/kg body weight/day prednisone = 2 weeks) within 60 days prior to Day 0.<br>             Or participant is living with somebody with the same<br><br>         17. Unusual dietary habits and excessive or unusual vitamin intake likely, in the opinion<br>             of the Investigator, to affect safety parameters<br><br>         18. Participant is sero-positive to hepatitis C virus or hepatitis B virus.<br><br>         19. Body temperature (oral) =38.0ºC or acute illness within 5 days prior to vaccination<br><br>         20. Any other significant finding that, in the opinion of the Investigator, would increase<br>             the risk of the individual having an adverse outcome from participating in this study<br><br>         21. Participant is a member of the team or is related or in a dependent relationship with<br>             a member of the study team, as defined as the Sponsor or study site personnel<br>",NULL,Reactions to vaccine;Adverse events (AEs);Serious adverse events (SAEs),HAI antibody titers against A/California/07/2009;Increase in HAI titer against A/California/07/2009;HAI sero-response;Serum IgG response;Increase in serum IgG;Serum IgA response;Increase in serum IgA;Salivary IgA Response;Increase in salivary IgA,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03694808,https://clinicaltrials.gov/show/NCT03694808,Non-inferiority Study of Adjuvanted vs. High Dose Flu Vaccine in Residents of Long Term Care,Flu,Drug: Fluad Vaccine;Drug: Fluzone HD Vaccine,FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care,CT.gov,26/09/2018,23/09/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Phase 4,500,David H. Canaday,United States,NA,NULL,26/09/2018,"September 23, 2018",NCT036,07-Oct-19,1R01AI129709-01A1;10-27-29,; ;,"David Canaday, MD;Steven Gravenstein, MD, MPH;Beth Bednarchik, RN BSN CCRP",NULL,;;Beth.Bednarchik@UHHospitals.org,;;216-286-0764,University Hospitals Cleveland Medical Center/Case Western Reserve University/Louis Stokes Cleveland VA Medical Center;Brown University and Providence VA Medical Center;,; ;,"David Canaday, MD;Steven Gravenstein, MD, MPH;Beth Bednarchik, RN BSN CCRP",NULL,;;Beth.Bednarchik@UHHospitals.org,;;216-286-0764,University Hospitals Cleveland Medical Center/Case Western Reserve University/Louis Stokes Cleveland VA Medical Center;Brown University and Providence VA Medical Center;,Recruiting,Case Western Reserve University;US Department of Veterans Affairs;Brown University;National Institutes of Health (NIH);National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,65 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  > 65 years old<br><br>          -  Able to obtain consent from subject or legally authorized representative (subject to<br>             provide assent if cognitively/physically able to do so)<br><br>          -  Able to participate throughout the study period<br><br>        Exclusion Criteria:<br><br>          -  Recent illness (within 30 days) severe enough to require hospitalization or<br>             physician-directed outpatient pharmacotherapy<br><br>          -  Administration of immunomodulatory agents (e.g. oral corticosteroids except prednisone<br>             < 10 mg daily, cyclosporine, and biologics (DMARDS) for Rheumatologic/Dermatologic<br>             conditions) in the last 3 months<br><br>          -  Cancer requiring treatment in the past three years, except for non- melanoma skin<br>             cancers or cancers that have clearly been cured or carry an excellent prognosis<br>             including prostate cancer.<br><br>          -  Myocardial infarction, major heart surgery (i.e. valve replacement or bypass surgery),<br>             stroke, deep vein thrombosis or pulmonary embolus in the past 4 months<br><br>          -  Allergies or history of significant adverse reactions to any component of influenza<br>             vaccine including egg protein and latex or after a previous dose of any influenza<br>             vaccine.<br><br>          -  History of Guillian-Barré Syndrome within 6 weeks of a prior influenza vaccine.<br>",NULL,Non-inferiority in overall hemagglutinin inhibition (HAI) titer and seroconversion rate between FLUAD and FLUZONE HD at 1 month post-vaccination will be determined.,Non-inferiority in overall neuraminidase inhibition (NAI) titer and seroconversion rate between FLUAD and FLUZONE HD at 1 month post-vaccination will be determined.;Non-inferiority in overall serum virus neutralization (SVN) assays titer and seroconversion rate between FLUAD and FLUZONE HD at 1 month post-vaccination will be determined.;Heterologous immunity at 1 month post-vaccination will be compared between FLUAD and FLUZONE HD.,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03657719,https://clinicaltrials.gov/show/NCT03657719,"Open-labeled(Part 1), Single-group(Part 2), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Pharse II Clinical Trial to Evaluate Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects","Influenza, Human",Biological: GC3114;Biological: GCFLU Quadrivalent,A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects,CT.gov,27/08/2018,01/10/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",Phase 2,105,Green Cross Corporation,"Korea, Republic of",NA,NULL,27/08/2018,"October 1, 2018",NCT036,14-Jan-19,GC3114_P2,NA,"Woo Joo KIm, M.D, Ph.D",NULL,NA,NA,Korea University Guro Hospital,NA,"Woo Joo KIm, M.D, Ph.D",NULL,NA,NA,Korea University Guro Hospital,Completed,NULL,Please refer to primary and secondary sponsors,65 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Healthy adults aged over 65 years old<br><br>          -  Informed consent form has been signed and dated<br><br>        Exclusion Criteria:<br><br>          -  Known systemic hypersensitive to eggs, chicken proteins, or any of the vaccine<br>             components<br><br>          -  Personal history of Guillain-Barre syndrome(GBS)<br><br>          -  Subjects with severe chronic disease who are considered by investigator to be<br>             ineligible for the study<br><br>          -  Subjects who received a vaccination within 28 days before enrollment or who are<br>             scheduled for another vaccination during the study<br><br>          -  Immunocompromised subjects with immunodeficiency disease or subjects receiving<br>             immunosuppressive or immunomodulating therapy<br>",NULL,Adverse Event,Percentage of participants achieving pre-defined Seroconversion Before and following vaccination;Percentage of participants achieving pre-defined Seroprotection Before and following vaccination;Geometric Mean Titer of Antibodies to the Investigational Product Before and Following vaccination;Geometric Mean Ratio of Antibodies to the Investigational Product Before and Following vaccination,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03592277,https://clinicaltrials.gov/show/NCT03592277,Vitamins B1 and C to Improve Outcomes in Patients With Severe Sepsis,Sepsis;Septic Shock,Drug: Vitamin C;Drug: Vitamin B1,Vitamin C & Thiamine in Sepsis,CT.gov,18/06/2018,14/09/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,120,Saint Francis Care,United States,NA,NULL,18/06/2018,"September 14, 2018",NCT035,16-Nov-20,SF-18-42,; ;,"David Shapiro, MD;David Shapiro, MD;David S Shapiro, MD",NULL,;DShapiro@TrinityHealthOfNE.org;DShapiro@TrinityHealthOfNE.org,;860-714-5237;,Saint Francis Hospital and Medical Center;,; ;,"David Shapiro, MD;David Shapiro, MD;David S Shapiro, MD",NULL,;DShapiro@TrinityHealthOfNE.org;DShapiro@TrinityHealthOfNE.org,;860-714-5237;,Saint Francis Hospital and Medical Center;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,90 Years,All,"<br>        Patients must meet all inclusion criteria:<br><br>          1. Between the ages of 18 and 90 years old<br><br>          2. Have severe sepsis or septic shock. Severe sepsis and septic shock will be defined by<br>             the Surviving Sepsis 2012 guidelines.<br><br>          3. Weight more than 30 kg<br><br>          4. Full code<br><br>        Exclusion Criteria:<br><br>          1. Not diagnosed with severe sepsis or septic shock<br><br>          2. Younger than 18 or older than 90 years old<br><br>          3. With a history of nephrolithiasis<br><br>          4. Who are pregnant<br><br>          5. Weigh less than 30 kg<br><br>          6. Not located in the ICU<br><br>          7. Do not resuscitate (DNR) or do not intubate (DNI), no escalation of care, or comfort<br>             measures only (CMO)<br><br>          8. Currently on dialysis<br>",NULL,Mortality Rates,hospital length of stay;Intensive Care Unit length of stay;readmission rate;ventilator days;hours on vasopressors,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03581903,https://clinicaltrials.gov/show/NCT03581903,A Phase I Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,Influenza,Biological: H7N3 pLAIV;Biological: H7N9 pIIV,A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine,CT.gov,26/06/2018,19/09/2017,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 1,20,National Institute of Allergy and Infectious Diseases (NIAID),United States,NA,1,26/06/2018,"September 19, 2017",NCT035,08-Apr-19,16-003,NA,"Angela Branche, M.D.",NULL,NA,NA,University of Rochester,NA,"Angela Branche, M.D.",NULL,NA,NA,University of Rochester,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,49 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Adult males and non-pregnant, non-breastfeeding females between 18 years and 49 years<br>             of age, inclusive. Children will not be recruited or enrolled in this study because<br>             they are not in the apparent risk group, for safety considerations, and because of the<br>             need for isolation.<br><br>          -  Are in good health, as determined by medical history and targeted physical examination<br>             to ensure any existing medical diagnoses or conditions (except those exclusionary) are<br>             stable. More information on this criterion can be found in the protocol.<br><br>          -  Agree to storage of blood specimens for future research.<br><br>          -  Available for the duration of the trial. Subjects must be willing and able to remain<br>             within the Isolation Unit for the specified duration of confinement.<br><br>          -  Provide written informed consent prior to initiation of any study procedures,<br>             including future use of specimens.<br><br>          -  Female subjects of child-bearing potential must agree to use effective birth control<br>             methods for the duration of the study (for example, pharmacologic contraceptives<br>             including oral, parenteral, and transcutaneous delivery; condoms with spermicide;<br>             diaphragm with spermicide; intrauterine device; abstinence from heterosexual<br>             intercourse, surgical sterilization). All female subjects will be considered being of<br>             child bearing potential except those who have undergone hysterectomy or tubal ligation<br>             and those in whom menopause occurred at least 1 year prior to the study.<br><br>          -  Agrees not to participate in another clinical trial with an investigational product<br>             for the entire duration of the study.<br><br>          -  Female subjects of childbearing potential must have a negative urine and serum<br>             pregnancy test within 24 hours (urine) to 48 hours (serum) prior to study vaccination.<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy as determined by a positive human choriogonadotropin (beta-HCG) test.<br><br>          -  Currently breastfeeding or planning to breastfeed or become pregnant at some point<br>             during the duration of the study.<br><br>          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,<br>             rheumatologic, autoimmune, or renal disease by history, physical examination,<br>             electrocardiogram (EKG) and/or laboratory studies including urine testing. Alanine<br>             aminotransferase (ALT) levels greater than 2 times the upper normal limit will be<br>             exclusionary at baseline, prior to vaccination.<br><br>          -  Any current illness requiring daily medication other than the following: vitamins,<br>             birth control, anti-hypertensive medication, antihistamines, anti-depressant<br>             medication, cholesterol-lowering medication, treatment for gastroesophageal reflux<br>             disease, and thyroid medication unless approved by the principal investigator (PI).<br><br>          -  Behavioral or cognitive impairment or psychiatric disease that in the opinion of the<br>             investigator affects the ability of the subject to understand and cooperate with the<br>             study protocol.<br><br>          -  Previous enrollment in an H7 vaccine trial or in any study of an avian influenza<br>             vaccine.<br><br>          -  Seropositive to the H7N3 or H7N9 influenza A virus (serum HAI titer greater than 1:8).<br><br>          -  Positive urine drug toxicology test indicating narcotic use/dependency.<br><br>          -  Have medical, occupational, or family problems as a result of alcohol or illicit drug<br>             use during the past 12 months.<br><br>          -  Other condition that in the opinion of the investigator would jeopardize the safety or<br>             rights of a subject participating in the trial or would render the subject unable to<br>             comply with the protocol.<br><br>          -  Have a history of severe reactions following previous immunization with licensed or<br>             unlicensed influenza virus vaccines.<br><br>          -  Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other<br>             components of the study vaccine.<br><br>          -  Allergy to oseltamivir as determined by subject report.<br><br>          -  Current diagnosis of asthma or reactive airway disease (within the past 2 years).<br><br>          -  History of Guillain-Barré Syndrome.<br><br>          -  Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory Western blot tests<br>             for human immunodeficiency virus-1 (HIV-1).<br><br>          -  Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for<br>             hepatitis C virus (HCV).<br><br>          -  Positive hepatitis B virus surface antigen (HBsAg) by ELISA.<br><br>          -  Known immunodeficiency syndrome.<br><br>          -  Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs<br>             within 30 days prior to vaccination.<br><br>          -  Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to<br>             study vaccination.<br><br>          -  History of asplenia<br><br>          -  Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior<br>             to vaccination.<br><br>          -  Have known active neoplastic disease or a history of any hematologic malignancy.<br><br>          -  Receipt of blood or blood-derived products (including immunoglobulin) within 6 months<br>             prior to study vaccination.<br><br>          -  Current smoker unwilling to stop smoking for the duration of the inpatient stay.<br><br>               -  A current smoker includes anyone stating they currently smoke or use any amount<br>                  of a tobacco product, including electronic cigarettes.<br><br>               -  After admission to the unit, nicotine patches will be provided to current smokers<br>                  who request them for the inpatient portion of the study.<br><br>          -  Travel to the Southern Hemisphere within 14 days prior to study vaccination.<br><br>          -  Travel on a cruise ship within 14 days prior to study vaccination.<br><br>          -  Receipt of another investigational vaccine or drug within 30 days prior to study<br>             vaccination.<br>",NULL,Hemagglutination-inhibition (HAI) antibody response to H7N9 virus following administration of pIIV,"Frequency of reactogenicity events following each dose of vaccine;Severity of reactogenicity events following each dose of vaccine;Frequency of adverse events following each dose of vaccine;Severity of adverse events following each dose of vaccine;Frequency of vaccine viral shedding after each dose;Serum HAI and neutralizing antibody response following 1 or 2 doses of pLAIV;Neutralizing and HAI responses after pIIV boost against antigenic variants of H7 virus, including H7N7, H7N3, and H7N9 North American and Eurasian lineage viruses",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03614975,https://clinicaltrials.gov/show/NCT03614975,Immunologic Response to Influenza Vaccination in Children and Adolescents: A RCT Trial of Influenza Vaccines,"Influenza, Human;Immune Response",Biological: Flucelvax inactivated influenza vaccine;Biological: Fluzone inactivated influenza vaccine,Immunologic Response to Influenza Vaccination in Children and Adolescents,CT.gov,06/06/2018,13/09/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 4,166,Richard Zimmerman MD,United States,NA,NULL,06/06/2018,"September 13, 2018",NCT036,20-Jan-20,CDCU01IP001035;PRO18050091,NA,"Richard K Zimmerman, MD, MPH, MA",NULL,NA,NA,"University of Pittsburgh, School of Medicine, Dept. Family Medicine",NA,"Richard K Zimmerman, MD, MPH, MA",NULL,NA,NA,"University of Pittsburgh, School of Medicine, Dept. Family Medicine",Completed,Centers for Disease Control and Prevention,Please refer to primary and secondary sponsors,4 Years,20 Years,All,"<br>        Inclusion Criteria:<br><br>          -  aged 4-20 years;<br><br>          -  has prior vaccination history available (which can be determined based either on<br>             medical record review or through state registry review;<br><br>          -  plans to receive the current seasonal influenza vaccination at one of the recruiting<br>             sites<br><br>        Exclusion Criteria:<br><br>          -  unable or unwilling to completed required study activities, including informed<br>             consent, randomization to vaccine, and bloodwork;<br><br>          -  has already received influenza vaccine for the current season;<br><br>          -  has a known immunocompromising condition or is on an immunosuppressing medication<br>             (e.g., high dose steroids >10 days);<br><br>          -  is known to be pregnant;<br><br>          -  has a history of severe allergy to eggs or to influenza vaccine or any of its<br>             components<br>",NULL,Determining Seroconversion Response - Change in HI Titers From Pre- to Post Vaccination,Determining Geometric Mean Titers (GMTs) at Each Time Point;Determining Seroprotection Level at Each Time Point,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT03614975,NULL,12/11/2019,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT03530124,https://clinicaltrials.gov/show/NCT03530124,Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines,Apnea;Apnea Neonatal;Prematurity,Biological: PCV13;Biological: DTaP;Biological: HBV;Biological: IPV;Biological: Hib,Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines,CT.gov,08/05/2018,17/07/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 4,300,Duke University,United States,NA,NULL,08/05/2018,"July 17, 2018",NCT035,05-Oct-20,200 2012 53663 0010;Pro00088094,; ; ; ;,"Rachel G Greenberg, MD;Andrea Trembath, MD;Mary A Staat, MD;Patricia Wodi, MD;Rachel G Greenberg, MD",NULL,;;;;rachel.greenberg@duke.edu,;;;;919-668-4725,"Duke University;University of North Carolina;Children's Hospital Medical Center, Cincinnati;Centers for Disease Control and Prevention;",; ; ; ;,"Rachel G Greenberg, MD;Andrea Trembath, MD;Mary A Staat, MD;Patricia Wodi, MD;Rachel G Greenberg, MD",NULL,;;;;rachel.greenberg@duke.edu,;;;;919-668-4725,"Duke University;University of North Carolina;Children's Hospital Medical Center, Cincinnati;Centers for Disease Control and Prevention;",Recruiting,"Centers for Disease Control and Prevention;Children's Hospital Medical Center, Cincinnati;University of North Carolina",Please refer to primary and secondary sponsors,6 Weeks,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. =32 weeks gestational age at birth<br><br>          2. =6 weeks postnatal age at randomization<br><br>          3. Remains hospitalized after birth (has never been discharged home)<br><br>          4. Treating clinician deems infant eligible to receive 2-month vaccines<br><br>          5. English- or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s))<br><br>          6. Not planned for discharge within 60 hours of study entry<br><br>          7. The parent/guardian must be willing and capable of providing permission for their<br>             child to participate through the written informed consent process<br><br>        Exclusion Criteria:<br><br>          1. Receipt of DTaP, IPV, PCV13, or Hib prior to enrollment. Previous administration of<br>             the first dose of HBV is permitted<br><br>          2. Anticipated receipt of any vaccine other than DTaP, IPV, HBV, PCV13, or Hib during the<br>             first 60 hours after randomization<br><br>          3. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any<br>             hepatitis B vaccine<br><br>          4. History of a severe allergic reaction (e.g. anaphylaxis) to any component of the<br>             vaccines used in the study including neomycin, yeast and polymyxin B<br><br>          5. History of latex allergy<br><br>          6. Fever =38°C within 48 hours prior to randomization*<br><br>             *This may result in a temporary delay of randomization<br><br>          7. Active known respiratory infection within 48 hours prior to randomization*<br><br>             *This may result in a temporary delay of randomization<br><br>          8. Active infection being treated with systemic antimicrobials*<br><br>             *This may result in a temporary delay of randomization<br><br>          9. Requiring mechanical ventilation or support with nasal intermittent positive pressure<br>             ventilation (NIPPV)*<br><br>             *This may result in a temporary delay of randomization<br><br>         10. History of unstable progressive neurologic disorder of unknown cause<br><br>         11. Known cause of apnea other than apnea of prematurity<br><br>         12. Cyanotic heart disease (congenital or acquired)<br><br>         13. Major invasive medical or surgical procedure (including circumcision) within 48 hours<br>             prior to randomization or anticipated to have major invasive medical or surgical<br>             procedure during the first 60 hours after randomization*<br><br>             *This may result in a temporary delay of randomization<br><br>         14. Child or parent/LAR is an immediate relative of study staff or an employee who is<br>             supervised by study staff.<br><br>         15. Any condition that would, in the opinion of the site investigator, place the<br>             participant at an unacceptable risk of injury or render the participant unable to meet<br>             the requirements of the protocol<br>",NULL,Occurrence of Apnea,Number of Apneic Episodes;Duration of Apneic Episodes;Increase in Respiratory Support;Severe Cardiorespiratory Events,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03608514,https://clinicaltrials.gov/show/NCT03608514,Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.,Resolution of Septic Shock With Terlipressin,Drug: Experimental,Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study.,CT.gov,12/07/2018,01/07/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Phase 2/Phase 3,100,National Hepatology & Tropical Medicine Research Institute,Egypt,NA,NULL,12/07/2018,"July 1, 2018",NCT036,20-Aug-18,NHTMRI-ICU-B,NA,"Eman El-Desoki, Ph D",NULL,eman18350@gmail.com,1227409501,NULL,NA,"Eman El-Desoki, Ph D",NULL,eman18350@gmail.com,1227409501,NULL,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,70 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Adults aged between 18 & 70years who will be admitted to the intensive care unit (ICU)<br>             of National Hepatology & Tropical Medicine Research Institute (NHTMRI).<br><br>        All patients that will be included in the study should have septic shock diagnosed by<br>        having sepsis with an underlying circulatory and cellular/metabolic abnormality.<br><br>        Exclusion Criteria:<br><br>          -  Patients will be excluded if they are pregnant, have uncontrolled hypertension,<br>             ischemic skin necrosis, present or suspected coronary artery disease, present or<br>             suspected acute mesenteric ischemia, or peripheral vascular diseases (e.g. Raynaud's<br>             syndrome or related diseases) and hypersensitivity to Terlipressin.<br>",NULL,"Hemodynamic stability & optimization; mean blood pressure more than or equal 65mmHg;mortality;Hemodynamic stability & optimization; mean blood pressure;Hemodynamic stability & optimization, lactate clearance to be 2mmol/L",NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03345992,https://clinicaltrials.gov/show/NCT03345992,"A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome",Sepsis;Pneumonia;Gram-Negative Bacteria Infection;Multiple Organ Failure;Respiratory Distress Syndrome;Mortality;Biomarkers,Drug: Clarithromycin;Drug: Water for injection,Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System,CT.gov,09/11/2017,15/12/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,110,Hellenic Institute for the Study of Sepsis,Belgium;Greece;Belgium;Greece,EUCTR2017-001056-55-BE,NULL,09/11/2017,"December 15, 2017",NCT033,10-Aug-20,INCLASS,NA,"Apostolos Armaganidis, MD, PhD",NULL,NA,NA,"National Kapodistrian University of Athens, Medical School",NA,"Apostolos Armaganidis, MD, PhD",NULL,NA,NA,"National Kapodistrian University of Athens, Medical School","Active, not recruiting",European Commission,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Adult patients (=18 years)<br><br>          -  Patients of both genders<br><br>          -  Informed consent form signed by patient or by first-degree relative in case of patient<br>             unable to consent<br><br>          -  Negative (blood or urinary) pregnancy test for female patients of reproductive age<br><br>          -  Willingness to receive contraception during and seven days after the administration of<br>             the study drug.<br><br>          -  Presence of one or more of the following infections: hospital-acquired pneumonia<br>             (HAP), health-care associated pneumonia (HCAP), ventilator-associated pneumonia (VAP),<br>             primary Gram-negative bacteremia and intra-abdominal infections.<br><br>          -  Presence of sepsis as defined by: Sequential Organ Failure Assessment (SOFA) score of<br>             2 or more points for patients who are admitted with infection at the emergency<br>             department or increase of admission SOFA score by 2 or more points consequent to<br>             infection, for patients already hospitalized<br><br>          -  Respiratory dysfunction defined as one Partial Arterial Oxygen Pressure to Fraction of<br>             Inspired Oxygen (PaO2/FiO2) ratio inferior to 200, independently of the Positive End<br>             Expiratory Pressure (PEEP) level.<br><br>          -  Total SOFA points for organ dysfunctions other than the respiratory function more than<br>             3<br><br>        Exclusion Criteria:<br><br>          -  Denial for informed consent<br><br>          -  Age inferior to 18 years<br><br>          -  Pregnancy (confirmed by blood or urinary pregnancy test) or lactation for female<br>             patients of reproductive age.<br><br>          -  Unwillingness to receive contraception during and seven days after the administration<br>             of the study drug.<br><br>          -  HIV infection (with known Cluster of Differentiation 4-positive [CD4] cell count =<br>             200/mm3)<br><br>          -  Solid organ, or bone marrow transplantation<br><br>          -  Corticosteroid oral or intravenous intake greater than 0.4 mg/kg of equivalent<br>             prednisone daily over the last 15 days<br><br>          -  Known active neoplasms compromising short-term survival (1 month)<br><br>          -  Neutropenia <1000/mm3<br><br>          -  Known allergy to macrolides<br><br>          -  Previous participation in the study<br><br>          -  Administration of a macrolide for the current infection<br>",NULL,Mortality rate at 28 days,Mortality rate at 90 days;Mortality rate at 28 days for patients with septic shock;Rate of early sepsis response at 3 days;Rate of sepsis resolution at 7 days;New sepsis episode until 28 days;Time to new sepsis episode until 28 days;Cell population analysis;Transcriptome analysis;Metabolome analysis;Microbiome analysis;Cost of hospitalization,parent,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02691130,https://clinicaltrials.gov/show/NCT02691130,"A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults",Influenza;Healthy,Biological: Multimeric 001 (M-001);Biological: H5N1 influenza vaccine;Biological: Saline,Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults,CT.gov,11/02/2016,01/11/2015,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,224,BiondVax Pharmaceuticals ltd.,Hungary,NA,1,11/02/2016,Nov-15,NCT026,19-Feb-18,BVX-007,NA,"Dora Mathiasz, MD",NULL,NA,NA,St Istvan St Laszlo hospital,NA,"Dora Mathiasz, MD",NULL,NA,NA,St Istvan St Laszlo hospital,Completed,Seventh Framework Programme,Please refer to primary and secondary sponsors,18 Years,60 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Healthy male or non-pregnant female (as indicated by a negative urine pregnancy test<br>             immediately prior to vaccine administration) between the ages of 18 and 60 years,<br>             inclusive;<br><br>          -  Women of childbearing potential (not surgically sterile or postmenopausal for greater<br>             than or equal to one year) and men must agree to practice adequate contraception (a<br>             combination of barrier plus hormone methods or intra uterine device (IUD) for women<br>             and a condom for men) throughout the study treatment and for at least up to day 51<br>             (for female) and day 111 (for male) of the trial (i.e. 30 (for female) and 90 (for<br>             male) days after the last dose of the IMP);<br><br>          -  Is in good health, as determined by vital signs (heart rate, blood pressure, armpit<br>             temperature), blood chemistry test (electrolytes, renal/kidney function, liver<br>             function, C-reactive protein, complete blood count), medical history, general physical<br>             examination, self-reported illness and clinical judgment of the investigator;<br><br>          -  Able to understand and comply with planned study procedures;<br><br>          -  Provides signed informed consent form after receiving a detailed explanation of the<br>             study protocol prior to any study procedures.<br><br>        Exclusion Criteria<br><br>        A potential subject who meets any if the following criteria will be excluded from<br>        participation in this study:<br><br>          -  Has a known allergy to components of the vaccine (e.g. egg products).<br><br>          -  Has a history of severe reactions following immunization.<br><br>          -  Persons with immune deficiency/disorder, whether due to genetic defect,<br>             immunodeficiency disease, or immunosuppressive therapy.<br><br>          -  Has a positive urine pregnancy test prior to vaccination or women who are<br>             breastfeeding.<br><br>          -  Has a history of any of the following (reported by subjects):<br><br>               -  Acute disseminated encephalomyelitis (ADEM);<br><br>               -  Active neoplastic disease;<br><br>               -  Asthma or severe allergic disease;<br><br>               -  Bleeding disorders<br><br>               -  Chronic Hepatitis B and/or C infection;<br><br>               -  Chronic liver disease;<br><br>               -  Diabetes mellitus;<br><br>               -  Guillain-Barré syndrome;<br><br>               -  HIV;<br><br>               -  Rheumatoid arthritis or other autoimmune diseases;<br><br>               -  Severe renal disease;<br><br>               -  Transplant recipients;<br><br>               -  Unstable or progressive neurological disorders.<br><br>          -  Receipt of medicines/treatments that may affect evaluation of immunogenicity such as:<br><br>               -  Oral or parenteral steroids, high-dose inhaled steroids (greater than 800<br>                  micrograms/day of beclomethasone dipropionate or equivalent) or other<br>                  immunosuppressive or cytotoxic drugs;<br><br>               -  Immunoglobulin or other blood products (within the 3 months prior to vaccination<br>                  in this study);<br><br>               -  Experimental agent (vaccine, drug, biologic, device, blood product, or<br>                  medication) within 1 month prior to vaccination in this study, or expects to<br>                  receive an experimental agent (during the study period).<br><br>               -  Influenza antiviral medication (within the 4 weeks prior to vaccination in this<br>                  study).<br><br>          -  Has received any influenza vaccine within 6 months prior to vaccination in this study.<br><br>          -  Has influenza-like illness within 6 months prior to vaccination in this study.<br><br>          -  Has an acute illness, including an armpit temperature greater than 38 degrees Celsius<br>             (oC), within 1 week of vaccination.<br><br>          -  Has a history of alcohol or drug abuse.<br><br>          -  Any abnormal haematology values and/or serum chemistries judged by the Investigator as<br>             clinically significant.<br><br>          -  Ineligible subject based on the judgement of the investigator.<br><br>          -  In case there is uncertainty about the participant's medical status regarding any of<br>             the exclusion criteria mentioned, the participant's primary care physician will be<br>             consulted. Consultation of the primary care physician will only take place after<br>             having received written approval from the participant, and will concern medical<br>             information about exclusion criteria only.<br>",NULL,For each vaccine group the incidence rate of subjects with solicited AE(s) with 95% confidence interval;For each vaccine group the percentage of subjects with SAE(s) with 95% confidence interval;For each vaccine group the influenza-specific cellular immune responses evaluated by multi-parametric FACS analysis,For each vaccine group the antibody responses to the H5 vaccine strain evaluated by hemaglutination inhibition (HI) assay,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03911440,https://clinicaltrials.gov/show/NCT03911440,Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development,Atypical Pneumonia,Drug: Doxycycline;Drug: Azithromycin,Treatment and Vaccine Development of Mycoplasma Pneumoniae,CT.gov,09/04/2019,10/11/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,N/A,100,National Taiwan University Hospital,Taiwan,NA,1,09/04/2019,"November 10, 2018",NCT039,23-Apr-19,201712045MINA,NA,"Li-Min Huang, MD, PhD",NULL,lmhuang@ntu.edu.tw,886-2-23123456,NA,NA,"Li-Min Huang, MD, PhD",NULL,lmhuang@ntu.edu.tw,886-2-23123456,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,N/A,18 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Children aged 0-18 years, admitted due to lower respiratory tract infections.<br>             Mycoplamsa pneumonia is diagnosed.<br><br>          -  The diagnosis is made within 72 hours after fever onset.<br><br>          -  The patient and his/her guardians are willing to participate the study and able to<br>             follow the instruction.<br><br>        Exclusion Criteria:<br>",NULL,Defervescence,Hospital stay,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04020003,https://clinicaltrials.gov/show/NCT04020003,A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics,"ARDS, Human",Drug: Levosimendan,A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics,CT.gov,02/07/2019,01/07/2019,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 3,120,Shenzhen Second People's Hospital,China,NA,NULL,02/07/2019,"July 1, 2019",NCT040,22-Jul-19,20193357016,; ;,"Feng yongwen, master;Meng xinke, master;Nie Guohui, doctor",NULL,;mengxinke_2006@126.com;,;13751017051;0755-83366388,Shenzhen Second People's Hospital;,; ;,"Feng yongwen, master;Meng xinke, master;Nie Guohui, doctor",NULL,;mengxinke_2006@126.com;,;13751017051;0755-83366388,Shenzhen Second People's Hospital;,Recruiting,NULL,Please refer to primary and secondary sponsors,N/A,N/A,All,<br>        Inclusion Criteria:<br><br>        Clinical diagnosis of ARDS; joined this study with informed consents<br><br>        Exclusion Criteria:<br><br>        neurological and muscle diseases; Chronic severe liver and kidney failure; advanced<br>        malignant tumor; Primary left ventricular insufficiency;<br>,NULL,APACHE II score;SOFA score,Mechanical ventilation time;mecical expense,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03898973,https://clinicaltrials.gov/show/NCT03898973,Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood,Influenza,Biological: Quadrivalent inactivated influenza vaccine (IIV),Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood,CT.gov,30/03/2019,01/06/2019,TRUE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 4,50,Stanford University,NULL,NA,NULL,30/03/2019,Jun-19,NCT038,15-Apr-19,50328,NA,Philip Grant,NULL,pmgrant@stanford.edu,6507239443,NA,NA,Philip Grant,NULL,pmgrant@stanford.edu,6507239443,NA,Not yet recruiting,National Institutes of Health (NIH);National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,20 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          1. 20-75-year-old male and female patients<br><br>          2. Body mass index (BMI) 20-35 kg/m2<br><br>          3. Acceptable laboratory values: Absolute neutrophil count (ANC) > 750 cells/mm3;<br>             Hemoglobin >10 g/dL; Platelet count >75,000/mm3; Partial thromboplastin time (PTT)<br>             >1.2x ULN; Prothrombin time (PT) >1.2x ULN<br><br>          4. Willing and able to complete the informed consent process<br><br>          5. Availability for follow-up for the planned duration of the study<br><br>          6. Acceptable medical history by review of inclusion/exclusion criteria<br><br>        Exclusion Criteria:<br><br>          1. Prior off-study vaccination with seasonal influenza vaccine within three months of<br>             study vaccination<br><br>          2. Life-threatening reactions to previous influenza vaccinations<br><br>          3. Allergy to egg or egg products or to vaccine components<br><br>          4. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          5. History of immunodeficiency (including HIV infection)<br><br>          6. Known or suspected impairment of immunologic function; may include significant liver<br>             disease, diabetes mellitus treated with insulin or moderate to severe renal disease<br><br>          7. Chronic Hepatitis B or C.<br><br>          8. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible).<br>             Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review<br>             by the investigator.<br><br>          9. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         10. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator might jeopardize volunteer safety or compliance with the protocol.<br><br>         11. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         12. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg per day), Plavix, or Aggrenox will be<br>             reviewed by investigators to determine if study participation would affect the<br>             volunteer's safety or compliance with the protocol.<br><br>         13. Receipt of blood or blood products within the past 6 months or planned used during the<br>             study.<br><br>         14. A medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         15. Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned<br>             vaccinations prior to completion of last annual study visit (~ 28 days after study<br>             vaccination)<br><br>         16. Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned<br>             vaccination prior to completion of last study visit (~ 28 days after study enrollment)<br><br>         17. Need for allergy immunization (that cannot be postponed) until after the last study<br>             visit.<br><br>         18. History of Guillain-Barre# syndrome<br><br>         19. Use of investigational agents within 30 days prior to enrollment or planned use during<br>             the study.<br><br>         20. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or<br>             donation of platelets within 2 weeks of enrollment or planned donation prior to<br>             completion of the last visit.<br><br>         21. Pregnancy<br><br>         22. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety,<br>",NULL,HAI titer,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03845231,https://clinicaltrials.gov/show/NCT03845231,Mucosal Correlates of Protection After Influenza Viral Challenge of Vaccinated and Unvaccinated Healthy Volunteers,Influenza,Biological: Flucelvax(R);Other: Human Challenge virus,Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route,CT.gov,16/02/2019,29/04/2019,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 2,82,National Institute of Allergy and Infectious Diseases (NIAID),United States,NA,NULL,16/02/2019,"April 29, 2019",NCT038,16-Nov-20,19-I-0058;190058,NA,"Matthew J Memoli, M.D.",NULL,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,"Matthew J Memoli, M.D.",NULL,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),Completed,NULL,Please refer to primary and secondary sponsors,18 Years,55 Years,All,"<br>        -  INCLUSION CRITERIA:<br><br>               1. Greater than or equal to 18 and less than or equal to 55 years of age.<br><br>               2. Non-smoker.<br><br>               3. Have not received influenza vaccination of any type (whether licensed or<br>                  unlicensed experimental vaccine) on or after September 1, 2018. Participants who<br>                  enroll in our study must be informed of the Centers for Disease Control and<br>                  Prevention (CDC) recommendation to receive seasonal influenza vaccination<br>                  annually. Enrollees accept that half of study participants will receive licensed<br>                  approved vaccination per the usual route, and half will receive it by an<br>                  unapproved route with unknown efficacy and side effects. Enrollees should not<br>                  plan to receive seasonal influenza vaccination from another source from<br>                  enrollment through the final study visit (Phase 2, Day 56).<br><br>               4. Willingness to remain in isolation for the duration of viral shedding (at a<br>                  minimum 9 days) and to comply with all study requirements.<br><br>               5. A male subject is eligible for the study if he meets one of the following<br>                  criteria, beginning at least 4 weeks prior to enrollment and continuing until 8<br>                  weeks after administration of the human challenge virus:<br><br>                    1. Is infertile, including history of successful vasectomy.<br><br>                    2. Agrees to practice abstinence.<br><br>                    3. Agrees that, with heterosexual intercourse with a fertile female partner, he<br>                       will use a condom with spermicide and his female partner (including those<br>                       who have undergone bilateral tubal ligation) will use an acceptable form of<br>                       contraception (see inclusion criterion 6c).<br><br>               6. A female participant is eligible for this study if she is not pregnant or<br>                  breastfeeding and meets one of the following criteria, beginning at least 4 weeks<br>                  prior to enrollment and continuing until 8 weeks after administration of the<br>                  human challenge virus::<br><br>                    1. infertile, including postmenopausal status, (as defined by no menses for<br>                       greater than or equal to 1 year) or history of hysterectomy.<br><br>                    2. Agrees to practice abstinence.<br><br>                    3. Agrees that, with heterosexual intercourse with a fertile male partner, she<br>                       will use an acceptable form of contraception and her male partner will use a<br>                       condom with spermicide. Acceptable effective methods of female contraception<br>                       include the following: bilateral tubal ligation, implant of levonorgestrel,<br>                       injectable progestogen, intrauterine device oral contraceptive pills and<br>                       diaphragm with spermicide.<br><br>               7. Willing to have samples stored for future research.<br><br>               8. HIV uninfected with a negative test within 60 days of Phase 2, Day 0.<br><br>               9. Agrees not to use IN medications (including but not limited to nasal<br><br>                  sprays, sinus rinses), over-the-counter medications (including but not<br><br>                  limited to aspirin, decongestants, antihistamines, and other non-steroidal<br>                  anti-inflammatory drugs), and herbal medications (including but not limited to<br>                  herbal tea or St. John s Wort), from 14 days prior to study enrollment through<br>                  the final study visit (Phase 2, Day 56), unless approved by the investigator<br><br>              10. Agrees not to donate blood or blood products from enrollment through the final<br>                  study visit (Phase 2, Day 56).<br><br>        EXCLUSION CRITERIA:<br><br>          1. Presence of self-reported or medically documented significant medical condition<br>             including but not limited to:<br><br>               1. Chronic pulmonary disease (e.g., asthma, emphysema).<br><br>               2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure,<br>                  cardiac surgery, ischemic heart disease, known anatomic defects).<br><br>               3. Chronic medical conditions requiring close medical follow-up or hospitalization<br>                  during the past 5 years (e.g., insulin-dependent diabetes mellitus, renal<br>                  dysfunction, hemoglobinopathies).<br><br>               4. Immunosuppression, immune deficiency (such as IgA deficiency) or ongoing<br>                  malignancy.<br><br>               5. Neurological and neurodevelopmental conditions (e.g., Bell s palsy, cerebral<br>                  palsy, epilepsy, stroke, seizures).<br><br>               6. Postinfectious or postvaccine neurological sequelae including Guillain Barre<br>                  syndrome.<br><br>               7. Individual with body mass index less than or equal to 18 and greater than or<br>                  equal to 40.<br><br>          2. Have close or household (i.e., share the same apartment or house) high-risk contacts<br>             including but not limited to:<br><br>               1. Persons greater than or equal to 65 years of age.<br><br>               2. Children less than or equal to 5 years of age.<br><br>               3. Residents of nursing homes.<br><br>               4. Persons of any age with significant chronic medical conditions such as:<br><br>                    -  Chronic pulmonary disease (e.g., severe asthma, chronic obstructive<br>                       pulmonary disease).<br><br>                    -  Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart<br>                       failure, cardiac surgery, ischemic heart disease, known anatomic defects).<br><br>                    -  Contacts who required medical follow-up or hospitalization during the past 5<br>                       years because of chronic metabolic disease (e.g., insulin-dependent diabetes<br>                       mellitus, renal dysfunction, hemoglobinopathies).<br><br>                    -  Immunosuppression or cancer.<br><br>                    -  Neurological and neurodevelopmental conditions (e.g., cerebral palsy,<br>                       epilepsy, stroke, seizures).<br><br>                    -  Individuals who are receiving long-term aspirin therapy.<br><br>                    -  Women who are pregnant or who are trying to become pregnant.<br><br>          3. Acute illness within 7 days prior to quadrivalent IIV administration or inoculation<br>             with the human challenge virus.<br><br>          4. Individuals who have grade 3 or above clinically significant laboratory values outside<br>             the limits thus specified by normal laboratory parameters.<br><br>          5. Clinically significant abnormality as deemed by the PI on echocardiographic (ECHO)<br>             testing.<br><br>          6. Clinically significant abnormality as deemed by the PI on the pulmonary function test<br>             (PFT).<br><br>          7. Known allergy to influenza vaccination or excipients contained in the influenza<br>             vaccine used.<br><br>          8. Known allergy to lidocaine or phenylephrine.<br><br>          9. Known allergy to treatments for influenza (including but not limited to oseltamivir or<br>             nonsteroidal anti-inflammatory medications).<br><br>         10. Known allergy to 2 or more classes of antibiotics (e.g",NULL,Influenza infection,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03383887,https://clinicaltrials.gov/show/NCT03383887,Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits,Obstructive Sleep Apnea (OSA),Drug: Placebo oral capsule;Drug: DAW1033D oral capsule,DAW1033D in Obstructive Sleep Apnea,CT.gov,13/12/2017,13/12/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 1/Phase 2,11,Brigham and Women's Hospital,United States,NA,NULL,13/12/2017,"December 13, 2017",NCT033,10-Feb-20,2014p001033D,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,21 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>        - AHI > 15<br><br>        Exclusion Criteria:<br><br>          -  Any medical condition other than well controlled hypertension, diabetes,<br>             hyperlipidemia<br><br>          -  Any medication known to influence breathing, sleep/arousal or muscle physiology.<br><br>          -  Claustrophobia.<br><br>          -  Inability to sleep supine.<br><br>          -  Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.<br><br>          -  Individuals with underlying cardiac disease, such as arrhythmias.<br><br>          -  Individuals taking psychiatric medications, or any of the studied medications for<br>             medical care.<br><br>          -  History of seizures<br><br>          -  For women: Pregnancy.<br><br>          -  History of panic disorder / hyperventilation syndrome / Attention<br>             deficit-hyperactivity disorder (ADHD) / autism<br>",NULL,"Apnea Hypopnea Index (AHI, Events/Hour of Sleep)",Collapsibility of the Upper Airway: Passive and Active V0 (L/Min) Genioglossus Muscle Responsiveness to Increased Ventilatory Drive (GG%Max/cmH2O).,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT03383887,NULL,05/02/2020,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT03567577,https://clinicaltrials.gov/show/NCT03567577,"Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial",ARDS,Drug: Solnatide 25 mg powder for reconstitution for solution for inhalation;Drug: 0.9% Saline Solution,Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS,CT.gov,23/04/2018,23/05/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,80,Apeptico Forschung und Entwicklung GmbH,Austria;Germany;Austria;Germany,NA,NULL,23/04/2018,"May 23, 2018",NCT035,16-Jul-20,AP301-II-002,NA,"Bernhard Fischer, Prof. Dr.",NULL,b.fischer@apeptico.com,0043-664143,NA,NA,"Bernhard Fischer, Prof. Dr.",NULL,b.fischer@apeptico.com,0043-664143,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Informed consent<br><br>          2. Male or female =18 years of age.<br><br>          3. Patient has been admitted to an ICU, is mechanically ventilated (according to the<br>             ventilation and weaning protocol in Appendix I) and stable in this condition for at<br>             least 8 hours.<br><br>          4. Moderate-to-severe ARDS diagnosis as defined by the Berlin Definition:<br><br>               -  Onset of ARDS within 1 week of a known clinical insult or new or worsening<br>                  respiratory symptoms.<br><br>               -  Bilateral opacities not fully explained by effusions, lobar/lung collapse, or<br>                  nodules.<br><br>               -  Respiratory failure not fully explained by cardiac failure or fluid overload<br>                  (origin of oedema).<br><br>               -  PaO2/FiO2 = 200 mm Hg with Positive End-Expiratory Pressure (PEEP) =5 cm H2O.<br><br>          5. ARDS diagnosis not older than 48 hours.<br><br>          6. Extravascular lung water index (EVLWI) = 10 ml/PBW as assessed with a validated<br>             bedside measurement (single indicator transpulmonary thermodilution measurement with<br>             the PiCCO® system).<br><br>          7. Patient who meets criteria for extensive hemodynamic monitoring as per international<br>             intensive care medicine standards.<br><br>          8. For patients that are temporarily unable to consent (e.g. comatose patients) a<br>             subsequent informed consent has to be provided.<br><br>          9. Male and Female (WOCBP) patients using adequate contraception.<br><br>        Exclusion Criteria:<br><br>          1. History of clinically relevant allergies or idiosyncrasies to solnatide.<br><br>          2. Known use of any other investigational or non-registered drug within 30 days prior to<br>             study enrolment.<br><br>          3. Severe state of septic shock with a Mean Arterial Pressure (MAP) = 65 mm Hg and a<br>             serum lactate level > 4 mmol/L (36 mg/dL) despite adequate volume resuscitation.<br><br>          4. An underlying clinical condition that, in the opinion of the Investigator, would make<br>             it very unlikely for the patient to be successfully weaned from ventilation due to<br>             severe underlying diseases (e.g. severe malnutrition, severe neurological diseases,<br>             pulmonary fibrosis or COPD).<br><br>          5. Extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any<br>             form of extra-corporeal lung support. In no way are patients to be denied or delayed<br>             these procedures to avoid exclusion from the study.<br><br>          6. Neutrophil count < 0.3 x 109/L.<br><br>          7. Cancer treatment (chemotherapy or biological) or therapy with other immunosuppressive<br>             agents for organ transplantation within 2 weeks.<br><br>          8. Cachexia (BMI < 18.5 kg/m2).<br><br>          9. Cardiogenic pulmonary oedema diagnosed by echocardiography or pulmonary artery<br>             catheter.<br><br>         10. Severe skin burns involving more than 15% of body surface.<br><br>         11. Subjects who are extremely unlikely to survive more than 48 hours due to the acute<br>             conditions of the patient in the opinion of the Investigator.<br><br>         12. Subjects transferred from a hospital not participating in this study who are already<br>             planned to be re-transferred during the observation period.<br><br>         13. Subjects who are not expected to survive the next month because of an underlying<br>             uncorrectable medical condition or a do not resuscitate order.<br><br>         14. Women known to be pregnant, lactating or having a positive or indeterminate pregnancy<br>             test.<br>",NULL,Safety endpoint: Any cause death;Safety endpoint: Drug-related adverse events;Safety endpoint: All adverse events,EVLWI;PVPI;Change of ventilatory settings;Murray lung injury score;Oxygenation ratio (PaO2 / FiO2 ratio);Time to extubation;Ventilator-free days (VFD);Days of hospitalization and in ICU,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03489018,https://clinicaltrials.gov/show/NCT03489018,The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan Infants,"Pneumococcal Infection;Streptococcus Pneumoniae Infection;Invasive Pneumococcal Disease, Protection Against",Biological: PCV10;Biological: PCV13,The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants,CT.gov,29/03/2018,21/03/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Phase 4,2100,London School of Hygiene and Tropical Medicine,Kenya,NA,NULL,29/03/2018,"March 21, 2019",NCT034,28-Sep-20,QA1075,; ;,"J. Anthony G Scott, DTMH FMedSci;Katherine E. Gallagher, PhD;Katherine Gallagher",NULL,;katherine.gallagher@lshtm.ac.uk;kgallagher@kemri-wellcome.org,;+254707867625;0707867625,"London School of Hygiene & Tropical Medicine, Keppel Street, London;",; ;,"J. Anthony G Scott, DTMH FMedSci;Katherine E. Gallagher, PhD;Katherine Gallagher",NULL,;katherine.gallagher@lshtm.ac.uk;kgallagher@kemri-wellcome.org,;+254707867625;0707867625,"London School of Hygiene & Tropical Medicine, Keppel Street, London;",Recruiting,"University College, London;KEMRI-Wellcome Trust Collaborative Research Program;Bill and Melinda Gates Foundation;National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU)",Please refer to primary and secondary sponsors,6 Weeks,8 Weeks,All,"<br>        Inclusion Criteria:<br><br>          -  Healthy infants aged 6-8 weeks of age (HIV positive or negative but with no symptoms<br>             of current clinical immunosuppression i.e. HIV infection at WHO clinical stage 1);<br><br>          -  Parents are willing to provide informed consent for their child to participate in the<br>             study<br><br>          -  Parents and infant are likely to remain in the study area until the infant is 18<br>             months of age and comply with study requirements including the requirement to return<br>             to the same health facility to obtain all other childhood vaccines.<br><br>        Exclusion Criteria:<br><br>          -  Infants >8 weeks of age at time of enrolment<br><br>          -  Signs or symptoms of immunosuppression or HIV infection clinical stage 2 or above.<br><br>          -  Acute illness (e.g. febrile disease) on the day of vaccination<br><br>          -  Contraindications precluding vaccination (e.g. hypersensitivity to any component of<br>             the vaccine, including diphtheria toxoid)<br><br>          -  Previous PCV vaccination<br><br>          -  Family are planning to migrate out of the study areas before the end of the study<br>             follow-up<br><br>          -  Family are planning to obtain the subsequent vaccine doses of the routine immunisation<br>             schedule elsewhere and therefore their child may receive a full dose under the routine<br>             vaccination programme.<br>",NULL,Immunogenicity: The ratio of IgG GMCs at 1-month post boost,Immunogenicity: the proportion of children who 'seroconvert' to vaccine-serotypes after vaccination;The proportion of children with evidence of vaccine-serotype carriage;The proportion of children with evidence of vaccine-serotype carriage;The direct vaccine effectiveness of full/fractional doses of PCV13 against carriage of serotypes 6A and 19A;Opsonophagocytic activity of vaccine-induced antibody to 4 serotypes,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04016246,https://clinicaltrials.gov/show/NCT04016246,Respiratory Effect of the LISA (Less Invasive Surfactant Administration) Method With Sedation by Propofol Versus Absence of Sedation: Double-blind Comparative Randomized Clinical Trial.,Respiratory Distress Syndrome in Premature Infant,Drug: Propofol-Lipuro;Drug: Placebos,Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.,CT.gov,07/06/2019,07/10/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Phase 3,542,"University Hospital, Grenoble",France,NA,NULL,07/06/2019,"October 7, 2019",NCT040,03-Feb-20,38RC18.123,;,"Thierry DEBILLON, MD PHD;Marie CHEVALLIER, MD",NULL,;MChevallier3@chu-grenoble.fr,;+33476769248,CHU de Grenoble Alpes;,;,"Thierry DEBILLON, MD PHD;Marie CHEVALLIER, MD",NULL,;MChevallier3@chu-grenoble.fr,;+33476769248,CHU de Grenoble Alpes;,Recruiting,NULL,Please refer to primary and secondary sponsors,N/A,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Preterm Infants < 32 wGA (weeks of gestational age)<br><br>          -  Presenting a RDS (respiratory distress syndrome)<br><br>               -  in the first 48 hours of life<br><br>               -  treated by CPAP (continuous positive airway pressure) or BiPAP (Bilevel Positive<br>                  Airway Pressure)<br><br>               -  requiring surfactant :<br><br>                    -  FIO2 : (fraction of inspired oxygen)<br><br>                         -  if 28 - 31 SA : FiO2 =30% for a duration = 10mn<br><br>                         -  if <28 SA FIO2 =25% for a duration =10mn<br><br>                    -  SpO2 (arterial oxygen saturation) : to obtain a SpO2 between =88 and = 95%<br><br>          -  Available IntraVenous line (peripheral, umbilical or central catheter)<br><br>          -  Recipient of the French Social Security<br><br>          -  Informed consent form signed<br><br>        Exclusion Criteria:<br><br>          -  Congenital and/or major malformations<br><br>          -  FIO2 >60%<br><br>          -  Silverman score >6<br><br>          -  Contraindication to the use of Propofol :<br><br>          -  Low Blood Pressure with 2 successive measurements (Mean < Gestational Age expressed in<br>             Weeks of Gestation) persisting after one volume expansion,<br><br>          -  Use of inotropic medication to maintain a normal blood pressure.<br><br>          -  Use of sedative or analgesic drugs (except paracetamol and ibuprofen) in the previous<br>             24h<br><br>          -  Coma, convulsions, areactivity at neurological examination<br>",NULL,need for mechanical ventilation after the procedure,"At two years of corrected age: audition;At two years of corrected age: vision;At two years of corrected age: motor function;At two years of corrected age: ASQ (Ages and Stages Questionnaire);In-hospital morbidity and mortality: death during hospitalization;In-hospital morbidity and mortality: death 36weeks of Gestational Age;In-hospital morbidity and mortality: patent ductus arteriosus;In-hospital morbidity and mortality;In-hospital morbidity and mortality: retinopathy;In-hospital morbidity and mortality : sepsis;In-hospital morbidity and mortality: Necrotizing Enterocolitis;In-hospital morbidity and mortality: pneumothorax;BPD (bronchopulmonary dysplasia) at 36 weeks of Gestational Age;Tolerance and efficacy (Per procedure events): Viby Mogensen score;Tolerance and efficacy (Per procedure events): emergency intubation;Tolerance and efficacy (Per procedure events): Apnea;Number of laryngoscopies;number of ketamine administrations for rescue;FANS during LISA and 1h after LISA;Rate of MV (mechanical ventilation ) in each class of GA (<28, 28-31wGA)",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04020263,https://clinicaltrials.gov/show/NCT04020263,Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock,Cardiogenic Shock,Drug: Levosimendan 2.5 MG/ML Injectable Solution;Drug: Placebo,Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock,CT.gov,28/06/2019,01/12/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Phase 3,610,"Central Hospital, Nancy, France",France,NA,NULL,28/06/2019,"December 1, 2019",NCT040,29-Jul-19,2019-001563-74,; ; ;,"Clément DELMAS, Dr;Nicolas GIRERD, Pr;Patrick ROSSIGNOL, Pr;Bruno LEVY, Pr",NULL,;;;b.levy@chru-nancy.fr,;;;+33 3 83 15 40 84,CHU Toulouse;CHRU Nancy;CHRU Nancy;,; ; ;,"Clément DELMAS, Dr;Nicolas GIRERD, Pr;Patrick ROSSIGNOL, Pr;Bruno LEVY, Pr",NULL,;;;b.levy@chru-nancy.fr,;;;+33 3 83 15 40 84,CHU Toulouse;CHRU Nancy;CHRU Nancy;,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>        Adult patient with cardiogenic shock defined by:<br><br>          -  Adequate intravascular volume<br><br>          -  Norepinephrine infusion <1 microgram/kg/min to maintain MAP at least at 65 mmHg for at<br>             least 3 hours and less than 12h or dobutamine = 5 microgram/kg/min since at least 3h<br>             and less than 12h<br><br>          -  Tissue hypoperfusion: at least 2 signs (lactate = 2 mmol/l, mottling, oliguria, ScVO2<br>             = 60% or veno-arterial PCO2 gap = 5 mmHg)<br><br>          -  Clinical pulmonary congestion or elevated natriuretic peptides or echocardiographic<br>             sign of elevated left ventricular pressure or elevated right atrial pressure.<br><br>        Exclusion Criteria:<br><br>          -  Myocardial sideration after cardiac arrest of non-cardiac etiology<br><br>          -  Immediate or anticipated (within 6 hours) indication of Extra Corporel Life Support<br><br>          -  Extra Corporel Life Support (Extracorporeal Membrane Oxygenation (ECMO) or Impella)<br><br>          -  Chronic renal failure requiring hemodialysis<br><br>          -  Cardiotoxic poisoning<br><br>          -  Septic cardiomyopathy<br><br>          -  Previous levosimendan administration within 15 days<br><br>          -  Cardiac arrest resuscitation >30 minutes<br><br>          -  Cerebral deficit with fixed dilated pupils<br><br>          -  Patient moribund on the day of randomization<br><br>          -  Irreversible neurological pathology<br><br>          -  Known hypersensitivity to levosimendan or placebo, or one of its excipients<br><br>          -  Woman of childbearing age without effective contraception<br><br>          -  Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health<br>             Code:<br><br>               -  Pregnant, parturient or breastfeeding woman<br><br>               -  Person deprived of liberty for judicial or administrative decision<br><br>               -  Person under psychiatric care<br><br>               -  Minor person (non-emancipated)<br><br>               -  Adult person under legal protection (any form of public guardianship)<br>",NULL,Proportion of All-cause mortality;Proportion of Extra Corporel Life Support implantation;Proportion of Dialysis,"Proportion of All-cause mortality;Proportion of Extra Corporel Life Support implantation;Proportion of dialysis;Proportion of death;Proportion of cardiac transplantation;Proportion of escalation to permanent Left Ventricular Assist Device;Proportion of stroke;Proportion of recurrent myocardial infarction;Proportion of urgent coronary revascularization;Proportion of dialysis;Proportion of re-hospitalization for heart failure;Amount of administered dobutamine;Duration of administered dobutamine;Duration with abnormal lactate value;Number of days with organ failure(s);The number of days between inclusion and D30, without organ failure;Duration of catecholamine hemodynamic support;The number of days between inclusion and D30 without hemodynamic support;Duration of mechanical ventilation;The number of days alive without mechanical ventilation;Duration of intensive care unit stay;Duration of hospitalization;Occurrence of arrhythmias",NA,EUCTR2019-001563-74-FR,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03640052,https://clinicaltrials.gov/show/NCT03640052,Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea,Obstructive Sleep Apnea,Drug: Placebo oral capsule;Drug: LTM1201L;Drug: LTM1201LN;Drug: LTM1201LB;Drug: LTM1201LD,Pharmacological Activation of HMN for OSA,CT.gov,17/08/2018,30/10/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,10,Brigham and Women's Hospital,United States,NA,NULL,17/08/2018,"October 30, 2018",NCT036,03-Dec-18,2018P001201,NA,"Lauren Hess, RPSGT",NULL,lhess1@bwh.harvard.edu,617-732-8976,NULL,NA,"Lauren Hess, RPSGT",NULL,lhess1@bwh.harvard.edu,617-732-8976,NULL,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,70 Years,All,"<br>        Inclusion Criteria:<br><br>          -  AHI > 10 events/h during NREM supine sleep<br><br>        Exclusion Criteria:<br><br>          -  Any medical condition other than well controlled hypertension and mild diabetes.<br><br>          -  Any medication known to influence breathing, sleep/arousal, or muscle physiology.<br><br>          -  Claustrophobia.<br><br>          -  Inability to sleep supine.<br><br>          -  Allergy to any of the medications tested in the protocol.<br><br>          -  History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis,<br>             hypervitaminosis D.<br><br>          -  Individuals with underlying cardiac disease, such as arrhythmias.<br><br>          -  Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of<br>             the studied medications for medical care.<br><br>          -  For women: Pregnancy.<br><br>          -  Pulmonary hypertension<br><br>          -  Severe OSA with a mean SaO2 lower than 88%<br>",NULL,"Apnea hypopnea Index (AHI, average number of events for every hour of sleep)",Collapsibility of the upper airway: VPassive and VActive (ventilation as % of eupneic value),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03122639,https://clinicaltrials.gov/show/NCT03122639,Vascular Endothelial Activation in Obstructive Sleep Apnea,Obstructive Sleep Apnea of Adult,Drug: Atorvastatin 10mg;Drug: Placebo,Endothelial Function in Obstructive Sleep Apnea,CT.gov,12/04/2017,01/09/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Early Phase 1,245,Columbia University,United States,NA,NULL,12/04/2017,"September 1, 2017",NCT031,11-Feb-19,2R01HL106041-06A1;AAAR0444,; ;,"Sanja Jelic, MD;Sanja Jelic, MD;Sanja Jelic, MD",NULL,;sj366@cumc.columbia.edu;sj366@cumc.columbia.edu,;2125438875;212-543-8875,Columbia University;,; ;,"Sanja Jelic, MD;Sanja Jelic, MD;Sanja Jelic, MD",NULL,;sj366@cumc.columbia.edu;sj366@cumc.columbia.edu,;2125438875;212-543-8875,Columbia University;,Recruiting,"National Heart, Lung, and Blood Institute (NHLBI)",Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Patients aged =18 years with newly diagnosed obstructive sleep apnea (OSA) who were<br>             never treated with CPAP. OSA is defined as apnea-hypopnea index (AHI) =5 events/hour<br>             of sleep.<br><br>        Exclusion Criteria:<br><br>          -  A history of hypertension, coronary artery disease, heart failure, stroke, diabetes,<br>             malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue,<br>             smoking within the past 5 years, regular use of any medications.<br>",NULL,Change in proportion of CD59 on the endothelial cell (EC) surface (the percent [%] of the total cellular CD59 protein that is expressed on the endothelial cell surface).,MAC deposition on EC surface (measurement unit is fluorescent area quantified as micrometer square).,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02987374,https://clinicaltrials.gov/show/NCT02987374,Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization,Influenza;Influenza;Influenza;Influenza,Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM);Biological: 2011-2012 Fluzone IIV3 (IM),Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization,CT.gov,06/12/2016,01/05/2012,TRUE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 4,10,Stanford University,NULL,NA,1,06/12/2016,May-12,NCT029,16-Dec-17,U19AI057229-06;SU-24167,; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD",NULL,;;;;;;;;;,;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD;Cornelia Dekker, MD;Stephen Quake, PhD",NULL,;;;;;;;;;,;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,Completed,National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,18 Years,30 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Otherwise healthy, 18-30 year old young adult.<br><br>          2. Availability for follow-up for the planned duration of the study at least 180 days<br>             after immunization.<br><br>          3. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with 2010-2011 seasonal TIV or LAIV.<br><br>          2. Prior off-study vaccination with the current 2011-2012 seasonal TIV or LAIV<br><br>          3. Weight less than 110 pounds.<br><br>          4. Allergy to egg or egg products, or to vaccine components, including gelatin or<br>             thimerosal (thimerosal in TIV multidose vials only).<br><br>          5. Life-threatening reactions to previous influenza vaccinations<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids. Corticosteroid nasal sprays and topical steroids are permissible.<br><br>         13. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         14. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         15. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year.<br><br>         16. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         17. Receipt of blood or blood products within the past 6 months.<br><br>         18. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         19. Receipt of inactivated vaccine 14 days prior to study enrollment, planned vaccinations<br>             prior to completion of Visit 09 (Day 28 after study vaccination), or planned<br>             vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         20. Receipt of live, attenuated vaccine 60 days prior to study enrollment, planned<br>             vaccination prior to completion of Visit 09 (Day 28 after study vaccination), or<br>             planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         21. History of Guillain-Barré Syndrome<br><br>         22. Pregnant or lactating woman<br><br>         23. Use of investigational agents within 30 days prior to study enrollment or planned use<br>             during the study period.<br><br>         24. Donation of the equivalent of a unit of blood within 6 weeks prior to study<br>             enrollment, or during the first 5 weeks of study participation.<br><br>         25. A member of the study team or their family member, to include investigators, research<br>             laboratory staff, clinical research staff.<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Otherwise healthy, 18-30 year old young adult.<br><br>          2. Availability for follow-up for the planned duration of the study at least 180 days<br>             after immunization.<br><br>          3. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with 2010-2011 seasonal TIV or LAIV.<br><br>          2. Prior off-study vaccination with the current 2011-2012 seasonal TIV or LAIV<br><br>          3. Weight less than 110 pounds.<br><br>          4. Allergy to egg or egg products, or to vaccine components, including gelatin or<br>             thimerosal (thimerosal in TIV multidose vials only).<br><br>          5. Life-threatening reactions to previous influenza vaccinations<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids. Corticosteroid nasal sprays and topical steroids are permissible.<br><br>         13. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         14. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         15. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year.<br><br>         16. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         17. Receipt of blood or blood products within the past 6 months.<br><br>         18. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         19. Receipt of inactivated vaccine 14 days prior to study enrollment, planned vaccinations<br>             prior to completion of Visit 09 (Day 28 after study vaccination), or planned<br>             vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         20. Receipt of live, attenuated vaccine 60 days prior to study enrollment, planned<br>             vaccination prior to completion of Visit 09 (Day 28 after study vaccination), or<br>             planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         21. History of Guillain-Barré Syndrome<br><br>         22. Pregnant or lactating woman<br><br>         23. Use of investigational agents within 30 days prior to study enrollment or planned use<br>             during the study period.<br><br>         24. Donation of the equivalent of a unit of blood within 6 weeks prior to study<br>             enrollment, or during the first 5 weeks of study participation.<br><br>         25. A member of the study team or their family member, to include investigators, research<br>             laboratory staff, clinical research staff.<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Otherwise healthy, 18-30 year old young adult.<br><br>          2. Availability for follow-up for the planned duration of the study at least 180 days<br>             after immunization.<br><br>          3. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with 2010-2011 seasonal TIV or LAIV.<br><br>          2. Prior off-study vaccination with the current 2011-2012 seasonal TIV or LAIV<br><br>          3. Weight less than 110 pounds.<br><br>          4. Allergy to egg or egg products, or to vaccine components, including gelatin or<br>             thimerosal (thimerosal in TIV multidose vials only).<br><br>          5. Life-threatening reactions to previous influenza vaccinations<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids. Corticosteroid nasal sprays and topical steroids are permissible.<br><br>         13. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         14. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         15. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year.<br><br>         16. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         17. Receipt of blood or blood products within the past 6 months.<br><br>         18. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         19. Receipt of inactivated vaccine 14 days prior to study enrollment, planned vaccinations<br>             prior to completion of Visit 09 (Day 28 after study vaccination), or planned<br>             vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         20. Receipt of live, attenuated vaccine 60 days prior to study enrollment, planned<br>             vaccination prior to completion of Visit 09 (Day 28 after study vaccination), or<br>             planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         21. History of Guillain-Barré Syndrome<br><br>         22. Pregnant or lactating woman<br><br>         23. Use of investigational agents within 30 days prior to study enrollment or planned use<br>             during the study period.<br><br>         24. Donation of the equivalent of a unit of blood within 6 weeks prior to study<br>             enrollment, or during the first 5 weeks of study participation.<br><br>         25. A member of the study team or their family member, to include investigators, research<br>             laboratory staff, clinical research staff.<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Otherwise healthy, 18-30 year old young adult.<br><br>          2. Availability for follow-up for the planned duration of the study at least 180 days<br>             after immunization.<br><br>          3. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with 2010-2011 seasonal TIV or LAIV.<br><br>          2. Prior off-study vaccination with the current 2011-2012 seasonal TIV or LAIV<br><br>          3. Weight less than 110 pounds.<br><br>          4. Allergy to egg or egg products, or to vaccine components, including gelatin or<br>             thimerosal (thimerosal in TIV multidose vials only).<br><br>          5. Life-threatening reactions to previous influenza vaccinations<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids. Corticosteroid nasal sprays and topical steroids are permissible.<br><br>         13. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         14. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         15. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year.<br><br>         16. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         17. Receipt of blood or blood products within the past 6 months.<br><br>         18. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         19. Receipt of inactivated vaccine 14 days prior to study enrollment, planned vaccinations<br>             prior to completion of Visit 09 (Day 28 after study vaccination), or planned<br>             vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         20. Receipt of live, attenuated vaccine 60 days prior to study enrollment, planned<br>             vaccination prior to completion of Visit 09 (Day 28 after study vaccination), or<br>             planned vaccination 14 days prior to Visit 10 (6 months after study vaccination).<br><br>         21. History of Guillain-Barré Syndrome<br><br>         22. Pregnant or lactating woman<br><br>         23. Use of investigational agents within 30 days prior to study enrollment or planned use<br>             during the study period.<br><br>         24. Donation of the equivalent of a unit of blood within 6 weeks prior to study<br>             enrollment, or during the first 5 weeks of study participation.<br><br>         25. A member of the study team or their family member, to include investigators, research<br>             laboratory staff, clinical research staff.<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>",NULL,Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine,Number of Participants With Related Adverse Events,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT02987374,NULL,26/12/2016,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT03020498,https://clinicaltrials.gov/show/NCT03020498,Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire - Years 2 (2010) & 3 (2011),Influenza;Influenza;Influenza,Biological: Fluzone;Biological: FluMist;Biological: Fluzone;Biological: FluMist;Biological: Fluzone;Biological: FluMist,B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011),CT.gov,11/01/2017,01/09/2010,TRUE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 4,91,Stanford University,NULL,NA,1,11/01/2017,Sep-10,NCT030,11-Jun-18,2U19AI057229-06;SU-17218-2010-2011,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD",NULL,;;;;;;;;;;;;;;;;;;;;;;;,;;;;;;;;;;;;;;;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD",NULL,;;;;;;;;;;;;;;;;;;;;;;;,;;;;;;;;;;;;;;;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,Completed,National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,8 Years,100 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory 8-17 year old identical twins, 8-30 year old non-twins, or 70-100<br>             year old elderly non-twin adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study at least 28 days<br>             after immunization.<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with seasonal TIV or LAIV or H1N1.<br><br>          2. Prior off-study vaccination with the current seasonal TIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Asthma or history of wheezing<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in<br>             all groups; inhaled steroid use is not permissible except for non-LAIV Group C only).<br>             Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable for<br>             volunteers 70-100 yrs of age after review by the investigator.<br><br>         13. Participants in close contact with anyone who has a severely weakened immune system<br>             should not receive LAIV (Groups A and B only)<br><br>         14. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         15. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         16. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         17. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         18. Receipt of blood or blood products within the past 6 months<br><br>         19. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         20. Inactivated vaccine 14 days prior to vaccination<br><br>         21. Live, attenuated vaccine within 60 days of vaccination<br><br>         22. History of Guillain-Barré Syndrome<br><br>         23. Pregnant or lactating woman<br><br>         24. Use of investigational agents within 30 days prior to enrollment<br><br>         25. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory 8-17 year old identical twins, 8-30 year old non-twins, or 70-100<br>             year old elderly non-twin adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study at least 28 days<br>             after immunization.<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with seasonal TIV or LAIV or H1N1.<br><br>          2. Prior off-study vaccination with the current seasonal TIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Asthma or history of wheezing<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in<br>             all groups; inhaled steroid use is not permissible except for non-LAIV Group C only).<br>             Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable for<br>             volunteers 70-100 yrs of age after review by the investigator.<br><br>         13. Participants in close contact with anyone who has a severely weakened immune system<br>             should not receive LAIV (Groups A and B only)<br><br>         14. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         15. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         16. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         17. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         18. Receipt of blood or blood products within the past 6 months<br><br>         19. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         20. Inactivated vaccine 14 days prior to vaccination<br><br>         21. Live, attenuated vaccine within 60 days of vaccination<br><br>         22. History of Guillain-Barré Syndrome<br><br>         23. Pregnant or lactating woman<br><br>         24. Use of investigational agents within 30 days prior to enrollment<br><br>         25. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory 8-17 year old identical twins, 8-30 year old non-twins, or 70-100<br>             year old elderly non-twin adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study at least 28 days<br>             after immunization.<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Prior vaccination with seasonal TIV or LAIV or H1N1.<br><br>          2. Prior off-study vaccination with the current seasonal TIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Asthma or history of wheezing<br><br>          6. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          7. History of immunodeficiency (including HIV infection)<br><br>          8. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          9. Blood pressure >150 systolic or >95 diastolic at first study visit<br><br>         10. Hospitalization in the past year for congestive heart failure or emphysema.<br><br>         11. Chronic Hepatitis B or C.<br><br>         12. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in<br>             all groups; inhaled steroid use is not permissible except for non-LAIV Group C only).<br>             Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable for<br>             volunteers 70-100 yrs of age after review by the investigator.<br><br>         13. Participants in close contact with anyone who has a severely weakened immune system<br>             should not receive LAIV (Groups A and B only)<br><br>         14. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         15. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         16. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         17. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         18. Receipt of blood or blood products within the past 6 months<br><br>         19. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         20. Inactivated vaccine 14 days prior to vaccination<br><br>         21. Live, attenuated vaccine within 60 days of vaccination<br><br>         22. History of Guillain-Barré Syndrome<br><br>         23. Pregnant or lactating woman<br><br>         24. Use of investigational agents within 30 days prior to enrollment<br><br>         25. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         26. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>",NULL,Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine,Number of Participants With Related Adverse Events,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT03020498,NULL,09/03/2017,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT02853929,https://clinicaltrials.gov/show/NCT02853929,Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery,Diphtheria;Hepatitis B;Acellular Pertussis;Haemophilus Influenzae Type b;Tetanus;Poliomyelitis,Biological: Infanrix hexa,Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery,CT.gov,14/07/2016,19/09/2016,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 4,551,GlaxoSmithKline,Australia;Canada;Czechia;Finland;Italy;Spain;Australia;Canada;Czechia;Finland;Italy;Spain;Czech Republic,NA,NULL,14/07/2016,"September 19, 2016",NCT028,03-Jun-19,2014-001120-30;201334,NA,GSK Clinical Trials,NULL,NA,NA,GlaxoSmithKline,NA,GSK Clinical Trials,NULL,NA,NA,GlaxoSmithKline,Completed,NULL,Please refer to primary and secondary sponsors,9 Months,19 Months,All,"<br>        Inclusion Criteria:<br><br>          -  Subjects' parent(s)/Legally acceptable representatives (LAR(s)) who, in the opinion of<br>             the investigator, can and will comply, with the requirements of the protocol (e.g.<br>             completion of the diary cards, return for follow-up visits).<br><br>          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to<br>             performing any study specific procedure.<br><br>          -  A male or female child 9 months of age at the time of enrolment.<br><br>          -  Healthy subjects as established by medical history and clinical examination before<br>             entering into the study.<br><br>          -  Subjects born to mothers who were vaccinated in 116945 [DTPA (BOOSTRIX)-047] study and<br>             having completed their primary vaccination series as per protocol requirement in study<br>             201330 [DTPA (BOOSTRIX)-048 PRI].<br><br>        Exclusion Criteria:<br><br>          -  Child in care<br><br>          -  Concurrently participating in another clinical study, within three months prior to the<br>             booster vaccine dose and at any time during the present booster study, in which the<br>             subject has been or will be exposed to an investigational or a non-investigational<br>             vaccine/product (pharmaceutical product or device).<br><br>          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants<br>             or other immune-modifying drugs during the period within six months prior to the<br>             booster vaccine dose. For corticosteroids, this will mean prednisone =0.5mg/kg/day, or<br>             equivalent. Inhaled and topical steroids are allowed.<br><br>          -  Administration of long-acting immune-modifying drugs at any time during the study<br>             period (e.g. infliximab).<br><br>          -  A vaccine not foreseen by the study protocol administered during the period starting<br>             from 30 days before the booster dose of study vaccine and ending 30 days after*, with<br>             the exception of inactivated influenza vaccine and other vaccines given as a part of<br>             the national/regional immunization schedule, that are allowed at any time during the<br>             study period.<br><br>               -  In case an emergency mass vaccination for an unforeseen public health threat<br>                  (e.g.: a pandemic) is organised by the public health authorities, outside the<br>                  routine immunization program, the time period described above can be reduced if<br>                  necessary for that vaccine provided it is licensed and used according to its SPC<br>                  or Product Information (PI) and according to the local governmental<br>                  recommendations and provided a written approval of the Sponsor is obtained.<br><br>          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on<br>             medical history and physical examination (no laboratory testing required).<br><br>          -  Major congenital defects.<br><br>          -  Serious chronic illness.<br><br>          -  Administration of immunoglobulins and/or any blood products during the period within<br>             three months before the booster dose of study vaccines or planned administration<br>             during the study period.<br><br>          -  Encephalopathy defined as an acute, severe central nervous system disorder occurring<br>             within 7 days following vaccination with Infanrix hexa and generally consisting of<br>             major alterations in consciousness, unresponsiveness, generalised or focal seizures<br>             that persist more than a few hours, with failure to recover within 24 hours.<br><br>          -  History of Hib, diphtheria, tetanus, pertussis, pneumococcal, poliovirus and hepatitis<br>             B diseases since the conclusion visit of study 201330 [DTPA (BOOSTRIX)-048 PRI].<br><br>          -  Previous booster vaccination against Hib, diphtheria, tetanus, pertussis,<br>             pneumococcus, hepatitis B and/or poliovirus since the conclusion visit of study 201330<br>             [DTPA (BOOSTRIX)-048 PRI].<br><br>          -  History of any reaction or hypersensitivity likely to be exacerbated by any component<br>             of the vaccines (e.g: antigen, excipients).<br><br>          -  Hypersensitivity to latex.<br><br>          -  History of any neurological disorders or seizures.<br><br>          -  Any condition that in the judgment of the investigator would make intramuscular<br>             injection unsafe.<br><br>          -  Acute disease and/or fever at the time of vaccination.<br><br>               -  Fever is defined as temperature = 37.5°C /99.5°F for oral, axillary or tympanic<br>                  route, or = 38.0°C /100.4°F on rectal route.<br><br>               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory<br>                  infection) without fever may be enrolled at the discretion of the investigator.<br>",NULL,"Number of seroprotected subjects for anti-diphtheria, anti-tetanus, anti-HBs, anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3 and anti-polyribosyl-ribitol phosphate.;Number of subjects with a booster response to PT, FHA and PRN antigens.","Number of seroprotected subjects against anti-diphtheria, anti-tetanus, anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3, anti-HBs and anti-PRP.;Number of seropositive subjects Anti-PT, anti-FHA and anti-PRN and anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F);Anti-D, anti-T, anti-PT, anti-FHA, anti-PRN, anti-poliovirus type 1, 2, 3, anti-HBs and anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and anti-PRP antibody concentrations or titres.;Number of seropositive subjects for anti-PT, anti-FHA and anti-PRN.;Number of subjects with solicited local and general symptoms.;Number of subjects with unsolicited adverse events (AEs).;Number of subjects with serious adverse events (SAEs).;Neurodevelopmental status measured by ASQ-3 score.",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02739568,https://clinicaltrials.gov/show/NCT02739568,"Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness",Excessive Daytime Sleepiness;Obstructive Sleep Apnea,Drug: Pitolisant (BF2.649);Drug: Placebo,Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA,CT.gov,31/03/2016,01/04/2016,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 3,389,Bioprojet,"Bulgaria;North Macedonia;Bulgaria;North Macedonia;Macedonia, The Former Yugoslav Republic of",NA,NULL,31/03/2016,Apr-16,NCT027,20-Jul-20,P15 13/ BF2.649,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,100 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Male and/or female outpatients aged from at least 18 years<br><br>          -  Patients complaining of EDS refusing to be treated by nCPAP therapy or having been<br>             submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of<br>             EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy<br><br>          -  Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP)<br>             between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for<br>             patients without nCPAP therapy = 15; for patients under nCPAP therapy less or equal to<br>             10<br><br>          -  For patients submitted to nCPAP therapy: nCPAP = 4 hours / day (compliance checked on<br>             the clock-time counter of the CPAP machine)<br><br>          -  Mini Mental State Examination (MMSE) = 28<br><br>          -  Beck Depression Inventory - 13 items (BDI-13) score < 16 and item G (suicidal<br>             ideation) of BDI-13 = 0<br><br>          -  Body Mass Index (BMI )less or equal to 40 kg/m²<br><br>          -  Epworth Sleepiness Scale (ESS) = 12<br><br>          -  Female patients with child-bearing potential using a medically accepted method of<br>             birth control (i.e. oral contraceptives of normal average dosage) agreeing to continue<br>             this method throughout the study, and during the month following treatment<br>             discontinuation, being negative to serum pregnancy test performed at the screening<br>             visit<br><br>          -  If specified by the investigator, the patient must be willing not to operate a car (if<br>             sleepy at wheel) or heavy machinery for the duration of the trial or as long as the<br>             investigator deems it clinically indicated. In addition, the patient should be willing<br>             to maintain during the study their usual behaviors which could affect their diurnal<br>             sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration)<br><br>          -  Patients having signed and dated the informed consent form<br><br>        Exclusion Criteria:<br><br>          -  Patients suffering from chronic severe insomnia in accordance with the International<br>             Classification of Sleep Disorders (ICSD 2005) without OSA<br><br>          -  Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria<br><br>          -  Patients with sleep debt not due to OSA (according to the physician' s judgment)<br><br>          -  Patients with non-respiratory sleep fragmentation (restless leg syndrome…)<br><br>          -  Shift work, professional drivers<br><br>               -  Refusal from the patient to stop any current therapy for EDS or predictable risk<br>                  for the patient to stop the therapy<br><br>               -  Patients suffering from a psychiatric disease<br><br>               -  Acute or chronic disease preventing the improvement assessment, e.g. severe<br>                  chronic obstructive pulmonary disease (COPD)<br><br>               -  Current or recent (within one year) history of drug, alcohol, narcotic or other<br>                  substance abuse or dependence<br><br>               -  Any significant serious abnormality of the cardiovascular system, e.g. recent<br>                  myocardial infarction, angina, hypertension or dysrhythmias (within the previous<br>                  6 months), Electrocardiogram Fridericia corrected QT interval higher than 450 ms,<br>                  history of left ventricular hypertrophy or mitral valve prolapse<br><br>               -  Severe co-morbid medical or biological conditions that may jeopardize study<br>                  participation at the discretion of the investigator (particularly in the<br>                  cardiovascular system and the instable diabetes)<br><br>               -  Positive serology tests (HIV, HCV and HBsAg)<br><br>               -  Pregnant or breast-feeding women<br><br>               -  Women with child-bearing potential and no efficient birth-control method<br><br>               -  Patients unable to understand the study protocol<br><br>               -  Patients with suspected or known hypersensitivity to study medication<br><br>               -  Patients with a dominant arm deficiency impeding the achievement of the tests<br><br>               -  Patients using a prohibited medication<br><br>               -  Congenital galactose poisoning, glucose and galactose malabsorption, deficit in<br>                  lactase<br><br>               -  Patients participating in another study or being in a follow-up period for<br>                  another study<br>",NULL,Epworth sleepiness scale (ESS),Percentage of ESS responders;Reduction of sleepiness and sleep episodes on the sleep diary;Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test;European Quality of Life Questionnaire (EQ-5D);Leeds Sleep Evaluation Questionnaire (LSEQ);The Pichot Fatigue Scale;Trail Making Test parts (A and B);Improvement in Clinical Global Impression (CGI);Aggregate Z-score of secondary endpoints.,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03202394,https://clinicaltrials.gov/show/NCT03202394,"A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome","Respiratory Distress Syndrome, Adult",Drug: BIO-11006;Drug: Placebo,Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS,CT.gov,20/06/2017,05/08/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,38,"BioMarck Pharmaceuticals, Ltd.",United States,NA,NULL,20/06/2017,"August 5, 2017",NCT032,06-Jul-20,BIM-CL-005,NA,"Brian Dickson, MD",NULL,NA,NA,Biomarck Pharmaceuticals,NA,"Brian Dickson, MD",NULL,NA,NA,Biomarck Pharmaceuticals,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Has provided (or relative has) written informed consent and authorization for use and<br>             disclosure of protected health information<br><br>          2. Has a clinical diagnosis of sepsis or septic shock defined as:<br><br>               -  Known or suspected infection<br><br>               -  Systemic inflammatory response syndrome (SIRS), defined as meeting at least 2 of<br>                  the following 3 criteria for a systemic inflammatory response:<br><br>                    -  White blood cell count >12,000 or <4,000 or >10% band forms<br><br>                    -  Body temperature >38°C (any route) or <36°C (by core temperatures only:<br>                       indwelling catheter, esophageal, rectal)<br><br>                    -  Heart rate >90 beats/min or receiving medications that slow heart rate or<br>                       pace rhythm<br><br>          3. Enrollment must occur within 48 hours of first meeting ARDS criteria per the Berlin<br>             definition of ARDS (ARDS Task Force 2012) and no more than 72 hours from the<br>             initiation of mechanical ventilation. (The bilateral opacities, respiratory failure,<br>             and decreased P/F ratio must all be present within a 24 hour time period of one<br>             another.):<br><br>               -  Lung injury of acute onset, within 1 week of an apparent clinical insult, with<br>                  progression of respiratory symptoms<br><br>               -  Bilateral opacities on chest imaging not fully explained by effusions, lobar/lung<br>                  collapse, or nodules.<br><br>               -  Respiratory failure not fully explained by cardiac failure or fluid overload.<br>                  (Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema<br>                  if no risk factor present.)<br><br>               -  Decreased arterial partial pressure of oxygen (PaO2)/ fraction of inspired oxygen<br>                  (FIO2) ratio while on a minimum Positive End Expiratory Pressure (PEEP) of 5 cm<br>                  water (H2O):<br><br>                    -  Moderate ARDS: 101 to 200 mmHg (= 26.6 kPa)<br><br>                    -  Severe ARDS: = 100 mmHg (= 13.3 kPa)<br><br>        Exclusion Criteria:<br><br>          1. Age < 18 years or >75 years old<br><br>          2. Greater than 48 hours since first meeting ARDS criteria per the Berlin definition of<br>             ARDS<br><br>          3. Pregnant or breastfeeding (negative pregnancy test required prior to randomization for<br>             female patients of childbearing potential.)<br><br>          4. Prisoner<br><br>          5. Any other irreversible disease or condition for which 6 month mortality is estimated<br>             to be > 50%<br><br>          6. Moderate to severe liver failure (Child Pugh Score > 12)<br><br>          7. Severe chronic respiratory disease with a PaCO2 > 50 mmHg or the use of home oxygen<br><br>          8. Patient, surrogate, or physician not committed to full support (exception: a patient<br>             will not be excluded if he/she would receive all supportive care except for attempts<br>             at resuscitation from cardiac arrest).<br><br>          9. Major trauma in the prior 5 days<br><br>         10. Lung transplant patient<br><br>         11. No consent/inability to obtain consent<br><br>         12. Moribund patient not expected to survive 24 hours<br><br>         13. World Health Organization (WHO) Functional Class III or IV pulmonary hypertension<br><br>         14. No intent/unwillingness to follow lung protective ventilation strategy or fluid<br>             management protocol<br><br>         15. Currently receiving extracorporeal life support or high frequency oscillatory<br>             ventilation<br><br>         16. Known hypersensitivity to BIO 11006<br><br>         17. Burn victims >20% Total Body Surface Area (TBSA) or with known airway inhalation<br>             injury<br>",NULL,Incidence of treatment-emergent adverse events,Incidence of mortality;Number of Intensive Care Unit (ICU)-free days;Number of ventilator-free days;Change in oxygen saturation / fraction of inspired oxygen (S/F) ratio;Change in pro-inflammatory biomarkers from baseline to end of treatment,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03027609,https://clinicaltrials.gov/show/NCT03027609,"Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia",Pseudomonas Aeruginosa Pneumonia,Drug: AR-105;Drug: placebo,Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia,CT.gov,17/01/2017,29/03/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,158,"Aridis Pharmaceuticals, Inc.","United States;Australia;Belarus;Belgium;Czechia;France;Georgia;Greece;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Spain;Taiwan;Ukraine;Australia;Belarus;Belgium;Czechia;France;Georgia;Greece;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Spain;Taiwan;Ukraine;United States",EUCTR2016-004261-10-DE,NULL,17/01/2017,"March 29, 2017",NCT030,25-Nov-19,AR-105-002,NA,"Bruno François, MD",NULL,NA,NA,Hospital Dupuytren,NA,"Bruno François, MD",NULL,NA,NA,Hospital Dupuytren,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Informed consent<br><br>          -  =18 years of age, = 20 years of age (Taiwan only),= 19 (S. Korea only)<br><br>          -  pneumonia due to P. aeruginosa<br><br>          -  ventilated<br><br>          -  intubated<br><br>          -  APACHE II score between 10 and 35<br><br>        Exclusion Criteria (main criteria):<br><br>          -  being moribund<br><br>          -  effective antibiotic therapy =48 hours<br><br>          -  immunocompromised<br><br>          -  underlying pulmonary disease that may preclude the assessment of a therapeutic<br>             response<br>",NULL,"Clinical Cure: treatment success, treatment failure","Mortality, all-cause, the difference in the number of patients who die with Standard of Care (SOC) alone and AR-105 plus SOC;Microbiological outcome: eradicated, not eradicated;Health Economics assessments: time ventilated, time in ICU, time in the hospital;Safety - adverse events;Safety - immunogenicity, concentration of anti-drug antibody;Pharmacokinetic: AR-105 blood level",parent,EUCTR2016-004261-10-BE;EUCTR2016-004261-10-CZ;EUCTR2016-004261-10-DE;EUCTR2016-004261-10-ES;EUCTR2016-004261-10-GR;EUCTR2016-004261-10-HU;EUCTR2016-004261-10-PL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03282240,https://clinicaltrials.gov/show/NCT03282240,Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older,Influenza,Biological: QIV-HD;Biological: Licensed TIV-HD1;Biological: Investigational TIV-HD2,Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants =65 Years in the US,CT.gov,12/09/2017,08/09/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor).",Phase 3,2670,"Sanofi Pasteur, a Sanofi Company",United States;United States;United States,NA,NULL,12/09/2017,"September 8, 2017",NCT032,12-Nov-18,U1111-1183-5556;QHD00013,; ;,Medical Director;Medical Director;Medical Director,NULL,;;,;;,"Sanofi Pasteur, a Sanofi Company;Sanofi Pasteur, a Sanofi Company;Sanofi Pasteur, a Sanofi Company",; ;,Medical Director;Medical Director;Medical Director,NULL,;;,;;,"Sanofi Pasteur, a Sanofi Company;Sanofi Pasteur, a Sanofi Company;Sanofi Pasteur, a Sanofi Company",Completed,NULL,Please refer to primary and secondary sponsors,65 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Aged = 65 years on the day of inclusion<br><br>          -  Informed consent form has been signed and dated<br><br>          -  Able to attend all scheduled visits and to comply with all trial procedures<br><br>        Exclusion Criteria:<br><br>          -  Participation at the time of trial enrollment (or in the 4 weeks preceding the trial<br>             vaccination) or planned participation during the present trial period in another<br>             clinical trial investigating a vaccine, drug, medical device, or medical procedure<br><br>          -  Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or<br>             planned receipt of any vaccine prior to Visit 2<br><br>          -  Previous vaccination against influenza (in the preceding 6 months) with either the<br>             trial vaccine or another vaccine<br><br>          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months<br><br>          -  Known or suspected congenital or acquired immunodeficiency; or receipt of<br>             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,<br>             within the preceding 6 months; or long-term systemic corticosteroid therapy<br>             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)<br><br>          -  Known systemic hypersensitivity to any of the vaccine components, or history of a<br>             life-threatening reaction to the vaccines used in the trial or to a vaccine containing<br>             any of the same substances<br><br>          -  Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on<br>             investigator's judgment<br><br>          -  Deprived of freedom by an administrative or court order, or in an emergency setting,<br>             or hospitalized involuntarily<br><br>          -  Alcohol or substance abuse that, in the opinion of the investigator, might interfere<br>             with the trial conduct or completion<br><br>          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might<br>             interfere with trial conduct or completion<br><br>          -  Identified as an Investigator or employee of the Investigator or trial center with<br>             direct involvement in the proposed trial, or identified as an immediate family member<br>             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with<br>             direct involvement in the proposed trial<br><br>          -  Personal or family history of Guillain-Barré syndrome<br><br>          -  Neoplastic disease or any hematologic malignancy (except localized skin or prostate<br>             cancer that is stable at the time of vaccination in the absence of therapy and<br>             subjects who have a history of neoplastic disease and have been disease free for = 5<br>             years)<br><br>          -  Moderate or severe acute illness/infection (according to Investigator judgment) on the<br>             day of vaccination or febrile illness (temperature = 38.0°C [= 100.4°F]). A<br>             prospective participant should not be included in the trial until the condition has<br>             resolved or the febrile event has subsided<br>",NULL,Geometric Mean Titers of Influenza Antibodies Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Percentage of Participants Achieving Seroconversion Against Antigens Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine,Geometric Mean Titers of Influenza Antibodies Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Geometric Mean Titer Ratios of Influenza Antibodies Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Percentage of Participants Achieving Seroconversion Against Antigens After Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Percentage of Participants Achieving Seroprotection Against Antigens Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Geometric Mean Titers of Influenza Antibodies (Seroneutralization) Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Geometric Mean Titer Ratios of Influenza Antibodies (Seroneutralization) Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine;Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination with Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza Vaccine,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03235986,https://clinicaltrials.gov/show/NCT03235986,"A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone",Neonatal Respiratory Distress Syndrome,Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I);Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II);Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I);Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II),"A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)",CT.gov,26/07/2017,28/08/2017,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,166,Chiesi Farmaceutici S.p.A.,Italy,NCT03235986,NULL,26/07/2017,"August 28, 2017",NCT032,08-Jun-20,2016-004547-36;CCD-01534CA1-01,NA,"Carlo Dani, MD",NULL,NA,NA,"Careggi Hospital, Florence (Italy)",NA,"Carlo Dani, MD",NULL,NA,NA,"Careggi Hospital, Florence (Italy)",Terminated,NULL,Please refer to primary and secondary sponsors,28 Weeks,32 Weeks,All,"<br>        Inclusion Criteria:<br><br>          1. Written informed consent obtained by parents/legal representative (according to local<br>             regulation) prior to or after birth<br><br>          2. Inborn neonates from 28+0 to 32+6 weeks of gestational age (GA), spontaneously<br>             breathing and stabilised on nCPAP<br><br>          3. Clinical course consistent with RDS.<br><br>          4. Receiving CPAP pressure 5-8 centimeter of water (cm H2O) and fraction of inspired<br>             oxygen (FiO2) between 0.25 and 0.40 to maintain saturation of peripheral oxygen (SpO2)<br>             between 88% and 95% for at least 30 minutes. Randomization should occur between 60<br>             minutes and 12 hours after birth.<br><br>        Exclusion Criteria:<br><br>          1. Early need for endotracheal intubation for cardiopulmonary resuscitation in delivery<br>             room or within 1 hour from birth because of severe RDS<br><br>          2. Respiratory Distress not secondary to surfactant deficiency<br><br>          3. Use of surfactant prior to study entry and need for endotracheal administration of any<br>             other treatment.<br><br>          4. Major congenital anomalies.<br><br>          5. Evidence of severe birth asphyxia<br><br>          6. Mothers with prolonged rupture of the membranes<br><br>          7. Presence of air leaks.<br><br>          8. Presence of IVH (intraventricular hemorrhage ) = III.<br><br>          9. Hypotension or evidence of hemodynamic instability.<br><br>         10. Any condition that, in the opinion of the Investigator, would place the neonate at<br>             undue risk.<br><br>         11. Participation in another clinical trial<br>",NULL,Percentage of neonates with respiratory failure;Adverse Events;Adverse Drug Reactions,NULL,child,NCT03235986;EUCTR2016-004547-36-AT;EUCTR2016-004547-36-CZ;EUCTR2016-004547-36-FR;EUCTR2016-004547-36-GB;EUCTR2016-004547-36-HU;EUCTR2016-004547-36-IT;EUCTR2016-004547-36-PL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02774044,https://clinicaltrials.gov/show/NCT02774044,Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial,Respiratory Distress Syndrome,Drug: Cadisurf;Drug: Survanta,Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates,CT.gov,10/05/2016,01/06/2016,TRUE,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment",Phase 2/Phase 3,900,Ramesh K Agarwal,NULL,NA,NULL,10/05/2016,Jun-16,NCT027,30-May-16,N1617,NA,"Ramesh Kumar Agarwal, DM (Neonatology)",NULL,ra.aiims@gmail.com,0911-26596167,NA,NA,"Ramesh Kumar Agarwal, DM (Neonatology)",NULL,ra.aiims@gmail.com,0911-26596167,NA,Not yet recruiting,"Maulana Azad Medical College, New Delhi;Lade Hardinge Medical College, New Delhi;Chacha Nehru Bal Chikitsalya, Delhi;Postgraduate Institute of Medical Education and Research, Chandigarh;King Edward Memorial Hospital, Mumbai;Lokmanya Tilak Municipal General Hospital, Mumbai;Institute of Child health and Hospital for Children, Chennai;Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry;All India Institute of Medical Sciences, New Delhi;St. John's Medical College, Bangalore;King Edward Memorial Hospital, Pune;Government Medical College, Chandigarh;Wellcome Trust",Please refer to primary and secondary sponsors,26 Weeks,32 Weeks,Both,"<br>        Inclusion Criteria:<br><br>          -  Neonates born at the study sites and fulfilling all of the following criteria will be<br>             eligible for enrolment in the study<br><br>               1. Gestational age =32 completed weeks<br><br>               2. Onset of respiratory distress within six hours of age<br><br>               3. If baby meets criteria for surfactant replacement therapy:<br><br>                    1. FiO2 needed is 40% or higher while the baby is on CPAP to maintain<br>                       pre-ductal oxygen saturation between 90% to 95% or<br><br>                    2. Baby needs intubation because of CPAP failure or severe respiratory<br>                       distress (Chest X-ray is not mandatory for deciding the need for SRT).<br>                       Detailed SOPs will be developed with respect to assessing the eligibility<br>                       for SRT<br><br>                       Exclusion Criteria:<br><br>                       Neonates with any of the following criteria will be excluded:<br><br>               1. Gestation below 26 wk<br><br>               2. Babies with severe birth asphyxia as defined by the need for chest compressions<br>                  and/or initial (umbilical arterial/or within 1 hour of birth) pH <7.0<br><br>               3. Major congenital malformations<br><br>               4. Prophylactic surfactant administration, i.e. administration of surfactant before<br>                  the infant develops respiratory distress<br><br>               5. Air leak or pulmonary hemorrhage prior to enrollment<br><br>               6. Shock requiring vasopressor support prior to enrollment<br>",NULL,BPD free survival,Area under the curve for (AUC) for oxygen requirement (FiO2) requirement in first 48 h;Pulmonary haemorrhage;Any air leak within 72 hours of administration of surfactant;IVH grade 3 or 4;Periventricular Leukomalacia (PVL)-cystic and non-cystic;PVL-cystic and non-cystic;Sepsis;Respiratory support at 72 h;Respiratory support at 7 days of age;Retinopathy of prematurity (ROP);Neonatal Mortality;Duration of mechanical ventilation and CPAP;Duration of hospital stay,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02836340,https://clinicaltrials.gov/show/NCT02836340,"TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest",Cardiac Arrest;Hypoxic Ischemic Brain Injury;Cardiac Arrest;Hypoxic Ischemic Brain Injury;Cardiac Arrest;Hypoxic Ischemic Brain Injury,Drug: 2-Iminobiotin;Drug: 2-Iminobiotin;Drug: 2-Iminobiotin,"TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA",CT.gov,01/06/2016,01/05/2016,TRUE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,24,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Netherlands;Netherlands;Netherlands;Netherlands;Netherlands;Netherlands,NA,NULL,01/06/2016,May-16,NCT028,11-Jun-18,AMC-TIBOHCA,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD",NULL,;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl,;;;;;;;;;;;;;;;;;,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD;Janneke Horn, MD, PhD;Janneke Horn, MD;Janneke Horn, MD",NULL,;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl;;j.horn@amc.uva.nl;j.horn@amc.uva.nl,;;;;;;;;;;;;;;;;;,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);;Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Admission to the ICU after OHCA and successful CPR due to a cardiac cause<br><br>          -  Post anoxic coma on admission<br><br>          -  Ability to start study medication as soon as possible, but ultimately within 6h after<br>             OHCA via a central venous line<br><br>          -  Age 18 years or older<br><br>          -  Eligible for treatment with a target temperature management of 36° C<br><br>        Exclusion Criteria:<br><br>          -  No informed consent<br><br>          -  Known co-morbidity with a life expectancy of <6 months prior to cardiac arrest<br><br>          -  Women aged 49 or less<br><br>          -  Severe cognitive impairment (documented dementia) known prior to OHCA<br><br>          -  Inability to insert a central venous line<br>      ;<br>        Inclusion Criteria:<br><br>          -  Admission to the ICU after OHCA and successful CPR due to a cardiac cause<br><br>          -  Post anoxic coma on admission<br><br>          -  Ability to start study medication as soon as possible, but ultimately within 6h after<br>             OHCA via a central venous line<br><br>          -  Age 18 years or older<br><br>          -  Eligible for treatment with a target temperature management of 36° C<br><br>        Exclusion Criteria:<br><br>          -  No informed consent<br><br>          -  Known co-morbidity with a life expectancy of <6 months prior to cardiac arrest<br><br>          -  Women aged 49 or less<br><br>          -  Severe cognitive impairment (documented dementia) known prior to OHCA<br><br>          -  Inability to insert a central venous line<br>      ;<br>        Inclusion Criteria:<br><br>          -  Admission to the ICU after OHCA and successful CPR due to a cardiac cause<br><br>          -  Post anoxic coma on admission<br><br>          -  Ability to start study medication as soon as possible, but ultimately within 6h after<br>             OHCA via a central venous line<br><br>          -  Age 18 years or older<br><br>          -  Eligible for treatment with a target temperature management of 36° C<br><br>        Exclusion Criteria:<br><br>          -  No informed consent<br><br>          -  Known co-morbidity with a life expectancy of <6 months prior to cardiac arrest<br><br>          -  Women aged 49 or less<br><br>          -  Severe cognitive impairment (documented dementia) known prior to OHCA<br><br>          -  Inability to insert a central venous line<br>",NULL,Number of patients with treatment related adverse events;Number of patients with treatment related adverse events;Number of patients with treatment related adverse events,Cerebral Performance Category;Plasma levels of 2-IB;IQ-Code,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03208101,https://clinicaltrials.gov/show/NCT03208101,"A Single-center, Randomized, Active-controlled, Parallel-group, Open-label, Phase I Study to Evaluate Safety and Immunogenicity of Single Injection of LBVD or Eupenta Co-administered With Imovax Polio in Healthy Adults",Diphtheria;Tetanus;Pertussis;Poliomyelitis;Hepatitis B;Haemophilus Influenzae Type b Infection,Biological: DTP-HepB-IPV-Hib vaccine;Biological: DTP-HepB-Hib vaccine & IPV,A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults,CT.gov,30/06/2017,03/07/2017,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 1,42,LG Chem,"Korea, Republic of",NA,NULL,30/06/2017,"July 3, 2017",NCT032,09-Sep-19,LG-VDCL001,NA,WJ Kim,NULL,NA,NA,Korea University Guro Hospital,NA,WJ Kim,NULL,NA,NA,Korea University Guro Hospital,Completed,NULL,Please refer to primary and secondary sponsors,19 Years,55 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Healthy adults between 19 and 55 years of age at the time of Visit 1 (Screening)<br><br>          2. Persons who or whose legal representatives have voluntarily signed an informed consent<br>             after receiving explanation about the objectives, methods, effects, etc. of the<br>             clinical study<br><br>          3. Persons who are surgically sterile, postmenopausal women, or agree to use<br>             contraceptive measures<br><br>        Exclusion Criteria:<br><br>          1. Persons who have an experience of participation in another interventional clinical<br>             study within 3 months prior to Visit 1 (Screening)<br><br>          2. Persons who have a record of vaccination with the tetanus toxoid (TT)/tetanus<br>             diphtheria (Td)/tetanus diphtheria pertussis (Tdap) vaccine or other vaccines<br>             containing tetanus-diphtheria for adults or who are suspected to have been vaccinated<br>             with either of them within 5 years prior to Visit 1 (Screening)<br><br>          3. Persons who were vaccinated within 4 weeks prior to Visit 1 (Screening) or who are<br>             scheduled to be vaccinated with the vaccines other than the study vaccine during the<br>             study period<br><br>          4. Persons with a history of diphtheria, tetanus, pertussis, hepatitis B virus, polio<br>             virus, or the invasive diseases caused by Haemophilus influenzae type b<br>",NULL,Number of subjects with immediate reactions;Number of subjects with solicited adverse events;Number of subjects with any unsolicited adverse events,Proportions of the subjects who have shown seroprotection/vaccine-response to each antigen and the subjects who have shown seroconversion 28 days post-vaccination with the study vaccine (Day 29) compared to pre-vaccination.;GMC or GMT values for each antigen prior to and 28 days post-vaccination with the study vaccine (Day 29),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03651557,https://clinicaltrials.gov/show/NCT03651557,"A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy and Safety of Neu2000KWL in Patients Who Resuscitated After Out-of-hospital Cardiac Arrest Patient and Receiving Therapeutic Hypothermia",Cardiac Arrest,Drug: Neu2000KWL High-dose group;Drug: Neu2000KWL Low-dose group;Drug: Placebo,Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients,CT.gov,26/07/2018,29/11/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",Phase 2,150,GNT Pharma,"Korea, Republic of",NA,NULL,26/07/2018,"November 29, 2018",NCT036,18-Mar-19,Neu2000KWL-P02,NA,"Jin-Ho Choi, MD",NULL,NA,NA,"Professor, Department of Emergency Medicine, Samsung Medical Center",NA,"Jin-Ho Choi, MD",NULL,NA,NA,"Professor, Department of Emergency Medicine, Samsung Medical Center",Enrolling by invitation,Samsung Medical Center;Chonnam National University Hospital;Gangnam Severance Hospital;Kyungpook National University;Pusan National University Hospital;Soonchunhyang University Hospital,Please refer to primary and secondary sponsors,19 Years,80 Years,All,"<br>        Inclusion Criteria:<br><br>          1. 19 Years to 80 Years (Adult)<br><br>          2. Out-of-hospital cardiac arrest caused by non-perfusing cardiac rhythm<br><br>          3. Successful resuscitation accompanied by ROSC time of more than 20 min<br><br>          4. Therapeutic hypothermia is planned or initiated<br><br>          5. The first infusion is planned within 4 hours after ROSC<br><br>          6. Informed consent is obtained from patient or family member(s)<br><br>          7. No concern with previous cardiovascular surgery<br><br>        Exclusion Criteria:<br><br>          1. Hypersensitivity to aspirin or sulfasalazine<br><br>          2. Unwitnessed cardiac arrest<br><br>          3. CPR time > 60 min<br><br>          4. Therapeutic hypothermia is not planned<br><br>          5. Use of extracorporeal membrane oxygenation (ECMO) at initiation of in-hospital<br>             resuscitation (E-CPR)<br><br>          6. Very poor prognosis is expected: patients with (A) non-cardiac or respiratory arrest,<br>             (B) poor basal neurological status (C) secondary cardiac arrest caused by trauma,<br>             major bleeding, acute neurologic disease including stroke or tumor, (D) multiorgan<br>             failure or advanced malignancy<br><br>          7. Pregnant or lactating women<br><br>          8. Participated in other clinical studies within 90 days before randomization; or<br>             participating in other clinical trials at present<br><br>          9. Intracranial bleeding verified by first brain CT imaging<br><br>         10. The investigators consider the patients are not suitable for this trial<br>",NULL,Verification of difference between of Neuron specific enolase (NSE) value at after 4th infusion of Neu2000KWL.,"Verification of difference between the cumulative of neuron specific enolase (NSE) values at after 6th infusion of Neu2000KWL;Verification of the difference between groups of Change in NSE values at after the 2nd infusion of Neu2000KWL and after the 6th infusion;Verification of difference between each group of NSE values at after 6th infusion after 1st infusion of Neu2000KWL and 24 hours after end of last infusion;Verification of difference between the cerebral infarction at analysis of brain MRI's Apparent Diffusion Coefficient(ADC) images within 48 hours of the last infusion of Neu2000KWL;Verification of difference between groups of Neurological function evaluated by cerebral performance category (CPC) and modified Rankin Scale (mRS) at 5 day, 14 day, or discharge within 14 days, and 90 days after 1st infusion of Neu2000KWL.;Verification of difference between groups of Cumulative value of blood S100beta from 6th infusion after 1st infusion of Neu2000KWL.",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03607071,https://clinicaltrials.gov/show/NCT03607071,Outcome of Myocardial Inflammation After Steroid Therapy in Thai Systemic Sclerosis Patients: an Open Label Study,Myocardial Inflammation,Drug: Prednisolone and taper,Outcome of Steroid Therapy for Myocardial Inflammation in Scleroderma,CT.gov,20/07/2018,15/05/2018,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,20,Khon Kaen University,Thailand,NA,NULL,20/07/2018,"May 15, 2018",NCT036,21-Sep-20,SSc-KKU,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Inclusion Criteria:<br><br>        • The adult scleroderma patients who were defined as having myocardial inflammation by<br>        cardiac MRI.<br><br>        Exclusion Criteria:<br><br>          -  Current infection that needs systemic antibiotic therapy<br><br>          -  Active viral hepatitis B or C<br><br>          -  Uncontrolled diabetes mellitus<br>,NULL,Changing of degree of myocarditis evaluated by cardiac MRI after treatment compare to baseline,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03816878,https://clinicaltrials.gov/show/NCT03816878,"An Exploration of a Prime-Boost Approach for Universal Influenza Vaccination: Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",Influenza,Biological: H5N1 pISV,"Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals",CT.gov,23/01/2019,08/01/2019,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).,Phase 1,35,National Institute of Allergy and Infectious Diseases (NIAID),United States,NA,NULL,23/01/2019,"January 8, 2019",NCT038,06-Jan-20,CIR 327,NA,"Kawsar R. Talaat, MD",NULL,NA,NA,Johns Hopkins Bloomberg School of Public Health,NA,"Kawsar R. Talaat, MD",NULL,NA,NA,Johns Hopkins Bloomberg School of Public Health,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,18 Years,60 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Adult males and non-pregnant females between 18 years and 60 years of age inclusive.<br><br>          -  General good health, without significant medical illness, physical examination<br>             findings, or significant laboratory abnormalities as determined by the investigator.<br><br>          -  Available for the duration of the trial.<br><br>          -  Able to demonstrate understanding of key study concepts, study rationale, and study<br>             participation requirements by scoring greater than or equal to 70% on a written<br>             comprehension assessment in 3 or fewer attempts.<br><br>          -  Willingness to participate in the study as evidenced by signing the informed consent<br>             document.<br><br>          -  Willingness to allow storage and testing of laboratory samples for future research.<br><br>          -  Received 2 doses of live attenuated H2N2, H6N1, or H9N2 vaccine in a prior trial<br>             (Cohort 1) or H2N2, H6N1 and H9N2 naïve (Cohort 2)<br><br>          -  Willingness to forego seasonal influenza virus vaccination from 1 month before<br>             vaccination until 3 months after vaccination.<br><br>          -  Female subjects of childbearing potential must agree to have used effective birth<br>             control methods beginning at least one month prior to vaccination, and continuing with<br>             'per label/fully effective use' for the chosen method for duration of the study, from<br>             amongst these:<br><br>               -  pharmacologic/hormonal contraceptives, including oral, parenteral, subcutaneous,<br>                  and transcutaneous delivery;<br><br>               -  condoms with spermicide;<br><br>               -  diaphragm with spermicide;<br><br>               -  intrauterine device;<br><br>               -  absolute abstinence from heterosexual intercourse as a matter of normal preferred<br>                  lifestyle;<br><br>               -  or must be surgically sterile or must be age 50 AND have had no menses at all for<br>                  at least one full year.<br><br>               -  All females must provide urine for pregnancy testing prior to enrollment<br>                  (immediately prior vaccination), as well as a statement of menstrual history and<br>                  a summary of all potentially reproductive sexual activity for the month prior to<br>                  vaccination, and at each study contact throughout the study, and report known or<br>                  suspected pregnancy immediately.<br><br>          -  Willingness to refrain from blood donation during the course of the study.<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy as determined by a positive test for human choriogonadotropin (beta-HCG), an<br>             indicator of pregnancy or history of recent unprotected intercourse in a woman of<br>             reproductive capacity.<br><br>          -  Currently breast-feeding.<br><br>          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hematologic,<br>             hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination,<br>             and/or laboratory studies.<br><br>          -  Behavioral or cognitive impairment or psychiatric disease that in the opinion of the<br>             investigator affects the ability of the subject to understand and cooperate with the<br>             study protocol.<br><br>          -  Have medical, occupational, or family problems as a result of alcohol or illicit drug<br>             use during the past 12 months.<br><br>          -  Other condition that in the opinion of the investigator would jeopardize the safety or<br>             rights of a subject participating in the trial or would render the subject unable to<br>             comply with the protocol.<br><br>          -  History of anaphylaxis in response to any vaccine or vaccine component.<br><br>          -  History of life-threatening reaction to prior influenza vaccine.<br><br>          -  Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory test for human<br>             immunodeficiency virus type 1 (HIV-1).<br><br>          -  Positive ELISA and confirmatory test (e.g., HCV RNA PCR) for hepatitis C virus (HCV).<br><br>          -  Positive hepatitis B virus surface antigen (HBsAg) by ELISA.<br><br>          -  Known immunodeficiency syndrome or history suggestive of impaired immune function.<br><br>          -  History of Guillain-Barré syndrome.<br><br>          -  Use of chronic oral or intravenous administration (greater than or equal to 14 days)<br>             of immunosuppressive doses of steroids, i.e., prednisone greater than 10 mg per day,<br>             immunosuppressants or other immune-modifying drugs within 30 days of starting this<br>             study.<br><br>          -  Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to<br>             study vaccination.<br><br>          -  Receipt of blood or blood-derived products (including immunoglobulin) within 6 months<br>             prior to study vaccination.<br><br>          -  Receipt of another investigational vaccine or drug within 30 days prior to study<br>             vaccination.<br><br>          -  In addition to the above, participants in Cohort 1 (pandemic live attenuated influenza<br>             vaccine [pLAIV] recipients) and Cohort 2 (naïve cohort) must also not experience any<br>             of the following:<br><br>               -  Previous enrollment in an H5N1 influenza vaccine trial.<br><br>          -  Participants in Cohort 2 (naïve cohort) will be excluded if they are:<br><br>               -  Seropositive to the H5N1 influenza A virus (serum hemagglutination inhibition<br>                  assay (HAI) titer greater than 1:8).<br><br>               -  Have previously received an investigational live attenuated influenza vaccine<br>                  (LAIV) in another study.<br>",NULL,"Fold rise in titer of anti-group 1 stalk-antibodies in recipients of the pandemic live attenuated influenza vaccines (pLAIVs) (H2N2, H6N1 and H9N2) compared to the control pLAIV-naïve cohort",Number of vaccine-related adverse events in the recipients of the pLAIV compared to the control cohort,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03900988,https://clinicaltrials.gov/show/NCT03900988,"A Randomized, Double Blind, Placebo Controlled Trial of Intravenous N-acetylcysteine and Oseltamivir Versus Intravenous 5% Dextrose and Oseltamivir in Adults Hospitalized With Influenza Complicated by Lower Respiratory Tract Infection.",Influenza,Drug: N-acetyl cysteine;Drug: 5% Dextrose,Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia,CT.gov,31/03/2019,01/10/2020,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",Phase 4,160,Chinese University of Hong Kong,NULL,NA,NULL,31/03/2019,"October 1, 2020",NCT039,13-Jul-20,NAC Influenza/Hui/2019,;,"David SC Hui, MD;Susanna So-Shan Ng, MBChB",NULL,;drsssng@gmail.com,;852 3505 2785,Chinese University of Hong Kong;,;,"David SC Hui, MD;Susanna So-Shan Ng, MBChB",NULL,;drsssng@gmail.com,;852 3505 2785,Chinese University of Hong Kong;,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  influenza A and B virus infections confirmed by polymerase chain reaction (PCR) and/or<br>             immunofluorescence assays,<br><br>          -  hospitalized for the management of severe manifestations of influenza,<br><br>          -  presenting within 5 days from illness onset,<br><br>          -  clinical evidence of lower respiratory tract infection (e.g. shortness of breath,<br>             tachypnea, oxygen desaturation <93% on room air, crepitations on auscultation,<br>             infiltrations or consolidations on chest radiograph)<br><br>          -  ability to provide written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  use of systemic corticosteroids (except for those who need low dose hydrocortisone<br>             50mg qid for refractory septic shock)<br><br>          -  use of other immunosuppressants (e.g. post-chemotherapy, post-transplant, autoimmune<br>             diseases)<br><br>          -  known immuno-compromised conditions (e.g. active haematological malignancies,<br>             HIV/AIDS),<br><br>          -  pregnancy<br><br>          -  lactation,<br><br>          -  end-stage renal failure<br><br>          -  hepatic failure<br><br>          -  cardiac failure<br><br>          -  patients on anticoagulation,<br><br>          -  patients with scheduled major surgery within 2 weeks (NAC may affect blood clotting),<br><br>          -  patients who have received macrolide antibiotics and NSAID for 1 week prior to<br>             enrolment due to their immuno-modulating effects.<br>",NULL,Normalization of respiratory status in day,viral ribonucleic acid (RNA) in copies per milliliter;Interleukin 6 in pg/ml;interleukin-8 in pg/ml;interleukin 17 in pg/ml;Chemokine ligand 9 (CxCL9/MIG) in pg/ml;Soluble tumour necrosis factor receptor-1 (sTNFR-1) in pg/ml;interleukin 18 in pg/ml;CRP in mg/L;phospho-p38 and phospho-ERK (activated MAPKs) in mean fluorescence intensity(MFI);phospho-inhibitor kB/IkB (NF-kB) in mean fluorescence intensity(MFI);resolution of symptoms in days;ICU admission in days;mortality in days;Incidence of Treatment-Emergent Adverse Events in numbers;a six step ordinal scale of clinical status,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04130230,https://clinicaltrials.gov/show/NCT04130230,Safety and Efficacy of Neostigmine Infusion as Adjuvant Therapy in Sepsis and Septic Shock,"Sepsis, Septic Shock",Drug: Neostigmine;Drug: Standard therapy,Adjuvant Use of Neostigmine in Sepsis and Septic Shock.,CT.gov,08/10/2019,06/03/2019,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,Phase 2,50,Mansoura University,Egypt,NA,NULL,08/10/2019,"March 6, 2019",NCT041,28-Oct-19,2019-3,; ;,"Mamdouh M El-Shishtawy, Professor;Mona M El-Tamalawy, Master;",NULL,;mona.m.eltamalawy@gmail.com;,;01220650700;1220650700,Faculty of Pharmacy-Mansoura University;,; ;,"Mamdouh M El-Shishtawy, Professor;Mona M El-Tamalawy, Master;",NULL,;mona.m.eltamalawy@gmail.com;,;01220650700;1220650700,Faculty of Pharmacy-Mansoura University;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,85 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Age 18-85 years.<br><br>          -  Patients diagnosed with sepsis or septic shock according to Third International<br>             Consensus Definitions for Sepsis and Septic Shock mentioned above.<br><br>          -  Patients who have = 2 of the following four criteria plus documented infection:<br><br>               1. Fever = 38 °C or hypothermia = 36 °C.<br><br>               2. Tachycardia = 100/min.<br><br>               3. Tachypnea = 20/min or hyperventilation.<br><br>               4. Leukocytosis = 12000/mm3 or leukopenia = 4000/mm3 or = 10% immature neutrophils<br>                  in the differential count.<br><br>        Exclusion criteria:<br><br>          -  Known hypersensitivity to choline esterase inhibitors.<br><br>          -  Known absolute contra-indications against choline esterase inhibitors such as,<br>             myotonic dystrophy; depolarization block by depolarizing muscle relaxants;<br>             intoxication by irreversibly acting cholinesterase inhibitors; closed craniocerebral<br>             trauma; obstruction in the gastrointestinal tract (mechanical constipation);<br>             obstruction in the urinary tract (mechanical urinary retention)<br><br>          -  Known relative contraindications against choline esterase inhibitors: bronchial<br>             asthma; bradycardia; AV-conduction disturbances.<br><br>          -  Having undergone solid organ transplantation.<br><br>          -  Pregnant and lactating women.<br><br>          -  Participation in another clinical trial.<br><br>          -  Presence of primary or concomitant illness, impending death.<br>",NULL,Sequential organ failure assessment (SOFA score),NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03068741,https://clinicaltrials.gov/show/NCT03068741,Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP),Severe Sepsis or Septic Shock,Drug: Comparison 1: Prehospital Ceftriaxone;Drug: Comparison 1: Placebo;Drug: Comparison 2: Liberal fluids;Drug: Comparison 2: Conservative fluids,Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP),CT.gov,06/02/2017,23/03/2020,FALSE,Interventional,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 4,2040,Dr. Damon Scales,Canada,NA,NULL,06/02/2017,"March 23, 2020",NCT030,22-Jun-20,The PITSTOP RCT,; ;,"Damon Scales, MD PhD FRCPC;Damon Scales, MD PhD FRCPC;Chief Greg Sage",NULL,;damon.scales@sunnybrook.ca;,;416-480-5291;,Sunnybrook Health Sciences Centre;,; ;,"Damon Scales, MD PhD FRCPC;Damon Scales, MD PhD FRCPC;Chief Greg Sage",NULL,;damon.scales@sunnybrook.ca;,;416-480-5291;,Sunnybrook Health Sciences Centre;,Recruiting,Canadian Institutes of Health Research (CIHR);Sunnybrook Research Institute,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Patients with Sepsis, defined as (all 3 must be present): i) Paramedic suspects<br>             possible infection: e.g. suspected pneumonia, urinary tractinfection, skin infection,<br>             bone and joint infection, intra-abdominal infection, meningitis ii) Presence of fever:<br>             Temperature = 38.0°C iii) Presence of hypotension: Systolic blood pressure < 100mmHg<br><br>          2. Age = 18 years<br><br>        Exclusion Criteria:<br><br>          1. Post cardiac arrest<br><br>          2. Suspected ST-segment elevation myocardial infarction (STEMI)<br><br>          3. Suspected acute cerebrovascular accident (CVA)<br><br>          4. Acute severe trauma<br><br>          5. Obvious severe non-traumatic bleeding<br><br>          6. Signs of fluid overload<br><br>          7. Suspected congestive heart failure (CHF)<br><br>          8. Known Clostridium difficile infection within the last 6 weeks<br><br>          9. Known pregnancy or breastfeeding<br><br>         10. Known allergy or sensitivity to penicillin or cephalosporin<br><br>         11. Receiving oral or subcutaneous anticoagulants or low molecular weight heparin<br><br>         12. Paramedic is unable to identify patient by first and last name and/or health card<br>             number<br>",NULL,Primary outcome: mortality prior to hospital discharge to day 90.,"Organ dysfunction during first 24 hours (mechanical ventilation, vasopressor therapy (any), dialysis;Organ dysfunction during hospitalization (mechanical ventilation);duration of hospital admission (if any);duration of first ICU admission (if any);Proportion of patients with positive blood cultures obtained in hospital;Microbiology results (if any);Proportion of patients receiving antibiotics within first 24 hours of hospitalization;Frequency distribution and mean time to first dose of antibiotics (if any) within first 24 hours of hospitalization;Proportion of patients receiving IV fluids (>250mL) within first 24 hours of hospitalization;Total amount of IV fluids administered during transport and first 24 hours of hospitalization (if any);Proportion of patients with pulmonary edema identified during transport to hospital and on initial chest x-ray;Proportion of patients with blood, urine, sputum cultures that grow organisms resistant to ceftriaxone;Proportion of patients diagnosed with sepsis or infection by emergency department physician;Proportion of hospitalized patients who grow any antibiotic-resistant organism (methicilin resistant S. aureus, Clostridium difficile, extended beta-lactamase resistant organisms);Proportion of patients with anaphylaxis or suspected allergic reactions to study medication",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03020537,https://clinicaltrials.gov/show/NCT03020537,"U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 5, 2013",Influenza;Influenza;Influenza,Biological: Fluzone;Biological: Fluzone;Biological: Fluzone,"B-cell Immunity to Influenza (SLVP017)- Year 5, 2013",CT.gov,11/01/2017,01/10/2013,TRUE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 4,8,Stanford University,NULL,NA,1,11/01/2017,Oct-13,NCT030,11-Jun-18,2U19AI057229-06;SU-17218-2013,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD",NULL,;;;;;;;;;;;;;;;;;;;;;;;,;;;;;;;;;;;;;;;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;,"Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD;Cornelia Dekker, MD;Harry Greenberg, MD;Stephen Quake, PhD;Xiaosong He, PhD",NULL,;;;;;;;;;;;;;;;;;;;;;;;,;;;;;;;;;;;;;;;;;;;;;;;,Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University;Stanford University,Completed,National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,1 Year,30 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory children 1-2 years of age or 18-30 year-old young adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study (after last study<br>             immunization, approximately 8 weeks for Group A and 4 weeks for Group B).<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Group A: Prior vaccination with a seasonal flu vaccine (IIV). Group B: Prior<br>             vaccination with the 2012-2013 seasonal flu vaccine (IIV or LAIV).<br><br>          2. Prior off-study vaccination with the current 2013-2014 seasonal IIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components.<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          6. History of immunodeficiency (including HIV infection)<br><br>          7. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          8. Chronic Hepatitis B or C.<br><br>          9. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible; use<br>             of inhaled steroids, or oral steroids (<20mg prednisone-equivalent/day), may be<br>             acceptable after review by the investigator.<br><br>         10. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         11. Autoimmune disease (including rheumatoid arthritis) treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         12. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         13. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         14. Receipt of blood or blood products within the past 6 months<br><br>         15. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         16. Inactivated vaccine within 14 days prior to study vaccination (inform study staff of<br>             any non-study vaccinations received during study period)<br><br>         17. Live, attenuated vaccine within 30 days prior to first study vaccination, or planned<br>             immunization with a live, attenuated vaccine before completion of study visits (inform<br>             study staff of any non-study vaccinations received during study period).<br><br>         18. Need for allergy immunizations (that cannot be rescheduled if necessary) during the<br>             study period<br><br>         19. History of Guillain-Barre Syndrome<br><br>         20. Pregnant or lactating woman<br><br>         21. Use of investigational agents within 30 days prior to enrollment or planned use of<br>             investigational agents prior to completion of study visits<br><br>         22. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         23. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory children 1-2 years of age or 18-30 year-old young adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study (after last study<br>             immunization, approximately 8 weeks for Group A and 4 weeks for Group B).<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Group A: Prior vaccination with a seasonal flu vaccine (IIV). Group B: Prior<br>             vaccination with the 2012-2013 seasonal flu vaccine (IIV or LAIV).<br><br>          2. Prior off-study vaccination with the current 2013-2014 seasonal IIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components.<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          6. History of immunodeficiency (including HIV infection)<br><br>          7. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          8. Chronic Hepatitis B or C.<br><br>          9. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible; use<br>             of inhaled steroids, or oral steroids (<20mg prednisone-equivalent/day), may be<br>             acceptable after review by the investigator.<br><br>         10. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         11. Autoimmune disease (including rheumatoid arthritis) treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         12. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         13. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         14. Receipt of blood or blood products within the past 6 months<br><br>         15. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         16. Inactivated vaccine within 14 days prior to study vaccination (inform study staff of<br>             any non-study vaccinations received during study period)<br><br>         17. Live, attenuated vaccine within 30 days prior to first study vaccination, or planned<br>             immunization with a live, attenuated vaccine before completion of study visits (inform<br>             study staff of any non-study vaccinations received during study period).<br><br>         18. Need for allergy immunizations (that cannot be rescheduled if necessary) during the<br>             study period<br><br>         19. History of Guillain-Barre Syndrome<br><br>         20. Pregnant or lactating woman<br><br>         21. Use of investigational agents within 30 days prior to enrollment or planned use of<br>             investigational agents prior to completion of study visits<br><br>         22. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         23. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy, ambulatory children 1-2 years of age or 18-30 year-old young adults.<br><br>          2. Willing to complete the informed consent process.<br><br>          3. Availability for follow-up for the planned duration of the study (after last study<br>             immunization, approximately 8 weeks for Group A and 4 weeks for Group B).<br><br>          4. Acceptable medical history by medical history and vital signs.<br><br>        Exclusion Criteria:<br><br>          1. Group A: Prior vaccination with a seasonal flu vaccine (IIV). Group B: Prior<br>             vaccination with the 2012-2013 seasonal flu vaccine (IIV or LAIV).<br><br>          2. Prior off-study vaccination with the current 2013-2014 seasonal IIV or LAIV<br><br>          3. Allergy to egg or egg products, or to vaccine components.<br><br>          4. Life-threatening reactions to previous influenza vaccinations<br><br>          5. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          6. History of immunodeficiency (including HIV infection)<br><br>          7. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          8. Chronic Hepatitis B or C.<br><br>          9. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible; use<br>             of inhaled steroids, or oral steroids (<20mg prednisone-equivalent/day), may be<br>             acceptable after review by the investigator.<br><br>         10. Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors<br>             such as breast cancer or prostate cancer with recurrence in the past year, and any<br>             hematologic cancer such as leukemia).<br><br>         11. Autoimmune disease (including rheumatoid arthritis) treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         12. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         13. Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet<br>             agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox must be<br>             reviewed by investigator to determine if this would affect the volunteer's safety.<br><br>         14. Receipt of blood or blood products within the past 6 months<br><br>         15. Medical or psychiatric condition or occupational responsibilities that preclude<br>             participant compliance with the protocol<br><br>         16. Inactivated vaccine within 14 days prior to study vaccination (inform study staff of<br>             any non-study vaccinations received during study period)<br><br>         17. Live, attenuated vaccine within 30 days prior to first study vaccination, or planned<br>             immunization with a live, attenuated vaccine before completion of study visits (inform<br>             study staff of any non-study vaccinations received during study period).<br><br>         18. Need for allergy immunizations (that cannot be rescheduled if necessary) during the<br>             study period<br><br>         19. History of Guillain-Barre Syndrome<br><br>         20. Pregnant or lactating woman<br><br>         21. Use of investigational agents within 30 days prior to enrollment or planned use of<br>             investigational agents prior to completion of study visits<br><br>         22. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment<br><br>         23. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>",NULL,Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine;Number of Participants Who Received Influenza Vaccine,Number of Participants With Related Adverse Events,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT03020537,NULL,09/03/2017,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT03143101,https://clinicaltrials.gov/show/NCT03143101,A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age,Influenza;Healthy;Influenza;Healthy;Influenza;Healthy;Influenza;Healthy,Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation;Biological: FluMist Quadrivalent 2017-2018 formulation;Biological: FluMist Quadrivalent 2015-2016 formulation;Biological: FluMist Trivalent 2015-2016 formulation,Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age,CT.gov,04/05/2017,08/05/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 4,200,MedImmune LLC,United States;United States;United States;United States;United States,NA,NULL,04/05/2017,"May 8, 2017",NCT031,16-Dec-17,D2560C00013,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,AstraZeneca,Please refer to primary and secondary sponsors,24 Months,47 Months,All,"<br>        Key Inclusion Criteria:<br><br>          -  Age 24 months to < 48 months of age<br><br>          -  Healthy by medical history and physical examination or presence of stable underlying<br>             chronic medical condition for which hospitalization has not been required in the<br>             previous year<br><br>        Key Exclusion Criteria:<br><br>          -  History of allergic disease or reactions likely to be exacerbated by any component of<br>             the investigational product<br><br>          -  Acute illness or evidence of significant active infection (including fever >/= 100.4<br>             degrees Fahrenheit (F) (38.0 degrees Celsius (C)) at randomization<br><br>          -  History of asthma or history of recurrent wheezing<br><br>          -  Any known immunosuppressive condition or immune deficiency disease<br><br>          -  Current or expected receipt of immunosuppressive medications within a 28 day window<br>             around vaccination<br><br>          -  Use of aspirin or salicylate-containing medications within 28 days prior to<br>             randomization or expected receipt thru 28 days after vaccination<br><br>          -  Use of antiviral agents with activity against influenza viruses within 48 hours prior<br>             to first dose of investigational product or anticipated use of such agents through the<br>             end of the study follow-up period<br><br>          -  Receipt of any non-study seasonal influenza vaccine within 90 days of Dose 1 or<br>             planned receipt of non-study seasonal influenza vaccine prior to 28 days after last<br>             vaccination<br><br>          -  Receipt of immunoglobulin or blood products within 90 days before randomization into<br>             the study or expected receipt during study participation<br><br>          -  Known or suspected mitochondrial encephalomyopathy<br><br>          -  History of Guillian-Barre syndrome<br><br>          -  Administration of intranasal medications within 10 days prior to randomization, for<br>             expected receipt through 10 days after administration of each dose of investigational<br>             product<br>      ;<br>        Key Inclusion Criteria:<br><br>          -  Age 24 months to < 48 months of age<br><br>          -  Healthy by medical history and physical examination or presence of stable underlying<br>             chronic medical condition for which hospitalization has not been required in the<br>             previous year<br><br>        Key Exclusion Criteria:<br><br>          -  History of allergic disease or reactions likely to be exacerbated by any component of<br>             the investigational product<br><br>          -  Acute illness or evidence of significant active infection (including fever >/= 100.4<br>             degrees Fahrenheit (F) (38.0 degrees Celsius (C)) at randomization<br><br>          -  History of asthma or history of recurrent wheezing<br><br>          -  Any known immunosuppressive condition or immune deficiency disease<br><br>          -  Current or expected receipt of immunosuppressive medications within a 28 day window<br>             around vaccination<br><br>          -  Use of aspirin or salicylate-containing medications within 28 days prior to<br>             randomization or expected receipt thru 28 days after vaccination<br><br>          -  Use of antiviral agents with activity against influenza viruses within 48 hours prior<br>             to first dose of investigational product or anticipated use of such agents through the<br>             end of the study follow-up period<br><br>          -  Receipt of any non-study seasonal influenza vaccine within 90 days of Dose 1 or<br>             planned receipt of non-study seasonal influenza vaccine prior to 28 days after last<br>             vaccination<br><br>          -  Receipt of immunoglobulin or blood products within 90 days before randomization into<br>             the study or expected receipt during study participation<br><br>          -  Known or suspected mitochondrial encephalomyopathy<br><br>          -  History of Guillian-Barre syndrome<br><br>          -  Administration of intranasal medications within 10 days prior to randomization, for<br>             expected receipt through 10 days after administration of each dose of investigational<br>             product<br>      ;<br>        Key Inclusion Criteria:<br><br>          -  Age 24 months to < 48 months of age<br><br>          -  Healthy by medical history and physical examination or presence of stable underlying<br>             chronic medical condition for which hospitalization has not been required in the<br>             previous year<br><br>        Key Exclusion Criteria:<br><br>          -  History of allergic disease or reactions likely to be exacerbated by any component of<br>             the investigational product<br><br>          -  Acute illness or evidence of significant active infection (including fever >/= 100.4<br>             degrees Fahrenheit (F) (38.0 degrees Celsius (C)) at randomization<br><br>          -  History of asthma or history of recurrent wheezing<br><br>          -  Any known immunosuppressive condition or immune deficiency disease<br><br>          -  Current or expected receipt of immunosuppressive medications within a 28 day window<br>             around vaccination<br><br>          -  Use of aspirin or salicylate-containing medications within 28 days prior to<br>             randomization or expected receipt thru 28 days after vaccination<br><br>          -  Use of antiviral agents with activity against influenza viruses within 48 hours prior<br>             to first dose of investigational product or anticipated use of such agents through the<br>             end of the study follow-up period<br><br>          -  Receipt of any non-study seasonal influenza vaccine within 90 days of Dose 1 or<br>             planned receipt of non-study seasonal influenza vaccine prior to 28 days after last<br>             vaccination<br><br>          -  Receipt of immunoglobulin or blood products within 90 days before randomization into<br>             the study or expected receipt during study participation<br><br>          -  Known or suspected mitochondrial encephalomyopathy<br><br>          -  History of Guillian-Barre syndrome<br><br>          -  Administration of intranasal medications within 10 days prior to randomization, for<br>             expected receipt through 10 days after administration of each dose of investigational<br>             product<br>      ;<br>        Key Inclusion Criteria:<br><br>          -  Age 24 months to < 48 months of age<br><br>          -  Healthy by medical history and physical examination or presence of stable underlying<br>             chronic medical condition for which hospitalization has not been required in the<br>             previous year<br><br>        Key Exclusion Criteria:<br><br>          -  History of allergic disease or reactions likely to be exacerbated by any component of<br>             the investigational product<br><br>          -  Acute illness or evidence of significant active infection (including fever >/= 100.4<br>             degrees Fahrenheit (F) (38.0 degrees Celsius (C)) at randomization<br><br>          -  History of asthma or history of recurrent wheezing<br><br>          -  Any known immunosuppressive condition or immune deficiency disease<br><br>          -  Current or expected receipt of immunosuppressive medications within a 28 day window<br>             around vaccination<br><br>          -  Use of aspirin or salicylate-containing medications within 28 days prior to<br>             randomization or expected receipt thru 28 days after vaccination<br><br>          -  Use of antiviral agents with activity against influenza viruses within 48 hours prior<br>             to first dose of investigational product or anticipated use of such agents through the<br>             end of the study follow-up period<br><br>          -  Receipt of any non-study seasonal influenza vaccine within 90 days of Dose 1 or<br>             planned receipt of non-study seasonal influenza vaccine prior to 28 days after last<br>             vaccination<br><br>          -  Receipt of immunoglobulin or blood products within 90 days before randomization into<br>             the study or expected receipt during study participation<br><br>          -  Known or suspected mitochondrial encephalomyopathy<br><br>          -  History of Guillian-Barre syndrome<br><br>          -  Administration of intranasal medications within 10 days prior to randomization, for<br>             expected receipt through 10 days after administration of each dose of investigational<br>             product<br>",NULL,Proportion of subjects with strain-specific hemagglutination inhibition seroconversion rates;Proportion of subjects with strain-specific hemagglutination inhibition seroconversion rates;Proportion of subjects with strain-specific hemagglutination inhibition seroconversion rates,Proportion of subjects that shed vaccine viruses;Duration of shedding of vaccine viruses;Quantification of the titer of shed vaccine viruses;Level of serum neutralizing antibody responses induced by trivalent and quadrivalent formulations of FluMist against antigenically matched influenza strains;Level of mucosal antibody responses induced by trivalent and quadrivalent formulations of FluMist against antigenically matched influenza strains;Safety and tolerability of trivalent and quadrivalent formulations of FluMist;Proportion of subjects with any strain-specific antibody response,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03454217,https://clinicaltrials.gov/show/NCT03454217,Impact of Tramadol and Oxycodone on Sleep Apnea,Sleep Apnea,Drug: Oxycodone;Drug: Tramadol,Impact of Tramadol and Oxycodone on Sleep Apnea,CT.gov,27/02/2018,27/02/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Phase 4,60,Centre Hospitalier Universitaire Vaudois,Switzerland,NA,NULL,27/02/2018,"February 27, 2018",NCT034,26-Aug-19,CER 2017-01976,; ;,"Eric Albrecht;Eric Albrecht, PD-MER;Eric Albrecht, PD-MER",NULL,;eric.albrecht@chuv.ch;eric.albrecht@chuv.ch,;+41 79 556 63 41;+41 79 556 63 41,Lausanne University Hospital;,; ;,"Eric Albrecht;Eric Albrecht, PD-MER;Eric Albrecht, PD-MER",NULL,;eric.albrecht@chuv.ch;eric.albrecht@chuv.ch,;+41 79 556 63 41;+41 79 556 63 41,Lausanne University Hospital;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Inclusion Criteria:<br><br>          -  patients scheduled for orthopaedic surgery on the lower limb under a spinal<br>             anaesthesia<br><br>          -  physical status I-III<br><br>        Exclusion Criteria:<br><br>          -  planned surgical duration more than 3 hours<br><br>          -  contraindication to spinal anaesthesia<br><br>          -  severe respiratory disease<br><br>          -  patient treated for sleep apnea syndrome<br><br>          -  allergy to tramadol or oxycodone<br>,NULL,Apnea hypopnea index while lying supine,Apnea hypopnea index in another position than supine;Mean pulse oxymetry;Apnea hypopnea index while lying supine;Apnea hypopnea index in another position than supine;Mean pulse oxymetry;Pains scores (numeric rating scale);Opioid (oxycodone or tramadol) consumption,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04198883,https://clinicaltrials.gov/show/NCT04198883,SINGaporean Program Performed With an eXPANsion Medical Device,Heart Attack,Combination Product: Protheracytes,SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand),CT.gov,04/07/2019,27/11/2018,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 1/Phase 2,10,CellProthera,Singapore,NA,1,04/07/2019,"November 27, 2018",NCT041,06-Jan-20,CellProthera,NA,Frederic Flandrin,NULL,NA,NA,CellProthera,NA,Frederic Flandrin,NULL,NA,NA,CellProthera,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          1. De Novo AMI with or without ST segment elevation and with a detection of rise and/or<br>             fall of cardiac biomarker values (troponin) with at least one value above the 99th<br>             percentile of the upper reference limit.<br><br>          2. Anterior wall AMI<br><br>          3. PTCA and stent(s) implantation (=Day 0)<br><br>          4. LVEF = 45% after stent(s) implantation: Combination of a LVEF = 45 % and of anterior<br>             akinetic segment(s) - by echography at Day 2 ± 1 after stent(s) implantations<br><br>          5. Age must be = 21 and = 80 years<br><br>          6. Men and Non-pregnant non-lactating women who take efficacious contraceptive measures<br>             such as oral contraceptive medications or efficacious and permanent intra-uterine<br>             device (drug eluted or not) (IUD) or subcutaneous permanent contraceptive implants or<br>             menopaused women (at least a 2 years confirmed menopause) or surgically sterilized<br>             women.<br><br>          7. Having previously signed a written informed consent prior to any study-specific<br>             procedures.<br><br>          8. LVEF remaining = 45% assessed by a 2nd echography at Day 8 (± 2) after stent(s)<br>             implantation.<br><br>             If these criteria have been validated, then the following assessments will be carried<br>             out only after the 2nd echography<br><br>          9. LVEF remaining = 45% assessed by cMRI<br><br>         10. Identification of anterior akinetic segment(s) of interest assessed by cMRI<br><br>         11. Identification of non-viability of anterior segment(s) of interest assessed by cMRI<br><br>        Exclusion Criteria:<br><br>          1. Previous and known symptomatic CHF, from class II to IV (included)<br><br>          2. History of CABG (Coronary Artery Bypass Surgery) surgery<br><br>          3. History of former significant mitral valve replacement surgery or heart<br>             transplantation.<br><br>          4. Severe valve disease: mitral, aortic stenosis / insufficiency.<br><br>          5. Diagnosis of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral<br>             regurgitation, tachycardia, or myocarditis<br><br>          6. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter<br>             access to LV<br><br>          7. Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive<br>             device.<br><br>          8. Documented presence of a known LV thrombus<br><br>          9. Sepsis<br><br>         10. Endocarditis<br><br>         11. Infectious pericarditis<br><br>         12. Pericardial tamponade<br><br>         13. Left ventricular aneurysm, collagen tissue disease<br><br>         14. Severe peripheral vascular disease precluding femoral artery access as determined at<br>             the time of original catheterization.<br><br>         15. Pacemaker, implantable cardiac defibrillator, and intra-cerebral aneurysm clips.<br><br>         16. History of metallic foreign body in their eye<br><br>         17. Former or current aortic dissection<br><br>         18. Inadequate bone marrow function: Haemoglobin < 10 g/dL and Platelet count < 100 x 109<br>             / L<br><br>         19. Previous G-CSF or other Hematopoietic Growth Factor administrations.<br><br>         20. Blood transfusion(s) within the previous 4 weeks (to exclude potential non-autologous<br>             ACPs (Angiogenic Cells Precursors) in the harvested blood).<br><br>         21. Hepatic failure or history of liver cirrhosis or hepatic severe impairment.<br><br>         22. Constitutional or acquired coagulopathy<br><br>         23. Treated chronic renal failure, or haemodialysis or renal severe impairment (creatinine<br>             clearance < 30ml/min).<br><br>         24. Prior or concomitant malignancies except non-melanoma skin cancer or adequately<br>             treated in situ cervical cancer or previous cancer in complete response without any<br>             treatment in the last 5 years.<br><br>         25. History of prior mediastinal radiation exposure<br><br>         26. Serious underlying medical conditions at the investigator's discretion, which could<br>             impair the ability of the patient to participate in the trial (e.g. ongoing infection,<br>             active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple<br>             Sclerosis).<br><br>         27. Chronic immunomodulatory or cytotoxic drug treatment intake.<br><br>         28. Active bleeding or major surgery within 1 month.<br><br>         29. Human immunodeficiency HIV1-2, HTLV1, HTLV2<br><br>         30. History or current Hepatitis B (prior vaccination accepted)<br><br>         31. History or current Hepatitis C<br><br>         32. Syphilis<br><br>         33. Chronic Obstructive Pulmonary Disease.<br><br>         34. Active participation in any other clinical trials<br><br>         35. Current or recent treatment (within the 60 days period before PTCA and stent(s)<br>             implantation) with another investigational drug or procedure.<br><br>         36. Any other co-existing conditions that will preclude participation in the study or<br>             compromise ability to give informed consent.<br><br>         37. Requirement of i.v. catecholamines or mechanical hemodynamic support (aortic balloon<br>             pump) initiated 24 hours before cMRI.<br><br>         38. Splenomegaly<br><br>         39. Phenylketonuria<br><br>         40. History of iron-Dextran allergy<br><br>         41. History of murin protein allergy<br>",NULL,"MACE,SAE and AE",Change of Cardiac function assessed by cMRI,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03208361,https://clinicaltrials.gov/show/NCT03208361,Efficacy of High Doses of Oral Penicillin V Versus High Doses of Oral Amoxicillin in the Treatment of Non-severe Community-acquired Pneumonia in Adults,Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP);Community-acquired Pneumonia (CAP),Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin;Drug: Penicillin V;Drug: Amoxicillin,Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.,CT.gov,26/06/2017,05/11/2013,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,43,Jordi Gol i Gurina Foundation,Spain;Spain;Spain;Spain;Spain,EUCTR2012-003511-63-ES,1,26/06/2017,"November 5, 2013",NCT032,16-Dec-17,2012-003511-63;IJG-PEN-2012,; ; ; ;,"Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD",NULL,;;;;,;;;;,IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol,; ; ; ;,"Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD;Car Llor Vilà, MD, PhD",NULL,;;;;,;;;;,IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol;IDIAP Jordi Gol,Terminated,NULL,Please refer to primary and secondary sponsors,18 Years,75 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Patients 18 years to 75 years (inclusive).<br><br>          -  Signs and symptoms of lower respiratory tract infection.<br><br>          -  Radiological confirmation of the diagnosis of pneumonia or not radiological<br>             confirmation but the patient has the following symptoms: high fever (> 38.5 ° C),<br>             cough and purulent sputum and auscultation of crackles in a pulmonary focus, the<br>             researcher undertakes to confirm after inclusion pneumonia with mandatory radiological<br>             study.<br><br>          -  Signature of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Impaired consciousness: confused state, delirium, drowsiness, stupor or coma, at the<br>             discretion of the investigator<br><br>          -  Respiratory rate> 30 breaths / minute<br><br>          -  Heart rate> 125 beats / minute<br><br>          -  Systolic blood pressure <90 mm ??Hg or diastolic BP <60 mm Hg<br><br>          -  Hypersensitivity to beta-Lactamics<br><br>          -  O2 saturation <92%<br><br>          -  Axillary temperature> 40 ° C<br><br>          -  bronchial Asthma<br><br>          -  Pregnancy or lactation<br><br>          -  Significant comorbidities: renal failure, liver cirrhosis, heart failure, chronic<br>             obstructive pulmonary disease, ischemic heart disease diagnosed less than 6 months,<br>             stroke diagnosed less than 6 months ago and / or type 1 diabetes mellitus<br><br>          -  Significant alteration in chest radiography: alveolar infiltrates in more than one<br>             lobe or bilateral pleural effusion or pulmonary cavitation<br><br>          -  Problems to meet the treatment at home: sociopathy or psychiatric problems, drug and<br>             alcohol addiction, or, an unsuitable family environment<br><br>          -  Lack of tolerance to oral therapy: presence of nausea and vomiting, gastrectomy,<br>             post-surgery or frank diarrhea<br><br>          -  Immunosuppression: chronic HIV infection, transplant, neutropenic, or, patients<br>             receiving immunosuppressive therapy<br><br>          -  active malignancy<br><br>          -  terminal disease<br><br>          -  Hospitalization in the last month<br><br>          -  Taking any systemic antibiotic in the previous three days or a full use of oral<br>             antibiotics prior to inclusion in the previous two weeks (use of urinary antiseptics<br>             is not a reason for exclusion).<br><br>          -  Difficulty to attend follow-up visits<br><br>          -  Refusal to participate in the study<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients 18 years to 75 years (inclusive).<br><br>          -  Signs and symptoms of lower respiratory tract infection.<br><br>          -  Radiological confirmation of the diagnosis of pneumonia or not radiological<br>             confirmation but the patient has the following symptoms: high fever (> 38.5 ° C),<br>             cough and purulent sputum and auscultation of crackles in a pulmonary focus, the<br>             researcher undertakes to confirm after inclusion pneumonia with mandatory radiological<br>             study.<br><br>          -  Signature of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Impaired consciousness: confused state, delirium, drowsiness, stupor or coma, at the<br>             discretion of the investigator<br><br>          -  Respiratory rate> 30 breaths / minute<br><br>          -  Heart rate> 125 beats / minute<br><br>          -  Systolic blood pressure <90 mm ??Hg or diastolic BP <60 mm Hg<br><br>          -  Hypersensitivity to beta-Lactamics<br><br>          -  O2 saturation <92%<br><br>          -  Axillary temperature> 40 ° C<br><br>          -  bronchial Asthma<br><br>          -  Pregnancy or lactation<br><br>          -  Significant comorbidities: renal failure, liver cirrhosis, heart failure, chronic<br>             obstructive pulmonary disease, ischemic heart disease diagnosed less than 6 months,<br>             stroke diagnosed less than 6 months ago and / or type 1 diabetes mellitus<br><br>          -  Significant alteration in chest radiography: alveolar infiltrates in more than one<br>             lobe or bilateral pleural effusion or pulmonary cavitation<br><br>          -  Problems to meet the treatment at home: sociopathy or psychiatric problems, drug and<br>             alcohol addiction, or, an unsuitable family environment<br><br>          -  Lack of tolerance to oral therapy: presence of nausea and vomiting, gastrectomy,<br>             post-surgery or frank diarrhea<br><br>          -  Immunosuppression: chronic HIV infection, transplant, neutropenic, or, patients<br>             receiving immunosuppressive therapy<br><br>          -  active malignancy<br><br>          -  terminal disease<br><br>          -  Hospitalization in the last month<br><br>          -  Taking any systemic antibiotic in the previous three days or a full use of oral<br>             antibiotics prior to inclusion in the previous two weeks (use of urinary antiseptics<br>             is not a reason for exclusion).<br><br>          -  Difficulty to attend follow-up visits<br><br>          -  Refusal to participate in the study<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients 18 years to 75 years (inclusive).<br><br>          -  Signs and symptoms of lower respiratory tract infection.<br><br>          -  Radiological confirmation of the diagnosis of pneumonia or not radiological<br>             confirmation but the patient has the following symptoms: high fever (> 38.5 ° C),<br>             cough and purulent sputum and auscultation of crackles in a pulmonary focus, the<br>             researcher undertakes to confirm after inclusion pneumonia with mandatory radiological<br>             study.<br><br>          -  Signature of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Impaired consciousness: confused state, delirium, drowsiness, stupor or coma, at the<br>             discretion of the investigator<br><br>          -  Respiratory rate> 30 breaths / minute<br><br>          -  Heart rate> 125 beats / minute<br><br>          -  Systolic blood pressure <90 mm ??Hg or diastolic BP <60 mm Hg<br><br>          -  Hypersensitivity to beta-Lactamics<br><br>          -  O2 saturation <92%<br><br>          -  Axillary temperature> 40 ° C<br><br>          -  bronchial Asthma<br><br>          -  Pregnancy or lactation<br><br>          -  Significant comorbidities: renal failure, liver cirrhosis, heart failure, chronic<br>             obstructive pulmonary disease, ischemic heart disease diagnosed less than 6 months,<br>             stroke diagnosed less than 6 months ago and / or type 1 diabetes mellitus<br><br>          -  Significant alteration in chest radiography: alveolar infiltrates in more than one<br>             lobe or bilateral pleural effusion or pulmonary cavitation<br><br>          -  Problems to meet the treatment at home: sociopathy or psychiatric problems, drug and<br>             alcohol addiction, or, an unsuitable family environment<br><br>          -  Lack of tolerance to oral therapy: presence of nausea and vomiting, gastrectomy,<br>             post-surgery or frank diarrhea<br><br>          -  Immunosuppression: chronic HIV infection, transplant, neutropenic, or, patients<br>             receiving immunosuppressive therapy<br><br>          -  active malignancy<br><br>          -  terminal disease<br><br>          -  Hospitalization in the last month<br><br>          -  Taking any systemic antibiotic in the previous three days or a full use of oral<br>             antibiotics prior to inclusion in the previous two weeks (use of urinary antiseptics<br>             is not a reason for exclusion).<br><br>          -  Difficulty to attend follow-up visits<br><br>          -  Refusal to participate in the study<br>      ;<br>        Inclusion Criteria:<br><br>          -  Patients 18 years to 75 years (inclusive).<br><br>          -  Signs and symptoms of lower respiratory tract infection.<br><br>          -  Radiological confirmation of the diagnosis of pneumonia or not radiological<br>             confirmation but the patient has the following symptoms: high fever (> 38.5 ° C),<br>             cough and purulent sputum and auscultation of crackles in a pulmonary focus, the<br>             researcher undertakes to confirm after inclusion pneumonia with mandatory radiological<br>             study.<br><br>          -  Signature of informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Impaired consciousness: confused state, delirium, drowsiness, stupor or coma, at the<br>             discretion of the investigator<br><br>          -  Respiratory rate> 30 breaths / minute<br><br>          -  Heart rate> 125 beats / minute<br><br>          -  Systolic blood pressure <90 mm ??Hg or diastolic BP <60 mm Hg<br><br>          -  Hypersensitivity to beta-Lactamics<br><br>          -  O2 saturation <92%<br><br>          -  Axillary temperature> 40 ° C<br><br>          -  bronchial Asthma<br><br>          -  Pregnancy or lactation<br><br>          -  Significant comorbidities: renal failure, liver cirrhosis, heart failure, chronic<br>             obstructive pulmonary disease, ischemic heart disease diagnosed less than 6 months,<br>             stroke diagnosed less than 6 months ago and / or type 1 diabetes mellitus<br><br>          -  Significant alteration in chest radiography: alveolar infiltrates in more than one<br>             lobe or bilateral pleural effusion or pulmonary cavitation<br><br>          -  Problems to meet the treatment at home: sociopathy or psychiatric problems, drug and<br>             alcohol addiction, or, an unsuitable family environment<br><br>          -  Lack of tolerance to oral therapy: presence of nausea and vomiting, gastrectomy,<br>             post-surgery or frank diarrhea<br><br>          -  Immunosuppression: chronic HIV infection, transplant, neutropenic, or, patients<br>             receiving immunosuppressive therapy<br><br>          -  active malignancy<br><br>          -  terminal disease<br><br>          -  Hospitalization in the last month<br><br>          -  Taking any systemic antibiotic in the previous three days or a full use of oral<br>             antibiotics prior to inclusion in the previous two weeks (use of urinary antiseptics<br>             is not a reason for exclusion).<br><br>          -  Difficulty to attend follow-up visits<br><br>          -  Refusal to participate in the study<br>",NULL,Disappearance of fever;Disappearance or improvement of cough;Improvement of general condition;Disappearance or reduction of auscultation of crackles;No other antimicrobial treatment necessary;Disappearance of fever;Disappearance or improvement of cough;Improvement of general condition;Disappearance or reduction of auscultation of crackles;No other antimicrobial treatment necessary;Disappearance of fever;Disappearance or improvement of cough;Improvement of general condition;Disappearance or reduction of auscultation of crackles;No other antimicrobial treatment necessary,Disappearance of fever;disappearance or improvement of cough;improvement of general condition;disappearance or reduction of auscultation of crackles;No other antimicrobial treatment necessary;Total Clinical Resolution;Total Clinical Resolution;Radiological resolution;Adverse Events,child,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03911817,https://clinicaltrials.gov/show/NCT03911817,Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients,Septic Shock,Drug: Midodrine,Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients,CT.gov,09/04/2019,15/11/2017,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: Single (Participant).,Phase 4,60,Ain Shams University,Egypt,NA,1,09/04/2019,"November 15, 2017",NCT039,20-Jan-20,169,NA,"Lamiaa ELwakeel, PhD",NULL,NA,NA,Ain Shams University,NA,"Lamiaa ELwakeel, PhD",NULL,NA,NA,Ain Shams University,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,80 Years,All,<br>        Inclusion Criteria:<br><br>          1. Adult patients (18-80)years<br><br>          2. Hypotensive (systolic blood pressure<90mm Hg)and require IV vasopressor for more than<br>             24 hours<br><br>          3. Require IV vasopressor at rate < 8mcg/min and unable to wean for >24 hours<br><br>        Exclusion Criteria:<br><br>          1. Severe organic heart disease (ejection fraction <30 percent due to higher risk of<br>             arrythmia)<br><br>          2. Bradycardia (HR<50 b/m)due to higher likelihood of symptomatic bradycardia<br><br>          3. Chronic kidney disease (serum creatinine >2mg/dl) as midodrine and its active<br>             metabolites are almost completely execreated in urine<br><br>          4. Thyrotoxicosis<br><br>          5. Known allergy to midodrine<br>,NULL,Time of weaning of IV vasopressor in both groups,Mortality;Time to ICU discharge after midodrine initiation;Time to ICU discharge after IV vasopressor discontinuation;ICU length of stay,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03958396,https://clinicaltrials.gov/show/NCT03958396,The Pharmacokinetic and Pharmacodynamics Profiles of Remifentanil in Children With Obstructive Sleep Apnea.,Obstructive Sleep Apnea,Drug: Remifentanil Infusion,Remifentanil in Children With Obstructive Sleep Apnea,CT.gov,16/05/2019,01/09/2015,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Early Phase 1,30,Washington University School of Medicine,NULL,NA,1,16/05/2019,"September 1, 2015",NCT039,23-Mar-20,201504056,NA,"Anshuman Sharma, MD",NULL,NA,NA,Washington University School of Medicine,NA,"Anshuman Sharma, MD",NULL,NA,NA,Washington University School of Medicine,Completed,NULL,Please refer to primary and secondary sponsors,8 Years,14 Years,All,"<br>        OSA Group:<br><br>        Inclusion Criteria:<br><br>          -  8-14 years old<br><br>          -  ASA physical status 1 or 2<br><br>          -  undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive<br>             sleep apnea<br><br>        Exclusion Criteria:<br><br>          -  Inability to cooperate with study requirements (IV placement, sitting quietly, wearing<br>             goggles, etc.)<br><br>        Control (Non-OSA) Group:<br><br>        Inclusion Criteria:<br><br>          -  8-14 years old<br><br>          -  ASA physical status 1 or 2<br><br>          -  no known obstructive sleep apnea presenting for any procedure requiring general<br>             anesthtic<br><br>        Exclusion Criteria:<br><br>          -  Inability to cooperate with study requirements (IV placement, sitting quietly, wearing<br>             goggles, etc.)<br>",NULL,Change in end-expired carbon dioxide from baseline over time - OSA Group;Change in end-expired carbon dioxide from baseline over time - Control (non-OSA) Group;Change in respiratory rate from baseline over time - OSA Group;Change in respiratory rate from baseline over time - Control (non-OSA) Group;Change in pupil diameter from baseline over time - OSA Group;Change in pupil diameter from baseline over time - Control (non-OSA) Group;Remifentanil plasma concentration - OSA Group;Remifentanil plasma concentration - Contro (non-OSA) Group,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02719743,https://clinicaltrials.gov/show/NCT02719743,"An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age",Influenza;Influenza;Influenza,Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).;Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).;Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).,A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age,CT.gov,21/03/2016,07/07/2016,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,185,GlaxoSmithKline,Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand;Taiwan;Thailand,NA,NULL,21/03/2016,"July 7, 2016",NCT027,11-Jun-18,2015-003458-42;116938,; ; ; ; ;,GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials,NULL,;;;;;,;;;;;,GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline,; ; ; ; ;,GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials;GSK Clinical Trials,NULL,;;;;;,;;;;;,GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline;GlaxoSmithKline,Completed,NULL,Please refer to primary and secondary sponsors,6 Months,35 Months,All,"<br>        Inclusion Criteria:<br><br>          -  Subject's parent(s)/ Legally Acceptable Representative(s) [LAR(s)] who, in the opinion<br>             of the investigator, can and will comply with the requirements of the protocol.<br><br>          -  Male or female children 6 months to less than 36 months old at the time of the first<br>             vaccination. Children who are not 36 months old as of Day 0, the day of first vaccine<br>             dose under this protocol, can be enrolled.<br><br>          -  Written informed consent obtained from the parent(s)/legally acceptable<br>             representative(s) [LAR(s)] of the subject prior to performance of any study specific<br>             procedure.<br><br>          -  Healthy subjects as established by medical history and standard physical examination<br>             before entering into the study.<br><br>          -  Born full-term to be confirmed by interview with parent/LAR or available medical<br>             records.<br><br>        Exclusion Criteria:<br><br>          -  Child in care.<br><br>          -  Medical history of physician-confirmed infection with an H5N1 virus.<br><br>          -  Previous vaccination at any time with an H5N1 vaccine.<br><br>          -  Concurrently participating in another clinical study, or use of an investigational or<br>             a non-registered vaccine, pharmaceutical product, or device within 30 days preceding<br>             the first dose of study vaccine, or planned use during the study period.<br><br>          -  Presence in the parent(s) / LAR(s) of evidence of substance abuse or of neurological<br>             or psychiatric diagnoses which, even if stable, are deemed by the investigator to<br>             render the parent(s)/LAR(s) unable/unlikely to provide accurate safety reports.<br><br>          -  Acute disease and/or fever at the time of enrolment.<br><br>          -  Administration of immunoglobulins, any blood products, or long-acting immune-modifying<br>             drugs during the period starting 3 months before the first dose of study vaccine, or<br>             planned administration during the study period.<br><br>          -  History of any neurological disorders or seizures, or Guillain-Barré Syndrome.<br><br>          -  Diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in<br>             a subject's parent or sibling.<br><br>          -  Administration of an inactive vaccine within 14 days or of a live attenuated vaccine<br>             within 30 days before the first vaccination.<br><br>          -  Planned administration of any vaccine not foreseen by the study protocol between Day 0<br>             and Day 42 or planned administration of an inactive vaccine within 14 days or of a<br>             live attenuated vaccine within 30 days before through 30 days after the booster<br>             vaccination. Note: routine vaccinations may be provided on Day 42 after all study<br>             assessments have been performed.<br><br>          -  History of any reaction or hypersensitivity likely to be exacerbated by any component<br>             of the vaccine; a history of anaphylactic-type reaction to consumption of eggs; or a<br>             history of severe adverse reaction to a previous influenza vaccine.<br><br>          -  Any medical condition that in the judgment of the investigator would make<br>             intramuscular injection unsafe.<br><br>          -  Chronic administration of immunosuppressants or other immune-modifying drugs during<br>             the period starting six months prior to the first vaccine. For corticosteroids, this<br>             will mean a dose of prednisone or equivalent of > 2 mg/kg/day of body weight or = 20<br>             mg/day (for persons who weigh = 10 kg). Inhaled and topical steroids are allowed.<br><br>          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on<br>             medical history and physical examination.<br><br>          -  Family history of congenital or hereditary immunodeficiency.<br><br>          -  Major congenital defects.<br><br>          -  Any condition which, in the opinion of the investigator, prevents the subject from<br>             participating in the study.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subject's parent(s)/ Legally Acceptable Representative(s) [LAR(s)] who, in the opinion<br>             of the investigator, can and will comply with the requirements of the protocol.<br><br>          -  Male or female children 6 months to less than 36 months old at the time of the first<br>             vaccination. Children who are not 36 months old as of Day 0, the day of first vaccine<br>             dose under this protocol, can be enrolled.<br><br>          -  Written informed consent obtained from the parent(s)/legally acceptable<br>             representative(s) [LAR(s)] of the subject prior to performance of any study specific<br>             procedure.<br><br>          -  Healthy subjects as established by medical history and standard physical examination<br>             before entering into the study.<br><br>          -  Born full-term to be confirmed by interview with parent/LAR or available medical<br>             records.<br><br>        Exclusion Criteria:<br><br>          -  Child in care.<br><br>          -  Medical history of physician-confirmed infection with an H5N1 virus.<br><br>          -  Previous vaccination at any time with an H5N1 vaccine.<br><br>          -  Concurrently participating in another clinical study, or use of an investigational or<br>             a non-registered vaccine, pharmaceutical product, or device within 30 days preceding<br>             the first dose of study vaccine, or planned use during the study period.<br><br>          -  Presence in the parent(s) / LAR(s) of evidence of substance abuse or of neurological<br>             or psychiatric diagnoses which, even if stable, are deemed by the investigator to<br>             render the parent(s)/LAR(s) unable/unlikely to provide accurate safety reports.<br><br>          -  Acute disease and/or fever at the time of enrolment.<br><br>          -  Administration of immunoglobulins, any blood products, or long-acting immune-modifying<br>             drugs during the period starting 3 months before the first dose of study vaccine, or<br>             planned administration during the study period.<br><br>          -  History of any neurological disorders or seizures, or Guillain-Barré Syndrome.<br><br>          -  Diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in<br>             a subject's parent or sibling.<br><br>          -  Administration of an inactive vaccine within 14 days or of a live attenuated vaccine<br>             within 30 days before the first vaccination.<br><br>          -  Planned administration of any vaccine not foreseen by the study protocol between Day 0<br>             and Day 42 or planned administration of an inactive vaccine within 14 days or of a<br>             live attenuated vaccine within 30 days before through 30 days after the booster<br>             vaccination. Note: routine vaccinations may be provided on Day 42 after all study<br>             assessments have been performed.<br><br>          -  History of any reaction or hypersensitivity likely to be exacerbated by any component<br>             of the vaccine; a history of anaphylactic-type reaction to consumption of eggs; or a<br>             history of severe adverse reaction to a previous influenza vaccine.<br><br>          -  Any medical condition that in the judgment of the investigator would make<br>             intramuscular injection unsafe.<br><br>          -  Chronic administration of immunosuppressants or other immune-modifying drugs during<br>             the period starting six months prior to the first vaccine. For corticosteroids, this<br>             will mean a dose of prednisone or equivalent of > 2 mg/kg/day of body weight or = 20<br>             mg/day (for persons who weigh = 10 kg). Inhaled and topical steroids are allowed.<br><br>          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on<br>             medical history and physical examination.<br><br>          -  Family history of congenital or hereditary immunodeficiency.<br><br>          -  Major congenital defects.<br><br>          -  Any condition which, in the opinion of the investigator, prevents the subject from<br>             participating in the study.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subject's parent(s)/ Legally Acceptable Representative(s) [LAR(s)] who, in the opinion<br>             of the investigator, can and will comply with the requirements of the protocol.<br><br>          -  Male or female children 6 months to less than 36 months old at the time of the first<br>             vaccination. Children who are not 36 months old as of Day 0, the day of first vaccine<br>             dose under this protocol, can be enrolled.<br><br>          -  Written informed consent obtained from the parent(s)/legally acceptable<br>             representative(s) [LAR(s)] of the subject prior to performance of any study specific<br>             procedure.<br><br>          -  Healthy subjects as established by medical history and standard physical examination<br>             before entering into the study.<br><br>          -  Born full-term to be confirmed by interview with parent/LAR or available medical<br>             records.<br><br>        Exclusion Criteria:<br><br>          -  Child in care.<br><br>          -  Medical history of physician-confirmed infection with an H5N1 virus.<br><br>          -  Previous vaccination at any time with an H5N1 vaccine.<br><br>          -  Concurrently participating in another clinical study, or use of an investigational or<br>             a non-registered vaccine, pharmaceutical product, or device within 30 days preceding<br>             the first dose of study vaccine, or planned use during the study period.<br><br>          -  Presence in the parent(s) / LAR(s) of evidence of substance abuse or of neurological<br>             or psychiatric diagnoses which, even if stable, are deemed by the investigator to<br>             render the parent(s)/LAR(s) unable/unlikely to provide accurate safety reports.<br><br>          -  Acute disease and/or fever at the time of enrolment.<br><br>          -  Administration of immunoglobulins, any blood products, or long-acting immune-modifying<br>             drugs during the period starting 3 months before the first dose of study vaccine, or<br>             planned administration during the study period.<br><br>          -  History of any neurological disorders or seizures, or Guillain-Barré Syndrome.<br><br>          -  Diagnosed with excessive daytime sleepiness or narcolepsy; or history of narcolepsy in<br>             a subject's parent or sibling.<br><br>          -  Administration of an inactive vaccine within 14 days or of a live attenuated vaccine<br>             within 30 days before the first vaccination.<br><br>          -  Planned administration of any vaccine not foreseen by the study protocol between Day 0<br>             and Day 42 or planned administration of an inactive vaccine within 14 days or of a<br>             live attenuated vaccine within 30 days before through 30 days after the booster<br>             vaccination. Note: routine vaccinations may be provided on Day 42 after all study<br>             assessments have been performed.<br><br>          -  History of any reaction or hypersensitivity likely to be exacerbated by any component<br>             of the vaccine; a history of anaphylactic-type reaction to consumption of eggs; or a<br>             history of severe adverse reaction to a previous influenza vaccine.<br><br>          -  Any medical condition that in the judgment of the investigator would make<br>             intramuscular injection unsafe.<br><br>          -  Chronic administration of immunosuppressants or other immune-modifying drugs during<br>             the period starting six months prior to the first vaccine. For corticosteroids, this<br>             will mean a dose of prednisone or equivalent of > 2 mg/kg/day of body weight or = 20<br>             mg/day (for persons who weigh = 10 kg). Inhaled and topical steroids are allowed.<br><br>          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on<br>             medical history and physical examination.<br><br>          -  Family history of congenital or hereditary immunodeficiency.<br><br>          -  Major congenital defects.<br><br>          -  Any condition which, in the opinion of the investigator, prevents the subject from<br>             participating in the study.<br>",NULL,"Calculation of immunogenicity-fever indices based on evaluation of humoral immune response in terms of vaccine-homologous hemagglutination Inhibition (HI) and microneutralization (MN) antibodies for each group;Evaluation of Mean Geometric Increase (MGI), in terms of HI and MN antibodies against vaccine-homologous antigen.;Calculation of immunogenicity-fever indices based on evaluation of humoral immune response in terms of vaccine-homologous hemagglutination Inhibition (HI) and microneutralization (MN) antibodies for each group;Evaluation of Mean Geometric Increase (MGI), in terms of HI and MN antibodies against vaccine-homologous antigen.;Calculation of immunogenicity-fever indices based on evaluation of humoral immune response in terms of vaccine-homologous hemagglutination Inhibition (HI) and microneutralization (MN) antibodies for each group;Evaluation of Mean Geometric Increase (MGI), in terms of HI and MN antibodies against vaccine-homologous antigen.","Evaluation of humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens post primary immunization.;Evaluation of humoral immune response in terms of vaccine-homologous MN antibody post the primary immunization.;Evaluation of humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens.;Evaluation of humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens.;Evaluation of humoral immune response in terms of HI antibodies against vaccine-homologous/heterologous antigens.;Evaluation of humoral immune response in terms of vaccine-homologous MN antibody.;Evaluation of humoral immune response in terms of vaccine-homologous MN antibody.;Evaluation of Cell mediated Immunity (CMI) in terms of frequencies of antigen-specific cells(CD3+/CD4+/CD8+).;Occurrence of solicited local and general AEs.;Occurrence of unsolicited adverse events (AEs).;Occurrence of unsolicited adverse events (AEs).;Occurrence and relationship to vaccination of adverse events with medically attended events (MAEs).;Occurrence and relationship to vaccination of potential immune-mediated diseases (pIMDs), serious adverse events (SAEs) and adverse events of special interest (AESIs).",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03186742,https://clinicaltrials.gov/show/NCT03186742,Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea,"Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy;Hypertension,Essential;Obstructive Sleep Apnea;Left Ventricular Hypertrophy",Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab;Drug: Eplerenone 50 mg Tab,Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy,CT.gov,10/06/2017,01/07/2014,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,125,Poznan University of Medical Sciences,NULL,NA,1,10/06/2017,"July 1, 2014",NCT031,16-Dec-17,565/14,; ; ; ; ; ; ; ; ;,"Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD",NULL,;;;;;;;;;,;;;;;;;;;,"Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland",; ; ; ; ; ; ; ; ;,"Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD;Andrzej Tykarski, Prof;Szczepan Cofta, PhD",NULL,;;;;;;;;;,;;;;;;;;;,"Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland;Department of Hypertension, Angiology and Internal Disease. Poznan University of Medical Sciences, Poland;Department of Respiratory Diseases, Allergology and Lung Oncology. Poznan University of Medical Sciences, Poland",Completed,NULL,Please refer to primary and secondary sponsors,18 Years,65 Years,All,"<br>        Inclusion Criteria:<br><br>          -  confirmation of resistant hypertension(RAH). RAH was recognized when in spite of the<br>             use of at least 3 antihypertensive agents (including a diuretic) in maximum doses, it<br>             was impossible to achieve the target values of BP (< 140/90 mmHg).<br><br>          -  diagnosing of moderate or severe sleep apnea (OSA) on the basis of apnoea-hypopnea<br>             index (AHI) in polysomnography. AHI was defined by the total number of apnoea's and<br>             hypopneas per hour of sleep. The severity of OSA was determined as: mild (AHI 5-15),<br>             moderate (AHI 15 - 30) and severe (AHI = 30)<br><br>          -  signing informed and written consent to participation in the study.<br><br>        Exclusion Criteria:<br><br>          -  secondary hypertension (other than primary hyperaldosteronism),<br><br>          -  myocardial infarction,<br><br>          -  stroke within 6 months before the study,<br><br>          -  congestive heart failure with New York Heart Association (NYHA) grade III-IV,<br><br>          -  chronic kidney disease (GFR < 30 ml/min),<br><br>          -  active addiction to alcohol or psychoactive substances,<br><br>          -  active cancer disease.<br>      ;<br>        Inclusion Criteria:<br><br>          -  confirmation of resistant hypertension(RAH). RAH was recognized when in spite of the<br>             use of at least 3 antihypertensive agents (including a diuretic) in maximum doses, it<br>             was impossible to achieve the target values of BP (< 140/90 mmHg).<br><br>          -  diagnosing of moderate or severe sleep apnea (OSA) on the basis of apnoea-hypopnea<br>             index (AHI) in polysomnography. AHI was defined by the total number of apnoea's and<br>             hypopneas per hour of sleep. The severity of OSA was determined as: mild (AHI 5-15),<br>             moderate (AHI 15 - 30) and severe (AHI = 30)<br><br>          -  signing informed and written consent to participation in the study.<br><br>        Exclusion Criteria:<br><br>          -  secondary hypertension (other than primary hyperaldosteronism),<br><br>          -  myocardial infarction,<br><br>          -  stroke within 6 months before the study,<br><br>          -  congestive heart failure with New York Heart Association (NYHA) grade III-IV,<br><br>          -  chronic kidney disease (GFR < 30 ml/min),<br><br>          -  active addiction to alcohol or psychoactive substances,<br><br>          -  active cancer disease.<br>      ;<br>        Inclusion Criteria:<br><br>          -  confirmation of resistant hypertension(RAH). RAH was recognized when in spite of the<br>             use of at least 3 antihypertensive agents (including a diuretic) in maximum doses, it<br>             was impossible to achieve the target values of BP (< 140/90 mmHg).<br><br>          -  diagnosing of moderate or severe sleep apnea (OSA) on the basis of apnoea-hypopnea<br>             index (AHI) in polysomnography. AHI was defined by the total number of apnoea's and<br>             hypopneas per hour of sleep. The severity of OSA was determined as: mild (AHI 5-15),<br>             moderate (AHI 15 - 30) and severe (AHI = 30)<br><br>          -  signing informed and written consent to participation in the study.<br><br>        Exclusion Criteria:<br><br>          -  secondary hypertension (other than primary hyperaldosteronism),<br><br>          -  myocardial infarction,<br><br>          -  stroke within 6 months before the study,<br><br>          -  congestive heart failure with New York Heart Association (NYHA) grade III-IV,<br><br>          -  chronic kidney disease (GFR < 30 ml/min),<br><br>          -  active addiction to alcohol or psychoactive substances,<br><br>          -  active cancer disease.<br>      ;<br>        Inclusion Criteria:<br><br>          -  confirmation of resistant hypertension(RAH). RAH was recognized when in spite of the<br>             use of at least 3 antihypertensive agents (including a diuretic) in maximum doses, it<br>             was impossible to achieve the target values of BP (< 140/90 mmHg).<br><br>          -  diagnosing of moderate or severe sleep apnea (OSA) on the basis of apnoea-hypopnea<br>             index (AHI) in polysomnography. AHI was defined by the total number of apnoea's and<br>             hypopneas per hour of sleep. The severity of OSA was determined as: mild (AHI 5-15),<br>             moderate (AHI 15 - 30) and severe (AHI = 30)<br><br>          -  signing informed and written consent to participation in the study.<br><br>        Exclusion Criteria:<br><br>          -  secondary hypertension (other than primary hyperaldosteronism),<br><br>          -  myocardial infarction,<br><br>          -  stroke within 6 months before the study,<br><br>          -  congestive heart failure with New York Heart Association (NYHA) grade III-IV,<br><br>          -  chronic kidney disease (GFR < 30 ml/min),<br><br>          -  active addiction to alcohol or psychoactive substances,<br><br>          -  active cancer disease.<br>",NULL,Number of patients with reduction of left ventricular hypertrophy after Eplerenone therapy;Number of patients with reduction of left ventricular hypertrophy after Eplerenone therapy;Number of patients with reduction of left ventricular hypertrophy after Eplerenone therapy,Reduction in blood pressure after Eplerenone therapy;Reduction in (AHI) apnea-hypopnea index after Eplerenone therapy,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03275415,https://clinicaltrials.gov/show/NCT03275415,Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study,Respiratory Distress Syndrome;Bronchopulmonary Dysplasia,Drug: budesonide;Drug: Saline,Intratracheal Budesonide/Surfactant Prevents BPD,CT.gov,05/09/2017,01/10/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).",Phase 4,380,Taipei Medical University,NULL,NA,NULL,05/09/2017,"October 1, 2018",NCT032,24-Sep-18,N201705026,;,"Tsu F Yeh, M.D., Ph.D.;Tsu F Yeh, M.D., Ph.D.",NULL,;tfyeh@mail.ncku.edu.tw,;886-2-27361661,"Maternal Child Health Research Center, Taipei Medical University;",;,"Tsu F Yeh, M.D., Ph.D.;Tsu F Yeh, M.D., Ph.D.",NULL,;tfyeh@mail.ncku.edu.tw,;886-2-27361661,"Maternal Child Health Research Center, Taipei Medical University;",Not yet recruiting,"Taipei Medical University Hospital;National Taiwan University Hospital;Taipei Veterans General Hospital, Taiwan;Mackay Memorial Hospital;Chung Shan Medical University;Chang Gung Memorial Hospital;China Medical University Hospital",Please refer to primary and secondary sponsors,N/A,4 Hours,All,"<br>        Inclusion Criteria:<br><br>          -  1) birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires<br>             resuscitation, 3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 =<br>             0.30, pressure > 5 cmH2O b) severe retraction c) apnea d) PCO2 = 60 mmHg.<br><br>        Exclusion Criteria:<br><br>          -  1) lethal cardiopulmonary status, 2) severe congenital anomalies.<br>",NULL,incidence of death or BPD,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03453801,https://clinicaltrials.gov/show/NCT03453801,"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection",Influenza;Healthy,Biological: Fluzone®;Biological: FluMist®,"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection",CT.gov,27/02/2018,30/09/2014,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,Phase 1,80,Stanford University,United States,NA,1,27/02/2018,"September 30, 2014",NCT034,24-Feb-20,U19AI057229-11;SU-31256,; ;,"Cornelia L Dekker, MD;Mark M Davis, PhD;Philip M Grant, MD",NULL,;;,;;,Stanford University;Stanford University;Stanford University,; ;,"Cornelia L Dekker, MD;Mark M Davis, PhD;Philip M Grant, MD",NULL,;;,;;,Stanford University;Stanford University;Stanford University,Completed,National Institute of Allergy and Infectious Diseases (NIAID),Please refer to primary and secondary sponsors,6 Months,10 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Otherwise healthy non-twins 6 months - 10 years old, or 2-5 year old identical (MZ)<br>             twins.<br><br>          2. Willing to complete the informed consent process (including assent for minors 7 years<br>             old and above).<br><br>          3. Availability for follow-up for the planned duration of the study - annually until<br>             2018-2019 influenza vaccination season<br><br>          4. Acceptable medical history by review of inclusion/exclusion criteria and vital signs.<br><br>          5. Non-twin flu/MMRV naive group: Willing to have primary care physician immunize child<br>             with the MMRV vaccine and return for a study visit approximately 60 days later.<br><br>        Exclusion Criteria:<br><br>          1. Prior off-study vaccination with the current year's seasonal influenza vaccine.<br><br>          2. Life-threatening reactions to previous influenza vaccinations<br><br>          3. Allergy to egg or egg products, or to vaccine components<br><br>          4. Active systemic or serious concurrent illness, including febrile illness on the day of<br>             vaccination<br><br>          5. History of immunodeficiency (including HIV infection)<br><br>          6. Known or suspected impairment of immunologic function, including, but not limited to,<br>             clinically significant liver disease, diabetes mellitus treated with insulin, moderate<br>             to severe renal disease, or any other chronic disorder which, in the opinion of the<br>             investigator, might jeopardize volunteer safety or compliance with the protocol.<br><br>          7. Chronic Hepatitis B or C.<br><br>          8. Recent or current use of immunosuppressive medication, including systemic<br>             glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible in<br>             all groups; inhaled steroid use is not permissible)<br><br>          9. Malignancy<br><br>         10. Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive<br>             medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion<br>             of the investigator, might jeopardize volunteer safety or compliance with the<br>             protocol.<br><br>         11. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular<br>             medical follow up or hospitalization during the preceding year<br><br>         12. Receipt of blood or blood products within the past 6 months or planned used during the<br>             study.<br><br>         13. Receipt of Inactivated vaccine 14 days prior to study enrollment, or planned<br>             vaccinations prior to completion of last study visit ( ~ 28 Day after study<br>             vaccination)<br><br>         14. Receipt of live, attenuated vaccine within 60 days prior to enrollment of planned<br>             vaccination prior to completion of last study visit (~ 28 Day after study vaccination)<br><br>         15. Need for allergy immunization (that cannot be postponed) during the study period.<br><br>         16. History of Guillain-Barré syndrome<br><br>         17. Use of investigational agents within 30 days prior to enrollment or planned use during<br>             the study.<br><br>         18. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or<br>             planned donation prior to completion of the last visit.<br><br>         19. Any condition which, in the opinion of the investigator, might interfere with<br>             volunteer safety, study objectives or the ability of the participant to understand or<br>             comply with the study protocol.<br>",NULL,Frequency of antigen-specific T memory phenotype cells (TMP),T cell receptor (TCR) repertoire analysis deep phenotyping by mass cytometry (CyTOF);Deep phenotyping by mass cytometry (CyTOF),NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03773822,https://clinicaltrials.gov/show/NCT03773822,"Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock. A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled Study",Cardiogenic Shock,Combination Product: Hydrocortisone + Flucortac;Other: Placebo,Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.,CT.gov,21/11/2018,19/04/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 3,380,CMC Ambroise Paré,France,NA,NULL,21/11/2018,"April 19, 2019",NCT037,14-Apr-20,2018/05,NA,"Armand MEKONTSO DESSAP, MD",NULL,armand.dessap@aphp.fr,(+33)1 46 25 24 33,NA,NA,"Armand MEKONTSO DESSAP, MD",NULL,armand.dessap@aphp.fr,(+33)1 46 25 24 33,NA,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Aged =18 years<br><br>          2. Cardiogenic shock state, according to the consensual definition:<br><br>               1. Systemic arterial hypertension (systolic blood pressure <90 mmHg or mean arterial<br>                  pressure = 65 mmHg) or signs of peripheral hypoperfusion, requiring treatment<br>                  with catecholamines to maintain systolic blood pressure = 90 mmHg and regression<br>                  of signs of hypoperfusion;<br><br>               2. Presence of at least one sign of systemic hypoperfusion among the following:<br>                  marbling, oliguria = 25 ml / h, impairment of consciousness, arterial<br>                  hyperlactatemia> 2 mmol / L;<br><br>               3. Presence of at least one sign of hypocontractility or low flow among the<br>                  following: cardiac index = 2.2 L / min / m2, left ventricular ejection fraction<br>                  (LVEF) = 40% or full time velocity (ITV) under aortic = 18 cm, or need for<br>                  catecholamines to maintain an index<br><br>               4. Clinical signs of right or pulmonary congestion or elevation of filling pressures<br>                  as measured by Doppler (E / A> 2 if FEVG =40% or E / Ea> 13 if LVEF> 40% or PAPS><br>                  35mmHg) or right heart catheterization (pulmonary artery occlusion pressures><br>                  15mmHg or PAPm> 25mmHg) as recommended<br><br>          3. Having received informed information about the study and having signed a consent to<br>             participate in the study<br><br>          4. Benefiting from a social security<br><br>        Exclusion Criteria:<br><br>          1. Cardiogenic shock state with catecholamine infusion for more than 24 hours;<br><br>          2. Presence Presence of septic shock at inclusion;<br><br>          3. Cardiopulmonary arrest recovered within days (7 days) prior to inclusion;<br><br>          4. Patients already on circulatory support (ECMO) before inclusion (patients who are<br>             assisted after inclusion will not be excluded);<br><br>          5. Cardiogenic shock on viral myocarditis;<br><br>          6. Prior corticosteroid therapy (= 30 mg prednisone or equivalent = 1 month);<br><br>          7. Receiving one of the following treatments: ketoconazole, rifampicin, phenytoin,<br>             phenobarbital, cyclosporine and clarithromycin;<br><br>          8. Known history of hypersensitivity to fludrocortisone or hydrocortisone;<br><br>          9. Known pregnancy or breastfeeding;<br>",NULL,Patients not treated with corticosteroids at day 7,Modification of mean arterial pressure;Rates of patients requiring the introduction of intravenous insulin therapy after randomization;Rate of patients with nosocomial infection;Number of patients alive at day 7 without failure (SOFA) score);Number of patients with Circulatory assistance;Number of patients use of mechanical ventilation;Clearance of lactatemia;Duration of support by catecholamines;Length of stay in intensive care and hospital;Modification of the cardiac index;Mortality at 28 and 90 days after randomisation,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03690583,https://clinicaltrials.gov/show/NCT03690583,Assessment of the Immunomodulatory Effect of Zinc Supplementation on the Clinical Evolution of Children With Pneumonia,"Pneumonia;Children, Only;Pneumonia;Children, Only",Drug: Zinc sulfate;Other: Glucose;Drug: Zinc sulfate;Other: Glucose,Immunomodulation by Zinc Supplementation in Children With Pneumonia,CT.gov,20/09/2018,29/01/2014,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",Phase 1,103,Universidad Nacional Autonoma de Mexico,Mexico;Mexico,NA,1,20/09/2018,"January 29, 2014",NCT036,09-Oct-18,CONACYT SALUD 2012-01-182274,;,"Rosa M Wong-Chew, MD, DSc;Rosa M Wong-Chew, MD, DSc",NULL,;,;,"Facultad de Medicina, Universidad Nacional Autonoma de Mexico;Facultad de Medicina, Universidad Nacional Autonoma de Mexico",;,"Rosa M Wong-Chew, MD, DSc;Rosa M Wong-Chew, MD, DSc",NULL,;,;,"Facultad de Medicina, Universidad Nacional Autonoma de Mexico;Facultad de Medicina, Universidad Nacional Autonoma de Mexico",Completed,Hospital General de Mexico;Hospital Pediatrico de Coyoacan,Please refer to primary and secondary sponsors,1 Month,5 Years,All,"<br>        Inclusion Criteria:<br><br>          -  Children 1 month to 5 years old with clinical and/or radiological diagnosis of<br>             pneumonia<br><br>          -  Admitted to the Emergency room at the participant institutions<br><br>        Exclusion Criteria:<br><br>          -  Prematurity<br><br>          -  Cardiopathy<br><br>          -  Pneumopathy<br><br>          -  Immunosuppression (congenital, chemotherapy or other cause)<br>      ;<br>        Inclusion Criteria:<br><br>          -  Children 1 month to 5 years old with clinical and/or radiological diagnosis of<br>             pneumonia<br><br>          -  Admitted to the Emergency room at the participant institutions<br><br>        Exclusion Criteria:<br><br>          -  Prematurity<br><br>          -  Cardiopathy<br><br>          -  Pneumopathy<br><br>          -  Immunosuppression (congenital, chemotherapy or other cause)<br>",NULL,"Time of improvement of respiratory distress;Time of improvement of oxygen desaturation;Time of improvement of clinical symptoms (cough, rales);Time of improvement of fever;Duration of hospitalization;Time of improvement of respiratory distress;Time of improvement of oxygen desaturation;Time of improvement of clinical symptoms (cough, rales);Time of improvement of fever;Duration of hospitalization",Cytokines pattern measured by flow cytometry in blood samples;Lymphoproliferation measured by incorporation of a fluorochrome in lymphocytes stimulated with Concanavalin A,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03330132,https://clinicaltrials.gov/show/NCT03330132,Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial,"Influenza, Human",Biological: Standard inactivated influenza vaccine (NH formulation);Biological: MF 59 adjuvanted inactivated influenza vaccine (NH formulation);Biological: High-dose inactivated influenza vaccine (NH formulation);Biological: Recombinant hemagglutinin inactivated influenza vaccine (NH formulation),Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong,CT.gov,10/10/2017,07/10/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).",Phase 4,1861,The University of Hong Kong,China;China;China,NA,NULL,10/10/2017,"October 7, 2017",NCT033,12-Nov-18,YHT005.1,; ;,"Benjamin J COWLING, PhD;Benjamin J COWLING, PhD;Benjamin J COWLING, PhD",NULL,;;,;;,The University of Hong Kong;The University of Hong Kong;The University of Hong Kong,; ;,"Benjamin J COWLING, PhD;Benjamin J COWLING, PhD;Benjamin J COWLING, PhD",NULL,;;,;;,The University of Hong Kong;The University of Hong Kong;The University of Hong Kong,"Active, not recruiting",Centers for Disease Control and Prevention,Please refer to primary and secondary sponsors,65 Years,82 Years,All,"<br>        Inclusion Criteria:<br><br>        • Adult aged 65-82 years attending ECC and EDC who has not received 2017/18 seasonal<br>        influenza vaccine and is willing to receive annual influenza vaccination<br><br>        Exclusion Criteria:<br><br>          -  Individuals who show signs of dementia (do not pass the Mini-cog test under Appendix<br>             1a: Recruitment Screening Log) or significant cognitive impairment and are not<br>             competent to give their consent.<br><br>          -  Individuals who report medical conditions not suitable to receive inactivated<br>             influenza vaccines, such as:<br><br>               -  Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza<br>                  vaccine; or to a vaccine component, including egg protein;<br><br>               -  Moderate or severe acute illness with or without fever after any previous<br>                  influenza vaccination; or<br><br>               -  A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza<br>                  vaccination.<br><br>          -  Individuals, who report medical conditions not suitable to receive intramuscular<br>             injection, such as:<br><br>               -  bleeding disorders<br><br>               -  habitually taking anticoagulants (with the exception of antiplatelets such as<br>                  aspirin).<br><br>          -  Individuals who have any medical conditions not suitable to receive inactivated<br>             influenza vaccines as determined by a clinician.<br>",NULL,Difference in antibody titres,Seroprotection;CMI responses;Adverse events;PCR confirmed infection,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02831608,https://clinicaltrials.gov/show/NCT02831608,"Influenza Vaccination After Myocardial Infarction (IAMI Trial): A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on National Angiography and Angioplasty Registries","Myocardial Infarction;Influenza, Human;Influenza Vaccines;Heart Failure;Stroke",Biological: Influenza vaccine;Biological: Placebo,Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis,CT.gov,07/07/2016,01/10/2016,TRUE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 4,2573,"Ole Frobert, MD, PhD",Australia;Bangladesh;Czechia;Denmark;Latvia;Norway;Sweden;United Kingdom;Australia;Bangladesh;Czechia;Denmark;Latvia;Norway;Sweden;United Kingdom,EUCTR2014-001354-42-SE,NULL,07/07/2016,Oct-16,NCT028,27-Jul-20,IAMI Trial;IAMI-2014,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,"Active, not recruiting","Swedish Heart Lung Foundation;Sanofi Pasteur, a Sanofi Company;Uppsala University;Lytics",Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Patients with a diagnosis of ST-elevation myocardial infarction (STEMI) or<br><br>          -  Patients with a diagnosis of non-STEMI or<br><br>          -  Patients with stable coronary artery disease =75 years of age undergoing<br>             angiography/PCI AND with at least one additional risk criterion<br><br>        and<br><br>          -  A finalized coronary angiography/PCI (optional for sites in Bangladesh).<br><br>          -  Male or female subjects =18 years.<br><br>          -  Written informed consent.<br><br>        Exclusion Criteria:<br><br>          -  Influenza vaccination during the current influenza season or anticipating to be<br>             vaccinated during the current influenza season.<br><br>          -  Indication for influenza vaccination for some indication other than myocardial<br>             infarction.<br><br>          -  Severe allergy to eggs or previous allergic reaction to influence vaccine.<br><br>          -  Suspicion of febrile illness or acute, ongoing infection.<br><br>          -  Hypersensitivity to the active substances or ingredients of Vaxigrip or against any<br>             residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and<br>             octoxinol.<br><br>          -  Subjects with endogenic or iatrogenic immunosuppression that may result in reduced<br>             immunization response.<br><br>          -  Inability to provide informed consent.<br><br>          -  Age below 18 years.<br><br>          -  Previous randomization in the IAMI trial.<br>",NULL,"The number of participants with death, a new myocardial infarction or stent thrombosis (first occurring) according to ICD-10 codes.","The number of participants with stroke/transient ischemic attack according to ICD-10 codes.;The number of participants with hospitalization for heart failure according to ICD-10 codes.;The number of participants with: arrhythmia according to ICD-10 codes.;The number of participants with: stent thrombosis.;The number of participants with: a new myocardial infarction according to ICD-10 codes.;The number of participants with: death according to ICD-10 codes.;The number of participants with a new revascularization;The number of participants with: cardiovascular death according to ICD-10 codes.;The number of participants with: cardiovascular death, a new myocardial infarction or stent thrombosis assessed separately for each diagnosis according ICD-10 codes.;Length of hospital stay per participant.",child,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT04023305,https://clinicaltrials.gov/show/NCT04023305,Sevoflurane pharmacokInetics During Inhaled Sedation Relies on the Morphotype of ARDS in ICU Patients,Acute Respiratory Distress Syndrome,Drug: Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts,Sevoflurane PharmacokInetics in ARDS,CT.gov,10/07/2019,23/02/2020,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,N/A,30,"University Hospital, Clermont-Ferrand",France,NA,NULL,10/07/2019,"February 23, 2020",NCT040,16-Jul-20,2018-003511-21;SPIDERMAN Study,;,"Raiko Blondonnet, MD, MSc;Lise Laclautre",NULL,;promo_interne_drci@chu-clermontferrand.fr,;+33 73 754 963,"University Hospital, Clermont-Ferrand;",;,"Raiko Blondonnet, MD, MSc;Lise Laclautre",NULL,;promo_interne_drci@chu-clermontferrand.fr,;+33 73 754 963,"University Hospital, Clermont-Ferrand;",Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Age =18 years<br><br>          -  Presence for = 12 hours of all of the following conditions, within one week of a<br>             clinical insult or new or worsening respiratory symptoms :<br><br>        a PaO2/FiO2 < 200 mmHg with positive end-expiratory pressure (PEEP) = 8 cmH2O (or, if<br>        arterial blood gas not available : SpO2/FiO2 ratio that is equivalent to a PaO2/FiO2 < 200<br>        mmHg with PEEP =8 cmH2O, and a confirmatory SpO2/FiO2 ratio between 1-6 hours after the<br>        initial SpO2/FiO2 ratio determination) b Bilateral opacities not fully explained by<br>        effusions, lobar/lung collapse, or nodules c Respiratory failure not fully explained by<br>        cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to<br>        exclude hydrostatic edema if no risk factor present<br><br>        Exclusion Criteria:<br><br>          -  Lack of informed consent<br><br>          -  Continuous sedation with inhaled sevoflurane at enrollment<br><br>          -  Currently receiving ECMO therapy<br><br>          -  Chronic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting<br><br>          -  Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for<br>             CPAP/BIPAP used solely for sleep-disordered breathing<br><br>          -  Body mass index > 40 kg/m2<br><br>          -  Chronic liver disease defined as a Child-Pugh score of 12-15<br><br>          -  Expected duration of mechanical ventilation < 48 hours<br><br>          -  Tidal volume of 6 mL/kg predicted body weight (PBW) below 200 mL<br><br>          -  Decision to withhold life-sustaining treatment; except in those patients committed to<br>             full support except cardiopulmonary resuscitation<br><br>          -  Moribund patient, i.e. not expected to survive 24 hours despite intensive care<br><br>          -  Burns > 70% total body surface<br><br>          -  Previous hypersensitivity or anaphylactic reaction to sevoflurane<br><br>          -  Medical history of malignant hyperthermia<br><br>          -  Suspected or proven intracranial hypertension<br><br>          -  Know pregnancy - Pregnancy testing will be systematically performed to rule out<br>             pregnancy in female patients of reproductive age<br><br>          -  Enrollment in another interventional ARDS trial with direct impact on sedation and<br>             PEEP<br><br>          -  Endotracheal ventilation for greater than 120 hours (5 days)<br><br>          -  PaO2/FiO2 (if available) > 200 mmHg after meeting inclusion criteria and before start<br>             of the study<br>",NULL,Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane;Plasma concentrations of sevoflurane,Values of a bispectral index;Infusion rate of remifentanil;Infusion duration of sevoflurane;Dose of sevoflurane;Fraction of expired sevoflurane;Fraction of inspired sevoflurane;Plasma concentration of hexafluoroisopropanolol,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03160118,https://clinicaltrials.gov/show/NCT03160118,A Clinical Study of Biomarkers of Innate and Adaptive Immune Activation Associated With Symptoms and Immune Responses After Administration of a Single Dose of a Quadrivalent Inactivated Split Virus Influenza Vaccine to Healthy Young Adults.,Prevention of Influenza;Prevention of Influenza;Prevention of Influenza;Prevention of Influenza,"Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine;Drug: Seasonal,quadrivalent,influenza vaccine",Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults,CT.gov,24/03/2017,27/03/2017,FALSE,Interventional,Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).,Phase 4,20,"University Hospital, Ghent",Belgium;Belgium;Belgium;Belgium;Belgium,NA,NULL,24/03/2017,"March 27, 2017",NCT031,16-Dec-17,BioVacSafe - QIV,; ; ; ;,"Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD",NULL,;;;;,;;;;,University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent,; ; ; ;,"Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD;Geert Leroux-Roels, Prof., PhD",NULL,;;;;,;;;;,University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent;University Ghent / University Hospital Ghent,"Active, not recruiting","CEVAC Core Lab, University Ghent;Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany;deCODE genetics, Iceland;VisMederi srl, Sienna, Italy",Please refer to primary and secondary sponsors,24 Years,54 Years,All,"<br>        Inclusion Criteria:<br><br>          1. Healthy male or female subjects aged 24-54 years inclusive. (Healthy in the opinion of<br>             the investigator, based on medical history and clinical exam, with no active disease<br>             process that could interfere with the study endpoints)<br><br>          2. Has a body Mass Index =18 and =30<br><br>          3. Is able to read and understand the Informed Consent Form (ICF), and understand study<br>             procedures.<br><br>          4. The subject has signed the ICF.<br><br>          5. The subject is available for follow-up for the duration of the study.<br><br>          6. The subject agrees to abstain from donating blood during their participation in the<br>             study, or longer if necessary.<br><br>          7. If the subject is a heterosexually active female, she is willing to use an effective<br>             method of contraception (e.g. oral contraceptive pill; intrauterine device; injectable<br>             or implanted contraceptive; physiological or anatomical sterility) from 30 days prior<br>             to study vaccination until the end of the study.<br><br>          8. Willing to undergo urine pregnancy tests prior to vaccination at screening.<br><br>          9. The subject has venous access sufficient to allow blood sampling as per the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Pregnant or lactating.<br><br>          2. Known hypersensitivity to any component of the study vaccine (a-RIX-Tetra®): the<br>             active components (vaccine antigens) or any of the excipients (disodium phosphate<br>             dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate,<br>             a-tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken<br>             proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or<br>             those who have had a previous life-threatening reaction to previous influenza<br>             vaccinations.<br><br>          3. History of influenza infection in the past 5 years, defined here as severe respiratory<br>             infection with fever (> 38°C) and preventing normal daily activity during a minimum of<br>             3 days.<br><br>          4. Vaccination with the 2016/2017 seasonal influenza vaccine and/or any other seasonal<br>             influenza vaccine within the preceding 5 influenza seasons (i.e. since season<br>             2011/2012) before the first study visit.<br><br>          5. Presence of primary or acquired immunodeficiency states with a total lymphocyte count<br>             less than 1,200 per mm3 or presenting other evidence of lack of cellular immune<br>             competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving<br>             immunosuppressive therapy (including use of oral or parenteral corticosteroids in a<br>             dose = 5 mg prednisone daily or equivalent within one month prior to visit 1or<br>             cytotoxic or immunosuppressive or immunomodulating drugs within 6 months prior to<br>             visit 1).<br><br>          6. Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within<br>             6 months of Visit 1 considered by the study physician as likely to interfere with<br>             immune responses.<br><br>          7. Current intake of excessive amounts of alcohol (= 14 units for women and = 21 units<br>             for men) and not willing to adapt this use during the study period.<br><br>          8. Currently performing extreme physical activities (as evaluated by the investigator)<br>             and not willing to adapt this activity during the study period.<br><br>          9. Receipt of a vaccine within 30 days of visit 1, or requirement to receive another<br>             vaccine within the study period.<br><br>         10. Presence of an acute severe febrile illness at time of immunisation.<br><br>         11. History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or<br>             dependence within the 12 months preceding Visit 1.<br><br>         12. Smoking in the past 6 months OR > 5 pack-year lifetime history<br><br>         13. Receipt of blood products or immunoglobulins, or blood donation, within 3 months of<br>             study start.<br><br>         14. Any condition that, in the investigator's opinion, compromises the subject's ability<br>             to meet protocol requirements or to complete the study.<br><br>         15. Currently participating in another clinical study with an investigational or<br>             non-investigational drug or device, or has participated in a clinical trial within the<br>             3 months preceding Visit 1.<br><br>         16. Unable to read and speak Dutch or English to a fluency level adequate for the full<br>             comprehension of procedures required in participation and consent.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy male or female subjects aged 24-54 years inclusive. (Healthy in the opinion of<br>             the investigator, based on medical history and clinical exam, with no active disease<br>             process that could interfere with the study endpoints)<br><br>          2. Has a body Mass Index =18 and =30<br><br>          3. Is able to read and understand the Informed Consent Form (ICF), and understand study<br>             procedures.<br><br>          4. The subject has signed the ICF.<br><br>          5. The subject is available for follow-up for the duration of the study.<br><br>          6. The subject agrees to abstain from donating blood during their participation in the<br>             study, or longer if necessary.<br><br>          7. If the subject is a heterosexually active female, she is willing to use an effective<br>             method of contraception (e.g. oral contraceptive pill; intrauterine device; injectable<br>             or implanted contraceptive; physiological or anatomical sterility) from 30 days prior<br>             to study vaccination until the end of the study.<br><br>          8. Willing to undergo urine pregnancy tests prior to vaccination at screening.<br><br>          9. The subject has venous access sufficient to allow blood sampling as per the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Pregnant or lactating.<br><br>          2. Known hypersensitivity to any component of the study vaccine (a-RIX-Tetra®): the<br>             active components (vaccine antigens) or any of the excipients (disodium phosphate<br>             dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate,<br>             a-tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken<br>             proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or<br>             those who have had a previous life-threatening reaction to previous influenza<br>             vaccinations.<br><br>          3. History of influenza infection in the past 5 years, defined here as severe respiratory<br>             infection with fever (> 38°C) and preventing normal daily activity during a minimum of<br>             3 days.<br><br>          4. Vaccination with the 2016/2017 seasonal influenza vaccine and/or any other seasonal<br>             influenza vaccine within the preceding 5 influenza seasons (i.e. since season<br>             2011/2012) before the first study visit.<br><br>          5. Presence of primary or acquired immunodeficiency states with a total lymphocyte count<br>             less than 1,200 per mm3 or presenting other evidence of lack of cellular immune<br>             competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving<br>             immunosuppressive therapy (including use of oral or parenteral corticosteroids in a<br>             dose = 5 mg prednisone daily or equivalent within one month prior to visit 1or<br>             cytotoxic or immunosuppressive or immunomodulating drugs within 6 months prior to<br>             visit 1).<br><br>          6. Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within<br>             6 months of Visit 1 considered by the study physician as likely to interfere with<br>             immune responses.<br><br>          7. Current intake of excessive amounts of alcohol (= 14 units for women and = 21 units<br>             for men) and not willing to adapt this use during the study period.<br><br>          8. Currently performing extreme physical activities (as evaluated by the investigator)<br>             and not willing to adapt this activity during the study period.<br><br>          9. Receipt of a vaccine within 30 days of visit 1, or requirement to receive another<br>             vaccine within the study period.<br><br>         10. Presence of an acute severe febrile illness at time of immunisation.<br><br>         11. History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or<br>             dependence within the 12 months preceding Visit 1.<br><br>         12. Smoking in the past 6 months OR > 5 pack-year lifetime history<br><br>         13. Receipt of blood products or immunoglobulins, or blood donation, within 3 months of<br>             study start.<br><br>         14. Any condition that, in the investigator's opinion, compromises the subject's ability<br>             to meet protocol requirements or to complete the study.<br><br>         15. Currently participating in another clinical study with an investigational or<br>             non-investigational drug or device, or has participated in a clinical trial within the<br>             3 months preceding Visit 1.<br><br>         16. Unable to read and speak Dutch or English to a fluency level adequate for the full<br>             comprehension of procedures required in participation and consent.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy male or female subjects aged 24-54 years inclusive. (Healthy in the opinion of<br>             the investigator, based on medical history and clinical exam, with no active disease<br>             process that could interfere with the study endpoints)<br><br>          2. Has a body Mass Index =18 and =30<br><br>          3. Is able to read and understand the Informed Consent Form (ICF), and understand study<br>             procedures.<br><br>          4. The subject has signed the ICF.<br><br>          5. The subject is available for follow-up for the duration of the study.<br><br>          6. The subject agrees to abstain from donating blood during their participation in the<br>             study, or longer if necessary.<br><br>          7. If the subject is a heterosexually active female, she is willing to use an effective<br>             method of contraception (e.g. oral contraceptive pill; intrauterine device; injectable<br>             or implanted contraceptive; physiological or anatomical sterility) from 30 days prior<br>             to study vaccination until the end of the study.<br><br>          8. Willing to undergo urine pregnancy tests prior to vaccination at screening.<br><br>          9. The subject has venous access sufficient to allow blood sampling as per the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Pregnant or lactating.<br><br>          2. Known hypersensitivity to any component of the study vaccine (a-RIX-Tetra®): the<br>             active components (vaccine antigens) or any of the excipients (disodium phosphate<br>             dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate,<br>             a-tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken<br>             proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or<br>             those who have had a previous life-threatening reaction to previous influenza<br>             vaccinations.<br><br>          3. History of influenza infection in the past 5 years, defined here as severe respiratory<br>             infection with fever (> 38°C) and preventing normal daily activity during a minimum of<br>             3 days.<br><br>          4. Vaccination with the 2016/2017 seasonal influenza vaccine and/or any other seasonal<br>             influenza vaccine within the preceding 5 influenza seasons (i.e. since season<br>             2011/2012) before the first study visit.<br><br>          5. Presence of primary or acquired immunodeficiency states with a total lymphocyte count<br>             less than 1,200 per mm3 or presenting other evidence of lack of cellular immune<br>             competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving<br>             immunosuppressive therapy (including use of oral or parenteral corticosteroids in a<br>             dose = 5 mg prednisone daily or equivalent within one month prior to visit 1or<br>             cytotoxic or immunosuppressive or immunomodulating drugs within 6 months prior to<br>             visit 1).<br><br>          6. Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within<br>             6 months of Visit 1 considered by the study physician as likely to interfere with<br>             immune responses.<br><br>          7. Current intake of excessive amounts of alcohol (= 14 units for women and = 21 units<br>             for men) and not willing to adapt this use during the study period.<br><br>          8. Currently performing extreme physical activities (as evaluated by the investigator)<br>             and not willing to adapt this activity during the study period.<br><br>          9. Receipt of a vaccine within 30 days of visit 1, or requirement to receive another<br>             vaccine within the study period.<br><br>         10. Presence of an acute severe febrile illness at time of immunisation.<br><br>         11. History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or<br>             dependence within the 12 months preceding Visit 1.<br><br>         12. Smoking in the past 6 months OR > 5 pack-year lifetime history<br><br>         13. Receipt of blood products or immunoglobulins, or blood donation, within 3 months of<br>             study start.<br><br>         14. Any condition that, in the investigator's opinion, compromises the subject's ability<br>             to meet protocol requirements or to complete the study.<br><br>         15. Currently participating in another clinical study with an investigational or<br>             non-investigational drug or device, or has participated in a clinical trial within the<br>             3 months preceding Visit 1.<br><br>         16. Unable to read and speak Dutch or English to a fluency level adequate for the full<br>             comprehension of procedures required in participation and consent.<br>      ;<br>        Inclusion Criteria:<br><br>          1. Healthy male or female subjects aged 24-54 years inclusive. (Healthy in the opinion of<br>             the investigator, based on medical history and clinical exam, with no active disease<br>             process that could interfere with the study endpoints)<br><br>          2. Has a body Mass Index =18 and =30<br><br>          3. Is able to read and understand the Informed Consent Form (ICF), and understand study<br>             procedures.<br><br>          4. The subject has signed the ICF.<br><br>          5. The subject is available for follow-up for the duration of the study.<br><br>          6. The subject agrees to abstain from donating blood during their participation in the<br>             study, or longer if necessary.<br><br>          7. If the subject is a heterosexually active female, she is willing to use an effective<br>             method of contraception (e.g. oral contraceptive pill; intrauterine device; injectable<br>             or implanted contraceptive; physiological or anatomical sterility) from 30 days prior<br>             to study vaccination until the end of the study.<br><br>          8. Willing to undergo urine pregnancy tests prior to vaccination at screening.<br><br>          9. The subject has venous access sufficient to allow blood sampling as per the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Pregnant or lactating.<br><br>          2. Known hypersensitivity to any component of the study vaccine (a-RIX-Tetra®): the<br>             active components (vaccine antigens) or any of the excipients (disodium phosphate<br>             dodecahydrate, potassium dihydrogen phosphate, magnesium chloride hexahydrate,<br>             a-tocopheryl hydrogen succinate, polysorbate 80, octoxinol 10), eggs (chicken<br>             proteins, ovalbumin), gentamycin sulphate, formaldehyde, and sodium deoxycholate or<br>             those who have had a previous life-threatening reaction to previous influenza<br>             vaccinations.<br><br>          3. History of influenza infection in the past 5 years, defined here as severe respiratory<br>             infection with fever (> 38°C) and preventing normal daily activity during a minimum of<br>             3 days.<br><br>          4. Vaccination with the 2016/2017 seasonal influenza vaccine and/or any other seasonal<br>             influenza vaccine within the preceding 5 influenza seasons (i.e. since season<br>             2011/2012) before the first study visit.<br><br>          5. Presence of primary or acquired immunodeficiency states with a total lymphocyte count<br>             less than 1,200 per mm3 or presenting other evidence of lack of cellular immune<br>             competence e.g. leukaemias, lymphomas, blood dyscrasias, or patients receiving<br>             immunosuppressive therapy (including use of oral or parenteral corticosteroids in a<br>             dose = 5 mg prednisone daily or equivalent within one month prior to visit 1or<br>             cytotoxic or immunosuppressive or immunomodulating drugs within 6 months prior to<br>             visit 1).<br><br>          6. Regular use of non-steroidal anti-inflammatory drugs (oral or parenteral route) within<br>             6 months of Visit 1 considered by the study physician as likely to interfere with<br>             immune responses.<br><br>          7. Current intake of excessive amounts of alcohol (= 14 units for women and = 21 units<br>             for men) and not willing to adapt this use during the study period.<br><br>          8. Currently performing extreme physical activities (as evaluated by the investigator)<br>             and not willing to adapt this activity during the study period.<br><br>          9. Receipt of a vaccine within 30 days of visit 1, or requirement to receive another<br>             vaccine within the study period.<br><br>         10. Presence of an acute severe febrile illness at time of immunisation.<br><br>         11. History of alcohol, narcotic, benzodiazepine, rilatine, or other substance abuse or<br>             dependence within the 12 months preceding Visit 1.<br><br>         12. Smoking in the past 6 months OR > 5 pack-year lifetime history<br><br>         13. Receipt of blood products or immunoglobulins, or blood donation, within 3 months of<br>             study start.<br><br>         14. Any condition that, in the investigator's opinion, compromises the subject's ability<br>             to meet protocol requirements or to complete the study.<br><br>         15. Currently participating in another clinical study with an investigational or<br>             non-investigational drug or device, or has participated in a clinical trial within the<br>             3 months preceding Visit 1.<br><br>         16. Unable to read and speak Dutch or English to a fluency level adequate for the full<br>             comprehension of procedures required in participation and consent.<br>",NULL,"Frequency of local vaccine-related clinical events.;Severity of local vaccine-related clinical events.;Frequency of systemic vaccine-related clinical events.;Severity of systemic vaccine-related clinical events.;Change from pre-immunisation baseline values in pulse.;Change from pre-immunisation baseline values in body temperature;Change from pre-immunisation baseline values in blood pressure;Change from pre-immunisation baseline values in haematology (CBC, ESR, phenotyping of WBC) parameters;Change from pre-immunisation baseline values in biochemistry parameters;Change from pre-immunisation baseline values in global gene expression measured on whole blood samples;Change from pre-immunisation baseline values in serum HAI titre in serum samples;Change from pre-immunisation values of adaptive cellular immune response via enumeration of influenza-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry;Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples;Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro stimulation with influenza antigens;Frequency of local vaccine-related clinical events.;Severity of local vaccine-related clinical events.;Frequency of systemic vaccine-related clinical events.;Severity of systemic vaccine-related clinical events.;Change from pre-immunisation baseline values in pulse.;Change from pre-immunisation baseline values in body temperature;Change from pre-immunisation baseline values in blood pressure;Change from pre-immunisation baseline values in haematology (CBC, ESR, phenotyping of WBC) parameters;Change from pre-immunisation baseline values in biochemistry parameters;Change from pre-immunisation baseline values in global gene expression measured on whole blood samples;Change from pre-immunisation baseline values in serum HAI titre in serum samples;Change from pre-immunisation values of adaptive cellular immune response via enumeration of influenza-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry;Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples;Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro stimulation with influenza antigens;Frequency of local vaccine-related clinical events.;Severity of local vaccine-related clinical events.;Frequency of systemic vaccine-related clinical events.;Severity of systemic vaccine-related clinical events.;Change from pre-immunisation baseline values in pulse.;Change from pre-immunisation baseline values in body temperature;Change from pre-immunisation baseline values in blood pressure;Change from pre-immunisation baseline values in haematology (CBC, ESR, phenotyping of WBC) parameters;Change from pre-immunisation baseline values in biochemistry parameters;Change from pre-immunisation baseline values in global gene expression measured on whole blood samples;Change from pre-immunisation baseline values in serum HAI titre in serum samples;Change from pre-immunisation values of adaptive cellular immune response via enumeration of influenza-specific CD4+ T cells expressing activation markers and/or cytokines following in vitro stimulation and analysis by flow cytometry;Change from pre-immunisation baseline values in concentration of selected cytokines and acute phase proteins in serum samples;Change from pre-immunisation baseline values in PBMC cytokine secretion, proliferation or surface markers in response to in vitro stimulation with influenza antigens",NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02809209,https://clinicaltrials.gov/show/NCT02809209,"A Phase 1 Double Blinded, Randomized, Placebo Controlled Study in Vietnamese Healthy Adult Volunteers to Assess the Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Vision Influenza Vaccine (IVACFLU-S) Produced by IVAC",Influenza,Biological: IVACFLU-S;Biological: Placebo,Safety of the Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S),CT.gov,31/05/2016,01/10/2015,TRUE,Interventional,"Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention",Phase 1,30,"National Institute of Hygiene and Epidemiology, Vietnam",Vietnam,NA,1,31/05/2016,Oct-15,NCT028,04-Jul-16,84-CN-BDGDD;2015-IVACFLUSPLIT-01,NA,"Dang D Anh, PhD",NULL,NA,NA,"National Institute of Hygiene and Epidemiology, Vietnam",NA,"Dang D Anh, PhD",NULL,NA,NA,"National Institute of Hygiene and Epidemiology, Vietnam",Completed,"Thai Binh Center of Preventive Medicine, Thai Binh, Vietnam;World Health Organization;PATH",Please refer to primary and secondary sponsors,18 Years,45 Years,Both,"<br>        Inclusion Criteria:<br><br>          -  Male or female adult 18 through 45 years of age at the enrollment visit.<br><br>          -  Literate (by self-report) and willing to provide written informed consent.<br><br>          -  Healthy, as established by the medical history, physical examination, and screening<br>             laboratory evaluations.<br><br>          -  Capable and willing to complete Diary Cards and willing to return for all follow-up<br>             visits.<br><br>          -  For females, willing to utilize reliable birth control measures (e.g., intrauterine<br>             device, hormonal contraception, condoms) through the Day 22 visit.<br><br>        Exclusion Criteria:<br><br>          -  Participation in another clinical trial involving any therapy within the previous<br>             three months or planned enrollment in such a trial during the period of this study.<br><br>          -  Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to<br>             postpone receipt of such vaccines until after the Day 22 visit.<br><br>          -  Current or recent (within 2 weeks of enrollment) acute illness with or without fever.<br><br>          -  Receipt of immune globulin or other blood products within 3 months prior to study<br>             enrollment or planned receipt of such products prior to the Day 22 visit.<br><br>          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of<br>             immunosuppressants or other immune-modulating therapy within six months prior to<br>             study enrollment. (For corticosteroids, this means prednisone or equivalent, = 0.5 mg<br>             per kg per day; topical steroids are allowed.)<br><br>          -  History of asthma.<br><br>          -  Hypersensitivity after previous administration of any vaccine.<br><br>          -  Suspected or known hypersensitivity to any of the study vaccine components, including<br>             chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers).<br><br>          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary,<br>             metabolic, neurologic, psychiatric or renal functional abnormality, as determined by<br>             medical history, physical examination or clinical laboratory screening tests, which<br>             in the opinion of the investigator, might interfere with the study objectives.<br><br>          -  History of any blood or solid organ cancer.<br><br>          -  History of thrombocytopenic purpura or known bleeding disorder.<br><br>          -  History of seizures.<br><br>          -  Known or suspected immunosuppressed or immunodeficient condition of any kind.<br><br>          -  Confirmed HBV or HCV infection<br><br>          -  Known HIV infection (self-report).<br><br>          -  Known active tuberculosis or symptoms of active tuberculosis, regardless of cause<br>             (self-report).<br><br>          -  History of chronic alcohol abuse and/or illegal drug use.<br><br>          -  Pregnancy or lactation. (A negative pregnancy test will be required before<br>             administration of study product for all women of childbearing potential.)<br><br>          -  History of Guillain-Barré Syndrome<br><br>          -  Any condition that, in the opinion of the investigator, would increase the health<br>             risk to the subject if he/she participates in the study or would interfere with the<br>             evaluation of the study objectives.<br><br>        Note: Minor out-of-range laboratory values no greater than Grade 1 (see toxicity table in<br>        Appendix) will not be considered to be exclusionary at screening.<br>",NULL,Numbers of subjects with treatment-related adverse events immediately and within 7 days after vaccination,"Number of participants with abnormal laboratory values;Numbers of participants with treatment-related serious adverse events (SAEs) during study period;Numbers of subjects with a serum Hemagglutination Inhibition (HAI) antibody titer to each of the 3 vaccine components >=40;Numbers of subjects seroconverted against each of the 3 antigens after vaccination;Geometric mean titers (GMTs) of serum HAI antibodies pre- and post-vaccination for each of the 3 antigens of all participants;Numbers of subjects with four-fold rise from baseline for each of the influenza vaccine strain-specific H1, H3, and B neutralizing antibodies (MNT).;Geometric mean neutralization titers of neutralizing antibodies (MNT) pre- and post-vaccination for each of the 3 antigens.",NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT02903836,https://clinicaltrials.gov/show/NCT02903836,"A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults",Community-Acquired Bacterial Pneumonia (CABP),Drug: Nafithromycin 800 mg 3 days;Drug: Nafithromycin 800 mg 5 days;Drug: Moxifloxacin 400 mg,Phase II Study of Oral Nafithromycin in CABP,CT.gov,13/09/2016,18/11/2016,FALSE,Interventional,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2,231,Wockhardt,United States,NA,NULL,13/09/2016,"November 18, 2016",NCT029,06-Jan-20,W-4873-201,NA,"Ashima Bhatia, MD PDCR",NULL,NA,NA,Wockhardt,NA,"Ashima Bhatia, MD PDCR",NULL,NA,NA,Wockhardt,Completed,ACM,Please refer to primary and secondary sponsors,18 Years,N/A,All,<br>        Inclusion Criteria:<br><br>        Meet the clinical criteria for CABP based on following:<br><br>          1. Clinical symptoms (new or worsening)<br><br>          2. Vital sign abnormalities<br><br>          3. Laboratory abnormalities<br><br>          4. Radiographic evidence of CABP<br><br>          5. PORT score<br><br>        Exclusion Criteria:<br><br>          1. Subjects with any of the following confirmed or suspected types of pneumonia:<br><br>               1. Aspiration pneumonia<br><br>               2. Hospital-acquired bacterial pneumonia (HABP)<br><br>               3. Healthcare-associated bacterial pneumonia (HCAP)<br><br>               4. Ventilator-associated bacterial pneumonia (VABP)<br><br>               5. Pneumonia that may be caused by pathogen(s) resistant to either study drug<br><br>          2. Receipt of 1 or more dose(s) of a potentially effective systemic antibacterial<br>             treatment for treatment of the current CABP<br><br>          3. Suspected or confirmed non-infectious causes of pulmonary infiltrates<br><br>          4. Subjects requiring concomitant adjunctive or additional potentially-effective systemic<br>             antibacterial treatment for management of CABP<br>,NULL,Clinical Response in the ITT Population,Clinical Response in the Micro-ITT Population,NA,NULL,NULL,NULL,https://clinicaltrials.gov/ct2/show/results/NCT02903836,NULL,20/12/2019,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Yes,NULL,NULL,NULL,NULL,NULL,NULL
NCT04137887,https://clinicaltrials.gov/show/NCT04137887,Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine Versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older,Influenza (Healthy Volunteers),"Biological: Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD);Biological: Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)",Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older,CT.gov,11/10/2019,04/11/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,121000,"Sanofi Pasteur, a Sanofi Company",Finland,EUCTR2019-001401-25-FI,NULL,11/10/2019,"November 4, 2019",NCT041,17-Aug-20,2019-001401-25;U1111-1217-2654;QHD00012,;,Clinical Sciences & Operations;Trial Transparency email recommended (Toll free number for US & Canada),NULL,;Contact-US@sanofi.com,;800-633-1610,"Sanofi Pasteur, a Sanofi Company;",;,Clinical Sciences & Operations;Trial Transparency email recommended (Toll free number for US & Canada),NULL,;Contact-US@sanofi.com,;800-633-1610,"Sanofi Pasteur, a Sanofi Company;",Recruiting,NULL,Please refer to primary and secondary sponsors,65 Years,N/A,All,"<br>        Inclusion criteria :<br><br>        - Aged 65 years or older on the day of inclusion (65 years means from the day of the 65th<br>        birthday)<br><br>        Exclusion criteria:<br><br>          -  Participation at the time of study enrollment (or in the 4 weeks [28 days] preceding<br>             the study vaccination) or planned participation during the present study period in<br>             another clinical study investigating a vaccine, drug, medical device, or medical<br>             procedure<br><br>          -  Previous vaccination against influenza (in the preceding 6 months) with either the<br>             study vaccines or another vaccine<br><br>          -  Known systemic hypersensitivity to any of the vaccine components, or history of a<br>             life-threatening reaction to the vaccines used in the study or to a vaccine containing<br>             any of the same substances<br><br>        The above information is not intended to contain all considerations relevant to a patient's<br>        potential participation in a clinical trial.<br>",NULL,Number of unscheduled cardiovascular or respiratory inpatient hospitalizations;Number of inpatient hospitalizations with primary discharge diagnosis (for circulatory and respiratory systems diseases only),Number of inpatient hospitalizations with primary discharge diagnosis;Number of deaths;Number of inpatient hospitalizations with primary and secondary admission and discharge diagnoses;Number of hospital emergency room visits;Number of acute primary care visits to physician;Number of major acute cardiovascular events (MACE);Number of unscheduled cardiovascular or respiratory inpatient hospitalizations or hospital emergency room visits or primary care visits to physician;Number of participants reporting listed serious adverse events (SAEs);Number of participants reporting non-fatal SAEs,child,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03459391,https://clinicaltrials.gov/show/NCT03459391,"A Double-blind, Randomized, Placebo-controlled Study of the Safety,Tolerability and Pharmacokinetics of Increasing Doses of XC221 After Single and Repeated Oral Administration in Healthy Volunteers",Influenza;Acute Respiratory Infection;Influenza;Acute Respiratory Infection;Influenza;Acute Respiratory Infection,Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo;Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo;Drug: XC221 60 mg;Drug: XC221 200 mg;Drug: Placebo,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers",CT.gov,26/02/2018,22/05/2017,FALSE,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",Phase 1,32,PHARMENTERPRISES LLC,Russian Federation;Russian Federation;Russian Federation;Russian Federation;Russian Federation;Russian Federation,NA,1,26/02/2018,"May 22, 2017",NCT034,11-Jun-18,ARI-XC221-01,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Completed,NULL,Please refer to primary and secondary sponsors,18 Years,45 Years,Male,"<br>        Inclusion Criteria:<br><br>          1. Non-smoking men aged 18 to 45 years (inclusive);<br><br>          2. Verified diagnosis healthy according to standard clinical, laboratory and<br>             instrumental methods of examination;<br><br>          3. Body mass >50 kg and body mass index of 18.5 to 30 kg/m2 (inclusive);<br><br>          4. Negative result of tests for alcohol and drugs;<br><br>          5. Consent to use reliable methods of contraception during the study and 3 months after<br>             its completion (condoms with spermicide);<br><br>          6. Signed patient information sheet and informed consent form for participation in the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal<br>             system and also disease of digestive tract, liver, kidneys, blood;<br><br>          2. Laboratory abnormalities at screening;<br><br>          3. Surgical interventions on digestive tract in the anamnesis (except for an<br>             appendectomies);<br><br>          4. Systolic pressure is less than 90 mm Hg. or more than 130 mm Hg., diastolic pressure<br>             is less than 60 mm Hg. or more than 85 mm Hg., pulse rate less than 60/min. or more<br>             than 80/min.;<br><br>          5. Course intake of medicinal products (including herbs and biologically active<br>             additives) for preventive or curative purposes within 1 month prior to screening;<br><br>          6. Antibodies to HIV and hepatitis C virus, the presence of the hepatitis B surface<br>             antigen, a positive syphilis test;<br><br>          7. The presence of a sleep disorder (for example, night work, sleep disturbances,<br>             insomnia, recent return from another time zone, etc.);<br><br>          8. Signs of alcohol or drug abuse; taking alcohol or drugs during 4 days before<br>             screening; smoking 3 months before screening;<br><br>          9. History of allergies (including medicines and food products);<br><br>         10. Blood donation / plasma, surgical intervention (in a hospital environment) during 12<br>             weeks before screening;<br><br>         11. Participation in other clinical trials or taking the study drug during 3 months before<br>             screening;<br><br>         12. Acute infectious diseases less than 4 weeks before the start of the study;<br><br>         13. Impossibility to understand or follow protocol instructions/<br>      ;<br>        Inclusion Criteria:<br><br>          1. Non-smoking men aged 18 to 45 years (inclusive);<br><br>          2. Verified diagnosis healthy according to standard clinical, laboratory and<br>             instrumental methods of examination;<br><br>          3. Body mass >50 kg and body mass index of 18.5 to 30 kg/m2 (inclusive);<br><br>          4. Negative result of tests for alcohol and drugs;<br><br>          5. Consent to use reliable methods of contraception during the study and 3 months after<br>             its completion (condoms with spermicide);<br><br>          6. Signed patient information sheet and informed consent form for participation in the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal<br>             system and also disease of digestive tract, liver, kidneys, blood;<br><br>          2. Laboratory abnormalities at screening;<br><br>          3. Surgical interventions on digestive tract in the anamnesis (except for an<br>             appendectomies);<br><br>          4. Systolic pressure is less than 90 mm Hg. or more than 130 mm Hg., diastolic pressure<br>             is less than 60 mm Hg. or more than 85 mm Hg., pulse rate less than 60/min. or more<br>             than 80/min.;<br><br>          5. Course intake of medicinal products (including herbs and biologically active<br>             additives) for preventive or curative purposes within 1 month prior to screening;<br><br>          6. Antibodies to HIV and hepatitis C virus, the presence of the hepatitis B surface<br>             antigen, a positive syphilis test;<br><br>          7. The presence of a sleep disorder (for example, night work, sleep disturbances,<br>             insomnia, recent return from another time zone, etc.);<br><br>          8. Signs of alcohol or drug abuse; taking alcohol or drugs during 4 days before<br>             screening; smoking 3 months before screening;<br><br>          9. History of allergies (including medicines and food products);<br><br>         10. Blood donation / plasma, surgical intervention (in a hospital environment) during 12<br>             weeks before screening;<br><br>         11. Participation in other clinical trials or taking the study drug during 3 months before<br>             screening;<br><br>         12. Acute infectious diseases less than 4 weeks before the start of the study;<br><br>         13. Impossibility to understand or follow protocol instructions/<br>      ;<br>        Inclusion Criteria:<br><br>          1. Non-smoking men aged 18 to 45 years (inclusive);<br><br>          2. Verified diagnosis healthy according to standard clinical, laboratory and<br>             instrumental methods of examination;<br><br>          3. Body mass >50 kg and body mass index of 18.5 to 30 kg/m2 (inclusive);<br><br>          4. Negative result of tests for alcohol and drugs;<br><br>          5. Consent to use reliable methods of contraception during the study and 3 months after<br>             its completion (condoms with spermicide);<br><br>          6. Signed patient information sheet and informed consent form for participation in the<br>             study.<br><br>        Exclusion Criteria:<br><br>          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal<br>             system and also disease of digestive tract, liver, kidneys, blood;<br><br>          2. Laboratory abnormalities at screening;<br><br>          3. Surgical interventions on digestive tract in the anamnesis (except for an<br>             appendectomies);<br><br>          4. Systolic pressure is less than 90 mm Hg. or more than 130 mm Hg., diastolic pressure<br>             is less than 60 mm Hg. or more than 85 mm Hg., pulse rate less than 60/min. or more<br>             than 80/min.;<br><br>          5. Course intake of medicinal products (including herbs and biologically active<br>             additives) for preventive or curative purposes within 1 month prior to screening;<br><br>          6. Antibodies to HIV and hepatitis C virus, the presence of the hepatitis B surface<br>             antigen, a positive syphilis test;<br><br>          7. The presence of a sleep disorder (for example, night work, sleep disturbances,<br>             insomnia, recent return from another time zone, etc.);<br><br>          8. Signs of alcohol or drug abuse; taking alcohol or drugs during 4 days before<br>             screening; smoking 3 months before screening;<br><br>          9. History of allergies (including medicines and food products);<br><br>         10. Blood donation / plasma, surgical intervention (in a hospital environment) during 12<br>             weeks before screening;<br><br>         11. Participation in other clinical trials or taking the study drug during 3 months before<br>             screening;<br><br>         12. Acute infectious diseases less than 4 weeks before the start of the study;<br><br>         13. Impossibility to understand or follow protocol instructions/<br>",NULL,Number of Adverse events per treatment arm;Number of Adverse events per treatment arm;Number of Adverse events per treatment arm,Pharmacokinetics of XC221GI by assessing AUC0-inf;Pharmacokinetics of XC221A by assessing AUC0-inf;Pharmacokinetics of XC221GI by assessing Cmax;Pharmacokinetics of XC221A by assessing Cmax;Pharmacokinetics of XC221GI by assessing AUC0-t;Pharmacokinetics of XC221A by assessing AUC0-t;Pharmacokinetics of XC221GI by assessing Tmax;Pharmacokinetics of XC221A by assessing Tmax;Pharmacokinetics of XC221GI by assessing T1/2;Pharmacokinetics of XC221A by assessing T1/2,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03336619,https://clinicaltrials.gov/show/NCT03336619,"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza",Influenza,Drug: Nitazoxanide;Drug: Placebo,"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza",CT.gov,06/11/2017,17/01/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,1032,Romark Laboratories L.C.,United States;Australia;Puerto Rico;Australia;Puerto Rico;United States,NA,NULL,06/11/2017,"January 17, 2018",NCT033,25-May-20,RM08-3004,NA,"Jean-Francois Rossignol, M.D., Ph.D.",NULL,NA,NA,Romark Laboratories L.C.,NA,"Jean-Francois Rossignol, M.D., Ph.D.",NULL,NA,NA,Romark Laboratories L.C.,Completed,NULL,Please refer to primary and secondary sponsors,12 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Male and female subjects at least 12 years of age<br><br>          2. Presence of clinical signs and/or symptoms consistent with an acute illness compatible<br>             with influenza infection (each of the following is required):<br><br>               1. oral temperature =99.4°F or =37.4°C (obtained in office or self- measured within<br>                  12 hours prior to screening - if self-measured, subjects must also have taken an<br>                  antipyretic within 4 hours prior to screening), AND<br><br>               2. at least one of the following respiratory symptoms (cough, sore throat, nasal<br>                  obstruction), AND<br><br>               3. one of the following constitutional symptoms (fatigue, headache, myalgia,<br>                  feverishness).<br><br>          3. Confirmation of influenza A or B infection in the local community by one of the<br>             following means:<br><br>               1. the institution's local laboratory,<br><br>               2. the local public health system,<br><br>               3. the national public health system, OR<br><br>               4. a laboratory of a recognized national or multinational influenza surveillance<br>                  scheme.<br><br>          4. Onset of illness no more than 40 hours before enrollment in the trial.<br><br>             Note: Time of onset of illness is defined as either the earlier of:<br><br>               1. the time when the temperature was first measured as elevated, OR<br><br>               2. the time when the subject experienced the presence of at least one respiratory<br>                  symptom AND the presence of at least one constitutional symptom.<br><br>          5. Willing and able to provide written informed consent (including assent by legal<br>             guardian if under 18 years of age) and comply with the requirements of the protocol,<br>             including completion of the patient diary.<br><br>        Exclusion Criteria:<br><br>          1. Severity of illness requiring or anticipated to require in-hospital care.<br><br>          2. Moderate or severe persistent asthma.<br><br>          3. Cystic fibrosis in children.<br><br>          4. Stage III or IV (severe or very severe) chronic obstructive pulmonary disease (COPD).<br><br>          5. Class III or IV congestive heart failure (at least marked limitation of physical<br>             activity in which minimal ordinary activity results in fatigue, palpitation, dyspnea,<br>             or angina pain)<br><br>          6. Arrhythmia<br><br>          7. Immunosuppressive disorders or who are receiving immunosuppressive therapy (e.g., for<br>             organ or bone marrow transplants)<br><br>          8. Untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3<br>             in the last 6 months<br><br>          9. Persons with sickle cell anemia or other hemoglobinopathies<br><br>         10. Poorly controlled insulin-dependent diabetes mellitus (HBA1C > 8%)<br><br>         11. Residents of any age of nursing homes or other long-term care institutions<br><br>         12. Concurrent infection at the screening examination that requires systemic antimicrobial<br>             therapy.<br><br>         13. Females of childbearing potential who are either pregnant, breast-feeding or are<br>             sexually active without the use of birth control. Female subjects of child-bearing<br>             potential that are sexually active must have a negative baseline pregnancy test and<br>             must agree to continue an acceptable method of birth control for the duration of the<br>             study and for 1 month post- treatment. A double barrier method, oral birth control<br>             pills administered for at least 2 monthly cycles prior to study drug administration,<br>             an IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of<br>             one month prior to study drug administration are acceptable methods of birth control<br>             for inclusion into the study. Female subjects are considered of childbearing potential<br>             unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months<br>             if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral<br>             tubular ligation or bilateral oophorectomy.<br><br>         14. Receipt of any dose of NTZ, oseltamivir, zanamivir, peramivir, laninamivir, baloxavir,<br>             amantadine or rimantadine within 3 days prior to screening.<br><br>         15. Prior treatment with any investigational drug therapy within 30 days prior to<br>             screening.<br><br>         16. Subjects with active respiratory allergies or subjects expected to require<br>             anti-allergy medications during the study period for respiratory allergies.<br><br>         17. Known sensitivity to NTZ or any of the excipients comprising the NTZ tablets.<br><br>         18. Subjects unable to take oral medications.<br><br>         19. Presence of any pre-existing illness that, in the opinion of the Investigator, would<br>             place the subject at an unreasonably increased risk through participation in this<br>             study.<br><br>         20. Subjects who, in the judgment of the Investigator, will be unlikely to comply with the<br>             requirements of this protocol.<br>",NULL,Time from first dose to Symptom Response,Time to symptom response excluding the FLU-PRO Gastrointestinal and Eye domains;Proportions of subjects experiencing one or more complications of influenza;Time from first dose to Ability to Perform All Normal Activities,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03380507,https://clinicaltrials.gov/show/NCT03380507,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",Septic Shock;Critical Illness,Drug: Triple therapy group,"Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock",CT.gov,07/12/2017,17/03/2018,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2/Phase 3,212,Hamad Medical Corporation,Qatar,NA,NULL,07/12/2017,"March 17, 2018",NCT033,15-Apr-19,17207,; ;,"Mohamed Abdelaty, MD;Adham Mohamed, PharmD;Adham Mohamed, PharmD",NULL,;;adhammokhtar185@hotmail.com,;;0097433634585,Hamad Medical Corporation;Hamad Medical Corporation;,; ;,"Mohamed Abdelaty, MD;Adham Mohamed, PharmD;Adham Mohamed, PharmD",NULL,;;adhammokhtar185@hotmail.com,;;0097433634585,Hamad Medical Corporation;Hamad Medical Corporation;,Recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Age (above 18 years old)<br><br>          -  Suspected or documented infection<br><br>          -  Meeting the definition of septic shock (Sepsis 3 definitions); Patients with septic<br>             shock can be identified with a clinical construct of sepsis with persisting<br>             hypotension requiring vasopressor therapy to maintain MAP =65 mm Hg and having a serum<br>             lactate level >2 mmol/L despite adequate volume resuscitation.<br><br>          -  Receiving norepinephrine at a dose equal or more than 0.1 µg/kg/min for more than or<br>             equal 6 hours.<br><br>        Exclusion Criteria:<br><br>          -  Known pregnancy(1)<br><br>          -  Primary diagnosis of acute cerebral vascular event<br><br>          -  Acute coronary syndrome<br><br>          -  Status asthmaticus<br><br>          -  Major cardiac arrhythmia<br><br>          -  Active gastrointestinal hemorrhage<br><br>          -  Seizure<br><br>          -  Drug overdose<br><br>          -  Burn or trauma<br><br>          -  Requirement for immediate surgery(2)<br><br>          -  Absolute neutrophil count <500 mm3<br><br>          -  CD4 <50/mm³<br><br>          -  Do-not-resuscitate status<br><br>          -  Advanced directives restricting implementation of the protocol<br><br>          -  Terminally ill patients in palliative care<br><br>          -  Participation in another interventional study<br><br>          -  Known allergy or contraindication to one or more of the trial medications (Vitamin C,<br>             Thiamine, or Hydrocortisone)<br><br>               1. If the pregnancy status is unknown, the pregnancy test will not be done as part<br>                  of the usual care, the patient is unconscious, and consent cannot be obtained for<br>                  pregnancy test; we will not enroll the patient.<br><br>               2. Patients with septic shock and requiring immediate surgery will be evaluated<br>                  after surgery for inclusion.<br>",NULL,Hospital Mortality at 60 days,Need for Extracorporeal membrane oxygenation (ECMO);Renal replacement therapy for acute kidney injury;Lactate clearance;Duration of vasopressor therapy;Length of hospital stay;Length of ICU stay;Clinical evidence of organ dysfunction;Time to death,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03968640,https://clinicaltrials.gov/show/NCT03968640,Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients,Multiple Organ Failure,Dietary Supplement: CoQ10;Dietary Supplement: Placebo,Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients,CT.gov,28/05/2019,01/08/2019,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,290,American Burn Association,NULL,NA,NULL,28/05/2019,"August 1, 2019",NCT039,11-Jun-19,W81XWH-18-2-0030;ABA-MCTG-0005,;,"Herb Phelan, MD;Herb Phelan, MD",NULL,;Herb.Phelan@UTSouthwestern.edu,;(214) 648-6841,University of Texas;,;,"Herb Phelan, MD;Herb Phelan, MD",NULL,;Herb.Phelan@UTSouthwestern.edu,;(214) 648-6841,University of Texas;,Not yet recruiting,NULL,Please refer to primary and secondary sponsors,18 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          -  Age 18 years and older<br><br>          -  Burn patients with 20% or greater of total body surface area (TBSA) burn and equal to<br>             or less than 70% TBSA burn<br><br>          -  Capable of receiving routine oral, enteral nutrition, or a combination of routine oral<br>             and enteral nutrition<br><br>          -  Enrolled within 72 hours after burn injury<br><br>          -  Patient or legally authorized representative (LAR) who is capable of giving full<br>             informed consent<br><br>          -  Anticipated hospital stay: 2 weeks or more<br><br>        Exclusion Criteria:<br><br>          -  Patients with liver disease (bilirubin greater than 3 or diagnosis of liver cirrhosis)<br>             at the time of admission, hyperthyroidism that currently requires treatment, diagnosis<br>             of chronic heart failure, chronic renal failure requiring hemodialysis, malignancy<br>             currently undergoing treatment, or history of cancer or hematological malignancy<br>             treatment within 5 years<br><br>          -  History of HIV or AIDS<br><br>          -  Presence of concurrent injuries apart from burn injury that may produce long-term<br>             disabilities (e.g., spinal cord injury, anoxic brain injury)<br><br>          -  Participation in another research study that may confound the results of this study in<br>             the opinion of the site principal investigator<br><br>          -  Pregnant women<br><br>          -  Prisoners<br>",NULL,multi-organ dysfunction,impact of CoQ10 on composite scores of multi-organ function,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
NCT03450915,https://clinicaltrials.gov/show/NCT03450915,"A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (=50 Years).",Influenza,Biological: M-001;Biological: Saline,A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine,CT.gov,08/02/2018,01/08/2018,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 3,12463,BiondVax Pharmaceuticals ltd.,Poland,EUCTR2018-000468-27-HU,NULL,08/02/2018,"August 1, 2018",NCT034,24-Feb-20,BVX-010,NA,"Tamar Ben-Yedidia, PhD",NULL,NA,NA,BiondVax Pharmaceuticals ltd.,NA,"Tamar Ben-Yedidia, PhD",NULL,NA,NA,BiondVax Pharmaceuticals ltd.,"Active, not recruiting",NULL,Please refer to primary and secondary sponsors,50 Years,N/A,All,"<br>        Inclusion Criteria:<br><br>          1. Male and female subjects 50 years of age (inclusive) or older, mentally competent,<br>             willing and able to give the written informed consent prior to study entry<br><br>          2. Able to comply with the trial procedures and be available for all study visits.<br><br>          3. Medically stable. (Subjects may have underlying chronic conditions such as<br>             hypertension, diabetes, ischemic heart disease, or hypothyroidism, as long as their<br>             symptoms/signs are controlled. If they are on medication for a condition, the<br>             medication dose must have been stable for at least 3 months preceding vaccination).<br><br>          4. Women of childbearing potential (not surgically sterile or postmenopausal for greater<br>             than or equal to one year) and men must agree to practice adequate contraception<br>             (barrier or hormone methods or intra uterine device (IUD) for women and a condom for<br>             men) throughout the study treatment and for at least up to day 51 (for female) and day<br>             111 (for male) of the trial (i.e. 30 (for female) and 90 (for male) days after the<br>             last dose of the IMP)<br><br>          5. Female subjects of childbearing potential must have a negative urine or serum<br>             pregnancy test within 24 hours prior to study vaccination.<br><br>        Exclusion Criteria:<br><br>          1. History of neurological symptoms or signs, or anaphylactic shock following<br>             administration of any vaccine.<br><br>          2. Known or suspected (or have a high risk of developing) impairment/alteration of immune<br>             function (excluding that normally associated with advanced age).<br><br>          3. Receipt of: a) Immunosuppressive drugs: i) systemic glucocorticoids >/= 10 mg<br>             prednisone per day ii) cytotoxic drugs b) Investigational drugs within 30 days before,<br>             or planned during, the study c) Blood products within 3 months before, or planned<br>             during, the study d) Influenza vaccine within 6 months before the study) Other<br>             vaccines within 30 days before, or planned during, the study<br><br>          4. Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic<br>             disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD)<br>             that requires oxygen therapy, acute or progressive hepatic disease, acute or<br>             progressive renal disease, or congestive heart failure, as judged by the PI.<br><br>          5. An acute illness, including an axillary temperature greater than 38 Celsius (38ºC),<br>             occurred within 1 week before first vaccination<br><br>          6. Positive positive urine pregnancy test prior to vaccination or women who are<br>             breastfeeding.<br>",NULL,Clinical Efficacy: PCR and Culture Confirmed Influenza;Safety: Occurrence of vaccine-related serious adverse events (SAEs),Clinical Efficacy: PCR Confirmed Influenza;Lot consistency,parent,EUCTR2018-000468-27-HU,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
CTRI/2017/11/010688,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=11981,Effect of Sildenafil on mortality in term Neonates with hypoxemic respiratory failure due to persistent pulmonary hypertension - SIPHON,Health Condition 1: null- Hypoxic Respiratory failure due to Pulmonary hypertensionHealth Condition 2: I270- Primary pulmonary hypertension,Intervention1: Inj. Sildenafil: 0.5mg/kg/dose over 3 hrs three times daily for 3 days or drop in Right ventricular systolic pressure to half the systemic pressure whichever is earlier<br>Control Intervention1: Normal Saline (0.9%): same dose as the intervention drug (sildenafil) for 3 days or drop in Right ventricular systolic pressure to half the systemic pressure whichever is earlier<br>,A study on effect of Sildenafil on mortality of hypoxic babies with persistent pulmonary hypertension,CTRI,28/11/2017,20/06/2015,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Double Blind Double Dummy",N/A,24,DrDeepti,India,NA,1,28/11/2017,20/06/2015,CTRI/2,04-Nov-20,NIL,Dr Srinivas Murthy,NA,"Department of PediatricsJSS HospitalAgrahara, Mysore",drdsrinivasa@gmail.com,9980941161,"JSS Medical college, JSS University",Dr Srinivas Murthy,NA,"Department of PediatricsJSS HospitalAgrahara, Mysore",drdsrinivasa@gmail.com,9980941161,"JSS Medical college, JSS University",Suspended,NULL,Dr.Deepti (PI)Senior ResidentDepartment of pediatrics,NA,NA,NA,Inclusion criteria: Term neonates on mechanical ventilation with hypoxemic respiratory failure and ECHO demonstration of elevated right ventricular systolic pressure above the mean systemic pressure or right to left shunt via foetal channels in a structurally normal heart. <br/ ><br>2. ASD & VSD  <5mm <br/ ><br>,Exclusion criteria: 1)Congenital diaphragmatic hernia <br/ ><br>2)Surgical lung anomalies <br/ ><br>3)Severe external congenital anomalies <br/ ><br>,"To determine the effect of Sildenafil treatment on mortality rate in term newborns with hypoxemic respiratory failure due to pulmonary hypertensionTimepoint: 0,24,48, and 72 hrs","To determine the effect of Sildenafil on pulmonary pressures in the first 72 hours of treatment. <br/ ><br> <br/ ><br>2)To determine the effect of Sildenafil treatment on duration of mechanical ventilation in term newborns with hypoxemic respiratory failure due to pulmonary hypertension <br/ ><br>Timepoint: 0, 24,48 and 72 hrs",NA,NULL,NA,0,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Apr 20 2015 12:00AM,NA,JSS Medical College Ethical Comittee,NA,NA
CTRI/2019/07/020174,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34335,"COMPARISON OF EFFICACY OF ORAL AMOXICILLIN VERSUS PARENTERAL CEPHALOSPORIN IN TREATMENT OF UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA A PROSPECTIVE SINGLE BLINDED PARALLEL DESIGN,RANDOMIZED CONTROL TRIAL IN A TERTIARY CARE HOSPITAL OF METROPOLITAN    CITY.","Health Condition 1: J189- Pneumonia, unspecified organism",Intervention1: ORAL AMOXICILLIN<br>: 100 MG/KG/DAY TDS 7 TO 10 DAYS<br><br>Intervention2: INJECTABLE 3rd GENERATION CEPHALOSPORIN: 100 MG/KG/DAY BD FOR 7 TO 10 DAYS<br>Control Intervention1: INJECTABLE 3rd GENERATION CEPHALOSPORIN: 100 MG/KG/DAY BD FOR 7 TO 10 DAYS<br>,ORAL MEDICATION IS AS EFFECTIVE AS INJECTABLE  MEDICATION IN TREATMENT OF PNEUMONIA,CTRI,15/07/2019,15/07/2019,FALSE,Interventional,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Investigator Blinded",Phase 2/ Phase 3,100,DR SUSHANT S MANE,India,NA,NULL,15/07/2019,15/07/2019,CTRI/2,04-Nov-20,NIL,DR VAIJNATH T SATHE,NA,DEPARTMENT OF PAEDIATRICS 1ST FLOOR BALARAM BUILDING GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI ROOM NO 224 300 RESIDENT HOSTEL GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI,vtsathe1@gmail.com,7720905484,GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI,DR VAIJNATH T SATHE,NA,DEPARTMENT OF PAEDIATRICS 1ST FLOOR BALARAM BUILDING GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI ROOM NO 224 300 RESIDENT HOSTEL GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI,vtsathe1@gmail.com,7720905484,GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI,Not Yet Recruiting,NULL,GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITAL MUMBAI,NA,NA,NA,Inclusion criteria: ALL CHILD IN THE AGE GROUP OF 6 MONTHS TO 12 YEARS ADMITTED IN PAEDIATRIC WARD AND CLINICALLY DIAGNOSED AS UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA IRRESPECTIVE OF ETIOLOGY.,"Exclusion criteria: 1. LESS THAN 6 MONTHS OF AGE. <br/ ><br>2. CHILD ADMITTED IN PAEDIATRIC INTENSIVE CARE UNIT. <br/ ><br>3. CHILD WITH UNDERLYING IMMUNODEFICIENCY INCLUDING ACQUIRED AND CONGENITAL CAUSES. <br/ ><br>4. CHILD WITH CO-MORBID CONDITIONS LIKE DENGUE, MEASLES ETC. <br/ ><br>5. CHILD WITH UNDERLYING HEREDITARY DISORDER LIKE CYSTIC FIBROSIS, SICKLE CELL DISEASE, DISORDERS OF CILIA ETC. <br/ ><br>6. CHILD WITH UNDERLYING ANATOMICAL DISORDER LIKE PULMONARY SEQUESTRATION, LOBAR PNEUMONIA, GASTROESOPHAGEAL  REFLUX DISORDER, TRACHEOESOPHAGEAL FISTULA AND BRONCHOPULMONARY DYSPLASIA.","COMPARISON OF EFFICACY OF ORAL AMOXICILIN VERSUS PARENTERAL CEPHALOSPORIN IN CASE OF UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN IN TERMS OF DAY OF DEFERVENSCENCE OF FEVER, DAY OF SETTLEMENT OF RESPIRATORY DISTRESS, DAY OF SUBSIDENCE OF COUGH, DURATION OF ANTIBIOTIC, DURATION OF HOSPITAL STAYTimepoint: 18 MONTHS","COMPARISON OF EFFICACY OF ORAL AMOXICILIN VERSUS PARENTERAL CEPHALOSPORIN IN CASE OF UNCOMPLICATED COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN IN TERMS OF DAY OF DEFERVENSCENCE OF FEVER, DAY OF SETTLEMENT OF RESPIRATORY DISTRESS, DAY OF SUBSIDENCE OF COUGH, DURATION OF ANTIBIOTIC, DURATION OF HOSPITAL STAYTimepoint: 18 MONTHS",NA,NULL,NA,0,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan 12 2018 12:00AM,NA,INSTITUTIONAL ETHICS COMMITTEE GRANT GOVERNMENT MEDICAL COLLEGE AND SIR JJ GROUP OF HOSPITALS MUMBAI,NA,NA
CTRI/2017/09/009849,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18803,Effectiveness of enteral ivabradine for heart rate control in septic shock â?? A randomized controlled trial.,Health Condition 1: null- Septic shock,"Intervention1: Group I: Enteral ivabradine 2.5 mg every 6 hours, titrated to heart rate.<br>Intervention2: Group I: Enteral ivabradine 2.5 mg every 6 hours, titrated to heart rate, in addition to standard treatment of septic shock.<br>Control Intervention1: Group S: standard therapy for septic shock<br>Control Intervention2: Group S: Standard treatment for septic shock<br>",Trial of ivabradine for controlling high heart rate control in septic shock.,CTRI,19/09/2017,01/01/2018,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial<br>  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Open Label",N/A,60,All India Institute of Medical Sciences New Delhi,India,NA,NULL,19/09/2017,01/01/2018,CTRI/2,04-Nov-20,NIL,Priyankar Kumar Datta,NA,"Deptt. of Anaesthesiology, Pain Medicine & Critical Care, Room 5011, Acad Block, AIIMS, Ansari Nagar",anjantrikha@gmail.com,9868397801,"All India Institute of Medical Sciences, New Delhi",Anjan Trikha,NA,"Deptt. of Anaesthesiology, Pain Medicine & Critical Care, Room 5011, Acad Block, AIIMS, Ansari Nagar",anjantrikha@gmail.com,9868397801,"All India Institute of Medical Sciences, New Delhi",Not Yet Recruiting,NULL,"All India Institute of Medical Sciences, Ansari Nagar (East), New Delhi, Pin: 110029",NA,NA,NA,"Inclusion criteria: Adult patients with septic shock, at least 24 hours after initiation of resuscitation, with HR more than 95 bpm, requiring noradrenaline support (1 - 25 mcg.min-1) to maintain MAP more than 65 mm Hg in spite of adequate volume resuscitation [corrected central venous pressure (CVP) more than 10 mm Hg and inferior vena cava diameter (IVCd) more than 1.5 cm].","Exclusion criteria: 1. Patients with pre-existing cardiovascular disease (coronary artery disease, congestive heart failure, cardiac rhythm abnormalities and conduction defects, congenital heart disease, pace-maker in-situ). <br/ ><br>2. Patients with a history of pre-existing chronic renal failure with a glomerular filtration rate less than 15 ml.min-1. <br/ ><br>3. Patients with severe liver dysfunction (MELD score more than 30). <br/ ><br>4. Requirement of high dose noradrenaline (more than 25 mcg.min-1) or second vasopressor to maintain MAP more than 65 mm Hg. <br/ ><br>5. Any contraindication to enteral drug administration (including patients of gastro-intestinal perforation, mechanical bowel obstruction and post-gut resection-anastomosis). <br/ ><br>6. Pregnancy, lactation <br/ ><br>7. Patients less than 18 years and more than 75 years of age <br/ ><br>8. Patients with active bleeding <br/ ><br>9. Post-cardiac arrest patients <br/ ><br>10. Hb less than 7 g/dL <br/ ><br>11. BMI more than 35 <br/ ><br>12. Use of potent cytochrome P450 3A4 inhibitors such as antifungals of the azole-type (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin) and HIV protease inhibitors (nelfinavir, ritonavir).",The primary outcome is difference in HR between the two groups during the first 96 hour after recruitment.Timepoint: 96 hours,"The secondary outcomes include 96 hour difference in MAP, NA requirement, CI, SVI, LVEF, arterial lactate, PaO2-FiO2 ratio, proBNP, Troponin I (Trop I), creatinine, bilirubin and APACHE II score; difference in incidence of severe bradycardia, heart block, atrial fibrillation (AF) and MACE; requirement of RRT, duration of vasopressor requirement, mechanical ventilation and ICU stay; and 30-day ICU mortality.Timepoint: 96 hours, 30-day",NA,NULL,NA,0,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Aug 23 2017 12:00AM,NA,"Institute Ethics Committee, AIIMS, New Delhi",NA,NA
CTRI/2019/05/019109,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33492,A Randomized controlled trial to evaluate the efficacy of topical pharyngeal anaesthesia using 5 vs 10 sprays of 10% lignocaine during flexible bronchoscopy,Health Condition 1: J851- Abscess of lung with pneumoniaHealth Condition 2: J168- Pneumonia due to other specified infectious organismsHealth Condition 3: J981- Pulmonary collapseHealth Condition 4: J99- Respiratory disorders in diseasesclassified elsewhereHealth Condition 5: J22- Unspecified acute lower respiratory infection,Intervention1: 10 sprays of 10% topical lignocaine: 10 sprays of 10% topical lignocaine would be applied on the pharynx prior to flexible bronchoscopy and the outcomes would be assessed<br>Control Intervention1: 5 sprays of 10% topical lignocaine: 5 sprays of 10% topical lignocaine would be applied on the pharynx prior to flexible bronchoscopy and the outcomes would be assessed<br>,Comfort during Bronchoscopy procedure,CTRI,14/05/2019,01/06/2019,FALSE,Interventional,"Randomized, Parallel Group Trial<br>  Method of generating randomization sequence:Stratified block randomization  Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes  Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded",N/A,300,Department of Pulmonary Medicine and Sleep Disorders,India,NA,NULL,14/05/2019,01/06/2019,CTRI/2,04-Nov-20,NIL,Dr Karan Madan,NA,Dept of Pulmonary medicine and Sleep Disorders  Third Floor New Private Ward Porta CabinAll India Institute of Medical Sciences,drkaranmadan@gmail.com,NA,AIIMS New Delhi,Dr Karan Madan,NA,Dept of Pulmonary medicine and Sleep Disorders  Third Floor New Private Ward Porta CabinAll India Institute of Medical Sciences,drkaranmadan@gmail.com,NA,AIIMS New Delhi,Not Yet Recruiting,NULL,AIIMS New Delhi,NA,NA,NA,Inclusion criteria: All adults more than or equal to 18 yrs of age undergoing flexible bronchoscopy,Exclusion criteria: 1) Uncontrolled hypertension SBP  >180 mm Hg <br/ ><br>2) Symptomatic coronary artery disease <br/ ><br>3) Pregnancy <br/ ><br>4) Not giving informed consent for the procedure <br/ ><br>5) Hypoxemia (oxygen saturation [by pulse <br/ ><br>oximetry] less than 92% with Fio2 ofmore than or equal to 0.3  <br/ ><br>6) Bronchoscopy performed through an artificial airway <br/ ><br> <br/ ><br>,Operator rated overall procedure satisfaction on Visual Analogue scale (VAS)Timepoint: At study completion approximately 12 months,"1) Operator rated cough on VAS <br/ ><br>2) Time from introduction to reaching the vocal cords  <br/ ><br>3) Patient willingness to return for repeat bronchoscopy  <br/ ><br>4) Cumulative lignocaine dose: Patients receiving more than 8.2 mg/kg, patients receiving more than 6 mg/kg lignocaine <br/ ><br>5) Total dose of midazolam and fentanyl required <br/ ><br>7) ComplicationsTimepoint: At study completion approximately 12 months",NA,NULL,NA,0,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Apr 30 2019 12:00AM,NA,Institute Ethics Committee,NA,NA
DRKS00017475,http://www.drks.de/DRKS00017475,ARISS - Randomised controlled multicentre study of albumin replacement therapy in septic shock - ARISS,;R57.2 - Septic shock,Intervention 1: The intervention group receives human albumin intravenously. The dose begins with a starting dose of 60 g of human albumin 20% for 2-3 h and is from study day 1 after randomization depending on the albumin serum value:<br>= 30 g / l: no administration<br>= 25 g / l and <30 g / l: 40 g for 1-2 h<br>= 20 g / l and <25 g / l: 60 g for 2-3 h<br><20 g / l: 80 g over 3-4 h<br>customized.<br>The duration of the application is a maximum of 28 days after randomization. Intervention 2: The control group will receive the standard therapy of septic shock with any crystalloids as volume replacement therapy of first choice.,ARISS - Randomised controlled multicentre study of albumin replacement therapy in septic shock,DRKS,08/07/2019,21/10/2019,FALSE,interventional,Allocation: Randomized controlled trial;. Masking: Open (masking not used). Control: Active control (effective treament of control group). Assignment: Parallel. Study design purpose: Treatment;,IIIb,1662,Friedrich-Schiller-Universität Jena,Germany,NA,NULL,08/07/2019,21/10/2019,DRKS00,02-Nov-20,2018-001874-89;NCT03869385;2018-1227,Yasser,Sakr,Am Klinikum1,Yasser.Sakr@med.uni-jena.de,+49 (0) 3641 9323248,Universitätsklinikum Jena Klinik für Anästhesiologie und Intensivmedizin,Yasser,Sakr,Am Klinikum1,Yasser.Sakr@med.uni-jena.de,+49 (0) 3641 9323248,Universitätsklinikum Jena Klinik für Anästhesiologie und Intensivmedizin,Recruiting,NULL,Deutsche Forschungsgemeinschaft (DFG);Instituto GRIFOLS S.A.,18 Years,no maximum age,"Both, male and female","Inclusion criteria: The presence of septic shock meeting all of the following criteria (1):<br>o Clinically possible or probable or microbiologically confirmed infection according to the definitions of the International-Sepsis-Forums (ISF) (2)<br>o Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) = 65 mm Hg for at least 1 hour<br>o Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy <br>- Start of septic shock less than 24 hours prior to inclusion, so that the start dose of the trial drug in the albumin group will be possible within 6-24 hours after the start of the septic shock<br>- Age: = 18 years<br>- Written informed consent of the patient or his/her legal representative or confirmation of the urgency of participation in the clinical trial and possible benefit to the patient by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include patients who are unable to provide informed consent in whom subsequent consent may be obtained retrospectively. <br>- Patients of childbearing age: negative pregnancy test","Exclusion criteria: - Moribund conditions with life expectancy less than 28 days because of comorbid conditions or advanced malignant disease and palliative situations with life expectancy less than 6 months<br>- Presence of an end of life decision prior to obtaining informed consent: Do Not Resuscitate (DNR) and Withhold/Withdraw Life-Sustaining measures<br>- Previous participation in this study<br>- Participation in another interventional clinical trial within the past 3 months<br>- Shock states that can be explained by other reasons, e.g. cardiogenic, anaphylactic, and neurogenic shock<br><br>- History of hypersensitivity to albumin or any other component of the trial drug, e.g., B., sodium caprylate, sodium N-acetyltryptophanate<br>- Diseases in which albumin administration may be deleterious, e.g., decompensated heart failure or traumatic brain injury<br>- Clinical conditions where albumin administration is indicated, e.g., hepatorenal syndrome, nephrosis, burns, intestinal malabsorption syndrome<br>- Lactation","To investigate whether albumin administration and maintenance of serum albumin concentrations of at least 30 g/l in the ICU for up to 28 days after the onset of septic shock, will reduce total 90-day mortality compared to volume replacement therapy without albumin.","• 28- and 60-day mortality, <br>• ICU and hospital mortality,<br>• organ dysfunction/failure as assessed by the SOFA-Score: recorded daily up to 28 days in the ICU after randomisation in the study,<br>• ICU and hospital lengths of stay,<br>• ventilator- and vasopressor-free days,<br>• cost-benefit of volume replacement therapy: collection of data on the use of human albumin and other colloids and crystalloids, <br>• Total amount of fluid administration and total fluid balance, and <br>• safety-related parameters: occurrence of AEs and SAEs, especially anaphylactic shock, hypervolaemia, and pulmonary oedema.",NA,NULL,actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,approved,Feb  7 2019 12:00AM,NA,(leading) Ethics Committee-No. (Ethikkommission der Friedrich-Schiller-Universität Jena an der Medizinischen Fakultät),NA,NA
EUCTR2015-005383-42-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005383-42,"Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients). Phase II, monocentric, cross-over, duble dummy, randomized and controlled, pilot study. - BREATH",patient with central apneas syndrome and heart failure <br>MedDRA version: 20.0Level: LLTClassification code 10011949Term: Decompensation cardiacSystem Organ Class: 100000004849 <br>MedDRA version: 20.0Level: HLTClassification code 10040978Term: Sleep apnoeasSystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],"<br>Trade Name: Anxut 5 mg<br>Pharmaceutical Form: Capsule, soft<br>INN or Proposed INN: BUSPIRONE<br>Current Sponsor code: BUSPIRONE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>",BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients,EUCTR,07/01/2019,19/05/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: yesOther: yesOther trial design description: pilot studyIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,10,FONDAZIONE TOSCANA GABRIELE MONASTERIO,Italy,NA,1,07/01/2019,19/05/2016,EUCTR2,28-Feb-19,BREATH,UOC Medicina Cardiovascolare,NA,via Moruzzi 1,farmacisti@ftgm.it,585493507,Fondazione Toscana Gabriele Monasterio,UOC Medicina Cardiovascolare,NA,via Moruzzi 1,farmacisti@ftgm.it,585493507,Fondazione Toscana Gabriele Monasterio,Not Recruiting,NULL,Fondazione Toscana Gabreiele Monasterio,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1) Age between 18 and 80 years; 2) Heart failure (diagnosed according to Framingham criteria) with a left ventricular dysfunction (ejection fraction-EF <50%), New York Heart Association (NYHA) classes I-III; 3) Chemoreflex activation to hypercapnia (cut point = 0.79); 4) Central apneas at the cardiorespiratory monitoring, with an AHI= 15 events/hour (moderatesevere central apneas); 5) Capability and possibility to follow and complete the study; 6) Informed consent signature.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: 1<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 5<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 5<br>","Exclusion criteria: <br>1) Participation in the previous 3 months to other clinical studies;<br>2) Pregnant, breast-feeding women or fertile women that do not follow and adequate contraception (every woman must consent to abstinence from sexual intercourse, or adopt any two of the following contraception measures considered efficacious as: bilateral tube ligation, male sterilization, use of hormonal contraceptives that inhibit ovulation, copper intrauterine devices; every barrier device must be used together with a spermicide cream);<br>3) Recent acute heart failure or acute coronary syndrome (in the last 3 months);<br>4) Chronic severe renal insufficiency (creatinin clearance <20 ml/min/1.72 m2);<br>5) Chronic obstructive pulmonary disease (FEV1/FVC<70% and FEV1< 70%);<br>6) Hepatic insufficiency (transaminases AST/ALT > 100 U/L and/or gamma GT > 150 U/L);<br>7) Major unstable psychiatric disorders and/or use of psychoactive agents and agents that can influence respiratory drive (ATC: N02A (opiates), N02CC (serotonin agonists), N03 (antiepileptic agents), N04A (anticholinergic agents), N04B (dopaminergic agents), N05 (psycholeptic agents), N06 (antidepressants), S01EC01 (acetazolamide), R03DA (xanthine),<br>R03DB (xanthine and adrenergic agents);<br>8) Concomitant use of drugs that inhibit or induce hepatic metabolism, in light of buspiron hepatic<br>metabolism;<br>9) History of drug or alcohol dependence;<br>10) Administration of any experimental drug within 30 days of the enrollment in the present study;<br>11) Active malignancies;<br>12) Known or suspected allergy to the drugs subjected to investigation or to one or more of the excipients;<br>13) Lactose intolerance;<br>14) Incapability to sign the informed consent form;<br>15) Closed angle glaucoma;<br>16) Miastenia gravis;<br>17) Hereditary galactose intolerance, lactase deficieny or glucose-galactose malabsorption;<br>18) Any other condition or disease that, to the investigator judgment, may interfere with the present study.<br>","Main Objective: Evaluation of buspiron effects on chemoceptive sensitivity to carbon dioxide (CO2) in heart<br>failure patients with CO2 hypersensitivity;Secondary Objective: Evaluation of buspiron effects on the same patients on: 1) Nocturnal apneas; 2) Neurohormonal balance, with a specific focus on the adrenergic axis; 3) Sympathovagal balance, evaluated by means of the Holter ECG; 4) Exercise capacity, evaluated by means of the cardiopulmonary exercise test.;Primary end point(s): A difference of 0.5 of the hypercapnic ventilatory response (HCVR) compared to the<br>placebo, assessed with the rebreathing technique, evaluated at day 1 and repeated at day 8,<br>15 and 22. Briefly, the patient breaths into a closed circuit, with progressive increase of CO2,<br>while stabilizing FiO2 by means of external oxygen flow. Carbon dioxide sensitivity is<br>expressed as the linear regression slope between ventilation and the end tidal CO2 (et-CO2)<br>(additional technical details in the protocol);Timepoint(s) of evaluation of this end point: Day 1, 8, 15 and 22.",Secondary end point(s): Evaluation of the effects of the drug on exercise performance with the cardiopulmonary stress test by means of a cycle-ergometer.;Timepoint(s) of evaluation of this end point: Evaluation at day 0 and repeated at day 7 and day 21.,NA,NULL,Date trial authorised,NA,NA,"Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients). Phase II, monocentric, cross-over, duble dummy, randomized and controlled, pilot study.",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2015-005482-23-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005482-23,"Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 3–17 Years to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority versus Trivalent Influenza Vaccine.",Prophylaxis of Influenza <br>MedDRA version: 20.0Level: HLTClassification code 10022005Term: Influenza viral infectionsSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],"<br>Product Name: Quadrivalent Influenza Vaccine <br>Product Code: QIV<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: QIV<br>Other descriptive name: quadrivalent influenza vaccine <br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Trade Name:  Influvac® <br>Product Name: Influvac (Tiv containing B Yamagata strain) <br>Product Code: TIV (Yam)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: TIV (Yam)<br>Other descriptive name: trivalent influenza vaccine (Yam)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Influvac (TIV containing B-Victoria strain)<br>Product Code: TIV (Vic)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: TIV (Vic)<br>Other descriptive name: trivalent influenza vaccine (Vic)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>",A blinded study to compare the safety and immune response in children and adolescents aged 3-17 years between Abbott's Candidate Quadrivalant Influenza and Trivalent Influenza Vaccine.,EUCTR,25/04/2016,28/07/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 3",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,1200,Abbott Biologicals B.V.,Hungary;Estonia;Finland;Poland;Lithuania;Germany,EUCTR2015-005482-23-HU,NULL,25/04/2016,28/07/2016,EUCTR2,06-Nov-17,INFQ3002,Global Clinical Director,NA,C.J. van Houtenlaan 36,serge.vandewitte@abbott.com,+31 294 477184,Abbott Biologicals B.V.,Global Clinical Director,NA,C.J. van Houtenlaan 36,serge.vandewitte@abbott.com,+31 294 477184,Abbott Biologicals B.V.,Not Recruiting,NULL,Abbott Biologicals B.V.,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>•Male and female children and adolescents 3 to 17 years of age at the time of enrolment in stable health determined from medical history, physical examination and clinical judgment of the Investigator*. Subjects may have underlying illnesses as long as their symptoms/signs are controlled. <br>•The subject’s parent(s) or LAR(s) sign and date a written, informed consent form (ICF). An assent will also be obtained according to age appropriate country-specific regulations.<br>•Subject and parent(s) or LAR(s) are able and willing to attend all scheduled visits and to comply with all trial procedures.<br><br>*In Germany, due to local requirements, the investigator must adhere to the current recommendation of the German Standing Committee on Vaccination (STIKO) for the clinical trial conduct with children. Accordingly, German subjects may only be enrolled if an influenza vaccination is medically indicated (due to an increased health risk from an underlying disease such as chronic diseases of the respiratory tract [including asthma and COPD], chronic cardiovascular, liver and kidney diseases, chronic neurological diseases, diabetes and other metabolic diseases). This restriction implies that inclusion criterion nr. 5 is not violated (i.e. the requirements for stable underlying conditions are met) and that none of the exclusion criteria are met.<br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 1200<br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range <br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>1.Child in care (as defined in the protocol)<br>2.History of allergy to egg, chicken proteins, or history of any reaction or hypersensitivity to a previous dose of influenza vaccine components.<br>3.History of serious adverse reaction to any influenza vaccine.<br>4.History of Guillain-Barré syndrome. <br>5.History of seizures (subject who had a single uncomplicated febrile convulsion in the past could be included) or progressive neurological disease.<br>6.Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required). <br>7.Prior receipt of any seasonal or pandemic influenza vaccine (registered or investigational) or laboratory-confirmed influenza infection in the 6 months preceding the first study vaccination. <br>8.Receipt of any vaccine (including routine childhood vaccines) within the preceding 30 days or planned vaccination during the study within 30 days after any study vaccine administration.<br>9.Having fever and/or acute disease or infection on the day of first study vaccination (enrolment can be deferred for up to 2 weeks provided subject remains otherwise eligible).<br>10.Any known immunocompromising condition or immunosuppressive therapy within 6 months preceding enrolment.<br>11.Chronic systemic administration (defined as more than 14 days) of immunosuppressant or immune-modifying medication (such as corticosteroids and monoclonal antibodies) during 3 months prior to the first study vaccination or planned use thereof during the study. Topical use of corticosteroids (e.g., cream, ocular drops, inhalation and intranasal sprays), within the dosage noted on the product label, is allowed.<br>12. Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine including (but not limited to) bleeding disorder, acute or progressive clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and/or physical examination. <br><br>","Timepoint(s) of evaluation of this end point: 28 days after study vaccination (Day 29, primed subjects) or 28 days after the second study vaccination (Day 57, unprimed subjects).;Primary end point(s): The primary endpoint concerns the geometric mean HI antibody titers against the 4 vaccine strains ;Secondary Objective: 1.To demonstrate the superiority of QIV to TIV(Vic) and TIV(Yam)with respect to post-vaccination geometric mean HI antibody titers against the alternate-lineage B strain in a population of children and adolescents 3 to 17 years of age.<br>2.To describe the immunogenicity of each of the strains in QIV with respect to HI, Virus Neutralization (VN) and Neuraminidase Inhibition (NI) antibody titers in the study population overall and by subject age, preexisting antibody status and baseline health status.<br>3.To describe Cell-Mediated Immunity (CMI) values for a subset of subjects.<br>Safety Objective:<br>To compare the reactogenicity and safety of QIV with that of TIV in a population of children and adolescents 3 to 17 years of age.<br>;Main Objective: To demonstrate in a population of children and adolescents 3 to 17 years of age the non-inferiority of quadrivalent influenza vaccine (QIV) with respect to post-vaccination geometric mean Hemagglutination  Inhibition (HI) antibody titers against the shared strains compared with the trivalent influenza vaccines (TIV) with either the B-strain of the Victoria (TIV(Vic)) or the B-strain of the Yamagata lineage (TIV(Yam)).","Secondary end point(s): The secondary endpoints concern:<br>1)Change from baseline geometric mean HI antibody titers against the 4 vaccine strains. <br>2)Post-vaccination geometric mean VN and NI antibody titers and change from baseline against the 4 vaccine strains for a randomized subset of subjects. <br>3)Seroconversion rates and geometric mean fold increases for HI, VN and NI for the 4 vaccine strains for a randomized subset of subjects.<br>4)Post-vaccination CMI values for a subset of subjects and change from baseline.<br>Safety points:<br>1)All unsolicited (spontaneously reported) AEs <br>2)SAEs, AESIs and NCIs <br>3) Solicited injection site reactions and systemic reactions  ;Timepoint(s) of evaluation of this end point: 1)2)3)4: Day 29 for primed subjects <br>Day 57 for unprimed subjects <br><br>For Safety points:<br>1) From ICF signature to Day 29 (primed subjects) or Day 57 (unprimed subjects)<br>2) from ICF signature to final follow-up telephone call approximately 6 months later (Day 183)<br>3) within 7 days following each study vaccination.",parent,EUCTR2015-005482-23-EE;EUCTR2015-005482-23-FI;EUCTR2015-005482-23-HU;EUCTR2015-005482-23-LT,Date trial authorised,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2018-002876-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002876-41,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration) - PROLISA,"Respiratory Distress Syndrome of preterm babies born < 32 weeks of gestational age;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]",<br>                Trade Name: PROPOFOL LIPURO 1%<br>                Product Name: PROPOFOL<br>                Pharmaceutical Form: Emulsion for injection/infusion<br>                Pharmaceutical form of the placebo: Emulsion for injection<br>                Route of administration of the placebo: Intravenous use<br><br>,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration),EUCTR,08/08/2018,NA,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: no<br>                Single blind: no<br>                Double blind: yes<br>                Parallel group: yes<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: no<br>                Placebo: yes<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,542,CHU Grenoble-Alpes,France,NA,NULL,08/08/2018,NA,EUCTR2,30-Apr-19,38RC18.123,Tiphaine Montagnon,NA,DRCI-Pavillon Dauphiné-CS10217,arcpromoteur@chu-grenoble.fr,33476766814,CHU Grenoble-Alpes,Tiphaine Montagnon,NA,DRCI-Pavillon Dauphiné-CS10217,arcpromoteur@chu-grenoble.fr,33476766814,CHU Grenoble-Alpes,NA,NULL,Ministry of Health,NA,NA,<br> Female: yes<br> Male: yes<br>,Inclusion criteria: <br>                - Preterm Infants < 32 wGA<br>                - Presenting a RDS<br>                in the first 48 hours of life<br>                treated by CPAP <br>                requiring surfactant :<br>                FIO2 :<br>                if 28 - 31 SA : FiO2 =30% for a duration = 10mn<br>                if <28 SA FIO2 =25% for a duration =10mn<br>                SaO2 :<br>                To obtain a SaO2 between =88 and = 95% <br>                <br>                - Available Intra-Venous line<br>                - Covered by French Social Security <br>                - Informed consent form signed<br><br>                Are the trial subjects under 18? yes<br>                Number of subjects for this age range: 542<br>                F.1.2 Adults (18-64 years) no<br>                F.1.2.1 Number of subjects for this age range<br>                F.1.3 Elderly (>=65 years) no<br>                F.1.3.1 Number of subjects for this age range<br>,Exclusion criteria: <br>                - Congenital and/or major malformations<br>                - FIO2> 60%<br>                - Silverman score> at 6<br>                - Low Blood Pressure with 2 successive measurements (Mean < Gestational Age expressed in Weeks of Gestation) persisting after one volume expansion<br>                - Use of inotropic medication to maintain normal blood pressure. <br>                - Use of sedative or analgesic drugs (except paracetamol and ibuprofen) in the previous 24h<br><br>,"Main Objective: In a population of preterm babies less than <32wGA, our objective is to perform a double-blind, non-inferiority trial comparing sedation by Propofol versus placebo during the LISA procedure, evaluating the need for MV within 72hours of life.;<br>                Secondary Objective: 1. To compare sedation by Propofol versus placebo during the LISA procedure, evaluating the need for MV within 72hours of life, in each class of GA (<28, 28-31wGA)<br>                2. To assess comfort and reduction of pain in the intervention versus control group, during the LISA procedure and at 1 hour after it<br>                3. To assess the rate of ketamine administration for rescue in each group<br>                4. To assess the quality conditions of the procedure: per procedure events (tolerance) and the clinician’s satisfaction (efficacy) during the LISA procedure <br>                5. To assess BPD at 36wGA<br>                6. To assess in-hospital neonatal morbidity and mortality.<br>                7. To evaluate the neurodevelopmental outcome at two years corrected age among survivors.<br>            ;<br>                Primary end point(s): Rate of MV from the start of the LISA procedure up to 72 hours of life in each group.<br>                The need of MV will be indicated by:<br>                •Repeated and severe apnea with bradycardia and/or low oxygen saturation, according the American Academy of Pediatrics Guidelines (American Academy of Pediatrics, 2003):<br>                oRespiratory pause during 20 sec<br>                oOr a shorter respiratory pause if accompanied by bradycardia or cyanosis<br>                •High FIO2 justifying intubation for a second administration of surfactant and mechanical ventilation<br>                •Respiratory complications such pneumothorax, with an aggravation  of the respiratory distress syndrome<br>                •Any other cause where the clinician judges the necessity for mechanical ventilation: the motive for the respiratory assistance must be indicated in the case report form<br>            ;Timepoint(s) of evaluation of this end point: 72 hours","<br>                Secondary end point(s): 1.Rate of MV from the start of the LISA procedure up to 72 hours of life in each class of GA (<28, 28-31wGA)<br>                2.Faceless Acute Neonatal Scale (FANS) assessed during the LISA: this scale evaluates behavioral items (limb movements, vocal expression) and physiological items (heart rate variation, bradycardia or desaturation), on a scale from 0 (no pain) to 10 (maximal pain). Its reliability and validity have already been documented (Milesi, Arch Dis Child Fetal Neonatl Ed 2010). This scale allows a painful procedure to be evaluated, whether the face is visible or not.<br>                3.Rate of ketamine administration for rescue: This administration will be indicated after two (< 28 wGA) or 3 (28 – 31 wGA) administrations of the drug, if adequate comfort is not achieved (FANS=6) (See paragraph 5.3)<br>                4.Quality conditions<br>                5.BPD at 36 wGA according the definition proposed by Jobe with the distinction between severe, moderate and mild BPD (Jobe 2001)<br>                Final Evaluation at a post-conceptional age of 36wGA <br>                6.In-hospital neonatal morbidity and mortality<br>                7.At two years : ASQ questionnaire, Gross Motor Function Classification Scale in cases of  motor impairment, Visual and hearing function<br>            ;Timepoint(s) of evaluation of this end point: in the 2 years",NA,NULL,NA,NA,NA,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration),NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,NA,Jan  1 1990 12:00AM,NA,NA,NA,NA
EUCTR2018-000005-23-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000005-23,Ghrelin treatment of comatose patients after cardiac arrest:                 A clinical trial to promote cerebral recovery - Ghrelin in coma,Brain damage after cardiac arrest;Therapeutic area: Diseases [C] - Nervous System Diseases [C10],<br>                Product Name: acylated ghrelin<br>                Product Code: G-3370-R<br>                Pharmaceutical Form: Lyophilisate for suspension for injection<br>                INN or Proposed INN: Acyl-Ghrelin<br>                CAS Number: 258279-04-8<br>                Current Sponsor code: G-3370-R<br>                Other descriptive name: GHRELIN<br>                Concentration unit: µg/ml microgram(s)/millilitre<br>                Concentration type: up to<br>                Concentration number: 600-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,Ghrelin treatment of comatose patients after cardiac arrest:                 A clinical trial to promote cerebral recovery,EUCTR,19/11/2018,12/12/2018,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: no                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,208,University of Twente,Netherlands,NA,NULL,19/11/2018,12/12/2018,EUCTR2,28-Feb-19,Ghreline,Principal Investigator,NA,Wagnerlaan 55,jhofmeijer@rijnstate.nl,NA,Rijnstate Hospital,Principal Investigator,NA,Wagnerlaan 55,jhofmeijer@rijnstate.nl,NA,Rijnstate Hospital,Authorised-recruitment may be ongoing or finished,NULL,ZonMW,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                •Age =18 years<br>                •Out of hospital cardiac arrest<br>                •Successful cardiopulmonary resuscitation<br>                •Return of spontaneous circulation =12 hours ago<br>                •GCS score on admission = 8 or suspected coma in patients who are sedated<br>                •Admission to intensive care unit<br>                •Hemodynamic and respiratory stability as determined by the treating intensive care physician, with the minimum requirement of mean arterial pressure > 65 mmHg. Treatment with inotropes, vasopressors or IABP is allowed.<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 83<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 125<br>",Exclusion criteria: <br>                •Age <18 years<br>                •A known progressive neurological disease<br>                •Expected death within 48 hours<br>,"Main Objective: We aim to estimate safety and efficacy of intravenous treatment with acyl-ghrelin to promote cerebral recovery in comatose patients after cardiac arrest. Safety will be monitored throughout hospitalization and during follow-up using all AEs reported, and by interim analyses by an independent DSMB. Efficacy will be measured by the primary outcome measure, i.e. functional recovery as measured by the Cerebral Performance Category (CPC) scale at six months after cardiac arrest.;<br>                Secondary Objective: To estimate efficacy of ghrelin to modify<br>                1.Case fatality<br>                2.Time to awaken (time interval between resuscitation and Glasgow Coma Scale (GCS) score of 14)<br>                3.Long term outcome: CPC and cognitive functioning at 12 months<br>                4.Cardiovascular outcomes, including blood pressure, treatment with inotropic medication, treatment with vasopression, LVAD, cardiac biomarkers, and need for defibrillation<br>            ;Primary end point(s): The primary outcome measure will be functional outcome as expressed as the score on the cerebral performance category (CPC) at 6 months. ;Timepoint(s) of evaluation of this end point: 3 months, 6 months","<br>                Secondary end point(s): Secondary outcomes include case fatality at one week and 6 months, time to awaken (time interval between resuscitation and GCS score of 14), EMV score and estimated CPC score at 1 week, CPC score at 3 and 12 months, and cognitive functioning at 12 months. <br>                <br>                Cardiovascular secondary outcome measures are: <br>                Mean arterial blood pressure day 1-7 (mean, highest, lowest)<br>                Heart rate day 1-7 (mean, highest, lowest)<br>                Arrhythmia day 1-7: yes / no. If yes: type of arrhythmia<br>                Cumulative dose of vasopressive medication day 1-7<br>                Cumulative dose of inotropic medication day 1-7<br>                Sequential Organ Failure Assessment score day 1-7<br>                Kidney function day expressed as GFR day 1-7<br>                CVVH day 1-7: yes / no<br>                Assist devices day 1-7: yes / no<br>                Biomarkers are:<br>                Cardiac: troponine and CK / CK-MB ratio at day 0, 1, 2 or 3<br>                Neurological: NSE day 1, 2, 3<br>                Endocrinological: cortisol, growth hormone, prolactine, ACTH, IGF-1 day 1, 2, 3<br>                Gastro-intestinal outcome measure is: gastric residual volume (day 1-7, during ICU admission)<br>            ;Timepoint(s) of evaluation of this end point: Daily after administering medication/placebo for a week; 1 week, 3 months, 12 months",NA,NULL,Date trial authorised,NA,NA,Ghrelin treatment of comatose patients after cardiac arrest:                  A clinical trial to promote cerebral recovery,NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2015-002340-14-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14,"Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) - COVID-19 patients included. - REMAP-CAP",Severe Community Acquired Pneumonia <br>MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],<br>Trade Name: Levofloxacin<br>Product Name: Levofloxacin 5mg/ml Solution for Infusion<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: LEVOFLOXACIN HEMIHYDRATE<br>CAS Number: CAS 138199-7<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Solu-Cortef®(Hydrocortisone)<br>Product Name: hydrocortisone<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: HYDROCORTISONE<br>CAS Number: 50-23-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Trade Name: Ceftriaxone<br>Product Name: Ceftriaxone<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: CEFTRIAXONE<br>CAS Number: 73384-59-5<br>Concentration unit: g gram(s)<br>Concentration type: up to<br>Concentration number: 2-<br><br>Trade Name: Zedbac (azithromycin)<br>Product Name: azithromycin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: AZITHROMYCIN<br>CAS Number: 83905-01-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: Clarithromycin<br>Product Name: clarithromycin<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: CLARITHROMYCIN<br>CAS Number: 81103-11-9<br>Other descriptive name: CLARITHROMYCIN LACTOBIONATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: Erythrocin (Erythromycin)<br>Product Name: Erythrocin IV Lactobionate Injection<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: ERYTHROMYCIN LACTOBIONATE<br>CAS Number: 3847-29-8<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Augmentin (Amoxicilline-clavulanate)<br>Product Name: Amoxicillin-Clavulanate<br>,Adaptive trial in severe pneumonia (REMAP-CAP),EUCTR,19/11/2018,15/03/2019,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 20<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,6800,University Medical Center Utrecht,Croatia;Australia;Denmark;Germany;Netherlands;New Zealand;Romania;Belgium;Canada;Hungary;Czech Republic;France;United Kingdom;Ireland;Spain;Finland;Greece;Portugal,EUCTR2015-002340-14-NL,NULL,19/11/2018,15/03/2019,EUCTR2,28-Sep-20,REMAP-CAP;NCT02735707;2015-002340-14-NL,Julius Centrum UMCU,NA,Universiteitsweg 100,juliuscenter@umcutrecht.nl,+31(0)8875 681 81,University Medical Center Utrecht,Julius Centrum UMCU,NA,Universiteitsweg 100,juliuscenter@umcutrecht.nl,+31(0)8875 681 81,University Medical Center Utrecht,Authorised-recruitment may be ongoing or finished,NULL,FP7-HEALTH-2013-INNOVATION-1,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>General REMAP-CAP Inclusion Criteria:<br><br>1. Adult patient admitted to an ICU for acute severe CAP within 48 hours of hospital admission with<br>a.symptoms or signs or both that are consistent with lower respiratory tract infection (for example, acute onset of dyspnea, cough, pleuritic chest pain) AND<br>b.Radiological evidence of new onset infiltrate of infective origin (in patients with pre-existing radiological changes, evidence of new infiltrate)<br><br>Up to 48 hours after ICU admission, receiving organ support with one or more of: <br>a.Non-invasive or invasive ventilatory support;<br>b.Receiving infusion of vasopressor or inotropes or both<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 2000<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 2000<br>","Exclusion criteria: <br>General REMAP-CAP Exclusion Criteria: <br>1. Healthcare-associated pneumonia:<br>a.Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days<br>b.Resident of a nursing home or long-term care facility.<br>2.Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.<br>3.Previous participation in this REMAP within the last 90 days<br>Intervention-specific exclusions:<br>Known hypersensitivity to an agent specified as an intervention in this domain will exclude a patient from receiving that agent<br>•Receiving an agent that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent<br>•Known HIV infection will exclude a patient from receiving<br>lopinavir/ritonavir<br>•Receiving amiodarone as a usual medication prior to this hospitalization or any administration of amiodarone within the 72 hours prior to assessment of eligibility will exclude a patient from receiving lopinavir/ritonavir<br>Patients may also be excluded from receiving one or more interventions within the domain for patient-specific reasons. In such cases, patients will be randomly allocated a remaining intervention from among those available at that site.<br>Patients who are eligible for only a single intervention at a site (i.e. all other interventions are contraindicated) are not eligible for this domain. Patients in whom all interventions are contraindicated will be treated according to the current standard of care at the clinician's discretion.<br>•Known hypersensitivity to an agent specified as an intervention in this domain will exclude a patient from receiving that agent<br>•Receiving an agent that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent<br>•Intention to prescribe systemic corticosteroids for any reason, other than participation in the Corticosteroid Domain of this platform, will result in exclusion from receiving IFN-ß1a<br>•Known hypersensitivity to proteins produced by E. coli will result in exclusion from receiving anakinra<br>•Known or suspected pregnancy will result in exclusion from the anakinra and IFN-ß1a interventions. It is normal clinical practice that women admitted who are in an age group in which pregnancy is possible will have a pregnancy test conducted. The results of such tests will be used to determine interpretation of this exclusion criteria.<br>COVID-19 antiviral therapy domain:<br>Patients will be excluded from this domain if they have any of the following:<br>•More than 24 hours has elapsed since ICU admission<br>•Patient has already received more than 36 hours of treatment with any non-trial prescribed systemic antiviral medication intended to be active against COVID-19 during this hospital admission<br>•Patient has been randomized in a trial evaluating an antiviral intended to be active against COVID-19, where the protocol of that trial requires ongoing administration of study drug<br>•In areas where MERS-CoV infection is endemic, the patient has laboratory confirmed MERS-CoV infection<br>•The treating clinician believes that participation in the domain would not be in the best interests of the patient<br><br><br>There are domain-specific exclusion criteria in the Antibiotic, macrolide duration, corti","Main Objective: The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by the occurrence of death during the index hospital admission censored 90 days (or 21 days in case of pandemic) from the date of enrolment.<br>;Secondary Objective: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months (in case of a pandemic, 90 days outcome will be a secondary objective), health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS). ;Primary end point(s): The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days (or at 21 days in case of a pandemic).;Timepoint(s) of evaluation of this end point: 90 Days from the date of enrolment.","Secondary end point(s): The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months, health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS). ;Timepoint(s) of evaluation of this end point: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months (in case of a pandemic, 90 days outcome will be a secondary objective), health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS).",child,NULL,Date trial authorised,NA,NA,"Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) - COVID-19 patients included.",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Feb 25 2019 12:00AM,NA,NA,NA,NA
EUCTR2017-003037-28-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003037-28,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs. - TOPIRA,RA patients with active RA despite treatment with csDMARDs and previous use of max 1 TNFi. <br>                MedDRA version: 20.0                Level: PT                Classification code 10039073                Term: Rheumatoid arthritis                System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders            ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05],<br>                Trade Name: RoActemra<br>                Pharmaceutical Form: Solution for injection/infusion in pre-filled syringe<br>                INN or Proposed INN: TOCILIZUMAB<br>                CAS Number: 375823-41-9<br>                Other descriptive name: TOCILIZUMAB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 162-<br><br>                Trade Name: Prednisone<br>                Product Name: Prednisone<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Prednisone<br>                Current Sponsor code: Prednisone<br>                Other descriptive name: PREDNISONE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs.,EUCTR,22/07/2019,02/10/2019,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes                Randomised: yes                Open: yes                Single blind: no                Double blind: no                Parallel group: no                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: yes                Placebo: no                Other: no                Number of treatment arms in the trial: 2",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): yes,120,University Medical Center Utrecht,Netherlands,NA,NULL,22/07/2019,02/10/2019,EUCTR2,16-Dec-19,TOPIRA,Rheumatology & Clinical Immunology,NA,Heidelberglaan 100,reumatologie-research@umcutrecht.nl,31887557357,University Medical Center Utrecht,Rheumatology & Clinical Immunology,NA,Heidelberglaan 100,reumatologie-research@umcutrecht.nl,31887557357,University Medical Center Utrecht,Authorised-recruitment may be ongoing or finished,NULL,University Medical Center Utrecht;Roche,NA,NA,<br> Female: yes<br> Male: yes<br>,Inclusion criteria: <br>                •Able and willing to give written informed consent.<br>                •Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol.<br>                •At least 18 years of age.<br>                •Diagnosed as having RA and meeting the 2010 ACR/EULAR criteria for RA (Appendix A).<br>                •Active RA defined by CDAI>10 and at least 1 swollen joint of the 28 joint count.<br>                •On stable treatment with csDMARDs for = 8 weeks prior to the screening visit.<br>                •Previous treatment with =2 csDMARDs OR previous treatment with =1 csDMARD in combination with a maximum of 1 TNF inhibitor (Wash out period:  =2 weeks before first administration of study medication).<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 100<br>                F.1.3 Elderly (>=65 years) no<br>                F.1.3.1 Number of subjects for this age range 20<br>,"Exclusion criteria: <br>                •Having a contraindication for treatment with systemic GCs (as determined by the treating rheumatologist, in line with regular care).<br>                •Having a contraindication for treatment with TCZ, as described in the Summary of Product Characteristics (SPC) Paragraph 4.3, page 33. ‘Special warnings and precautions for use’ as described in the SPC Paragraph 4.4, page 33, should be strictly followed.<br>                •Use of systemic GCs (including i.a. GCs) within 4 weeks before the screening visit.<br>                •Current use of a bDMARD or tsDMARD. <br>                •Previous use of = 2 TNF-inhibitors. <br>                •Previous use of any other bDMARD (beside 1 TNFi) or tsDMARD.<br>                •Treatment with any investigational agent within 4 weeks prior to the screening visit.<br>                •Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren’s syndrome.<br>                •Female who is pregnant (by anamnesis) or breast feeding, or considering becoming pregnant during the study period.<br><br>","Main Objective: To assess whether adding TCZ (subcutaneously 162 mg/week) to current csDMARD therapy is more effective in reducing disease activity than adding prednisone (orally 10 mg/day) in a usual care treat-to-target strategy in patients with insufficient response to DMARD therapy (DMARD-IR).;<br>                Secondary Objective: Secondary Efficacy Objective(s):<br>                -To compare treatment strategies on drug retention (TCZ vs prednisone), as surrogate measure of drug efficacy and tolerability, and on drug treatment over time.<br>                -To assess whether TCZ is more effective than prednisone in reaching different criteria for response, clinical remission, and low disease activity; and on reduction of radiographic progression.<br>                -To compare treatments on costs and effects in a cost-effectiveness analysis<br>                <br>                Secondary Patient-Reported Outcome Objectives:<br>                -To assess whether TCZ is more effective than prednisone with regard to quality of life, functional ability, fatigue, sleep quality, and anxiety and depression.<br>                -To compare treatments on costs and quality of life (utility) in a cost-utility analysis<br>                <br>                Secondary Safety Objectives:<br>                -To assess the occurrence of serious adverse events (SAEs), glucocorticoid-associated AEs and TCZ-associated AEs<br>                <br>            ;Primary end point(s): Change in CDAI from baseline to 12 months;Timepoint(s) of evaluation of this end point: Baseline to 12 months","<br>                Secondary end point(s): SECONDARY EFFICACY ENDPOINTS:<br>                -Change in CDAI from baseline to 6 months<br>                -Change in SDAI and change in DAS28 from baseline to 12 months.<br>                -Drug retention rate, defined as the proportion of patients at 12 months on the treatment (TCZ/prednisone) to which they were allocated.<br>                -Switch rate, defined as the proportion of patients who switched during the study period to treatment of the other arm.<br>                -Average dose of TCZ or prednisone from baseline up to 12 months.<br>                -ACR20, ACR50, and ACR70 response (using 28 joint counts), EULAR good or moderate response.<br>                -Proportion of patients reaching a state of clinical remission at any time during the study defined by different criteria: CDAI=2.8 AND max 1 swollen joint of the 28 joint count, CDAI=2.8, SDAI=3, DAS28<2.6, and ACR-EULAR Boolean remission (defined by a tender joint count =1, a swollen joint count =1, a C-reactive protein =1mg/dL, and a patient global assessment =1 on a 0-10 scale).<br>                -Time to reach a state of clinical remission defined by the criteria mentioned before.<br>                -Proportion of patients reaching at least a state of low disease activity (defined by 2.8<CDAI=10, 3.3<SDAI=11, 2.6=DAS28<3.2,) during the study.<br>                -Change in Sharp/van der Heijde (SvH) score from baseline to 12 months<br>                -Change in quality of life from baseline to 12 months (using the EQ5D)<br>                -Change in functional ability from baseline to 12 months (using the Dutch consensus HAQ)<br>                -Change in fatigue (using the FACIT-F), sleep quality (using the PSQI) and anxiety and depression (using the HADS) from baseline to 12 months.<br>                -Direct medical (e.g. GP visits) and non-medical (e.g. travel expenses) costs as well as indirect costs (e.g. productivity loss) using the Health Care Utilisation and Work Productivity Questionnaire, and observed drug use and visits to the rheumatology clinic.<br>                -Quality Adjusted Life Years (based on EQ5-D utility scores over time).<br>                <br>                SECONDARY SAFETY ENDPOINTS:<br>                -GC Toxicity Index (GTI) score at 6, 9 and 12 months<br>                -The proportion of patients reaching =1 of the following categories of the GTI:<br>                oMajor increase in BMI<br>                oWorsening of glucose tolerance despite treatment<br>                oWorsening hypertension despite treatment<br>                oWorsening hyperlipidemia despite treatment<br>                oDecrease in bone density<br>                oModerate steroid myopathy or greater<br>                oModerate skin toxicity or greater<br>                oModerate neuropsychiatric symptoms or greater<br>                oGrade 3 infection or greater<br>                oAny category of the Specific List<br>                -The proportion of patients experiencing =1 TCZ-associated AE<br>                -The proportion of patients experiencing =1 SAE<br>                -The number of AEs of the GTI, of TCZ-associated AE and of SAE per patient<br>            ;Timepoint(s) of evaluation of this end point: As described in E.5.2.",NA,NULL,Date trial authorised,NA,NA,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs.,NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2016-001557-41-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001557-41,"A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) versus Fluarix Tetra Vaccine in Healthy Subjects.",healthy volunteers <br>MedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],"<br>Product Name: AdimFlu-S (QIS)<br>Product Code: AdimFlu-S (QIS)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>Current Sponsor code: A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A<br>Other descriptive name: A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Other descriptive name: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/BRISBANE/60/2008 - DERIVED STRAIN USED NYMC BX-35<br>Other descriptive name: B/BRISBANE/60/2008 - DERIVED STRAIN USED NYMC BX-35<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Other descriptive name: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Trade Name: a-RIX-Tetra<br>Product Name: a-RIX-Tetra<br>Product Code: a-RIX-Tetra<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>Current Sponsor code: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Other descriptive name: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Other descriptive name: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Current Sponsor code: B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008,",Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) in Healthy Subjects.,EUCTR,09/08/2016,09/09/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 4",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,2100,Adimmune Corporation,Taiwan;Belgium,NA,NULL,09/08/2016,09/09/2016,EUCTR2,11-Dec-17,Adim-QIS-01,Dr. Today Su,NA,"No. 3, Sec. 1, Tanxing Rd.",Today_su@adimmune.com.tw,8.86227E+15,Adimmune Corporation,Dr. Today Su,NA,"No. 3, Sec. 1, Tanxing Rd.",Today_su@adimmune.com.tw,8.86227E+15,Adimmune Corporation,Not Recruiting,NULL,Adimmune Corporation,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. Males or non-pregnant females and aged =18 years;<br>2. Stable health status is defined by the absence of a health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within 1 month prior to enrolment;<br>3. Willing and able to adhere to visit schedules and all study requirements. If necessary, the burden of a site visit can be removed by a subject-centric approach. At investigators’ discretion, registered nurses and technology can be used in off-site facilities such as nursing home for subject recruitment, monitoring, and sample collection;<br>4. Subjects are willing to provide signed study-specific informed consent.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 630<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 1470<br>","Exclusion criteria: <br>1. Subjects received seasonal influenza vaccine within 6 months prior to study vaccination;<br>2. Clinically or virologically confirmed influenza infection within 6 months preceding the study start;<br>3. Any known or suspected allergy to any constituent of influenza vaccines (including but not limited to egg proteins) or a history of severe adverse reaction to a previous influenza vaccine;<br>4. Personal or family history of Guillain-Barré Syndrome;<br>5. Diagnosed coagulant function abnormality (e.g. clotting factor deficiency, clotting hemorrhagic disease, abnormal platelet function);<br>6. An acute febrile illness within 1 week prior to vaccination;<br>7. Subjects with influenza-like illness as defined by the presence of fever (temperature = 38.0°C).<br>8. Female subjects who are pregnant, lactating or likely to become pregnant during the study; also women of childbearing potential who disagree to use an acceptable method of contraception (e.g. hormonal contraceptives, IUD, barrier device or abstinence) throughout the study;<br>9. Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports;<br>10. Treatment with an investigational drug or device within 3 months prior to study vaccination;<br>11. Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection;<br>12. Chronic administration (defined as more than 14 days in total) of immunosuppressant or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period. For corticosteroids, this will mean a dose equivalent to = 20 mg/day of prednisone or equivalent for persons for > 2 weeks. Inhaled and topical steroids are allowed;<br>13. Receipt of live virus vaccine (both licensed and investigated) within 1 month prior to study vaccine or expected receipt within 1 month after study vaccination; receipt of any inactivated vaccine (both licensed and investigated) within 2 weeks prior to study vaccination or expected receipt within 1 month after study vaccination;<br>14. Receipt of any blood products, including immunoglobulin, within 3 months prior to study vaccination, which might interfere with assessment of the immune response;<br>15. Underlying condition which in the investigators’ opinion may interfere with evaluation of the study vaccine or prevents the subject from participating in the study.<br>","Main Objective: To demonstrate the immunological non-inferiority of AdimFlu-S (QIS) compared to FluarixTetra in terms of GMT of HAI antibodies and seroconversion rates (SCRs) against the 4 virus strains at 21 days post-immunization on the whole study population (i.e. non-elderly and elderly subjects together);Secondary Objective: - To demonstrate the immunological non-inferiority of AdimFlu-S (QIS) compared to FluarixTetra in terms of GMT of HAI antibodies and SCR against the 4 virus strains at 21 days post-immunization according to 2 age categories (18-64 years old and =65 years old).<br>- To describe the immunogenicity of AdimFlu-S (QIS) and FluarixTetra in terms of GMTs and SPR at Day 0, 21 and 180 and SCR and GMTR at Day 21 and 180 in overall and each age subgroup (non-elderly 18-64 years old and elderly =65 years old).<br>- To demonstrate lot-to-lot consistency for AdimFlu-S (QIS) in terms of GMT of HAI antibody titers against the 4 vaccine strains at 21 days postimmunization. <br>- To evaluate the short term reactogenicity and safety and long term safety after administration of AdimFlu-S (QIS) overall and in each age subgroup (non-elderly 18-64 years old and elderly =65 years old).;Primary end point(s): GMT of HAI antibodies and seroconversion rates (SCRs) against the 4 virus strains at 21 days post-immunization on the whole study population.;Timepoint(s) of evaluation of this end point: 21 days post-immunization","Secondary end point(s): Demonstration of lot-to-lot consistency Immunogenicity of AdimFlu-S (QIS) and Fluarix Tetra in terms of HAI antibody titers: serum anti-hemagglutinin antibody against the four vaccine strains at baseline<br>and 21 days and 180 days after vaccination expressed as these endpoints:<br>- GMT at D0, D21 and D180;<br>- Individual post (D21 or D180) - to pre (D0)-vaccination GMTRs;<br>- SPR at D0, D21 and D180, seroprotection being defined as an HAI titer =1:40;<br>- SCR at D21 and D180, seroconversion being defined as:<br>*Either a pre-vaccination titer<1:10 and a post-vaccination titer =1:40, or<br>*A pre-vaccination titer =1:10 and a =4-fold increase in post-vaccination titer.<br>Description and comparison of immunogenicity of AdimFlu-S (QIS) and FluarixTetra in terms of VN or MN antibody titers at D0, D21 and D180 (30% of total subjects).;Timepoint(s) of evaluation of this end point: D21 and D180",NA,NULL,Date trial authorised,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2016-004133-25-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004133-25,"A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population Aged 5 Through 17 Years of Age.",Prophylaxis for influenza virus infection <br>MedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Trade Name: Afluria Quadrivalent<br>Product Name: Seqirus Quadrivalent Inactivated Influenza Vaccine (Seqirus QIV)<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ VICTORIA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Fluarix Quadrivalent<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>,A study to evaluate the immunogenicity and safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a pediatric population aged 5 through to 17 years of age,EUCTR,15/12/2016,NA,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,2222,Seqirus GmbH,United States,NCT02545543,NULL,15/12/2016,NA,EUCTR2,09-Jan-17,CSLCT-QIV-13-02;NCT02545543,Seqirus Clinical Trials,NA,45 Sidney Street,Seqirus.ClinicalTrials@Seqirus.com,NA,Seqirus,Seqirus Clinical Trials,NA,45 Sidney Street,Seqirus.ClinicalTrials@Seqirus.com,NA,Seqirus,NA,NULL,Seqirus GmbH,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>* Males or females 5 through 17 years of age on the day of first study vaccination.  <br>* Parent or legally acceptable representative able to provide written informed consent and be willing and able to adhere to all protocol requirements including blood draws. Participant assent will also be obtained if required.  <br>* If applicable, females of childbearing potential” (ie, ovulating, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen until at least 28 days after the last Study Vaccine. Females of childbearing potential must return a negative urine pregnancy test result, prior to any vaccination dose with the Study Vaccine.<br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 2222<br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range <br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>* History of allergic reactions to egg proteins or any components of the Study Vaccines.<br>* History of serious adverse reactions to any influenza vaccines.<br>* History of Guillain-Barré syndrome or other demyelinating disease.<br>* History of licensed or investigational influenza vaccination in the last 6 months.<br>* Clinical signs of active infection and/or an oral temperature of = 100°F (37.8°C) on the day of planned Study Vaccine administration or within 48 hours preceding vaccination.<br>* Current or recent,  acute or chronic medical conditions that in the opinion of the Investigator are clinically significant and/or unstable (such as illness exacerbations) within the preceding 30 days.<br>* History of any seizures, with the exception of a single febrile seizure.<br>* Self-reported or known seropositivity suggestive of acute or chronic viral infection for human immunodeficiency virus, hepatitis B or hepatitis C.<br>* Known or suspected congenital or acquired immunosuppressive conditions.<br>* Current or recent immunosuppressive or immunomodulatory therapy, as follows:<br>* Chronic or long-term systemic corticosteroids: = 0.125 mg/kg/day of oral prednisolone or equivalent daily;<br>* Sporadic systemic corticosteroids: = 0.5 mg/kg/day of oral prednisolone or equivalent for two or more short courses of > 3 days in the 3 months preceding vaccination;<br>* Antineoplastic chemotherapy or radiation therapy within the 6 months preceding vaccination.<br>Note: Use of topical, inhalant or localised tissue injections of corticosteroids prior to administration of the Study Vaccine or throughout the study are acceptable.<br>* Administration of immunoglobulin and/or any blood products within the 3 months preceding vaccination, or planned administration during the study.<br>* Participation in a clinical trial or use of an investigational compound within 28 days prior to the first dose of Study Vaccine, or within 28 days after receiving the final indicated dose of Study Vaccine, or plans to enter a study during this period.<br>* Vaccination with a licensed vaccine 28 days (for live or inactivated vaccines) prior to receiving the first dose of Study Vaccine, or plans to receive any licensed vaccine prior to the Study Exit Visit.<br>* Pregnant or lactating females.<br>","Main Objective: To demonstrate that vaccination with Seqirus QIV elicits an immune response that is not inferior to that of a US licensed comparator QIV containing the same virus strains as Seqirus QIV, among a pediatric population 5 through 17 years of age.;Secondary Objective: The secondary objectives of the study are to assess the following:<br>1. To assess safety and tolerability of Seqirus QIV, among children 5 through 17 years of age in two age strata: 5 through 8 years of age, and 9 through 17 years of age, as well as overall.<br>2. To characterize the immunogenicity of Seqirus QIV and the US-licensed comparator QIV in two age strata: 5 through 8 years of age, and 9 through 17 years of age, as well as overall.;Primary end point(s): 1. The Geometric Mean Titre (GMT) ratio of each virus strain<br>2. The difference in Seroconversion Rate (SCR) for each virus strain<br><br><br>;Timepoint(s) of evaluation of this end point: 1. 28 days after last vaccination<br>2. 28 days after last vaccination<br>",Secondary end point(s): 1. Safety Endpoint: The frequency and severity of solicited local adverse reactions<br>2. Safety Endpoint: The frequency and severity of solicited systemic adverse events (AEs)<br>3. Safety Endpoint: The frequency of cellulitis-like reaction<br>4. Safety Endpoint: The frequency and severity of unsolicited adverse events (AEs)<br>5. Safety Endpoint: The frequency of serious adverse events (SAEs)<br>6. Immunogenicity Endpoint: GMTs - Geometric mean of HI titers prevaccination (Day 1) and postvaccination (Study Exit Visit)<br>7. Immunogenicity Endpoint: Seroconversion rate<br>8. Immunogenicity Endpoint: Seroprotection rate<br>9. Immunogenicity Endpoint: Geometric mean fold increase<br><br><br><br><br><br>;Timepoint(s) of evaluation of this end point: 1. 7 days after each vaccination<br>2. 7 days after each vaccination<br>3. 28 days after each vaccination<br>4. 28 days after each vaccination<br>5. 180 days after the last vaccination dose<br>6. 28 days after last vaccination<br>7. 28 days after last vaccination<br>8. 28 days after last vaccination<br>9. 28 days after last vaccination,child,NULL,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2016-004763-40-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004763-40,Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women,Prophylaxix of influenza in Pregnant Women;Therapeutic area: Diseases [C] - Virus Diseases [C02],"<br>Trade Name: VaxigripTetra<br>Product Name: VaxigripTetra<br>Product Code: 481<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H1N1-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: mg/l milligram(s)/litre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H3N2-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Yamagata lineage)<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Victoria lineage)<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br><br>Trade Name: Vaxigrip<br>Product Name: Vaxigrip<br>Product Code: 314<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A / H1N1-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) A/H3N2-like strain<br>Other descriptive name: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) B-like strain (Victoria lineage or Yamaga",Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) inPregnant Women,EUCTR,16/03/2017,05/04/2017,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: yes<br>Other trial design description: blind observer<br>If controlled, specify comparator, Other Medicinial Product: yes<br>Placebo: no<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,729,Sanofi Pasteur,Finland,NA,NULL,16/03/2017,05/04/2017,EUCTR2,23-Jul-18,GQM14,"Global Medical Affairs,",NA,"2, avenue Pont Pasteur",nathalie.lavis@sanofipasteur.com,+33(0)437377173,Sanofi Pasteur,"Global Medical Affairs,",NA,"2, avenue Pont Pasteur",nathalie.lavis@sanofipasteur.com,+33(0)437377173,Sanofi Pasteur,Not Recruiting,NULL,Sanofi Pasteur,NA,NA,<br>Female: yes<br>Male: no<br>,Inclusion criteria: <br>- Aged at least 18 years on the day of inclusion<br>- Pregnant women with estimated gestational age of 20 to 32 weeks<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 729<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>,"Exclusion criteria: <br>- Previous vaccination against influenza with the 2017-2018 Northern hemisphere formulation with either the trial vaccines or another vaccine<br>- Pregnancy complications (in the current pregnancy)<br>- Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion<br><br>",Main Objective: Immunogenicity<br>To demonstrate the non-inferiority of immunogenicity response induced by one dose of VaxigripTetra compared with one dose of Vaxigrip  in pregnant women.<br><br>Safety<br>To describe the safety profile of one dose of VaxigripTetra or Vaxigrip ;Secondary Objective: Immunogenicity<br>-To demonstrate the superiority of the immune response induced by one dose of VaxigripTetra compared with one dose of Vaxigrip for the B strain not contained in Vaxigrip <br>-To describe the immune response induced by one dose of VaxigripTetra or Vaxigrip in pregnant women<br>-To evaluate the transplacental transfer of antibody from mother to newborn from the cord blood after one dose of VaxigripTetra or one dose of Vaxigrip<br><br>Safety<br>Descriptive analysis of the safety profile of VaxigripTetra and Vaxigrip in terms of pregnancy and birth outcomes<br>;Primary end point(s): Immunogenicity<br>Hemagglutination inhibition antibody titers obtained on Day (D)21. The GMT will be used as the main parameter<br><br>Safety<br>-Occurrence of unsolicited systemic adverse events (AEs) reported in the 30 minutes following vaccination<br>-Occurrence of solicited (prelisted in the subject diary card [DC] and the electronic Case Report Form [eCRF]) injection site reactions and systemic reactions occurring between D0 and D7 after vaccination<br>-Occurrence of unsolicited (spontaneously reported) non-serious AEs from D0 to D21 after vaccination<br>-Occurrence of serious adverse events (SAEs) (including adverse events of specific interest [AESIs]) up to delivery<br><br>;Timepoint(s) of evaluation of this end point: 21 days after the vaccination,"Secondary end point(s): Immunogenicity<br>The derived secondary endpoints for the description of the immune response will be based on D0 and on D21 as follows:<br>-Individual titers on D0 and on D21<br>-Individual titer ratio D21/D0<br>-Detectable titer = 10 (1/dilution [1/dil]) on D0 and on D21<br>-Titer = 40 (1/dil) on D0 and on D21<br>-Seroconversion or significant increase: Seroconversion: titer < 10 (1/dil) on D0 and post-injection titer = 40 (1/dil) on D21, or significant increase: titer = 10 (1/dil) on D0 and = 4-fold increase of post-injection titer on D21.<br><br>Safety<br>Pregnancy and birth outcomes will be described. <br>;Timepoint(s) of evaluation of this end point: - 21 days after the vaccination<br>- At the time of delivery for transplacental transfer of antibodies",NA,NULL,Date trial authorised,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2014-001097-34-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001097-34,"A Phase 2 Randomised, Double-blind, Placebo-controlled,                Single-dose, Dose-ranging Study of the Efficacy and                Safety of MEDI4893, a Human Monoclonal Antibody                Against Staphylococcus aureus Alpha Toxin in                Mechanically Ventilated Adult Subjects - SAATELLITE",Prevention of Staphyloccus aureus pneumonia <br>                MedDRA version: 20.0                Level: LLT                Classification code 10041942                Term: Staphylococcus aureus pneumonia                System Organ Class: 100000004862            ;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01],<br>                Product Name: MEDI4893<br>                Product Code: MEDI4893<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: NA<br>                CAS Number: NA<br>                Current Sponsor code: MEDI4893<br>                Other descriptive name: MEDI4893<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by bacterial infection with Staphylococcus aureus in high-risk patients.,EUCTR,10/10/2016,29/12/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,285,"MedImmune, LLC",Portugal;France;Hungary;Czech Republic;Greece;Belgium;Spain;Ireland;Germany;United Kingdom;Switzerland,NA,NULL,10/10/2016,29/12/2016,EUCTR2,28-Feb-19,CD-ID-MEDI4893-1139;NCT02296320;2014-001097-34-BE,Information Center,NA,One MedImmune Way,information.center@astrazeneca.com,001 301 398 0000,MedImmune,Information Center,NA,One MedImmune Way,information.center@astrazeneca.com,001 301 398 0000,MedImmune,Not Recruiting,NULL,"MedImmune, LLC",NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                Colonized with S aureus , expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.<br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 127<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 127<br>",Exclusion criteria: <br>                Staphylococcal disease at randomisation; lung injury score consistent with pneumonia; current lung disease; chronic tracheostomy patients; currently receiving systemic anti-staphylococcal antibiotics; moribund patients. <br>                <br><br>,"<br>                Main Objective: • To evaluate the effect of MEDI4893 in reducing the incidence of S aureus pneumonia<br>                • To evaluate the safety of a single IV dose of MEDI4893<br>            ;<br>                Secondary Objective: • To evaluate the serum pharmacokinetics (PK) of MEDI4893<br>                • To evaluate the serum anti-drug antibody (ADA) responses to MEDI4893<br>                • To evaluate the effect of MEDI4893 in reducing the incidence of S aureus pneumonia by mechanical<br>                ventilation status<br>            ;<br>                Primary end point(s): 1. Incidence of S aureus pneumonia <br>                <br>                2. Safety of MEDI4893<br>            ;<br>                Timepoint(s) of evaluation of this end point: 1. 30 Days post dose<br>                <br>                2.  TEAEs through 30 days and 90 days post dose, TESAEs, AESIs, NOCDs through 360 days post dose.<br>",<br>                Secondary end point(s): • MEDI4893 serum PK<br>                • MEDI4893 ADA response in serum<br>                • Incidence of S aureus pneumonia on mechanical ventilation<br>                • Incidence of S aureus pneumonia after extubation<br>            ;<br>                Timepoint(s) of evaluation of this end point: • Serum PK and ADA: 90 days<br>                • S aureus pneumonia: 30 days<br>,child,NULL,Date trial authorised,213,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results,"A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects",16/10/2019,01/01/1900,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results#baselineCharacteristicsSection,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results#subjectDispositionSection,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results#adverseEventsSection,https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-001097-34/results#endPointsSection,NA,NA,NA,02/10/2018,Yes,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2013-004614-18-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004614-18,An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment with Systemic Antibiotics,"documented or presumed bacterial infections, or at risk of a bacterial infection <br>MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10052596Term: Nosocomial pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]",<br>Trade Name: Zevtera©<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Ceftobiprole medocaril sodium<br>CAS Number: 252188-71-9<br>Current Sponsor code: BAL5788-001<br>Other descriptive name: CEFTOBIPROLE MEDOCARIL SODIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 666.6-<br><br>,"A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.",EUCTR,06/06/2016,11/07/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",Human pharmacology (Phase I): yesTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,45,Basilea Pharmaceutica International Ltd.,United States;Poland;Belgium;Ukraine;Lithuania;Latvia;Germany,EUCTR2013-004614-18-BE,NULL,06/06/2016,11/07/2016,EUCTR2,20-Jul-20,BPR-PIP-001;2013-004614-18-BE,Dr Agnes Kaelin Aebi,NA,Grenzacherstrasse 487,Agnes.KaelinAebi@basilea.com,4161567 15 34,Basilea Pharmaceutica International Ltd.,Dr Agnes Kaelin Aebi,NA,Grenzacherstrasse 487,Agnes.KaelinAebi@basilea.com,4161567 15 34,Basilea Pharmaceutica International Ltd.,Not Recruiting,NULL,Basilea Pharmaceutica International Ltd.,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>- Neonates and infants up to 3 months, with gestational age = 28 weeks<br>- Documented or presumed (or at risk of) bacterial infections, and currently receiving antibiotic treatment<br>- Expected to survive beyond the first 7 days after enrolment<br>- Sufficient vascular access to receive study drug, and to allow blood sampling at a site separate from the study drug infusion site<br>- Parent’s / legally acceptable representative’s informed consent to participate in the study<br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 45<br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range <br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>· Major birth defect or malformation syndrome<br>· Proven presence of an immunodeficiency<br>· HIV or other congenital viral or fungal infection<br>· Significant laboratory abnormalities<br>· Impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula or other applicable formula) less than 2/3 of normal for the applicable age group<br>· Any condition which would make the subject or caregiver, in the opinion of the investigator, unsuitable for the study.<br>","Main Objective: The primary objective is to characterize the pharmacokinetics of a single dose of ceftobiprole in neonates and infants aged up to 3 months. ;Secondary Objective: The secondary objective is to evaluate the safety and tolerability of ceftobiprole in neonates and infants aged up to 3 months.;Primary end point(s): Analyse plasma and urine for concentrations of ceftobiprole, and if applicable for concentrations of ceftobiprole medocaril and the open-ring metabolite (BAL1029). ;Timepoint(s) of evaluation of this end point: -2 to 0 h<br>-15 min<br>Pre dose<br>0 to 2 h<br>1 h<br>2 h<br>2 h 15 min<br>2 to 4 h<br>4 h (end of infusion)<br>4 to 8 h<br>6 h<br>8 h<br>8  to 12 h<br>12 h<br>",Secondary end point(s): Safety ;Timepoint(s) of evaluation of this end point: Day -1<br>Day 1<br>Day 7,child,NULL,Date trial authorised,NA,NA,An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment with Systemic Antibiotics,NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jun 22 2016 12:00AM,NA,NA,NA,NA
EUCTR2018-003117-18-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003117-18,"A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP)",Community-acquired pneumonia (CAP) <br>MedDRA version: 20.0Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],<br>Trade Name: Albutein 20% solución para perfusión<br>Product Name: Albúmina<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: ALBUMINA<br>CAS Number: 9006-53-5<br>Current Sponsor code: ALBUMINA<br>Other descriptive name: HUMAN SERUM ALBUMIN<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>,To evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP),EUCTR,12/04/2019,10/07/2019,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: STANDARD OF CARE<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,360,Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge,Spain,NCT04071041,NULL,12/04/2019,10/07/2019,EUCTR2,20-Jul-20,HUB-INF-ALBUCAP-402,Dr. Alexander Rombauts,NA,"Calle Feixa Llarga, s/n",arombauts@bellvitgehospital.cat,34932607625,Dr. Alexander Rombauts Servicio de Enfermedades Infecciosas. Hospital Universitario de Bellvitge,Dr. Alexander Rombauts,NA,"Calle Feixa Llarga, s/n",arombauts@bellvitgehospital.cat,34932607625,Dr. Alexander Rombauts Servicio de Enfermedades Infecciosas. Hospital Universitario de Bellvitge,Authorised-recruitment may be ongoing or finished,NULL,Fondos de Investigación Sanitarioas (FIS) Instituto Carlos III,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1) Adult patients (18 years or older), of both genders, hospitalized for CAP<br>2) Patients with a hypoalbuminemia (serum albumin =30 g/L)<br>3)Subjects, their legal  representative  or closest familiar (in case of incapacity of the subject due to the seriousness of the clinical situation: patients hospitalized in ICU, delirium) otorgates the informed consent.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 144<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 216<br>","Exclusion criteria: <br>1) Pregnancy and/or breastfeeding. If a subject is a female of childbearing potential, she must have a negative result on an approved urine pregnancy test at the time of screening.<br>2) Severe immunosuppressed patients (e.g. chemotherapy or radiotherapy in the previous 90 days, receiving immunosuppressants, chronic use of corticosteroids at a minimum dose of 15 mg/day in the last two weeks, transplantation of hematopoietic progenitors, solid organ transplantation, HIV patients with CD4 less than 200) <br>3) Imminent death<br>4) Congestive heart failure (NYHA class 3 or 4)<br>5) Known adverse reactions to albumin or some of its excipients<br>6) Conditions in which there is another indication for the administration of albumin (e.g. liver cirrhosis with ascites, malabsorption syndrome, nephrotic syndrome)<br>7) Participation in another clinical trial in the three previous months.<br>","Main Objective: To study the short-term efficacy (on day 5 from the beginning of the study treatment, 'end of treatment', EoT) of intravenous albumin in adult, hypoalbuminemic patients, hospitalized with CAP, evaluated as number of patients with clinical stability;Secondary Objective: CLINICAL ASSESSMENT CRITERIA: <br> 1) To study the short-term efficacy (on day 5 from starting the study treatment, 'end of treatment', EoT) of intravenous albumin in adult, hypoalbuminemic patients, hospitalized with CAP, evaluated as days to reach clinical stability <br>2) To study the long-term efficacy (30 days after hospital discharge, test of cure, ToC) of intravenous albumin in adult, hypoalbuminemic patients, hospitalized with CAP, evaluated as days to reach clinical stability<br>3) To assess the duration of antibiotic treatment (days, intravenous and total)<br>4) To assess the duration of hospital stay (days)<br>5) To assess the incidence of CAP-related comorbidities up to 30 days after discharge<br>6) To assess the all-cause mortality incidence up to 30 days after discharge<br>SECURITY ASSESSMENT CRITERIA: <br>To evaluate safety (incidence of adverse events according to seriousness and causality by treatment) of experimental vs. control treatment.;Primary end point(s): Number of patients achieving clinical stability on day 5 (EoT);Timepoint(s) of evaluation of this end point: On day 5 from starting study treatment, 'end of treatment', EoT.","Secondary end point(s): CLINICAL ASSESSMENT CRITERIA:<br>1) Time (days) to reach clinical stability on day 5; 2) Long-term efficacy: time to reach clinical stability (up to 30 days after discharge);  3) Duration of antibiotic treatment (days) ; 4)Length of hospital stay (days)<br>CAP-RELATED COMORBIDITY:<br> 1) Patients admitted in ICU; 2) Patients requiring mechanical ventilation; 3) Patients admitted in ICU and requiring mechanical ventilation; 4) Patients with a diagnosis of nosocomial infection; 5) Patients re-admitted in the first 30 days after discharge <br>MORTALITY:<br>1) Patients deceased on day 5 from the beginning of the study (early mortality).<br>2) Patients deceased on day 30 from the beginning of the study (30-day mortality); 3) Patients deceased, for CAP-related cause, up to 30 days from hospital discharge; 4) Patients deceased for any cause up to 30 days from hospital discharge<br>SECURITY ASSESSMENT CRITERIA:<br>1) Adverse events incidence according to seriousness and causality by treatment;Timepoint(s) of evaluation of this end point: On day 30 from hospital discharge, 'test of cure', ToC.",parent,NULL,Date trial authorised,NA,NA,"A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP)",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jun  6 2019 12:00AM,NA,NA,NA,NA
EUCTR2016-004009-15-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004009-15,"Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support",Influenza A infection in hospitalized patients who need supplemental oxygen <br>                MedDRA version: 20.1                Level: LLT                Classification code 10022002                Term: Influenza A virus infection                System Organ Class: 100000004862            ;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>                Product Code: VIS410<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: VIS410<br>                Current Sponsor code: VIS410<br>                Other descriptive name: VIS410<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,"Clinical trial to compare the benefit and safety of a single infusion of VIS410, the study medicine added to standard Tamiflu® treatment to that of treatment with Tamiflu® alone in hospitalized adults with flu infection requiring oxygen support",EUCTR,28/07/2017,28/09/2017,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: yes                Placebo: no                Other: no                Number of treatment arms in the trial: 3",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,120,"Visterra, Inc.",Serbia;United States;Belarus;Estonia;Spain;Thailand;Ukraine;Turkey;Russian Federation;France;Canada;Malaysia;Belgium;Singapore;Australia;Georgia;Bulgaria;South Africa;Latvia;New Zealand,EUCTR2016-004009-15-ES,NULL,28/07/2017,28/09/2017,EUCTR2,16-Dec-19,VIS410-203;2016-004009-15-ES,"David Oldach MD,",NA,"275 Second Avenue, 4th Floor",NA,1443629 0913,"Visterra, Inc.","David Oldach MD,",NA,"275 Second Avenue, 4th Floor",NA,1443629 0913,"Visterra, Inc.",Not Recruiting,NULL,"Visterra, Inc.",NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                Subjects meeting all of the following criteria are eligible to participate in this study:<br>                1. Male and female subjects aged = 18 years. For a country where the legal age of consent is >18 years old, the country requirements should be followed.<br>                2. Test positive for influenza A by rapid antigen test or with another commercially available test on an adequate nasopharyngeal specimen in accordance with the manufacturer's instructions, or an acceptable local test including, PCR, FIA, or ELISA<br>                3. Onset of influenza symptoms no more than 5 days before VIS410/placebo infusion; symptoms may include cough, dyspnea, sore throat, fever, myalgias, headache, nasal symptoms (rhinorrhea, congestion), fatigue, diarrhea, anorexia, nausea, and vomiting.<br>                4. Requirement for oxygen support including and positive pressure ventilation (PPV).<br>                5. Women of childbearing potential must have a negative pregnancy test within 2 days prior to VIS410/placebo infusion.<br>                6. Women should fulfill one of the following criteria:<br>                a. Post-menopausal; either amenorrhea = 12 months or follicle stimulating hormone > 40 mIU/mL as documented in their medical history<br>                b. Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation<br>                c. Women of childbearing potential participating in heterosexual relations must be willing to use adequate contraception from screening until 60 days post VIS410/placebo infusion (see Section 6.2).<br>                7. Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects who have a female partner of childbearing potential must use an effective birth control method (see Section 6.2) when having heterosexual intercourse, from screening until 60 days post VIS410/placebo infusion.<br>                8. Subject is able and willing to comply with study procedures, as per protocol.<br>                9. Subject, or a legally acceptable representative (LAR), is able to understand the purpose and risks of the study and willing to give voluntary written informed consent.<br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 60<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 60<br>","Exclusion criteria: <br>                Subjects meeting any of the following criteria are excluded from participation in this study:<br>                1. Known or suspected intolerance or hypersensitivity to VIS410, oseltamivir, pretreatment medications (diphenhydramine, or to both ibuprofen and acetylsalicylic acid [ASA]), or closely related compounds (eg, other monoclonal antibodies).<br>                2. Subjects who have received VIS410 in the past.<br>                3. Subjects who have a history of receiving monoclonal antibody products within 3 months prior to VIS410/placebo dosing or planned administration of another monoclonal antibody during the study period.<br>                4. Subjects who have taken more than 6 doses of an approved antiviral therapy for influenza within the prior 96 hours (eg, oral oseltamivir, inhaled zanamivir, IV peramivir, or oral ribavirin) between onset of symptoms and VIS410/placebo dosing.<br>                5. Subjects with known co-infection with influenza B or other viral respiratory infections (eg, respiratory syncytial virus {RSV}, parainfluenza viruses, respiratory adenoviruses).<br>                6. Subjects with lung transplant or history of severe chronic lung disease, including cystic fibrosis or any condition requiring home oxygen therapy.<br>                7. Subjects on extracorporeal membrane oxygenation at time of randomization.<br>                8. Subjects with end-stage renal disease (ESRD) who are not undergoing hemodialysis. <br>                9. Subjects with active graft-vs-host disease, hematopoietic stem cell transplant within the previous 90 days, or human immunodeficiency virus infection with a CD4 cell count of less than 200 per cubic millimeter.<br>                10. High probability of mortality within 48 hours of randomization as determined by the Investigator.<br>                11. Women who are pregnant, breast-feeding, or considering to become pregnant.<br>                12. Subjects in whom nasopharyngeal swabbing is not possible<br>                13. Subjects weighing less than 45 kg<br>                14. Enrollment in any other investigational drug or device study, any disease or vaccine study within 30 days prior to Day 1 or within 5 half-lives of the investigational compound, whichever is longer.<br>                15. Presence of any preexisting illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study.<br>                16. Subjects unable to comply with study protocol procedures and study visit schedules for whatever reason.<br>                17. Known or suspected alcohol or drug abuse, that is, abuse of a level that would compromise the safety or cooperation of the subject in the opinion of the Investigator.<br>","<br>                Primary end point(s): The primary efficacy outcome analysis compares Day 7 clinical status<br>                ordinal scale scores between treatment groups, and between all VIS410<br>                recipients versus placebo. Clinical status is measured daily for 14 days<br>                using the below seven-level ordinal scale, with the classifications<br>                presented from the worst clinical outcome to the best clinical outcome in<br>                descending order; for each day, subject status will be classified by the<br>                worst clinical outcome for which they qualify.<br>                _Death<br>                _ICU stay with mechanical ventilation<br>                _ICU stay without mechanical ventilation<br>                _Non-ICU hospitalization with supplemental oxygen<br>                _Non-ICU hospitalization without supplemental oxygen<br>                _Discharge with partial resumption of normal activities<br>                _Discharge with full resumption of normal activities<br>                The primary safety endpoint is the proportion of subjects with AEs and<br>                SAEs following administration of VIS410.<br>            ;<br>                Secondary Objective: • Among patients requiring supplemental oxygen therapy at the time of enrollment with baseline room air oxygen saturation of =92%, time to<br>                cessation of oxygen (O2) support resulting in stable oxygen saturation (SpO2) by pulse oximetry. Stable SpO2 is defined as two consecutive<br>                SpO2 values of > 92% on room air that are at least 8 hours apart.<br>                • For any patient requiring supplemental oxygen therapy at the time of<br>                enrollment (regardless of oxygen saturation), time to cessation of oxygen support.<br>                • Evaluate the effect of VIS410 + oseltamivir vs oseltamivir alone on the<br>                parameters described on the protocol.<br>                •Pharmacokinetics of VIS410 in serum<br>                • Immunogenicity of VIS410<br>                • Emergence of resistance to VIS410 and oseltamivir<br>            ;<br>                Main Objective: The primary efficacy objective is the evaluation of the effect of 2 dose levels of VIS410 + oseltamivir on clinical outcome as assessed by comparison of clinical status ordinal scale Day 7 scores between<br>                treatment groups, and between all VIS410 recipients versus placebo.<br>                <br>                The primary safety objective is to evaluate safety and tolerability of 2 dose levels of a single intravenous (IV) dose of VIS410 when administered in combination with oseltamivir in hospitalized subjects with influenza A infection<br>            ;Timepoint(s) of evaluation of this end point: The endpoints can be evaluated by hospital staff at any time while the patient is hospitalized or during patient visit in case of a discharged patient.","Timepoint(s) of evaluation of this end point: The endpoints can be evaluated by hospital staff at any time while the patient is hospitalized or during patient visit in case of a discharged patient.;<br>                Secondary end point(s): The difference between VIS410 + oseltamivir and oseltamivir alone<br>                treatment groups in the following endpoints:<br>                • Among patients requiring supplemental oxygen therapy at the time of<br>                enrollment with baseline room air oxygen saturation of = 92%, time to<br>                cessation of oxygen (O2) support resulting in stable oxygen saturation<br>                (SpO2) by pulse oximetry. Stable SpO2 is defined as two consecutive<br>                SpO2 values of > 92% on room air that are at least 8 hours apart.<br>                • For any patient requiring supplemental oxygen therapy at the time of<br>                enrollment (regardless of oxygen saturation), time to cessation of<br>                oxygen support<br>                • Peak viral load,viral AUC, duration of viral shedding, and time to<br>                resolution of viral load from nasopharyngeal swabs by TCID50 and qRTPCR<br>                • Time to clinical response defined as resolution of at least 4 of 5 vital signs<br>                _Afebrile with core temperature = 37.8°C, without use of antipyretics<br>                (oral < 37.2°C)<br>                _Oxygen saturation = 95% on room air without support or a return to<br>                pre-infection status, if pre-infection status was < 95%<br>                _Pulse rate = 100/min<br>                _Systolic blood pressure = 90 mm/Hg, without vasopressor use<br>                _Respiratory rate = 24 beats per minute<br>                _Respiratory rate = 24 beats per minute<br>                • Clinical status ordinal scale mean area under the curve for Days 1-7<br>                and Days 1-14 using linear numeric scores for the ordinal categories.<br>                • Comparison of clinical status ordinal scale scores for selected<br>                individual days (i.e., Days 3, 4, 5, and 6)<br>                • Comparison of clinical status ordinal scale scores using modified<br>                ordinal scale criteria (i.e,. pooling of selected severity criteria scores)<br>                • Comparison of discrete ordinal scale parameters, including days of<br>                ventilator support, days in intensive care, and duration of hospitalization<br>                • Number of days to resumption of usual activities<br>                • All-cause and attributable mortality rates at Day 14, 28 and 56<br>                • Total number of days in hospital and/or intensive care unit (ICU) from<br>                admission to discharge and rate of rehospitalization due to influenza A<br>                relapse/complication<br>                • The incidence, severity, and duration of signs and symptoms of<br>                influenza-like illness as assessed by the FluPRO Questionnaire (see<br>                Appendix 14.1)<br>                • Analysis of time to alleviation of signs and symptoms of influenza in<br>                the subset of subjects able to complete the Influenza Patient Reported<br>                Outcomes (FluPRO) Questionnaire at baseline and post-dose by Kaplan<br>                Meier analysis<br>                • The percentage of subjects with new bacterial<br>                pneumonia/superinfection<br>                • The percentage of subjects with influenza-related complications<br>                • VIS410 population pharmacokinetic (PK) parameters in serum<br>                • Titer of anti-VIS410 antibody positive samples<br>                • Genotypic and/or phenotypic assessment to determine the emergence<br>                of VIS410 and oseltamivir-resistant viruses<br>",child,NULL,Date trial authorised,NA,NA,"Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2015-003026-14-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003026-14,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA",Community-Acquired Bacterial Pneumonia <br>MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08],<br>Product Name: Delafloxacin<br>Product Code: RX-3341-83<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Delafloxacin meglumine<br>CAS Number: 352458-37-8<br>Current Sponsor code: RX-3341-83<br>Other descriptive name: DELAFLOXACIN MEGLUMINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Product Name: Delafloxacin oral tablet<br>Product Code: RX-3341-83<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Delafloxacin meglumine<br>CAS Number: 352458-37-8<br>Current Sponsor code: RX-3341-83<br>Other descriptive name: DELAFLOXACIN MEGLUMINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 450-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Moxifloxacin<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1.6-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Moxifloxacin<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>Product Name: Linezolid<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Linezolid<br>CAS Number: 165800-03-3<br>Other descriptive name: LINEZOLID<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administr,A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA,EUCTR,01/06/2016,12/09/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: yesOther trial design description: IV to oral switch If controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: yesOther specify the comparator: Matching Placebo to Delafloxacin oral, Moxifloxacin oral, Moxifloxacin IV and Linezolid IVNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,860,"Melinta Therapeutics, Inc.",Serbia;United States;Slovenia;Greece;Spain;Ukraine;Russian Federation;Colombia;Hungary;Argentina;Poland;Brazil;Romania;South Africa;Bulgaria;Georgia;Latvia;Germany,EUCTR2015-003026-14-HU,NULL,01/06/2016,12/09/2016,EUCTR2,10-Sep-18,ML-3341-306;NCT02679573;2015-003026-14-HU,Melinta Clinical Trials,NA,"300 Tri-State International, Suite 272",clinicaltrials@melinta.com,+1312724 9400,"Melinta Therapeutics, Inc.",Melinta Clinical Trials,NA,"300 Tri-State International, Suite 272",clinicaltrials@melinta.com,+1312724 9400,"Melinta Therapeutics, Inc.",Not Recruiting,NULL,"Melinta Therapeutics, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1.   Male or female 18 years of age or older<br>2.  Evidence of acute onset of CABP with 2 or more of the following symptoms (new or worsening)<br>•  Cough<br>•  Production of purulent sputum consistent with bacterial infection<br>•  Difficulty breathing<br>•  Chest pain due to pneumonia<br>AND have at least 2 of the following findings:<br>•  Fever (oral temperature >38.0°C)<br>•  Hypothermia (oral temperature <35.0°C)<br>•  Tachycardia (heart rate >100 beats/min)<br>•  Tachypnea (respiratory rate >18 breaths/min)<br>AND have at least 1 of the following findings:<br>•  Hypoxemia (oxygen saturation < 90% or PaO2 < 60 mmHg) on room air or with subject’s baseline (pre-CABP under study) supplemental oxygen<br>•  Clinical evidence of pulmonary consolidation and/or presence of pulmonary rales<br>•  An elevated white blood cell count (WBC) > 10,000/mm^3 or 15% immature neutrophils (bands), regardless of total peripheral WBC count or leukopenia with WBC < 4500/mm^3<br> 3.   Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study within 48 hours before the first dose of study drug<br>4.   PORT risk class of II to V<br>5.   Must be a suitable candidate for possible IV to oral switch antibiotic therapy and must also be able to swallow large tablets/capsules intact without crushing<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 559<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 301<br>","Exclusion criteria: <br>1.   A medical history of significant hypersensitivity or allergic reaction to antibiotics of the quinolone or oxazolidinone class or study drug excipients in the judgment of the investigator<br>2.   Any infection expected to require other systemic antibiotics in addition to study drug<br>3.  Receipt of systemic antibiotic therapy in the 7 days before enrollment<br>•  one dose of a single potentially effective, short-acting antibacterial drug or drug regimen for CABP within 24 hours before enrollment is allowed - limited to 25% of enrolled patients<br>4.   Respiratory infection confirmed or suspected to be secondary to hospital-required or ventilator-associated pneumonia or requires treatment in an intensive care setting, or mechanical ventilation<br>5.   Current or suspected diagnosis of viral, fungal, or aspiration pneumonia, noninfectious causes of pulmonary infiltrates, lung cancer, cystic fibrosis, tuberculosis, empyema (not including sterile parapneumonic effusions)<br>6.   Known anatomical or pathological obstruction or history of bronchiectasis or GOLD Stage 4 COPD or history of post obstructive pneumonia<br>7.   Severely compromised immune system<br>8.   Other exclusions include those described in the safety label for drugs in the quinolone and /or oxazolidinone classes such as QT prolongation, proarrhythmic conditions, concomitant use of drugs known to cause QT prolongation, peripheral neuropathy, tendon disorders, history of myasthenia gravis, liver disease, severe renal disease, seizures and concomitant use of MAO A or B inhibitor agents and adrenergic serotonergic agents<br><br>","Primary end point(s): The Clinical Outcome responder rate at 5 to 10 days after the last dose of<br>study drug (TOC) defined as resolution or near resolution of the symptoms of CABP present at study entry, and no use of additional antimicrobial therapy for the current infection, and no new symptoms associated with the current CABP infection (success) in the ModITT and ModCE populations.;Main Objective: EMA<br>To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP at 5 to 10 days after the last dose of study drug (TOC) compared to IV to oral comparator study drug arm in the Modified ITT (ModITT) and Modified CE (ModCE) populations.<br><br>FDA<br>To assess the clinical efficacy of IV to oral delafloxacin in adult subjects with CABP based on Early Clinical Response (ECR) defined as improvement at 96 hours (± 24 hours) after the first dose of study drug compared to IV to oral moxifloxacin in the<br>ITT population.;Secondary Objective: EMA<br>- To assess the clinical efficacy of IV to oral delafloxacin in adult subjects<br>with CABP based on ECR defined as improvement at<br>96 hours (± 24 hours) after the first dose of study drug compared to IV to oral moxifloxacin in the ModITT and ModCE populations.<br>- To assess the clinical efficacy of IV to oral delafloxacin in adult subjects<br>with CABP at the TOC visit compared to IV to oral<br>moxifloxacin in the Modified MITT (ModMITT) and Modified ME (ModME)<br>populations.<br>- To assess the microbiologic response to delafloxacin in respiratory pathogens in the ModMITT and ModME populations.<br>- To assess the safety and tolerability of IV to oral delafloxacin in adult subjects with CABP in safety population.<br>- To assess the all-cause mortality in adult subjects with CABP on Day 28 in ModITT.<br>- To assess delafloxacin PK in adult subjects with CABP in PK population.<br><br>FDA<br>Secondary objectives for FDA can be found at pages 34-35 of the current protocol amendment.;Timepoint(s) of evaluation of this end point: Days 5 to 10","Secondary end point(s): The secondary efficacy endpoints are:<br>- ECR defined as improvement at 96 hours (± 24 hours) after first dose<br>of study drug in at least 2 of the following symptoms: chest pain, frequency or severity of cough, amount and quality of productive sputum and difficulty breathing and no worsening of any of the other symptoms<br>in the ModITT and ModCE populations<br>- ECR with the addition of improvement in vital signs and no worsening of the 4 symptoms required as Response in the ModITT and ModCE populations<br>- Clinical Outcome at EOT (ModITT and ModCE)<br>- Clinical Outcome at TOC in the ModMITT and ModME populations<br>- Microbiologic response (ModMITT and ModME)<br>- All-cause mortality (ModITT);Timepoint(s) of evaluation of this end point: Clinical Outcome at the Test of Cure (TOC) visit, 5 to 10 days after the last dose of study drug<br>All-cause mortality (ModITT)- Day 28 <br>96 h ± 24 h for Early Clinical Response<br>",child,NULL,Date trial authorised,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2018-004056-37-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004056-37,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIRMARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TOHOUSEHOLD CONTACTS - Centerstone",Influenza <br>MedDRA version: 20.0Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.0Level: LLTClassification code 10016790Term: FluSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Product Name: Baloxavir marboxil<br>Product Code: RO7191686/F04<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: BALOXAVIR MARBOXIL<br>Current Sponsor code: RO7191686<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,A Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza from Otherwise Healthy Patients to Household Contacts,EUCTR,24/07/2019,11/09/2019,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,1130,F. Hoffmann-La Roche Ltd,United States;Hong Kong;Greece;Spain;Costa Rica;Turkey;Israel;United Kingdom;Switzerland;India;Mexico;Argentina;Brazil;Singapore;South Africa;Japan;China,NCT03969212,NULL,24/07/2019,11/09/2019,EUCTR2,16-Dec-19,MV40618;2018-004056-37-ES,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche Ltd,Trial Information Support Line-TISL,NA,Grenzacherstrasse 124,global.rochegenentechtrials@roche.com,NA,F. Hoffmann-La Roche Ltd,Authorised-recruitment may be ongoing or finished,NULL,F. Hoffmann-La Roche Ltd,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>Index Patient(s) (IP or IPs) will be screened first at the site whereas Household Contact(s) (HHC or HHCs) will be screened at the home or site after randomization. HHCs must be enrolled within 24 hours of IP randomization.  No HHC will be enrolled before all HHCs have been screened. <br>IP inclusion criteria<br>- Age >=12 and <=64 years<br>- Able to comply with the study protocol per investigator judgment<br>- Diagnosed with acute influenza infection by investigator<br>- Polymerase chain reaction [PCR] (+) or Rapid Influenza Diagnostic Test [RIDT] (+) for influenza A/B based local laboratory results<br>- Presence of (a) fever or (b) any influenza symptoms <br>- The time interval between the onset of fever or influenza symptoms and the pre-dose examinations is =48 hours<br>- IP lives in a household where:<br>o No HHC is known to have been diagnosed with influenza by a healthcare professional (HCP)<br>o All HHCs are expected to meet the HHC inclusion criteria required for All HHC living in the home at any time during the study” and none of the HHC exclusion criteria<br>o =2 HHCs are expected to participate in the full study who have not received the influenza vaccine within 6 months prior to screening<br>- Women of childbearing potential agree to remain abstinent or use contraceptive measures<br>Household Contact (HHC) inclusion criteria<br>1. All HHC living in the home at any time during the study must meet the following criteria<br>- PCR (-) or RIDT (-) based on local laboratory result at Day 0 Visit<br>- Willing to undergo screening visit as a scheduled/unscheduled visit after they return to the home if not at home at Day 0 Visit<br>       <br>2. HHC intended for full study must meet the following additional criteria for study entry <br>- No influenza symptoms within 7 days prior to screening; mild symptoms allowed if due to pre-existing condition (e.g. allergies)<br>- Tympanic temperature <38°C at screening<br>- Will reside in the IP’s house for at least 7 of the next 9 days and will be present for scheduled study visits<br>- Willing/able to measure/record temperature, or have another household member perform the task on his/her behalf. Furthermore, a responsible adult will assume responsibility to oversee or perform this task on behalf of minors<br>- Has not been diagnosed with influenza or taken antivirals for influenza =6 months prior to screening<br>- Does not have moderate or worse active infections OR taking systemic or an internally administered anti -biotic/ -viral/ -fungal <br>- HHC lives in a household where:<br>o No HHC has been diagnosed with influenza by an HCP<br>o All HHCs meet the HHC inclusion criteria required for All HHC living in the home at any time during the study” and none of the HHC exclusion criteria<br>o  =2 HHCs have not received the influenza vaccine =6 months prior to screening agree to participate in the full study<br><br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 113<br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 1017<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>IP exclusion criteria <br>- IPs with severe influenza virus infection requiring inpatient treatment<br>- IPs judged by the investigator to be at high risk for complications of influenza, after consideration of the following or other potential risk factors:<br>o Women who are pregnant or within 2 weeks post-partum;<br>o Chronic respiratory diseases including chronic obstructive pulmonary disorder current asthma and cystic fibrosis;<br>o Neurological and neurodevelopmental disorders, heart disease,  blood disorders,  endocrine disorders,  kidney disorders, liver disorders, metabolic disorders, and morbid obesity;<br>o Compromised immune system due to disease or medications;<br>o People younger than 19 years of age on long-term aspirin- or salicylate-containing medications;<br>o American Indians or Alaska Natives;<br>o People who live in nursing homes and other long-term care facilities<br>- IPs unable to swallow tablets <br>- Women who are breastfeeding or have positive pregnancy test at pre-dose screening (unless exempted due to postmenopausal status or surgically sterile). <br>- IPs weighing <40 kg<br>- IPs with concurrent (non-influenza) infections requiring systemic anti -microbial / -viral therapy at the pre-dose examinations<br>- IPs who have received an investigational monoclonal antibody for a viral disease in the last year<br>- IPs who have received an investigational therapy within 30 days or 5 drug-elimination half-lives, whichever is longer, prior to screening<br>- IPs living with another person who, based on available information meets the HHC exclusion criteria<br>- Known hypersensitivity to baloxavir marboxil or the drug product excipients<br>- Any other contraindication for treatment with baloxavir marboxil as deemed by the treating physician or Principal Investigator<br>HHC exclusion criteria<br>- Pregnant or within 2 weeks post-partum at screening<br>- Immunocompromised (including HHC receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus [HIV] infection)<br>- <2 years old<br>- HHC who have received an investigational therapy within the 30 days or 5 drug-elimination half-lives, whichever is longer, prior to screening.<br><br>","Secondary Objective: • To evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo to prevent transmission of influenza A or B beyond secondary within-household transmission<br>• To evaluate the safety and tolerability of a single, oral dose of baloxavir marboxil compared with placebo<br>• To evaluate index patients treated with baloxavir marboxil compared with those receiving placebo with respect to health status utility measures<br>;Primary end point(s): 1. Percentage of HHC who become PCR+ for influenza by Day 5 post IP randomization. HHCs may be symptomatic or asymptomatic and their virus subtype must match that of the IP in their household. The primary efficacy analysis population will consist of all enrolled unvaccinated HHCs of the randomized IPs.;Main Objective: • To evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo to prevent secondary within-household transmission of influenza A or B;Timepoint(s) of evaluation of this end point: 1. Baseline to Day 5 (5 days)",Secondary end point(s): 1. Percentage of HHCs who become PCR+ for influenza by Day 9 post IP randomization<br>2. Percentage of HHCs who become PCR+ for influenza by Day 5 post IP randomization AND report influenza symptoms at any time during the study.<br>3. Percentage of Households with at least one HHC who meets the Primary Endpoint<br>4. Percentage of IP with Adverse Events (AEs)<br>5. IP only: Change from baseline in health-related quality of life according to EuroQol 5 dimensions 5 (EQ-5D-5L; Appendix 3) questionnaire at Day 3 and Day 9 Visits<br>6. IP only: Change from Baseline in work productivity according to Work Productivity and Activity Impairment (WPAI) plus Classroom Impairment Questions Score at Day 9<br>;Timepoint(s) of evaluation of this end point: 1. Baseline to Day 9 (9 days)<br>2. Baseline up to Day 5 (5 days)<br>3. Baseline to Day 9 (9 days)<br>4. Baseline to Day 9 (9 days)<br>5. Day 3 and Day 9 (versus baseline)<br>6. Day 9 (versus baseline)<br>,child,NULL,Date trial authorised,NA,NA,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TO HOUSEHOLD CONTACTS",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2015-004546-26-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004546-26,"A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects with Uncomplicated Influenza A Infection",Influenza A infection <br>MedDRA version: 19.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Product Code: VIS410<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: VIS410<br>Other descriptive name: VIS410<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,"Clinical trial to see if there are differences in flu symptoms when people receive a single infusion of VIS410, the study medicine, compared with those who receive placebo and to find out if VIS410 is safe and well tolerated",EUCTR,01/12/2016,11/01/2017,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 3",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): yesTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): no,150,"Visterra, Inc.",Serbia;United States;Estonia;Ukraine;Lithuania;South Africa;Bulgaria;Latvia,EUCTR2015-004546-26-LV,NULL,01/12/2016,11/01/2017,EUCTR2,09-Oct-17,VIS410-202,"Ellie Hershberger, PharmD",NA,"One Kendall Square, Suite B3301",NA,1617498 1070,"Visterra, Inc.","Ellie Hershberger, PharmD",NA,"One Kendall Square, Suite B3301",NA,1617498 1070,"Visterra, Inc.",Not Recruiting,NULL,"Visterra, Inc.",NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>Subjects meeting all of the following criteria are eligible to participate in this study:<br>1. Male and female subjects aged =18 years and < 65 years<br>2. Women should fulfill one of the following criteria:<br>a. Post-menopausal; either amenorrhea =12 months or follicle stimulating hormone >40 mIU/mL as documented in their medical history.<br>b. Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation.<br>c. Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception from screening until 60 days post-infusion, per Section 7.1.2.<br>3. Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects who have a female partner of childbearing potential must use an effective birth control method (see Section 7.1.2) when having heterosexual intercourse, from screening until 60 days post-infusion.<br>4. Test positive for influenza A by Rapid Antigen Test performed with a commercially available test on an adequate nasopharyngeal specimen in accordance with the manufacturer's instructions<br>5. Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of moderate to severe intensity, or presence of at least one constitutional symptom (myalgia [aches and pains], headache, feverishness, or fatigue) of moderate to severe intensity<br>6. Onset of symptoms (time when the temperature was first measured as elevated [temperature of =100.4°F or =38°C], OR the time when the subject experienced at least one respiratory symptom or at least one constitutional symptom) no more than 72 hours before the start of infusion<br>7. Subject is able and willing to comply with study procedures, as per protocol<br>8. Subject is able and willing to give voluntary written informed consent<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 150<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>Exclusion Criteria:<br>Subjects meeting any of the following criteria are excluded from participation in this study:<br>1. Use of NSAIDs or antihistamines within 6 hours of study drug dosing with the exception of those used as part of the pretreatment regimen.<br>2. History of intolerance or allergic response to monoclonal antibodies and/or pretreatment medications diphenhydramine, ibuprofen and acetylsalicylic acid)<br>3. History of receiving monoclonal antibody products within 3 months prior to enrollment in this study or planned administration during the study period<br>4. Subjects in whom nasopharyngeal swabbing is not possible<br>5. Subject weight less than (<) 45 kg<br>6. Subjects with clinical history that would lead to increased risk of influenza complications including but not limited to clinically significant cardiac disease, moderate to severe asthma, or other moderate to severe chronic obstructive pulmonary disease, metabolic syndrome including moderate to severe diabetes or active tuberculosis.<br>7. History of chronic GI disease, including bleeding, ulceration, Irritable Bowel Syndrome, systemic mastocytosis or chronic diarrhea<br>8. Women who are pregnant, breast-feeding, or considering becoming pregnant.<br>9. Patients with hypoxemia requiring oxygen support.<br>10. Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the Investigator's opinion, indicates that such finding(s) could represent complications of influenza<br>11. Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy including systemic steroids.<br>12. Presence of known Acquired Immune Deficiency Syndrome-defining illness, chronic hepatitis B or hepatitis C.<br>13. Receipt of any dose of antiviral therapy such as, but not limited to, rimantadine, amantadine, peramivir, zanamivir, laninamivir or oseltamivir in the 7 days prior to screening<br>14. Enrollment in any other investigational drug or device study, any disease or vaccine study within 30 days prior to Day 1 or within 5 half-lives of the investigational compound, whichever is longer<br>15. Presence of any pre-existing illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study<br>16. Subjects unable to comply with study protocol procedures and study visit schedules for whatever reason<br>17. Subjects unable to take oral predose medication<br>18. Known or suspected alcohol or drug abuse, that is, abuse of a level that would compromise the safety or cooperation of the subject in the opinion of the Investigator<br>19. Subjects on chronic medications where the dose has not been stable for at least 3 months<br>","Secondary Objective: • Evaluate the efficacy of VIS410 compared with placebo on the time to alleviation of clinical symptoms of acute uncomplicated influenza<br>• Evaluate the effect of VIS410 on severity of influenza infection<br>• Assess the pharmacokinetics of VIS410 in serum<br>• Assess the effects of VIS410 on viral shedding<br>• Assess the immunogenicity of VIS410;Primary end point(s): Primary Endpoints:<br>• The proportion of subjects with adverse events (AEs) and serious adverse events (SAEs) following administration of VIS410<br>• The proportion of subjects with treatment-emergent AEs (TEAEs) including hypersensitivity reaction, anaphylactic reaction, and AEs of special interest (AESIs) following dosing;Timepoint(s) of evaluation of this end point: The primary endpoints will be evaluated throughout the study, as<br>assesments are done. End points defined by adverse events can be<br>reached at any time.;Main Objective: Assess the safety and tolerability of a single intravenous (IV) dose of VIS410 in patients with uncomplicated influenza infection","Secondary end point(s): Secondary Endpoints:<br>• The incidence, severity, and duration of signs and symptoms of influenza-like illness as assessed by the Influenza Patient Reported Outcomes questionnaire after a single IV dose of VIS410<br>• Percentage of participants requiring hospitalization for influenza-related complications<br>• Duration of hospitalization for influenza-related complications<br>• Percentage of participants with complications of influenza<br>• Percentage of participants with influenza A relapse/reinfection<br>• VIS410 pharmacokinetic (PK) parameters (Cmax, tmax, AUC0-8, AUC0-last, t1/2, Vd, CL) in serum<br>• The difference between VIS410 and placebo treatment groups in viral AUC from nasopharyngeal swabs<br>• The difference between VIS410 and placebo treatment groups in peak viral load and time to resolution of viral load from nasopharyngeal swabs<br>• Titer of anti-VIS410 antibody-positive samples;Timepoint(s) of evaluation of this end point: The  secondary endpoints will be evaluated throughout the study, as<br>assesments are done. End points defined by adverse events can be<br>reached at any time.",parent,EUCTR2015-004546-26-LV,Date trial authorised,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2015-003119-39-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003119-39,effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure - ZODIAC,"chronic heart failure and central sleep apnea <br>MedDRA version: 18.1Level: PTClassification code 10040979Term: Sleep apnoea syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders <br>MedDRA version: 18.1Level: LLTClassification code 10019276Term: Heart disease, unspecifiedSystem Organ Class: 100000004849;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",<br>Trade Name: stilnox<br>Product Name: zolpidem<br>Pharmaceutical Form: Buccal tablet<br>Pharmaceutical form of the placebo: Buccal tablet<br>Route of administration of the placebo: Oral use<br><br>,effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure,EUCTR,25/02/2016,29/10/2015,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: noCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,NA,Centre Hospitalier Universitaire de Grenoble,France,NA,1,25/02/2016,29/10/2015,EUCTR2,02-Oct-17,38RC15.175,ARC promoteur,NA,CS 1217,MCoutard@chu-grenoble.fr,+330476 76 84 55,Direction de la recherche Clinique,ARC promoteur,NA,CS 1217,MCoutard@chu-grenoble.fr,+330476 76 84 55,Direction de la recherche Clinique,Authorised-recruitment may be ongoing or finished,NULL,Centre hospitalier Universitaire de GRENOBLE,NA,NA,<br>Female: yes<br>Male: yes<br>,Inclusion criteria: <br>please report to the french version<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 30<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 18<br>,Exclusion criteria: <br>please report to the french version<br>,Main Objective: please report to the french version;Secondary Objective: please report to the french version;Primary end point(s): please report to the french version;Timepoint(s) of evaluation of this end point: please report to the french version,Secondary end point(s): please report to the french version;Timepoint(s) of evaluation of this end point: please report to the french version,NA,NULL,Date trial authorised,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2017-001270-41-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001270-41,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study - HEARTSCHOCK-NORDOB",Cardiogenic Shock;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],<br>                Trade Name: NORADRENALINE MYLAN<br>                Product Name: NORADRENALINE MYLAN<br>                Pharmaceutical Form: Solution for infusion<br><br>                Trade Name: Dobutamine<br>                Pharmaceutical Form: Solution for infusion<br><br>,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study",EUCTR,30/06/2017,17/07/2019,FALSE,Interventional clinical trial of medicinal product,"<br>                Controlled: yes<br>                Randomised: yes<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: no<br>                Cross over: no<br>                Other: no<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: no<br>                Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): no                Therapeutic confirmatory - (Phase III): yes                Therapeutic use (Phase IV): no,42,CHRU NANCY,France,NCT03340779,NULL,30/06/2017,17/07/2019,EUCTR2,10-Dec-19,CPRC2015/HSNORDOB-AUCHET/YB,Direction Recherche et Innovation,NA,Bâtiment Recherche - Rue du Morvan,rechclin-innov@chru-nancy.fr,33383 15 52 85,CHRU de Nancy,Direction Recherche et Innovation,NA,Bâtiment Recherche - Rue du Morvan,rechclin-innov@chru-nancy.fr,33383 15 52 85,CHRU de Nancy,Authorised-recruitment may be ongoing or finished,NULL,CHRU de Nancy,NA,NA,<br> Female: yes<br> Male: yes<br>,"Inclusion criteria: <br>                Patients with cardiogenic shock (ischemic, rythmic, valvular) defined by :<br>                - Cardiac index (CI) < 2,2 L/min/m² or CI < 2,5 L/min/m² under vasopressor/inotropic treatment<br>                - 0rgan hypoperfusion signs :<br>                a) mottles,<br>                b) capillary refill time greater or equal to 3 seconds ,<br>                c) urine output < 0,5 mL/kg/hour during at least one hour or renal replacement therapy,<br>                d) consciouness impairment,<br>                e) pulmonary oedema,<br>                f) hyperlactatemia (>  2 mmoL/L)<br><br>                - Mean arterial pressure > 65 mmHg under norepinephrine treatement<br><br>                - Patients with social coverage<br><br>                - Patient having given his / her consent, free, informed and in writing. If not, consent will be obtained from a family member / support person, if present. As soon as possible, the patient will be informed and his / her consent will be requested for the possible continuation of the research<br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 12<br>                F.1.3 Elderly (>=65 years) yes<br>                F.1.3.1 Number of subjects for this age range 30<br>","Exclusion criteria: <br>                < 18 years old<br>                Pregnancy<br>                Inclusion in other drug study in cardiogenic shock , inclusion in study with medical device (for instance valve replacement)<br>                Poisonings with cardiotoxicants<br>                Patient with intra-aortic ballon pump, extracorporeal life support, ventricular support device<br>                Patient under guardianship<br>","Timepoint(s) of evaluation of this end point: During hospitalization in the resuscitation department.;<br>                Primary end point(s): Composite criteria for efficacy of treatment :<br>                - increase of cardiac index > 15%,<br>                - increase of organ perfusion assessed by :<br>                -lactate clearance > 15%,<br>                - decrease of mottling (decrease of 2 points of Mottling score),<br>                - increase of musculaire oxygen saturation measured by NIRS > 15%,<br>                - urine output 50%,<br>                - increase of SVcO2 > 15% ;<br>                and safety (occurence of side effects) :<br>                - increase of heart rate > 15% ,<br>                - increase of oxygen consumption evaluated by decrease of ratio mean arterial pressure / heart rate > 15% (Buffington ratio).<br><br>                The primary endpoint is defined by the presence of 2 efficacy criterias without any side effects.<br>            ;<br>                Secondary Objective: - To evaluate the efficacy of the treatments on micro- and macrocirculation parameters<br>                - To evaluate the dose and the admistration's kinetics of the treatments<br>                - To evaluate the dose and the admistration's kinetics of the treatments<br>            ;Main Objective: Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study","Timepoint(s) of evaluation of this end point: During hospitalization in the resuscitation department.;<br>                Secondary end point(s): - Evaluation of efficacy by measure of heart rate, blood pressure, SVcO2, lactate clearance, muscular oxygen musculare, urine output, mottle<br>                - Evaluation of tolerance by measure of atrial and ventricular arythmia<br>                - Measure of catecholamines doses, time to reach the target<br>",parent,NULL,Date trial authorised,NA,NA,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study",NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2016-003433-20-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003433-20,Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis - ARAMIS,Patients hospitalized for Acute myocarditis <br>                MedDRA version: 19.0                Level: LLT                Classification code 10000932                Term: Acute myocarditis                System Organ Class: 100000004849            ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14],<br>                Trade Name: kineret<br>                Product Name: kineret<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: ANAKINRA<br>                CAS Number: 143090-92-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>,Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute MyocarditIS,EUCTR,04/11/2016,16/12/2016,FALSE,Interventional clinical trial of medicinal product,"Controlled: no                Randomised: yes                Open: no                Single blind: no                Double blind: yes                Parallel group: yes                Cross over: no                Other: no                If controlled, specify comparator, Other Medicinial Product: no                Placebo: yes                Other: no                Number of treatment arms in the trial: 2",Human pharmacology (Phase I): no                Therapeutic exploratory (Phase II): yes                Therapeutic confirmatory - (Phase III): no                Therapeutic use (Phase IV): no,120,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),France,NA,NULL,04/11/2016,16/12/2016,EUCTR2,28-Feb-19,P150921,DRCD Hôpital St Louis,NA,1 av. Claude Vellefaux,fadila.amerali@aphp.fr,NA,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),DRCD Hôpital St Louis,NA,1 av. Claude Vellefaux,fadila.amerali@aphp.fr,NA,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Authorised-recruitment may be ongoing or finished,NULL,DGOS,NA,NA,<br> Female: yes<br> Male: yes<br>,Inclusion criteria: <br>                Patients hospitalized for Acute myocarditis defined as:<br>                -Chest Pain (or modification of the ECG) AND Troponin Rise (*1.5 Normal range) AND Myocarditis proven by RMI in the first 72h after admission<br>                - Age > 18 and <65 years old<br>                -Accepting effective contraception during treatment duration (men and women childbearing potential)<br>                -Signed informed consent<br>                -Normal Coronary angiography or coronary CT Scan (made during the previous year is acceptable) (normal is defined as stenosis < 50%)<br><br>                Are the trial subjects under 18? no<br>                Number of subjects for this age range:<br>                F.1.2 Adults (18-64 years) yes<br>                F.1.2.1 Number of subjects for this age range 120<br>                F.1.3 Elderly (>=65 years) no<br>                F.1.3.1 Number of subjects for this age range<br>,"Exclusion criteria: <br>                -Active coronary disease<br>                -Clinical Suspicion or proven underlying disease: systemic lupus, antiphospholipid antibodies, Lyme disease, trypanosomiase disease, myositis, signs of sarcoidosis, giant cell myocarditis, chronic inflammatory disease, tuberculosis, HIV, HBV or HCV infection<br>                -Latex allergy<br>                -Pregnancy, breastfeeding<br>                -Contra-indication to ANAKINRA (known hypersensitivity to the active substance or to any of the excipients,<br>                -neutropenia < 1,5.109/L)<br>                -Renal failure, CrCl < 30 ml/min (MDRD)<br>                -Asthma<br>                -Malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study<br>                -History of malignancy<br>                -Non Steroidian Anti Inflammatory drug within the past 14 days<br>                -Anti TNF within the past 14 days<br>                -No affiliation to the French Health Care System sécurité sociale<br>                -Hepatic impairement = Child-Pugh Class C<br>                -Mechanical ventilation<br>                -Circulatory assistance.<br><br>","<br>                Main Objective: to assess the efficacy of ANAKINRA in Acute Myocarditis compared to placebo in addition to standard therapy.<br>            ;Primary end point(s): number of days alive free of any myocarditis complications defined as ventricular arrhythmias, heart failure, chest pain, ventricular dysfunction defined as LVEF<50%, within 28 days post hospitalization;<br>                Secondary Objective: -To assess the cost-effectiveness of ANAKINRA in the setting of acute myocarditis<br>                -To assess the effect of ACE discontinuation in patient with preserved LVEF<br>                -To determine if ANAKINRA improves NT proBNP fall<br>                - To determine if ANAKINRA improves troponin fall<br>                -To determine if ANAKINRA improves the rate of sustained or not sustained ventricular tachycardia, Heart Failure, or Cardiac Death<br>            ;Timepoint(s) of evaluation of this end point: 4YERS","<br>                Secondary end point(s): -Total cost, total QALYs, incremental cost effectiveness and cost utility ratios<br>                -LVFE at 6 month and one year assessed by cardiac MRI and TTE<br>                -All cause of death rate during the 12 months follow-up<br>                -Cardiovascular death at 12 months<br>                -Heart Failure at 12 months<br>                -Ventricular tachycardia during the 12 months follow-up<br>                -NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years), or above 1800 pg/mL (patients older than 75)<br>                -50% decrease of the troponin level at discharge compared to admission<br>            ;Timepoint(s) of evaluation of this end point: 4 yers",parent,NULL,Date trial authorised,NA,NA,Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis,NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,NA,NA,NA
EUCTR2018-002470-42-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002470-42,Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study - FluSHED-2,Prevention of influenza infection through immunisation <br>MedDRA version: 20.0Level: LLTClassification code 10016794Term: Flu vaccinationSystem Organ Class: 100000004865;Therapeutic area: Body processes [G] - Immune system processes [G12],<br>Trade Name: Fluenz Tetra<br>Product Name: Fluenz Tetra<br>Pharmaceutical Form: Nasal spray<br>INN or Proposed INN: various influenza strains as per below<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: as above-<br><br>,"An observational study of the nasal influenza vaccine, by measuring how much and what strains of flu virus are seen in the noses of children given the nasal flu vaccine in 2018-19, and comparing this to antibody levels in blood and oral fluid.",EUCTR,10/07/2018,30/08/2018,FALSE,Interventional clinical trial of medicinal product,"Controlled: no<br>Randomised: no<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): noTherapeutic use (Phase IV): yes,30,Imperial College London JRC Office,United Kingdom,NCT03735147,NULL,10/07/2018,30/08/2018,EUCTR2,27-Jul-20,FluSHED-2,Turner,NA,"Paediatric Research Unit, 2nd Floor Cambridge Wing",p.turner@imperial.ac.uk,2033127754,IMPERIAL COLLEGE LONDON,Turner,NA,"Paediatric Research Unit, 2nd Floor Cambridge Wing",p.turner@imperial.ac.uk,2033127754,IMPERIAL COLLEGE LONDON,Not Recruiting,NULL,NIHR,NA,NA,<br>Female: yes<br>Male: yes<br>,Inclusion criteria: <br>1.Children age 6 years to 15 years +364 days of age on enrolment <br>2.Children eligible to receive LAIV in accordance with Green Book advice [https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book]<br>3.Written informed consent given by parent/ guardian and assent from child (both must be in place to proceed).<br><br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: 0<br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range 0<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range 0<br>,"Exclusion criteria: <br>1.Contraindications to LAIV (notwithstanding allergy to egg protein), which include:<br>a.Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue)<br>b.Previous systemic allergic reaction to LAIV<br>c.Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the CI to confirm patient suitability<br>d.Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids*. <br><br>*High-dose steroids is defined as a treatment course for at least one month, equivalent to a dose greater than 20mg prednisolone per day (any age), or for children under 20kg, a dose greater than 1mg/kg/day. <br><br>NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled/low-dose oral systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.<br><br>e.Children / adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.<br>f.Pregnancy (determined by history). Where this cannot be confirmed, a urine pregnancy test will be performed.<br><br>","Main Objective: Technical version:   <br>To measure type-specific vaccine virus shedding in 2018/19 following LAIV administration.<br><br><br>Lay version:   <br>To measure the amount and strains of flu virus in the nose of children who have had the nasal flu vaccine in the week following their vaccination. ;Secondary Objective: Technical version: <br>Quantitative analysis of immunogenicity using a range of indicators (including HI and/or MN, and nasal IgA responses), and to measure the association between type-specific vaccine immunogenicity and virus shedding.<br><br>Lay version: <br>To try to understand if the amount of virus found in the nose can be considered a measure of how much immunity a child has developed following vaccination.;Primary end point(s): To measure type-specific vaccine virus shedding in 2018/19 and how this varies in the 8 days following vaccination.;Timepoint(s) of evaluation of this end point: Daily for 8 days following vaccination","Secondary end point(s): Quantitative analysis of immunogenicity using a range of indicators (including HI and/or MN, and nasal IgA responses), and to measure the association between type-specific vaccine immunogenicity and virus shedding.;Timepoint(s) of evaluation of this end point: Nasal, blood and oral fluid samples collected around 4 weeks (window 3-6 weeks) following vaccination",parent,NULL,Date trial authorised,NA,NA,Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study,NULL,01/01/1900,No results available,No results available,No results available,No results available,NA,NA,NA,NULL,NULL,Approved,Aug 30 2018 12:00AM,NA,NA,NA,NA
EUCTR2017-001239-38-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001239-38,"A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age",Seasonal influenza <br>MedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Product Name: Quadrivalent VLP Influenza Vaccine<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Quadrivalent VLP Influenza Vaccine<br>Other descriptive name: INFLUENZA VACCINE<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 60-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Intramuscular use<br><br>,"A Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age",EUCTR,29/05/2017,23/10/2017,FALSE,Interventional clinical trial of medicinal product,"Controlled: yes<br>Randomised: yes<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: yes<br>Cross over: no<br>Other: yes<br>Other trial design description: Observer blind<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: yes<br>Other: no<br>Number of treatment arms in the trial: 2<br>",Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,10000,Medicago R&D Inc.,United States;Philippines;Canada;Finland;Thailand;Germany;United Kingdom,EUCTR2017-001239-38-FI,NULL,29/05/2017,23/10/2017,EUCTR2,15-Oct-18,CP-PRO-QVLP-012,Daniel Croteau,NA,"1020 route de l’Église, bureau 600",croteaud@medicago.com,+1418658-9393 x378,Medicago R&D Inc,Daniel Croteau,NA,"1020 route de l’Église, bureau 600",croteaud@medicago.com,+1418658-9393 x378,Medicago R&D Inc,Not Recruiting,NULL,Medicago R&D Inc.,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>Subjects must meet all of the following inclusion criteria to be eligible for participation in this<br>study:<br>1. Subjects must be able to read, understand, and sign the informed consent form (ICF); complete study-related procedures; and communicate with the study staff at visits and by phone;<br>2. Subject must have a body mass index (BMI) below 40 kg/m2;<br>3. Subjects are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;<br>4. Male and female subjects must be 18 to 64 (has not yet had his/her 65th birthday) years of age, inclusive, at the Screening/Vaccination visit (Visit 1);<br>5. Subjects must be in good general health prior to study participation, with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments, as assessed by the Principal Investigator or sub-Investigator (there after referred as Investigator) and determined by medical history, physical examination, and vital signs;<br>Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator’s judgment, the condition is unlikely to confound the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination. Based on the Investigator’s judgment, a subject with more recent stabilization of a disease could also be eligible.<br>6. Female subjects must have a negative urine pregnancy test result at the Screening/Vaccination visit (Visit 1);<br>7. Female subjects of childbearing potential must use an effective method of contraception for one month prior to vaccination and agree to continue employing adequate birth control measures for at least 60 days post-vaccination. Moreover, female subjects must have no plan to become pregnant for at least two months post-vaccination. Abstinent subjects should be asked what method(s) they would use should their circumstances change, and subjects without a well-defined plan should be excluded. The following relationship or methods of contraception are considered to be effective:<br>- Hormonal contraceptives (e.g. injectable, topical [patch], or estrogenic vaginal ring);<br>- Intra-uterine device with or without hormonal release;<br>- Male partner using a condom plus spermicide or sterilized partner (at least one year prior to vaccination);<br>- Credible self-reported history of heterosexual abstinence until at least 60 days postvaccination;<br>- Female partner;<br>8. Non-childbearing females are defined as:<br>- Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than one month prior to vaccination); or<br>- Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 10000<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>Subjects who meet any of the following criteria will be excluded from participating in this study:<br>1. Any subject whose medical condition(s) is sufficiently severe that annual influenza vaccination would be routinely recommended in the jurisdiction of recruitment;<br>2. According to the Investigator’s opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. ‘Uncontrolled’ is defined as:<br>- Requiring a new medical or surgical treatment during the three months prior to study vaccine administration unless the criteria outlined in inclusion criterion no. 5 can be met (i.e. the Investigator can justify inclusion based upon the innocuous nature of medical/surgical events and/or treatments);<br>- Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the Investigator.<br>3. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug abuse which, in the Investigator’s opinion, would render the subject unable to provide informed consent or unable to provide valid safety observations and reporting;<br>4. Any autoimmune disease other than hypothyroidism on stable replacement therapy (including, but not limited to rhematoid arthritis, systemic lupus erythematosus, Crohn’s disease, and inflammatory bowel disease) or any confirmed or suspected immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), Hepatitis B or C infection, the presence of lymphoproliferative disease;<br>5. History of chronic pulmonary (including asthma, bronchopulmonary dysplasia, and cystic fibrosis) or cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic (including anemia and hemoglobinopathy), or metabolic disorders (including diabetes mellitus);<br>6. Because this is a placebo-controlled study, any subjects in close contact with individuals considered to be at high risk for developing influenza-related complications (individuals considered at high risk for complications include adults and children who have chronic pulmonary or cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus]);<br>7. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization up to blood sampling on Day 21. Immunization on an emergency basis will be evaluated case-by-case by the Investigator;<br>8. Administration of any adjuvanted or investigational influenza vaccine within one year prior to randomization or planned administration prior to the completion of the study;<br>9. Administration of any ‘standard’, non-adjuvanted influenza vaccine (e.g. live attenuated trivalent/quadrivalent inactivated influenza vaccine or split trivalent/quadrivalent inactivated influenza vaccine administered by intranasal, intradermal, or IM route) within six months prior to randomization and up to completion of the study;<br>10. Use of any investigational or non-registered product within 30 days or five half-lives, whichever is longer, prior to randomization or planned use during the study period. Subjects may not participate in any other investigational or marketed drug st","Main Objective: - To evaluate the efficacy, relative to placebo, of a single dose of the Quadrivalent VLP Influenza Vaccine given at a dose of 30 µg/strain, against laboratory-confirmed influenza caused by vaccine-matched strains.;Secondary Objective: Efficacy:<br>To evaluate the efficacy, relative to placebo, of a single dose of the Quadrivalent VLP Influenza Vaccine given at a dose of 30 µg/strain;<br>- Against any laboratory-confirmed influenza strain;<br>- Against laboratory-confirmed protocol-defined influenza-like illness (ILI) caused by vaccine-matched strains.<br>- As measured by the incidence of subjects presenting with symptoms of protocol-defined ILI, regardless of laboratory results.<br>Safety:<br>- To assess the safety and tolerability, relative to placebo, of a single dose of the Quadrivalent VLP Influenza Vaccine given at a dose of 30 µg/strain.<br>Immunogenicity:<br>- To assess, in a subset of 400 subjects, the immunogenicity of a single dose of Quadrivalent VLP Influenza Vaccine given at a dose of 30 µg/strain, as measured by hemagglutination inhibition (HI) assay, microneutralization (MN) assay, and single radial hemolysis (SRH) assay against homologous and heterologous (HI only) influenza strains.;Primary end point(s): Efficacy:<br>- Occurrences of laboratory-confirmed influenza illnesses (= 14 days post-vaccination) caused by influenza viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccine formulation.;Timepoint(s) of evaluation of this end point: = 14 days post-vaccination","Timepoint(s) of evaluation of this end point: Various times as detailed in the protocol;Secondary end point(s): Efficacy:<br>- Occurrences of laboratory-confirmed influenza illnesses (= 14 days post-vaccination) caused by any influenza viral types/subtypes (matched, mismatched, and un-typed);<br>- Occurrences of laboratory-confirmed influenza (according to protocol defined ILI) illnesses (= 14 days post-vaccination) caused by influenza viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccine formulation;<br>- Occurrences of protocol-defined ILI = 14 days postvaccination (confirmed or not).<br>Safety:<br>- Percentage, intensity, and relationship to vaccination of immediate complaints (15 minutes post-vaccination);<br>- Percentage, intensity, and relationship to vaccination of solicited local and systemic signs and symptoms (for seven days following study vaccine administration);<br>- Percentage, intensity, and relationship of TEAEs for 21 days following study vaccine administration;<br>- Occurrences of deaths, SAEs, AEs leading to withdrawal, and NOCDs up to the end of the surveillance period.<br>Immunogenicity (subset of subjects):<br>- HI antibody response induced by the Quadrivalent VLP Influenza Vaccine against the homologous and heterologous influenza strains on Days 0 and 21 will be assessed in a subset of 400 subjects (300 who received the VLP vaccine and 100 who received the placebo). HI antibody titers will be analyzed using the following parameters: geometric mean titers (GMT), seroconversion (SC) rate, seroprotection (SP) rate, and geometric mean fold rise (GMFR);<br>- MN antibody response induced by the Quadrivalent VLP Influenza Vaccine against the homologous influenza strains on Days 0 and 21, in a subset of subjects, will be analyzed using the following parameters: GMT, SC rate, and GMFR;<br>- SRH antibody response induced by the Quadrivalent VLP Influenza Vaccine against the homologous strains on Days 0 and 21, will be analysed using the following parameters: geometric mean area (GMA), SC rate, SP rate, and GMFR.",parent,NULL,Date trial authorised,NA,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
EUCTR2006-005558-63-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-005558-63,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",Influenza <br>MedDRA version: 18.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02],<br>Trade Name: FLUAD<br>Product Name: FLUAD<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>Trade Name: Agrippal<br>Product Name: Agrippal<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br><br>,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases",EUCTR,24/03/2016,28/11/2006,FALSE,Interventional clinical trial of medicinal product,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: noParallel group: noCross over: noOther: yesOther trial design description: observer-blindIf controlled, specify comparator, Other Medicinial Product: yesPlacebo: noOther: noNumber of treatment arms in the trial: 2",NULL,NA,Novartis Vaccines and Diagnostics S.r.l.,Italy,NCT00519064,1,24/03/2016,28/11/2006,EUCTR2,11-Apr-16,V70P3,Adele Longanella,NA,"Via Fiorentina, 1",adele.longanella@novartis.com,NA,Novartis Vaccines and Diagnostics S.r.l.,Adele Longanella,NA,"Via Fiorentina, 1",adele.longanella@novartis.com,NA,Novartis Vaccines and Diagnostics S.r.l.,Not Recruiting,NULL,Novartis Vaccines and Diagnostics S.r.l.,NA,NA,<br>Female: yes<br>Male: yes<br>,"Inclusion criteria: <br>1. 18 to 60 years of age adult volunteers, mentally competent, willing and able to give written informed consent prior to study entry;<br>2. able to comply with all the study requirements;<br>3. suffering from at least one of these chronic diseases:<br>• moderate to severe hypertension<br>• moderate to severe congestive heart failure<br>• COPD or moderate to severe asthma<br>• moderate to severe hepatic or renal insufficiency<br>• arteriosclerotic disease or insulin dependent diabetes mellitus<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 330<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>1. hypersensitivity to ovalbumin, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine;<br>2. history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;<br>3. known or suspected (or have a high risk of developing) impairment/ alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:<br>• receipt of immunosuppressive therapy (any parenteral or oral cortical steroid or cancer chemotherapy/radiotherapy) within 60 days prior to enrollment and for the full length of the study;<br>• receipt of immunostimulants;<br>• receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within 3 months prior to enrollment and for the full length of the study;<br>• suspected or known HIV infection or HIV-related disease;<br>4. known or suspected history of drug or alcohol abuse;<br>5. women who were pregnant, or women able to bear children but not willing to practice acceptable contraception for the first 3 weeks of the duration of the trial;<br>6. within the 12 months prior to enrollment, the individual had:<br>• received more than one injection of influenza vaccine;<br>7. within the 6 months prior to enrollment, the individual had:<br>• laboratory confirmed influenza disease;<br>• received influenza vaccine;<br>8. within the 4 weeks prior to enrollment the individual had received:<br>• another vaccine;<br>• any investigational agent;<br>9. within the 7 days prior to enrollment, the individual had experienced:<br>• any acute disease;<br>• infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis was acceptable);<br>10. had experienced an acute exacerbation of a COPD within the 14 days prior to enrollment;<br>11. within the 3 days prior to enrollment, individuals had experienced:<br>• fever (i.e., body temperature = 38°C);<br>12. were taking part in another clinical study;<br>13. had any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.<br>","Main Objective: Immunogenicity Objective<br>To compare the immunogenicity of a single intramuscular (IM) injection of FLUAD™ (FLUAD) vs. inactivated subunit virus influenza vaccine, with regards to A/H3N2 antigen, when administered to adult subjects with underlying chronic disease(s), as measured by Hemagglutination Inhibition (HI) test at day 22.<br>Safety Objective<br>To evaluate the safety of a single IM injection of the two influenza vaccines, when administered to adult subjects with underlying chronic disease(s).;Secondary Objective: • To compare the immunogenicity of a single IM injection of FLUAD vs. inactivated subunit virus influenza vaccine, with regards to B antigen, when administered to adult subjects with underlying chronic disease(s), as measured by HI test at day 22.<br>• To evaluate the immunogenicity of a single IM injection of FLUAD vs. inactivated subunit virus influenza vaccine, with regards to A/H1N1 antigen, when administered to adult subjects with underlying chronic disease(s), as measured by HI test at day 22. ;Primary end point(s): Immunogenicity<br>The immunogenicity of the two vaccines was evaluated considering the following measurements according to the CPMP/BWP/214/96 guideline:<br>• percentage of seroconversions or significant increase (seroconversion rate) in HI antibody titer<br>• mean geometric increase (i.e., GMR) in HI antibody and ratio of postvaccination GMTs between vaccines<br>• percentage of subjects achieving an HI titer =40 (seroprotection)<br>Safety<br>Number of subjects with reported local and systemic reactions as well as the number of subjects with reported SAEs and/or AEs per vaccination group.<br>Local reactions included: ecchymosis, erythema, induration, swelling, and pain at injection site.<br>Systemic reactions included: chills, malaise, myalgia, arthralgia, headache, sweating, fatigue and fever (derived from axillary temperature =38°C).;Timepoint(s) of evaluation of this end point: • Immunogenicity 21 days after vaccination<br>• AEs will be assessed for 6 days post the day of vaccination<br>• All adverse events (AEs) necessitating a physician’s visit or consultation and/or leading to premature study discontinuation will be collected for 3 weeks following vaccination.<br>• All serious adverse events (SAEs) will be collected during a 6 months follow-up, i.e., until day 181 (window: day 177- day 185).",Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable,child,NULL,Date trial authorised,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
IRCT20130812014333N127,http://en.irct.ir/trial/39381,Comparison of the effect of epinephrine in combination with methylprednisolone on neurological complications and the need for vasopressor after resuscitation in patients with cardiopulmonary arrest,Cardiopulmonary arrest. <br>Cardiac arrest,"Intervention 1: The intervention group, in addition to receiving one mg of epinephrine, in each respiratory resuscitation cycle, every 3 to 5 minutes later will received125 mg intravenous  methylprednisolone . Intervention 2: The intervention group, in addition to receiving one mg of epinephrine, in each respiratory resuscitation cycle, every 3 to 5 minutes later will  received 125 mg intravenous normal saline as placebo  .",Comparison of the effect of epinephrine in combination with methylprednisolone on neurological complications  in patients with cardiopulmonary arrest,IRCT,27/07/2019,15/05/2019,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomly Individually by random number table via code receipt, Blinding description: In this study, participants and researchers are unaware and will be keep blinded to the allocation of study groups.",3,342,Kermanshah University of Medical Sciences,Iran (Islamic Republic of),NA,1,27/07/2019,15/05/2019,IRCT20,07-Oct-19,NULL,Nasrin Bahrami,NA,"Emam Reza Hospital, Parastar Blvd",Rejimdarmani@yahoo.com,+98 83 3427 6330,Kermanshah University of Medical Sciences,Dr. Hooman Rafee Surori,NA,"Emam Reza Hospital, Parastar Boulevard",Hooman_rafiee@yahoo.com,+98 83 3427 6330,Kermanshah University of Medical Sciences,Complete,NULL,Kermanshah University of Medical Sciences,18 years,no limit,Both,Inclusion criteria: Above 18 years old<br>No previous  neurological disorders<br>Cardiopulmonary arrest,Exclusion criteria: Patients who do not have the possibility of injections during recovery due to the lack of peripheral blood vessels<br>Patients with cardiopulmonary arrest outside the hospital,Neurological complications. Timepoint: 24 hours after resuscitation. Method of measurement: Based on a doctor's Checking out and according to Cerebral performance category.;Hypertension. Timepoint: 24 hours after resuscitation. Method of measurement: Using Digital Blood Pressure.;Rhythm during resuscitation. Timepoint: 24 hours after resuscitation. Method of measurement: Using a heart rhythm monitoring device.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,"What will be shared: The main outcomes of the study will be shared.  When: 3months  To whom: If requested, results will be made available to other academic researchers  Conditions: Sharing scientific data is available to researchers  Where to obtain: To receive the documentation, email send for update manager Email: Rejimdarmani@yahoo.com  How to obtain: In a 15-day period, the documents will be sent e-mail  Comments:",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of Kermanshah University of Medical Sciences,NA,NA
IRCT20100512003915N20,http://en.irct.ir/trial/31038,Effect of intratracheal budesonide with surfactant in  management of respiratory distress syndrome for prevention of bronchopulmonary dysplasia in preterm infants,Respiratory distress syndrome of newborn. <br>Respiratory distress syndrome of newborn,"Intervention 1: Intervention group: neonates receive budesonide 0.25 mg/kg in addition to intratracheal surfactant. Intervention 2: Control group: neonates receive intratracheal surfactant 2.5 cc/kg (crusurf? Chessia, Italy).",Administration of budesonide with surfactant and prevention of bronchopulmonary dysplasia,IRCT,07/07/2018,16/04/2018,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: newborn infants who met study criteria randomly  allocate in two groups (surfactant and surfactant with budesonide) based on generated random number list, Blinding description: infants don't know the used drugs. clinical manager administer prepared drug according patients code. outcome is recorded by a nurse who is not aware administered drugs . researcher is blind about patients groups and records data.",3,128,Tabriz University of Medical Sciences,Iran (Islamic Republic of),NA,NULL,07/07/2018,16/04/2018,IRCT20,11-Sep-18,NULL,Manizheh Mostafa Gharehbaghi,NA,South Artesh St.,gharehbaghimm@yahoo.com,+98 41 3553 9161,Tabriz University of Medical Sciences,Manizheh Gharehbaghi,NA,South Artesh St.,gharehbaghimm@yahoo.com,+98 41 3553 9161,Tabriz University of Medical Sciences,Complete,NULL,Tabriz University of Medical Sciences,1 day,3 days,Both,Inclusion criteria: gestation age 26-30 weeks<br>birth weight less than 1250 grams<br>respiratory distress syndrome,"Exclusion criteria: 5 minute Apgar score less than 4<br>congenital heart disease except patent ductus arteriosus and atrial septal defect<br>necrotizing entrocololitis<br>major congenital anomalies, esophageal atresia, diaphragmatic hernia<br>chromosomal anomalies<br>shock",Reintubation in first 3 days after extubation. Timepoint: We evaluate the neonate immediately after intervention and daily till 3 days after intervention and extubation. Method of measurement: tracheal reintubation.;Need to second doses of surfactant. Timepoint: Daily till day 3 of birth and 3 days after intervention. Method of measurement: surfactant administration.;Bronchopulmonary dysplasia. Timepoint: Daily till 28 days after birth and day 28 after intervention. Method of measurement: need to supplemental oxygen.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,No - There is not a plan to make this available,Justification or reason for not sharing IPD is There is no further information,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethic Committee of Tabriz University of Medical Sciences,NA,NA
IRCT20160307026950N12,http://en.irct.ir/trial/39198,"Comparison of the effects of midazolam and dexmedetomidine on sedation levels, hemodynamics and complications in patients under brain stereotaxic surgery","Condition 1: respiratory apnea. Condition 2: systolic and diastolic blood pressure. Condition 3: heart rate. Condition 4: drug sedation level. Condition 5: bleeding. Condition 6: oxygen saturation level. <br>Apnea, not elsewhere classified <br>Hypotension due to drugs <br>Bradycardia, unspecified <br>Sedatives, hypnotics and antianxiety drugs <br>Haemorrhage and haematoma complicating a procedure, not elsewhere classified <br>Asphyxia and hypoxemia;R06.81;I95.2;R00.1;T81.0;R09.0","Intervention 1: Intervention group A: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and standard monitoring devices including pulsoximetry, capnography, and electrocardiogram are attached. Patients in this group received midazolam at a dose of 1 mg/kg IV bolus. Intervention 2: Intervention group B: Initially, personal consent is obtained from the patients. Then the patient is placed on the operating bed and standard monitoring devices including pulsoximetry, capnography, and electrocardiogram are attached. The second group received intravenous dose of 1 mcg/kg/min of dexmedetomidine.",The effects of midazolam and dexmedetomidine in patients under stereotaxic surgery,IRCT,06/06/2019,23/09/2017,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: patients randomly assigned to two different groups A and B with Random Allocation computer software, Blinding description: patients and anesthetic technician did not know about administering drugs.",3,64,Esfahan University of Medical Sciences,Iran (Islamic Republic of),NA,1,06/06/2019,23/09/2017,IRCT20,26-Aug-19,NULL,mehdi khademi,NA,shariati street,mehdi.kh199271@gmail.com,+98 66 3330 9832,Esfahan University of Medical Sciences,Dr. Behzad Nazemroaya,NA,"Department of Anesthesiology, AL-Zahra Hospital",behzad_nazem@med.mui.ac.ir,+98 31 3620 2020,Esfahan University of Medical Sciences,Complete,NULL,Esfahan University of Medical Sciences,18 years,60 years,Both,Inclusion criteria: patients candidates brain stereotaxic surgery<br>age between 18 and 60<br>No history of allergic reaction to both midazolam and dexmedetomidin,Exclusion criteria: any change in anesthesia or surgery plan due to any complication<br>patient expiration during surgery,"Systolic and diastolic blood pressure. Timepoint: preoperative periods, 1, 3, 5, 10 and 20 minutes during surgery. Method of measurement: Non-invasive barometer.;Heart rate. Timepoint: preoperative periods, 1, 3, 5, 10 and 20 minutes during surgery. Method of measurement: pulse oximetry device.;Respiratory rate. Timepoint: preoperative periods, 1, 3, 5, 10 and 20 minutes during surgery. Method of measurement: Count in minute.;Drug sedation level. Timepoint: after end of surgery. Method of measurement: Ramsay sedation scale.;Patient satisfaction. Timepoint: after end of surgery. Method of measurement: Visual Analogue Scale.;Surgeon satisfaction. Timepoint: after end of surgery. Method of measurement: Iowa Satisfaction with Anesthesia Scale.;Recovery time. Timepoint: From the moment of finishing surgery to full recovery time. Method of measurement: In minute using a chronometer.;Bleeding. Timepoint: after end of surgery. Method of measurement: Bleeding above 50 cc.;Low blood oxygen saturation. Timepoint: during surgery. Method of measurement: The drop in oxygen saturation below 90% by pulse oximeter.;Respiratory apnea. Timepoint: during surgery. Method of measurement: Respiratory arrest for more than 8 seconds measured by chronometer.",NULL,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is There is no further information,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of Isfahan University of Medical Sciences,NA,NA
IRCT20090808002306N5,http://en.irct.ir/trial/41645,Comparative clinical trial of an evidence based and clinical pharmacist-recommended treatment protocol for the antimicrobial therapy of aspiration pneumonia in opioid overdosed patients with the current treatment practice in the poisonings referral University hospital of Khorshid,"Aspiration pneumonia. <br>Lobar pneumonia, unspecified organism;J18.1",Intervention 1: Control group:Patients receiving ceftriaxone + clindamycin. Intervention 2: Case group:Patients receiving  Ampicillin/Sulbactam.,The efficacy of recommended treatment protocol for the antimicrobial therapy of aspiration pneumonia in opioid overdosed patients,IRCT,30/11/2019,09/11/2019,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria will be randomly assigned to two groups of case and control using Research randomizer software.",3,80,Esfahan University of Medical Sciences,Iran (Islamic Republic of),NA,1,30/11/2019,09/11/2019,IRCT20,17-Dec-19,NULL,Seyed mohammadreza tabatabaei,NA,"Isfahan university of Medical science,Hezarjerib Ave,Isfahan",mohamadtabatabaei1382@gmail.com,...,Esfahan University of Medical Sciences,Seyed Mohammadreza Tabatabaei,NA,"Isfahan university of Medical science,Hezarjerib Ave,Isfahan",mohamadtabatabaei1382@gmail.com,...,Esfahan University of Medical Sciences,Recruiting,NULL,Esfahan University of Medical Sciences,18 years,no limit,Both,Inclusion criteria: Patients older than 18 years old<br>Opioid Intoxication<br>Having aspiration pneumonia,Exclusion criteria: treatment with antibiotics and immunosuppressive drugs within two weeks before hospitalization<br>Patients with hospital-acquired aspiration pneumonia<br>Patients with known allergic drug used  in this study<br>Patients with lung abscess or empyema<br>weman with lung pregnancy or breastfeeding,Mortality. Timepoint: The Seventh day intervention. Method of measurement: Observation.;Relative Improvement. Timepoint: The third Day of Intervention. Method of measurement: Clinical and laboratory Monitoring.;Complete Improvement. Timepoint: The third Day of Intervention. Method of measurement: Clinical and laboratory Monitoring.,NULL,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is it is not necessary,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Iran National Committee for Ethics in Biomedical Research,NA,NA
IRCT2016052828134N1,http://en.irct.ir/trial/22888,Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,Condition 1: Pneumonia. Condition 2: dental plaque. Condition 3: dental plaque. <br>Influenza and pneumonia <br>Deposits [accretions] on teeth <br>Caries of dentine;Influenza and pneumonia;Deposits [accretions] on teeth;Caries of dentine,"Intervention 1: intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days. Intervention 2: Control group: Using 15 ml of normal saline, every 12 hours, for 4 days.;Treatment - Drugs;Treatment - Drugs;intervention group: Using 15 ml of Aloe Vera mouthwash, every 12 hours, for 4 days.;Control group: Using 15 ml of normal saline, every 12 hours, for 4 days.",Effects of Botanical mouthwash of Aloe Vera  on ventilator associated pneumonia of patients having Endotracheal tube hospitalized in the Intensive Care Unit,IRCT,21/06/2016,30/01/2016,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention.",2,79,Research Deputy of Shahid Beheshti university of medical sciences,Iran (Islamic Republic of),NA,NULL,21/06/2016,30/01/2016,IRCT20,22-Feb-18,NULL,Nasrin Mirbastegan,NA,"Opposite to Rajaee Heart Hospital, Cross of Valiasr and Neiaiesh Highway,Valiasr street",mirbastegan.nasrin@gmail.com,+98 21 8865 5366,Shahid Beheshti university of medical sciences,Mehryar Yoldashkhan,NA,"School of Nursing and Midwifery, Opposite to Rajaee Heart Hospital, Cross of Valiasr and Neiaiesh Highway,Valiasr street",yoldashkhan@yahoo.com,+98 21 8865 5366,School of  Nursing and Midwifery Shahid Beheshti university of medical sciences,Complete,NULL,Research Deputy of Shahid Beheshti university of medical sciences,18 years,65 years,Both,Inclusion criteria: Inclusion Criteria: 18-65 years old; having endotracheal tube through the mouth; admitted to ICU less than 12 hours; having natural teeth;don't have history of use antibiotic two weeks ago; don't have pregnancy and no history of allergy to herbal compounds;don't have HIV and use of steroid drugs; not have an injury in the mouth and around it;not have pneumonia;don't have history of use antibiotic on two weeks ago;don't have leukopenia and noutropenia and serum albumin <2/5 mg/dl;<br> Exclusion criteria: to discharge from the ICU or die before completing the study; inclination to continue the study;>6 score of clinical pulmonary infection score on 12 hours first time admission,Exclusion criteria:,Pneumonia. Timepoint: Immediately before intervention and four days later. Method of measurement: Modified clinical pulmonary infection score.,Dental plaque index. Timepoint: Immediately before intervention and four days later. Method of measurement: o'leary plaque index.,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics Committee of Shahid Beheshti university of medical sciences,NA,NA
IRCT20130917014693N9,http://en.irct.ir/trial/40932,Evaluation of a new protocol for controlling blood glucose and comparing it with old strategies for controlling blood glucose in patients who hospitalized in infectious ward,Condition 1: Diabetes. Condition 2: Pneumonia. Condition 3: cellulitis. Condition 4: Diabetic foot infection. <br>Diabetes mellitus due to underlying condition <br>Streptococcus pneumoniae as the cause of diseases classified elsewhere <br>Cellulitis of toe <br>Personal history of diabetic foot ulcer;B95.3;L03.03;Z86.31,"Intervention 1: Intervention group: In this group the needed daily insulin calculate. This dose includes short acting insulin (Regular, Exir Company) and long action insulin (NPH, Exir Company). The patients will receive this combined dose as twice day by subcutaneous injection. This dose will be administered every morning and every evening. This protocol will be continued in all of hospitalization duration. Intervention 2: Control group: In this group, the blood glucose level of patients will be determined before each essential meals by glucometer. Then, different doses of short acting insulin (Regular, Exir Company) will be administered by subcutaneous injection. This protocol will be continued in all of hospitalization duration.",Evaluation of a new protocol for controlling blood glucose in hospitalized patients,IRCT,15/08/2019,04/04/2017,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",3,108,Shahid Beheshti University of Medical Sciences,Iran (Islamic Republic of),NA,1,15/08/2019,04/04/2017,IRCT20,07-Oct-19,NULL,Zahra Sahraei,NA,"Niayesh Highway, Valiasr Ave, Tehran, Iran",zahra.sahraei@yahoo.com,+98 21 8820 0118,Shahid Beheshti University of Medical Sciences,Zahra Sahraei,NA,"Vali-e Asr Ave.,Niayesh junction",zahra.sahraei@yahoo.com,+98 21 8887 3704,Shahid Beheshti University of Medical Sciences,Complete,NULL,Shahid Beheshti University of Medical Sciences,18 years,65 years,Both,"Inclusion criteria: Patients with diabetes mellitus<br>Age more than 18 years ago<br>Patients under subcutaneous insulin regimen<br>Patients who hospitalized in infectious diseases ward due to pneumonia, cellulitis, and diabetic foot infection",Exclusion criteria: Pregnant women<br>Surgical patients<br>Patients on intravenous insulin<br>Patients with end stage renal disease<br>Patients on total parental nutrition<br>Patients who did not sign the patient informed consent form,Blood glucose level. Timepoint: Every six hours. Method of measurement: Glucometer.,Fever. Timepoint: Every six hours. Method of measurement: Mercury Therommeter.;Durration of hospitalization. Timepoint: At discharged. Method of measurement: Patient record.,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Yes - There is a plan to make this available,"What will be shared: Primary outcome data after making unrecognizable will be released.  When: Six months after publishing the results primary outcome data will be released.  To whom: Researchers after allowance of corresponding author could have the permission to have the data.  Conditions: Performing any analysis will be allowed only with the permission of corresponding author.  Where to obtain: Corresponding researcher  How to obtain: After requesting to reach data, corresponding author will check the allowance, then the researcher will be informed about it.  Comments:",NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Research Ethics Committee of School of Pharmacy and Nursing & Midwifery- Shahid Beheshti University,NA,NA
IRCT20180826040877N1,http://en.irct.ir/trial/33535,Evaluation of the effect of intratracheal Salbutamol in addition to Surfactant on clinical course of neonates with respiratory distress syndrome with gestational age less than 34 weeks and 7 days and more than 1000 g weight,Respiratory distress syndrome. <br>Respiratory distress syndrome of newborn,"Intervention 1: Intervention group: Neonates in intervention group are first treated with Surfactant (2.5ml/kg) and 8 hours after initial dose, subsequent dose (1.25 ml/kg) is received. After receiving Surfactant, neonates in intervention group are treated with intratracheal Salbutamol (0.1 mg/kg). Intervention 2: Control group: Neonates in control group are first treated with Surfactant (2.5ml/kg) and 8 hours after initial dose, subsequent dose (1.25 ml/kg) is received. After receiving Surfactant, neonates in control group are received nothing.",Salbutamol and neonatal respiratory distress syndrome,IRCT,15/01/2019,21/03/2017,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",N/A,84,Esfahan University of Medical Sciences,Iran (Islamic Republic of),NA,1,15/01/2019,21/03/2017,IRCT20,29-Jan-19,NULL,Razieh Goudarzi,NA,"Isfahan University of Mediacal Sciene, Hezar Jrib street, Isfahan City",dr.goudarzi1984@gmail.com,+98 917 368 2967,Esfahan University of Medical Sciences,Zohreh Badiei,NA,"Osfahan University of Mediacal Science, Hezar Jrib Street, Isfahan City",Badeie@med.mui.ac.ir,+98 31 3668 0048,Esfahan University of Medical Sciences,Complete,NULL,Esfahan University of Medical Sciences,no limit,245 days,Both,Inclusion criteria: Age less tan 34 weeks and 7 days<br>Weight more than 1000 grams<br>Documented respiratory distress syndrome based on clinical findings and chest- X- Ray,Exclusion criteria: Birth trauma<br>Major congenital anomalies<br>Perinatal asphyxia<br>Five minutes apgar score <=3<br>Severe metabolic acidosis at birth<br>Positive blood culture<br>Parent's unwillingness,INSURE Failure. Timepoint: During hospitalization. Method of measurement: Clinical examination.;Duration of N-CPAP need. Timepoint: During hospitalization. Method of measurement: observation.;Duration of oxygen need. Timepoint: During hospitalization. Method of measurement: observation.;Mortality. Timepoint: During hospitalization. Method of measurement: observation.;Duration of hospitalization. Timepoint: During hospitalization. Method of measurement: Extract from patient's profile.,Pneumothorax. Timepoint: During hospitalization. Method of measurement: Chest X ray.,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is The decision is made at the end of study.,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics connittee of Isfahan University of Medical Science,NA,NA
IRCT2016040316473N5,http://en.irct.ir/trial/15412,Comparing the effect of albumin and crystalloid serum as resuscitation fluid in survival of patients with severe sepsis shock,Septic shock. <br>Septic shock;Septic shock,Intervention 1: In intervention group: fluid resuscitation with crystalloid serum plus 100 cc albumin 20% per 1 liter of crystalloid serum. Intervention 2: In control group: fluid resuscitation only with crystalloid serum.;Treatment - Drugs;Treatment - Drugs;In intervention group: fluid resuscitation with crystalloid serum plus 100 cc albumin 20% per 1 liter of crystalloid serum.;In control group: fluid resuscitation only with crystalloid serum.,Comparing the effect of albumin and crystalloid serum as resuscitation fluid in survival of patients with severe sepsis shock,IRCT,06/07/2016,04/06/2016,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.",3,20,"Vice chancellor for research, Tabriz University Of Medical Sciences.",Iran (Islamic Republic of),NA,NULL,06/07/2016,04/06/2016,IRCT20,22-Feb-18,NULL,Dr Farzad Kakaei,NA,"Faculty of Medicine, Tabriz University Of Medical Sciences, Daneshgah Street, Tabriz.",Fkakaei@tbzmed.ac.ir,+98 41 3334 1317,Tabriz University of Medical Sciences.,Dr. Farzad Kakaei,NA,"Department of Surgery, Imam Reza Hospital, Daneshgah Street, Tabriz.",Fkakaei@tbzmed.ac.ir,+98 41 3334 1317,"Department Of Surgery, Tabriz University of Medical Sciences.",Complete,NULL,"Vice chancellor for research, Tabriz University Of Medical Sciences.",12 years,75 years,Both,"Inclusion criteria: Inclusion criteria: age between 12 to 75 years old; existence of at least two symptoms of  SIRS syndrome (body temperature above 38 or below 36 ° C.; respiratory rate above 20 or PCO2 less than 32 or need for mechanical ventilation; heart rate more than 90, leukocytosis above 12,000 or leukopenia less than 4000 or band cells in peripheral blood smear); existence of a focal infection based on positive culture or existence of an obvious infected area such as peritonitis or pneumonia; need to resuscitation with fluid (tachycardia; systolic blood pressure less than 100 mm Hg or mean arterial pressure less than 75 mm Hg; urine volume less than 0.5 cc/kg/hr; need for vasopressor to maintain blood pressure; central venous pressure (CVP) less than 10 mm Hg). <br>Exclusion criteria: brain death patients; patients undergoing plasmapheresis; contraindications of albumin infusion; heart failure or pulmonary failure or renal failure; transplant patients; patients with burns; heart surgery at 3 recent months.",Exclusion criteria:,Survival of patients. Timepoint: Daily for 28 days. Method of measurement: clinical examination.,Renal failure. Timepoint: Daily for 28 days. Method of measurement: Creatinine level.,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of Tabriz University of Medical Sciences,NA,NA
IRCT20181109041596N1,http://en.irct.ir/trial/35097,"Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION) according to evaluations of visual acuity and VEP tests as main outcomes, in comparison between drug and placebo groups.","AION; Anterior ischemic optic neuropathy: is a condition in which the optic nerve is affected by ischemia at its anterior section (intraocular), AION has two types: arteritic and non arteritic types. arteritic type dominantly results from giant cell arteritis. The etiologies suggested for non arteritic type contains: diabetes mellitus, hypertension and obstructive sleep apnea. This research spends to non arteritic type of disease..","Intervention 1: Intervention group: receivers of fluoxetine antidepressant, 20 mg daily. Intervention 2: Control group: Receivers of placebo of fluoxetine that are resemble exactly in appearance features to fluoxetine.",Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION),IRCT,07/01/2019,22/12/2018,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Other, Purpose: Treatment, Randomization description: In order to randomize allocation of patients in each group of study, we'll use the permuted block randomization method by means of blocks with 4 in size. According to the number of patients in each group of study (100 patients in each group), 25 blocks of four by means of online website  (www.sealedenvelope.com) will produce. For concealment, during randomization we'll use specific codes written on drug or placebo boxes which have been produced by computer. Each patient who enters the study will receive a box of drug or placebo according to the, Blinding description: During this study, participant will not be aware about if he receiving the drug or placebo because the shape and other features of boxes of both drugs and placebos are the same. The interviewer and investigator also will not be aware of which patients have received drug or place",3,100,Iran University of Medical Sciences,Iran (Islamic Republic of),NA,1,07/01/2019,22/12/2018,IRCT20,29-Jan-19,NULL,Mohammad Hussein Abbasi,NA,Faculty of medicine  iran university of medical science  hemmat highway tehran,m.h.abbasi9550@gmail.com,+98 21 2221 8220,Iran University of Medical Sciences,Mohammad Hussein Abbasi,NA,"Faculty of medicine, Iran university of medical science, Hemmat highway, Tehran",m.h.abbasi9550@gmail.com,+98 21 2221 8220,Iran University of Medical Sciences,Recruiting,NULL,Eye research center of Rasool Akram hospital - Iran university of medical science,18 years,no limit,Both,Inclusion criteria: Iranian patients<br>Age over 18 years old<br>Patients with diagnosis of AION; non-arteritic type,"Exclusion criteria: Pregnancy before or during study<br>Past medical history of cataract, glaucoma ( open or close angle ) congenital eye disease such as cloboma and involvement with disease effecting the central visual field of patient<br>Patients with past medication history of using fluoxetine or other psychological medications including antidepressants<br>Patients suffering from psychological disease<br>Patients who use medications including :arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine<br>Patients diagnosed with immunologic and collagen vascular disease<br>Patients with symptoms of or diagnosed with giant cell arteritis and positive CRP more than 3+ or ESR more than 40<br>Trauma or surgery history of eyes<br>Duration between involvement and interview more than 3 weeks<br>Patients without compliance of using fluoxetine or disagrement of patient to continue accompanying the study<br>Involvement by glaucoma<br>Involvement by cataract<br>Change in depression questionnaire score lower than 1 score in comparison to first and forth visit ( means the poor compliance of patient that has not used fluoxetine<br>Death of patient",1)Visual acuity: visual acuity of each patient will measure by snelene chart.                                                                                                                  2)Result of VEP test: both time( latency) and voltage parameters of VEP test will measure. Timepoint: 1)Visual acuity: in first visit and 6th month after initiation of treatment           2)VEP: in first visit and 6th month after initiation of treatment. Method of measurement: 1)Visual acuity: snelene chart                                                                             2)VEP test by means of VEP device.,"1)NLR: neutrophil to lymphocyte ratio                                                                 2)OC: thickness of retina                                                                                3)Perimetry: percent of scotoma in visual field                                                                            4)Depression score                                                                                                    5)demographic informations ( age, gender, profession & etc. ). Timepoint: 1)NLR: In first visit and 6th month after initiation of treatment                                                               2)OCT: In first visit and 6th month after initiation of treatment                                                                                3)Perimetry: In first visit and 6th month after initiation of treatment                                                                             4)Depression score: In first visit and 6th month after initiation of treatment                                                                                                                            5)Demographic information ( age, gender, profession & etc.): at first visit. Method of measurement: 1)NLR: CBC diff                                                                                                                             2)OCT: OCT device                                                                                                3)Perimetry: digital perimetry device                                                                         4)Depression score: DSM 5 questionnaire                                                                           5)Demographic information ( age, gender, profession & etc. ):  by means of personal information and epidemiology questionnaires.",NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Undecided - It is not yet known if there will be a plan to make this available,Justification or reason for indecision in sharing IPD is there is no further information,NULL,NULL,Approved,Jan  1 1900 12:00AM,NA,Ethics committee of medicine faculty of Iran university of medical science,NA,NA
ISRCTN56992547,http://isrctn.com/ISRCTN56992547,Efficacy of Dexmedetomine versus Ketofol for sedation of postoperative mechanically ventilated patients with obstructive sleep apnea,Obstructive sleep apnea <br>Respiratory <br>Obstructive sleep apnea,Patients are randomised into one of two groups using sealed closed opaque envelops.<br><br>Group 1: Patients receive a loading dose infusion of Dexmedetomine 1 ug/kg over 10 minutes followed by maintenance infusion of 0.5 ug/kg/h.<br><br>Group 2: Patients receive ketofol in an initial bolus dose 500 ug/kg of ketamine/propofol 1:1 followed by maintenance dose of 10 ug/kg/min.<br><br>Infusion starts for participants in both groups after admission to SICU for short term sedation of less than 12 hours. All participants are followed up until discharge from the SICU.,Efficacy of Dexmedetomine versus Ketofol for sedation of postoperative mechanically ventilated patients with obstructive sleep apnea,ISRCTN,12/04/2017,10/05/2016,FALSE,Interventional,Randomised parallel trial (Treatment),Not Applicable,24,Beni Suef University,Egypt,NA,1,12/04/2017,10/05/2016,ISRCTN,08-May-17,N/A,NA,NA,NA,NA,NA,NA,Hatem,Elmoutaz,Beni Suef UniversityFaculty of MedicineQism Bani Sweif,form@med.bsu.edu.eg,+20 100 171 6514,NA,Completed,NULL,Investigator initiated and funded,NA,NA,Both,Inclusion criteria: 1. Aged 18-50 years <br>2. Obstructive sleep apnea <br>3. Require mechanical ventilation postoperatively,"Exclusion criteria: 1. Prolonged sedation and mechanical ventilation<br>2. Epileptic patient<br>3. Patients with known allergy to the studied drugs<br>4. Pregnancy<br>5. Severe hepatic, renal or cardiac diseases","1. Duration of mechanical ventilation and stay in the SICU is measured in hours<br>2. Mean time to extubation is measured in minutes<br>3. Sedation level is assessed using Ramsay sedation scores at baseline, 1 hour after start of the sedation and then every 3 hours until weaning from mechanical ventilation and extubation","1. Heart rate is measured by ECG at baseline, 1 hour after start of the sedation and then every 3 hours until weaning from mechanical ventilation and extubation<br>2. Invasive mean blood pressure is measured by arterial line at baseline, 1 hour after start of the sedation and then every 3 hours until weaning from mechanical ventilation and extubation<br>3. Oxygen saturation is measured by pulse oximetry at baseline, 1 hour after start of the sedation and then every 3 hours until weaning from mechanical ventilation and extubation",NA,NULL,Anticipated,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL
ISRCTN15056916,http://isrctn.com/ISRCTN15056916,"A cluster-randomised, non-inferiority trial of the impact of a two-dose compared to a three-dose schedule of pneumococcal conjugate vaccine in rural Gambia.",Streptococcus pneumoniae disease and pneumococcal colonisation <br>Infections and Infestations <br>Streptococcus pneumoniae infection,"13-valent pneumococcal conjugate vaccine (PCV13) will be delivered in two schedules, one with doses scheduled at ages 6, 10 and 14 weeks (3+0 schedule) and the other with doses scheduled at ages 6 weeks and 9 months (1+1 schedule). The two schedules will be randomly allocated (1:1) to 68 geographic clusters where children attend one immunisation clinic.",Pneumococcal Vaccine Schedules (PVS),ISRCTN,15/11/2018,15/11/2018,FALSE,Interventional,Single-centre cluster-randomised non-inferiority parallel-group unmasked trial  (Prevention),Phase IV,50000,London School of Hygiene & Tropical Medicine,Gambia,NA,NULL,15/11/2018,15/11/2018,ISRCTN,20-Jul-20,SCC 1577 v1.2,NA,NA,NA,NA,NA,NA,Grant,Mackenzie,Basse Field Station                    MRCG at LSHTM,gmackenzie@mrc.gm,+220 5669255,NA,Ongoing,NULL,"Medical Research Council, Wellcome Trust, Department for International Development, National Institute for Health Research, Bill and Melinda Gates Foundation",NA,NA,Both,Inclusion criteria: <br>                1. Resident in the study area<br>                2. Children aged 6 weeks to 365 days will be eligible to receive the intervention<br>                3. Children aged 2 weeks to 59 months will be eligible for measurement of the primary endpoint and disease endpoints by disease surveillance<br>,"Exclusion criteria: <br>                1. Intent to move out of the study area before 4 months of age<br>                2. Aged over 364 days<br>                3. Contraindication to vaccination with PCV13, including severe hypersensitivity to a previous dose of PCV13<br>",Nasopharyngeal (NP) carriage of vaccine-type (VT) pneumococci in children aged 2 weeks to 59 months with clinical pneumonia will be measured in the 2nd and 4th year of the trial. Measurement in the 4th year is the primary analysis. Measurement in the 2nd year is a secondary analysis.,<br>                1. NP carriage of non-vaccine-type (NVT) pneumococci in children aged 2 weeks to 59 months with clinical pneumonia measured in the 4th year of the trial<br>                2. Population-based NP prevalence of VT and NVT pneumococci<br>                3. NP prevalence of VT and NVT pneumococci in infants presenting for the first dose of PCV aged 6-12 weeks measured in the 4th year of the trial<br>                4. Incidence of radiological pneumonia in children aged 2 weeks to 59 months will be measured by facility-based surveillance  throughout the trial<br>                5. Incidence of clinical pneumonia in children aged 2 weeks to 59 months will be measured by facility-based surveillance  throughout the trial<br>                6. Incidence of serotype-specific invasive pneumococcal disease (IPD in children aged 2 weeks to 59 months will be measured by facility-based surveillance  throughout the trial<br>                7. Incidence of hospitalisation in children aged 2 weeks to 59 months will be measured by facility-based surveillance  throughout the trial<br>                8. Mortality in children aged 2 weeks to 59 months will be measured by facility-based and demographic surveillance throughout the trial<br>,NA,NULL,Anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,Stored in repository,The protocol will be published in a peer-reviewed open-access journal in 2020. Final results will be published in a peer-reviewed open-access journal in 2023.         IPD sharing statement:        Anonymised datasets will be available indefinitely after publications of results. Data will be accessible by application to the MRCG at LSHTM scientific coordinating committee. Participant consent will be obtained. Approval of the Gambia government/MRCG at LSHTM joint ethics committee is required for data to be sent out of the country.,31/12/2022,NULL,NA,Jan  1 1900 12:00AM,NA,"1. Gambia Government/MRC Joint Ethics Committee; 19/03/201, L2018.E08, SCC1577v1.2                    2. London School of Hygiene & Tropical Medicine Observational/Interventions Research Ethics Committee, 26/02/2018, 14515",NA,NA
JPRN-UMIN000031793,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036145,NA,sleep apnea,Sodium glucose cotransporter 2inhibitor,An exploratory clinical study on the effects of SGLT2 inhibitors for type 2 diabetes (T2DM) patients with sleep apnea (SA),JPRN,19/03/2018,13/03/2018,FALSE,Interventional,Single arm Non-randomized,Not selected,30,Juntendo University Graduate School of Medicine,Japan,NA,1,19/03/2018,13/03/2018,JPRN-U,02-Apr-19,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,Recruiting,NULL,we have no funding source,20years-old,Not applicable,Male and Female,Inclusion criteria: Apnea Hypopnea Index over 15 patients with type 2 DM,"Exclusion criteria: Patients with moderate renal disease (eGFR&lt;30 ml/min)<br>patients with ketosis and diabetic coma<br>patients with severe infection, perioperative period and severe trauma<br>patients with poor control DM","Changes in apnea-hypopnea index (AHI), body weight, body composition, and HbA1c, as well as the levels of microalbuminuria and urine L-FABP",NULL,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,NA,Jan  1 1990 12:00AM,NA,NA,NA,NA
JPRN-UMIN000023355,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025429,Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial. - Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial.,pneumonia,"administration of clarithromycin, 200mg/day, 1 year<br>control",Effect of long-term clarithromycin antibiotic therapy on preventation of pneumonia in the elderly: a prospective randomised controlled trial.,JPRN,01/08/2016,08/12/2016,FALSE,Interventional,Parallel Randomized,Not selected,200,"Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine",Japan,NA,NULL,01/08/2016,08/12/2016,JPRN-U,23-Apr-19,NULL,NA,Mari Yamasue,"1-1 Idaigaoka, Hasama, Yufu, Oita",sai-mari@oita-u.ac.jp,097-549-4411,Oita University Faculty of Medicine Department of Respiratory Medicine and Infectious Diseases,NA,Mari Yamasue,"1-1 Idaigaoka, Hasama, Yufu, Oita",sai-mari@oita-u.ac.jp,097-549-4411,Oita University Faculty of Medicine Department of Respiratory Medicine and Infectious Diseases,Complete: follow-up complete,NULL,Taisho Toyama Pharmaceutical Co,65years-old,Not applicable,Male and Female,Inclusion criteria:,Exclusion criteria: 1) Patients under 65 years old<br>2) Patients with a history of the past of hypersensitivity for an ingredient of the clarithromycin<br>3) Patients having serious complications<br>4) Patients who is taking the drug that blood levels changes by clarithromycin<br>5) Patients who is already giving antimicrobial including the macrolide<br>6) Patients having nontuberculous acid-fast bacterial disease<br>7) Patients who judged the physician to be inappropriate for this study,Frequency of pneumonia,TTime to pneumonia recurrence,NA,NULL,NA,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,28/02/2019,NULL,YES,Jan  1 1900 12:00AM,NA,NA,NA,NA
JPRN-jRCT1041190001,https://jrct.niph.go.jp/latest-detail/jRCT1041190001,A Prospective Multicenter Randomized Controlled Trial for the Effect of High-dose Corticosteroid on Refractory Mycoplasma Pneumoniae Pneumonia in Children - HDCORMPC,"Mycoplasma pneumoniae Pneumonia <br>Mycoplasma, Corticosteroid;20086549/J15.7/ICD-10",High-dose Corticosteroid,The Effect of High-dose Corticosteroid on Refractory Mycoplasma Pneumoniae Pneumonia in children,JPRN,03/04/2019,01/04/2019,FALSE,Interventional,"randomized controlled trial, open(masking not used), historical control, parallel assignment, treatment purpose",N/A,80,Takahashi Yoshiyuki,Japan,NA,1,03/04/2019,01/04/2019,JPRN-j,07-Sep-20,NULL,Jun-ichi,Kawada,"65, Tsurumai,Showa-ku, Nagoya-shi",kawadaj@med.nagoya-u.ac.jp,-3024,Nagoya University Graduate School of Medicine,Yoshiyuki,Takahashi,"65, Tsurumai,Showa-ku, Nagoya-shi",ytakaha@med.nagoya-u.ac.jp,-3009,Nagoya University Graduate School of Medicine,Recruiting,NULL,NULL,1age,16age,Both,Inclusion criteria: Refractory Mycoplasma pneumoniae Pneumonia,Exclusion criteria: Respiratory Failure Required Intubation,The Interval between Administration of Corticosteroids and afebrile conditions,Duration of Hospitalization,NA,NULL,anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Mar  4 2019 12:00AM,ethics@med.nagoya-u.ac.jp,Certified Review Board of Nagoya University,-3194,ethics@med.nagoya-u.ac.jp
JPRN-UMIN000026129,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029759,The prospective study of nivolumab for advanced NSCLC patients with mild IIPs - The prospective study of nivolumab for advanced NSCLC patients with mild IIPs,non-small cell lung cancerinterstitial lung diseaseinterstitial pneumonia,"Nivolumab 3mg/kg, every 2 weeks",The prospective study of nivolumab for advanced NSCLC patients with mild IIPs,JPRN,15/02/2017,14/02/2017,FALSE,Interventional,Single arm Non-randomized,Not selected,18,Kobe city medical center general hospital,Japan,NA,1,15/02/2017,14/02/2017,JPRN-U,25-Feb-20,NULL,Daichi,Fujimoto,"2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan",daichi@kcho.jp,078-302-4321,Kobe city medical center general hospital Division of respiratory medicine,Keisuke,Tomii,"2-1-1 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan",ktomii@kcho.jp,078-302-4321,Kobe city medical center general hospital  Division of respiratory medicine,Complete: follow-up complete,NULL,kobe city medical center general hospital,20years-old,100years-old,Male and Female,Inclusion criteria:,"Exclusion criteria: 1)Subjects with the history of drug induced pneumonitis <br>2)Subjects with definite UIP pattern <br>3)Subjects with serious infection <br>4)Subjects with serious complications <br>5)Subjects with symptomatic brain metastases <br>6)Subjects with uncontrolled pleural effusion, ascites, and pericardial effusion",progression free survival,"overall survival, response rate, duration of response, safety",NA,NULL,NA,18,https://www.ncbi.nlm.nih.gov/pubmed/31182249,"Results: Eighteen patients were enrolled in this trial. Six months PFS rate was 56%, response rate was 39%, and disease control rate was 72%. There were no treatment-related deaths. One drug-related grade 3/4 nonhematologic event (grade 3 neurotoxicity) was observed. Two patients had grade 2 pneumonitis which improved by corticosteroid therapy. Conclusions: Nivolumab could be an effective therapy for NSCLC patients with mild IIPs.",17/02/2020,01/01/1900,"Eligible patients had previously-treated, inoperable NSCLC with mild IIPs.","Eligible patients had previously-treated, inoperable NSCLC with mild IIPs.",One drug-related grade 3/4 nonhematologic event (grade 3 neurotoxicity) was observed. Two patients had grade 2 pneumonitis which improved by corticosteroid therapy.,Six months PFS rate was 56%.,https://www.ncbi.nlm.nih.gov/pubmed/31182249,NA,NA,28/12/2018,Yes,YES,Feb 13 2017 12:00AM,rinken@kcho.jp,Kobe city medical center general hospital,078-302-4321,rinken@kcho.jp
JPRN-jRCTs041180086,https://jrct.niph.go.jp/latest-detail/jRCTs041180086,Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome - Clinical study about the safety of Suvorexant for severe sleep apnea syndrome,Sleep Apnea Syndrome,using orexin receptor antagonist Suvorexant,Clinical study about the safety of Suvorexant for severe sleep apnea syndrome,JPRN,12/03/2019,16/12/2016,FALSE,Interventional,"single arm study, open(masking not used), historical control, single assignment, treatment purpose",4,30,Imaizumi Kazuyoshi,Japan,NA,1,12/03/2019,16/12/2016,JPRN-j,25-Feb-20,NULL,Yuuki,Mieno,"1-98, Dengakugakubo, Kustukake Cho, Toyoake City, Aichi",mienon@fujita-hu.ac.jp,-9815,Fujita Health University Hospital,Kazuyoshi,Imaizumi,"1-98, Dengakugakubo, Kustukake Cho, Toyoake City, Aichi",jeanluc@fujita-hu.ac.jp,-9815,Fujita Health University Hospital,Recruiting,NULL,NULL,>= 20age old,Not applicable,Both,"Inclusion criteria: The patient who received enough explanation about this study, and provides agreement in the document.",Exclusion criteria: The patient 19 years or younger at the time of the agreement acquisition,Apnea hypopnea index on PSG,Epworth sleepiness scale,NA,NULL,actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Jun 13 2019 12:00AM,f-irb@fujita-hu.ac.jp,Fujita Health University Certified Clinical Research Review Board,-3439,f-irb@fujita-hu.ac.jp
JPRN-jRCTs031190084,https://jrct.niph.go.jp/latest-detail/jRCTs031190084,A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias - TORG1936 / AMBITIOUS study,Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia,"Atezolizumab 1200mg, every 3 weeks",TORG1936 / AMBITIOUS study,JPRN,27/08/2019,05/09/2019,FALSE,Interventional,"single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose",2,38,KATO Terufumi,Japan,NA,NULL,27/08/2019,05/09/2019,JPRN-j,06-Oct-20,NULL,Satoshi,IKEDA,"6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama",isatoshi0112@gmail.com,-10246,Kanagawa Cardiovascular and Respiratory Center,Terufumi,KATO,"2-3-2 Nakao, Asahi-ku, Yokohama",terufumikato@gmail.com,-2706,Kanagawa Cancer Center,Suspended,IKEDA Satoshi,Thoracic Oncology Research Group,>= 20age old,Not applicable,Both,"Inclusion criteria: 1)Histologically or cytologically proven non-small cell lung cancer <br>2)Unresectable stage 3/4 or recurrent<br>3)Received prior chemotherapy including platinum doublet<br>4)Chronic fibrotic IP<br>HRCT revealed (1) reticular shadow with basal and peripheral predominance suggestive of UIP pattern,or(2) peri-bronchovascular shadow suggestive of NSIP pattern<br>lOther interstitial lung disease of known etiology(infection, pneumoconiosis, drug, sarcoidosis, and collagen vascular disease)<br>l%FVC>70%<br>l%DLCO>35%<br>5)Age>=20 years<br>6)ECOG Performance Status 0-1<br>7)With measurable or evaluable lesions according to RECIST Version1.1<br>8)Vital organ functions are preserved<br>9)Received sufficient explanations about the name and severity of the illness   <br>10) Written informed consent",Exclusion criteria: 1)History of acute exacerbation of IPF<br>2)Treatment history with immune-checkpoint inhibitor<br>3)Systemic treatment with steroids at a daily dose>10mg of prednisolone equivalent or immunosupressants<br>4)Active autoimmune disease or history of autoimmune disease requiring treatment <br>5)Symptomatic brain metastasis or spinal cord metastases<br>6)Active viral hepatitis<br>7)Active infection<br>8)Synchronous or metachronous active double malignancies<br>9)Pregnant or breastfeeding <br>10) Disapprove of contraception during the protocol treatment period  <br>11) Treatment history with thoracic radiotherapy<br>12) History of serious drug allergies<br>13) Other conditions not suitable for the study,1 year-survival rate,"The incidence of acute exacerbation of IP within 1 year after treatment initiation, overall survival, progression free survival, objective response rate, time to treatment failure, mortality rate due to acute exacerbation of IP or pneumonitis during observation period, safety",NA,NULL,actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,Approval,Jul 23 2019 12:00AM,crbcr@adm.niigata-u.ac.jp,Niigata University Central Review Board of Clinical Research,-9655,crbcr@adm.niigata-u.ac.jp
JPRN-UMIN000035028,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039927,Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study - Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study,Influenza,Baloxavir marboxil<br>Oseltamivir<br>Laninamivir,Effect and safety of Baloxavir Marboxil in children with influenza: multicenter randomized controlled study,JPRN,27/11/2018,01/12/2018,FALSE,Interventional,Parallel Randomized,Not selected,600,Kyoto Chubu Medical CenterDepartment of Pediatrics,Japan,NA,NULL,27/11/2018,01/12/2018,JPRN-U,18-May-20,NULL,Masaya,Suematsu,25 Yagiueno Yagimachi Nantanshi Kyoto Japan,masa16@koto.kpu-m.ac.jp,-3242,Kyoto Chubu Medical Center Department of Pediatrics,Hisato,Ito,25 Yagiueno Yagimachi Nantanshi Kyoto Japan,hisato527@leto.eonet.ne.jp,-3242,Kyoto Chubu Medical Center Department of Pediatrics,Complete: follow-up continuing,Saiseikai Kyoto HospitalMatsui Pediatrics ClinicSato Clinic,Kyoto Chubu Medical CenterDepartment of Pediatrics,Not applicable,15years-old,Male and Female,Inclusion criteria:,"Exclusion criteria: 1)Patients or their parents do not accept the assigned drug<br>2)A symptom duration of more than 48 hours<br>3)Patients who have any chronic respiratory disease, cardiovascular disease, central nervous disorder, immune dysfunction, or other chronic comorbid condition except asthma<br>4)Patients with severe influenza virus infection requiring inpatient treatment",The time to resolution of fever,The number of days absent from school or preschool<br>The number of asthmatic symptoms<br>The number of pneumonia<br>The number of gastrointestinal symptoms<br>The number of abnormal behaviors<br>Drug adherence,NA,NULL,NA,368,NA,"The efficacy of baloxavir marboxil was similar to that of NAIs, and there was no difference in side effects.",10/05/2020,01/01/1900,NA,NA,NA,NA,NA,NA,NA,31/05/2019,Yes,YES,Nov  1 2018 12:00AM,masa16@koto.kpu-m.ac.jp,Kyoto Chubu Medical Center,-3242,masa16@koto.kpu-m.ac.jp
PER-016-17,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=016-17,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA","-J159 Bacterial pneumonia, unspecified <br>Bacterial pneumonia, unspecified;J159;Bacterial pneumonia, unspecified","Delafloxacin 300 mg will be administered as a 1-hour IV infusion every 12 hours (± 2 hours) for a minimum of 6 doses with an option to switch to delafloxacin 450 mg tablet administered orally every 12 hours (± 2 hours) for the remaining doses. <br>Moxifloxacin 400 mg will be administered as a 1-hour IV infusion every 24 (± 2 hours) hours for a minimum of 3 active doses with an option to switch to moxifloxacin 400 mg (over-encapsulated tablet) administered orally every 24 hours (± 2) for the remaining doses. <br>At local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA, in place of remaining moxifloxacin doses, can receive linezolid 600 mg administered as a 1-hour IV infusion every 12 hours (± 2 hours) for the remaining doses.<br>Each site will document a blinding plan prior to study start. All blinded IV dosing will be maintained with a 12-hour schedule. IV bags will be blinded. <br>Subjects in the moxifloxacin arm, when on IV therapy, will receive once-daily active therapy via alternating doses of IV moxifloxacin and IV placebo every 12 (± 2) hours. <br>Subjects in the delafloxacin arm, when on oral therapy, will receive oral placebo moxifloxacin QD or IV placebo linezolid BID to maintain blinding. <br>Subjects in the moxifloxacin/linezolid arm, when on oral therapy or when meet criteria for oral therapy, will receive placebo delafloxacin oral formulation to maintain blinding.<br>","A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA",PER,26/07/2017,04/09/2017,FALSE,Interventional,"Subjects who meet the entry criteria will be randomly assigned in a 1:1 ratio to receive delafloxacin or moxifloxacin. Randomization will be stratified by PORT Class, medical history of chronic obstructive pulmonary disease (COPD)/asthma, and prior systemic antimicrobial use. Enrollment will be limited to no more than 25% Port Class II and no more than 25% of subjects with prior antibacterial use. <br>Subjects will be randomized to receive either IV delafloxacin 300 mg every 12 hours (BID), with an option to switch to oral delafloxacin 450 mg BID; or IV moxifloxacin 400 mg every 24 hours (QD), with an option to switch to oral moxifloxacin 400 mg QD for the remaining doses. Subjects randomized to receive IV moxifloxacin 400 mg QD will receive alternating IV placebo QD to preserve the double blind nature of the study, such that all randomized subjects will receive an IV infusion on a BID basis. <br>The investigator may elect to switch subjects from moxifloxacin/moxifloxacin placebo",III,25,"Melinta Therapeutics, Inc.,",Germany;Belarus;Bulgaria;Latovia;Slovenia;Spain;Georgia;Hungary;Modalvia;Poland;Romania;Russian Federation;Ukraine;Australia;New Zealand;Serbia;South Africa;Argentina;Brazil;Canada;Chile;Colombia;Dominican Republic;Mexico;Peru;United States,NA,NULL,26/07/2017,04/09/2017,PER-01,04-Nov-20,NCT02679573;2015-003026-14,Eugenia,Paez,Calle Monte Rosa 233 Oficina 703,regulatorio@psi-cro.com,54 11 5670 0000,PSI CRO Peru S.A.C.,Cecilia,Dignani,Calle Monte Rosa 233 Oficina 703,regulatorio@psi-cro.com,54 11 5670 0000,PSI CRO Peru S.A.C.,Complete,NULL,"Melinta Therapeutics, Inc.",NA,NA,--,"Inclusion criteria: 1.Male and female subjects 18 years of age or older.<br>•Patients from a nursing home setting may be enrolled if they are normally ambulatory and are not on enteral feeding<br>2.Evidence of acute onset of CABP. <br>Subjects must have at least 2 of the following clinical signs and symptoms (new or worsening):<br>•Cough<br>•Production of purulent sputum  consistent with a bacterial infection<br>•Difficulty breathing (dyspnea)<br>•Chest pain due to pneumonia<br>AND<br>Subjects must also have at least 2 of the following findings:<br>•Fever (oral temperature > 38°C or equivalent) within 24 hours prior to randomization<br>•Hypothermia (oral temperature < 35°C or equivalent) within 24 hours prior to randomization <br>•Tachycardia (> 100 beats per minute)<br>•Tachypnea (elevated respiratory rate >18 breaths per minute)<br>AND<br>Subjects must also have at least 1 of the following findings: <br>•Hypoxemia (oxygen saturation < 90% or PaO2 < 60 mmHg on room air or with subject’s baseline [pre-CABP under study] supplemental oxygen flow rate)<br>•Clinical evidence of pulmonary consolidation and/or presence of pulmonary rales<br>•An elevated white blood cell count (WBC) > 10,000/mm3 or 15% immature neutrophils (bands), regardless of total peripheral WBC count or leukopenia with WBC < 4500/mm3<br>3.Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study (e.g., chest radiograph [CXR] [posteroanterior and lateral preferred; single view acceptable if conclusive] or computed tomography [CT] of thorax) as per local standard of care within 48 hours before the first dose of study drug. <br>4.PORT risk class of II, III, IV, or V PSI score (greater than 50). Subjects may be initially screened based on meeting CURB-65 score of 2 to 4. PORT risk class II will be limited to 25% of randomized subjects. <br>5.In the opinion of the investigator, the subject must be a suitable candidate for possible IV to oral switch antibiotic therapy and must also be able to swallow large tablets/capsules intact without crushing.<br>6.Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test prior to enrollment. Sexually active women and men with partners of childbearing potential must agree to use an acceptable form of contraception, as determined by the investigator (e.g., abstinence, oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy) during participation in the study and through the Follow-up Visit (Day 28). Female partners of male subjects should also use an additional reliable method of contraception, such as spermicide with male or female condoms, cervical sponge, intrauterine device, cervical cap or diaphragm, or oral, implantable, transdermal, or injectable contraceptives during study and through the Follow-up Visit (Day 28).<br>7.In the opinion of the investigator, the subject must be able and willing to comply with protocol requirements.<br>8.A written, voluntarily signed informed consent must be obtained from the subject or where allowed by local regulations, legally authorized representative, in accordance with local regulations, before the initiation of any study-related procedures. The subject or legally authorized representative must be able to read and/or understand the informed consent form as required by the legal jurisdiction and the institutional review board","Exclusion criteria: 1.Medical history of significant hypersensitivity or allergic reaction to antibiotics of the quinolone or oxazolidinone class or study drug excipients according to the judgment of the investigator. <br>2.Women who are pregnant or lactating.<br>3.Any infection expected to require other systemic antibacterial agents in addition to study drug.<br>4.Receipt of systemic antibiotic therapy in the 7 days before enrollment unless one of the following is documented:<br>•The subject received at least 48 hours of antibiotic therapy for CABP and the clinic notes  document treatment failure (i.e., not by patient history or pulmonary imaging alone) with new or worsening symptoms while on pre-study therapy or identification of a respiratory pathogen that is resistant to a pre-study antibiotic, which would be susceptible to study drug (delafloxacin or moxifloxacin) in subjects with new or worsening signs and symptoms of CABP. <br>•The subject received 1 dose of a single, potentially effective, short-acting antimicrobial drug or a short-acting antimicrobial drug regimen for treatment of the CABP under study within 24 hours of enrollment. (Note: 1 dose of a regimen is defined as the standard therapy for CABP at the study site.) Subjects who received prior antimicrobial drug under this criterion will be limited to no more than 25% of total randomized subjects.<br>5.Respiratory infection confirmed or suspected to be secondary to hospital-acquired or ventilator-associated pneumonia or that requires treatment in an intensive care setting at the time of informed consent.<br>6.Intubated at the time of informed consent or clinical presentation with pneumonia that would require invasive mechanical ventilation.<br>7.Current or suspected diagnosis of:<br>•Viral pneumonia, fungal pneumonia, including Pneumocystis jiroveci pneumonia<br>•Aspiration pneumonia<br>•Other noninfectious causes of pulmonary infiltrates (e.g., pulmonary embolism, hypersensitivity pneumonia, congestive heart failure)<br>•Primary or metastatic lung cancer<br>•Cystic fibrosis<br>•Active or suspected tuberculosis<br>•Empyema (not including sterile parapneumonic effusions)<br>8.Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented Global initiative for chronic Obstructive Lung Disease (GOLD) Stage 4 chronic obstructive pulmonary disease or a history of post obstructive pneumonia.<br>9.Severely compromised immune system, e.g.:<br>•Known absolute neutropenia (absolute neutrophil count < 500 cells/µL)<br>•Known human immunodeficiency virus infection (HIV) with a CD4 count < 350 cells/µL within the last 4 months<br>•Cancer chemotherapy or radiation in the last 3 months<br>•Hematological malignancy<br>•Bone marrow transplantation<br>•Chronic steroid use (> 20 mg prednisone per day or equivalent) prior to enrollment<br>10.Known history of Child-Pugh Class B or C liver disease and/or presence or possible signs of significant hepatic disease or alanine aminotransferase (ALT) > 3× the upper limit of normal (ULN).<br>11.Severe renal disease or creatinine clearance (CrCl) &#8804; 29 mL/min using Cockcroft-Gault formula or need for hemodialysis or peritoneal dialysis.<br>12.Uncorrected hypokalemia or known uncorrected hypomagnesemia at time of enrollment. <br>13.Ongoing treatment for seizures or untreated history of seizures.<br>14.History of peripheral neuropathy.<br>15.History of tendon damage/disorders due to quinolone therapy.<br>16.Known history of myasthenia gravis.<br>17.History of po",NULL,NULL,NA,NULL,anticipated,4,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,06/08/2018,NULL,Approved;Approved;Approved;Approved,Mar 28 2017 12:00AM;Mar  9 2017 12:00AM;Apr  6 2017 12:00AM;Mar 16 2017 12:00AM,mmateo@prisma.org.pe  ;juan.lema@upch.pe;manglar10@yahoo.com  ;hdosdemayo@hotmail.com,Comite Institucional de Etica en Investigacion de la Asociacion Benefica Prisma;Hospital Nacional Arzobispo Loayza;Hospital Nacional Cayetano Heredia;Hospital Nacional Dos de Mayo,616-5500 Anx. 246;88339014 - 3301677;97254626;3280028,mmateo@prisma.org.pe  ;juan.lema@upch.pe;manglar10@yahoo.com  ;hdosdemayo@hotmail.com
RBR-96cy3k,http://www.ensaiosclinicos.gov.br/rg/RBR-96cy3k/,Interference of Magnesium Sulfate in onset time and duration of Rocuronium in different doses,"Aspiration pneumonia,  neuromuscular nondepolarizing agents, intratracheal intubation <br>Pneumonia, Aspiration <br>Neuromuscular Nondepolarizing Agents <br>Intubation, Intratracheal;Pneumonia, Aspiration;Neuromuscular Nondepolarizing Agents;Intubation, Intratracheal","After the randomization, 180 patients will be divided into 2 groups:<br><br>a) Intervention (90 patients): receive, intravenously, Magnesium Sulfate (60 mg/kg plus 0.9% saline solution in 100 ml final volume) for 15 minutes prior to anesthesia. After, this group will be divided into 3 groups of equal size (30 patients) according to the dose of Rocuronium to be used for anesthetic induction: 0.3mg/kg, 0.6mg/kg or 1.2mg/kg.<br><br>b) placebo (90 patients): 100ml receive saline 0.9% for 15 minutes prior to the anesthesia. Next, this group divided into 3 groups of equal size (30 patients) according to the dose of Rocuronium to be used for anesthetic induction: 0.3mg/kg, 0.6mg/kg or 1.2mg/kg.<br><br>;Drug;Anesthesia, General;Intubation, Intratracheal;Neuromuscular Blocking Agents",Evaluation of onset time and duration of Rocuronium in differet doses when used with Magnesium Sulfate,RBR,09/09/2016,01/01/2014,FALSE,Intervention,"Clinical trial of treatment, parallel, double-blind, randomized controlled, two branch, phase 4",4,180,"Hospital Universitário Cassiano Antônio de Moraes - Vitória, ES, Brazil",Brazil,NA,1,09/09/2016,01/01/2014,RBR-96,04-Nov-20,Número parecer  337.287/2013;07364612.5.0000.5071,Carlos,David de Almeida,"Rua Ludwik Macal, 1230/501",cedalmeida@gmail.com,+55(27)999821227,Hospital Universitário Cassiano Antônio de Moraes,Carlos,David de Almeida,"Rua Ludwik Macal, 1230/501",cedalmeida@gmail.com,+55(27)999821227,Hospital Universitário Cassiano Antônio de Moraes,Recruitment completed,"Hospital Universitário Cassiano Antônio de Moraes - Vitória, ES, Brazil","Hospital Universitário Cassiano Antônio de Moraes - Vitória, ES, Brazil",18Y,65Y,-,Inclusion criteria: Patients of aged 18 to 65 years;  both gender; ASA physical status I or II; body mass index (BMI) between 18 and 27; with general anesthesia indication under tracheal intubation and controlled mechanical ventilation for elective surgical procedures indicating use of muscle relaxant.,"Exclusion criteria: Use drugs that can influence neuromuscular blockade (as phenytoin and aminoglycosides); hepatic, renal ou cardiac impairment; neuromuscular disease; predictability of difficulty in ventilation by mask or intubation; risk or confirmation of pregnancy; patients with inadequate preoperative fasting or at risk of pulmonary aspiration; electrolyte disorders, use magnesium supplementation; other contraindications to the use of parenteral magnesium; surgery associated with massive bleeding or high volume replacements; patients that develop electrolyte or acid-base disturbance, hypothermia or any other intraoperative condition that interferes with neuromuscular blockade","Variation in onset time (time until 5% of the initial motor response), clinical duration (time to 25% recovery of neuromuscular function) and 25-75% recovery time (time for recovery of 25 to 75% neuromuscular function) of neuromuscular blockade induced by rocuronium in different doses associated or not with Magnesium Sulfate, measured by accelerometry the first finger after single twitch (1 Hz) of the ulnar nerve,  considered significant a difference of 10% between groups (with or without Magnesium Sulfate), corresponding to approximately 10 seconds. <br>","Improvement in tracheal intubation conditions by clinical analysis of the reaction to the endotracheal tube introduction (none, mild and strong), the position of the vocal cords (abduction, intermediate or closed) and the quality of laryngoscopy (excellent, good or bad) evidenced by increasing conditions clinically acceptable according to Good clinical research practice in pharmacodynamics studies of neuromuscular blocking agents II: the Stockholm revision.<br>Reduced adrenergic response to tracheal intubation by heart rate and noninvasive blood pressure, detected from a variation of less than 5% in measurements before and after tracheal intubation.<br>Increased blood flow in the place  of the neuromuscular junction monitoring(adductor muscle of the first finger) after infusion of Magnesium Sulfate/Placebo, inferred by the skin temperature of thenar eminence and perfusion index (plethysmography pulse oximeter installed on the first chirodactyl) detected by increase greater than 10% for the perfusion index and 0.5 degrees celsius for temperature.",NA,NULL,actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,NULL,NULL,NA,Jan  1 1900 12:00AM,NA,NA,NA,NA
TCTR20191025002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5306,Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii Pneumonia prophylaxis in B-cell lymphoma patients receiving chemotherapy: A multicenter randomized double-blinded placebo-controlled trial,Age more than 18 yearsDiffused larged B-cell lymphoma patients (DLBCL)Chemotherapy with CHOP or R-CHOP <br>Diffused larged B-cell lymphoma (DLBCL)chemotherapyCHOP R-CHOPPneumocystis jirovecii pneumoniaTrimethoprim/Sulfamethoxazole;Diffused larged B-cell lymphoma (DLBCL)chemotherapyCHOP R-CHOPPneumocystis jirovecii pneumoniaTrimethoprim/Sulfamethoxazole,"Take Trimethoprim/Sulfamethoxazole single strength (Trimethoprim 80 mg and Sulfamethoxazole 160 mg) 2 tabs oral thrice a week every Monday, Wednesday and Friday for pneumocystis jirovecii pneumonia prophylaxis until 1 month after chemotherapy cessation, Take placebo 2 tabs oral thrice a week every Monday, Wednesday and Friday for pneumocystis jirovecii pneumonia prophylaxis until 1 month after chemotherapy cessation",Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii Pneumonia prophylaxis in B-cell lymphoma patients receiving chemotherapy: A multicenter randomized double-blinded placebo-controlled trial,TCTR,26/09/2019,01/12/2019,FALSE,Interventional,Randomized controlled trial,Phase 3,328,Faculty of Medicine Siriraj Hospital,Thailand,NA,NULL,26/09/2019,01/12/2019,TCTR20,04-Nov-20,NULL,Methee,Chayakulkeeree,"5th Floor, Asadang building, Siriraj Hospital Bangkok 10700",methee.cha@mahidol.ac.th,66850632416,Faculty of Medicine Siriraj Hospital,Methee,Chayakulkeeree,"5th Floor, Asadang building, Siriraj Hospital Bangkok 10700",methee.cha@mahidol.ac.th,66850632416,Faculty of Medicine Siriraj Hospital,Pending (Not yet recruiting),Faculty of Medicine Siriraj Hospital,Faculty of Medicine Siriraj Hospital,18 Years,0 N/A (No limit),Both,"Inclusion criteria: 1. Diffused larged B-cell lymphoma patients (DLBCL), 18 years of age or older<br>2. Intent to or receiving chemotherapy with CHOP or R-CHOP not more than 3 cycles",Exclusion criteria: 1. Receiving Trimethoprim/Sulfamethoxazole or Dapsone for pneumocystis jirovecii pneumonia prophylaxis before recruitment<br>2. History of pneumocystis jirovecii pneumonia before recruitment<br>3. Receiving Trimethoprim/Sulfamethoxazole or Dapson within 1 month before recruitment<br>4. Severe adverse reaction or allergic to Trimethoprim/Sulfamethoxazole or sulfa drug<br>5. Creatinine clearance < 30 mg/dL<br>6. Women who were pregnant or during breast feeding,"Incidence of pneumocystis jirovecii pneumonia [Timeframe 30 days after cessation of chemotherapy Incidence rate, Number of population]","Adverse effect of treatment  [Timeframe 14 days after cessation of chemotherapy 1. Laboratory test 2. Allergic reaction 3. Nausea and vomiting];Incidence of pneumocystis jirovecii pneumonia after treatment [Timeframe 90 day after cessation of chemotherapy 90-day incidence rate of pneumocystis jirovecii pneumonia];Cumulative dose of prednisolone in pneumocystis jirovecii pneumonia patients  [Timeframe 30 days after cessation of chemotherapy Cumulative dose of prednisolone];Incidence of bacterial infection [Timeframe 30 days after cessation of chemotherapy Incidence rate, number of population];The period of time of pneumocystis jirovecii pneumonia event after chemotherapy  [Timeframe 30 days after cessation of chemotherapy Time period ]",NA,NULL,Anticipated,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,30/06/2022,NULL,NA,Jan  1 1900 12:00AM,NA,NA,NA,NA
TCTR20190614001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4533,Effectiveness of Tongue Cleaning plus Chemical Mouthwash Agents  into the Number of  Oral Microorganism  on the  Aspiration Pneumonia in Bedridden Elderly Patients :   A Cross over study,- Aspiration pneumonia because the number of microorganism on the dorsal tongue  of the bedridden patients who were the elderly totally independent in the community <br>- tongue cleaning- Chemical mouthwash agent- Bedridden patients- Older people;- tongue cleaning- Chemical mouthwash agent- Bedridden patients- Older people,"Group 1 : Tongue cleaning using mechanical and Chlorhexidine gluconate mouthwash. It has washout period 1 week and change into another mouthwash., Group 2 : Tongue cleaning using mechanical and Povidone iodine mouthwash. It has washout period 1 week and change into another mouthwash., Group 2 : Tongue cleaning using mechanical and tap water. It has washout period 1 week and change into another mouthwash.",Effectiveness of Tongue Cleaning plus Chemical Mouthwash Agents  into the Number of  Oral Microorganism  on the  Aspiration Pneumonia in Bedridden Elderly Patients :   A Cross over study,TCTR,06/03/2019,01/08/2019,FALSE,Interventional,Randomized controlled trial,Phase 1,12,Naresuan University,Thailand,NA,NULL,06/03/2019,01/08/2019,TCTR20,04-Nov-20,NULL,Nilobon,Aiemyen,65000 Phitsanulok 65000,nilobon@scphpl.ac.th,811765067,Naresuan University and Sirindhron college of Publich health Phitsanulok,Nilobon,Aiemyen,65000 Phitsanulok 65000,nilobon@scphpl.ac.th,811765067,Naresuan University and Sirindhron college of Publich health Phitsanulok,Enrolling by invitation,Siridhron college of Public Health Phitsanulok,Naresuan University and Siridhron college of Public Health Phitsanulok,60 Years,100 Years,Both,Inclusion criteria: - the elderly totally independent in the community who have been with care giver,"Exclusion criteria: - the elderly totally independent who  have oral lesion, have history of side effect of mouth wash and do not  consent in the research  <br>",Number of Oral Microorganism [Timeframe Researcher record the data suddenly after intervention and 3 hours after intervention standard plate count],tongue coating [Timeframe Researcher record the data suddenly after intervention and 3 hours after intervention tongue coating index],NA,NULL,Actual,NA,NA,NA,NULL,01/01/1900,NA,NA,NA,NA,NA,NA,NA,20/12/2019,NULL,NA,Jan  1 1900 12:00AM,NA,NA,NA,NA